Re: SEROQUEL Law Firms have sold their clients down the river

[Guest guest]

"Awry," not "a rye" but I digress. This is exactly why I never urge anyone to sue. The deck is stacked against us in court and attorneys are looking for a quick and easy buck. No justice is to be had.TerrySent via BlackBerry by AT&TFrom: "jeremy9282" <jeremybryce1953@...>Sender: SSRI medications Date: Wed, 10 Aug 2011 12:02:28 -0000<SSRI medications >Reply SSRI medications Subject: SEROQUEL Law Firms have sold their clients down the river Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO REJECT this Insult on Top of Injury Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO REJECT this Insult on Top of InjuryI would like to thank a brave, courageous, and ethical anonymous source who has send in this letter correspondence they received from the law firm of Weitz & Luxenberg. This letter doesn't require a whole lot of commentary. It's obvious that Law Firms have sold their clients down the proverbial river while at the same time enriching themselves (who's best interest are you obligated too fulfill?). This settlement offer and the injured litigants legal representation has carried out a blatant miscarriage of justice, a forever horrible stain upon the American Justice system, and a orchestrated crime perpetrated upon victims of this well documented & evidenced unbridled & unregulated corporate criminal enterprise gone a rye.The time has now come for the victims to stand up to this criminal corporation "AstraZeneca" & their poison drug "Seroquel", to reject this horrible injustice and settlement offer. We want, what America & our Constitution promises us all, our day in court before a jury of our peers....____________________________________________________________Weitz & Luxenberg P.C.We are happy to report excellent news! After a long and hard fought legal battle, AstraZeneca has agreed to participate in a Settlement Program to resolve Weitz & Luxenberg ("W & L") Seroguel cases. Our patience and aggressive litigating has resulted in very favorable settlement terms for our clients which will be further outlined below. We have carefully reviewed all of the factors of this agreement and we believe that this settlement offers you the best, and very likely the only opportunity to receive a fair resolution of your lawsuit. Therefore, we strongly recommend that you sign and complete the enclosed "Release Form", "Track Selection Form" and "Brief Questionnaire" and AGREE to participate. As you know, we have engaged in a long legal battle with AstraZeneca over the past 6 years. Weitz & Luxenberg led the charge for the Plaintiffs around the Country. AstraZeneca put up a tremendous and expensive defense and they successfully were able to get a large number of cases to be permanently dismissed by the court. Weitz & Luxenberg is the only firm who took a case to trial anywhere in the Country. However, after a month-long trial, the jury unfortunately ruled in favor of the defendants. This loss did not affect the strength of our fight. Over the past year, even as almost every other plaintiffs firm settled their cases, Weitz & Luxenberg prepared two more cases for trial which was scheduled to begin this Summer. As a direct result of the endless and consistent pressure applied by the attorneys at Weitz & Luxenberg, we are happy to report that AstraZeneca has now agreed to participate in a favorable settlement program. Based on public reports regarding settlement programs reached with other plaintiff law firms we are confident that the settlement program outlined below has more favorable terms and for this reason we are recommending your participation.The defendants have argued that they refuse to pay anyone who cannot prove through medical records or via certification that they have used Seroquel. They also refuse to pay anyone whose case is not active in this litigation. We recently told you about the Order issued by the Court requiring you to confirm when you started taking Seroquel and when you stopped taking Seroquel. We cannot stress enough that you MUST read, complete and return this certification form to us immediately. The failure to return this form within the next 30 days will result in the permanent dismissal of your case. In order to protect your legal rights, to keep your case active and be permitted to participate in this Settlement Program you must take this Order very seriously and you must respond.Based on our experience in other litigations and having reviewed the media reports of the terms of other firms' Seroquel settlement programs, we know that the defendants are looking for a settlement program that includes all claimants (W & L Seroquel Plaintiffs) so that they will achieve complete closure of the entirYlitigation. Our goal in this negotiation was to obtain a settlement for the most amount of money using a fair method to pay our clients based upon the merits of their individual case. We also stressed our intentions that the case review and payment process be performed quickly yet fairly so that our clients can receive their settlements as soon as possible. A key part of this settlement program is that a claimant cannot be part of the settlement if their case is dismissed and unless they provide, at the very least, a certification that they in fact took Seroquel and suffered an injury. Therefore, please make sure that you return your certification form to us immediatelyWe have hired Hon.Marina Corodemus to act as the Special Master for the W & L Seroquel settlement program. Judge Corodemus previously ran the New Jersey Mass Tort Court and has a lot of experience in this field. She was appointed as a Special Master by the Vioxx State and Federal Court Judges to determine the appropriateness of Vioxx settlements and to resolve Vioxx appeals. She has also served as the Special Master in many other litigations such as Bextra and Celebrex which used similar settlement terms. We have met several times with Judge Corodemus and discussed the goals outlined above to get the most amount of money to the most amount of claimants in the fastest amount of time possible. We believe that Judge Corodemus is the perfect choice to create and oversee a settlement program in accordance with these goals. The W & L Seroquel Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only those clients with active cases (not dismissed as outlined above) can participate in this settlement program. Unlike other settlement programs that you may have read about in the media and internet, the W & L Settlement program does not award every case an equal settlement amount. The size of an individual's settlement will depend entirely on the merit of that individual's case. As a direct result of the large number of cases represented by W & L, and the merits of those cases, we are confident that we have obtained the best possible settlement for our clients. After complex negotiations, AstraZeneca has agreed to deposit $92.25 Million dollars into a trust account to be used for this Settlement Program. This amount is completely confidential and you should NOT discuss this with anyone. A settlement of this type is called an "Aggregate Settlement" where a fair and reasonable sum of money is obtained to resolve multiple cases. In order to maintain proper representation of each individual client, W & L is NOT involved in the allocation decision making, which will be handled exclusively by Judge Corodemus. W & L has reviewed the general framework of the settlement plan with Judge Corodemus and we strongly believe that it is fair and reasonable and offers each of our clients the best possible outcome under the circumstances of this litigation. Track I offers the Seroquel claimant a settlement of $12,000. This track involves a simple review of each case and will result in a quick approval by Judge Corodemus without an analysis of the specific details of the case such as injury, amount of Seroquel taken, how close the last Seroquel use was to the date of the injury or the individual claimant's risk factors. a) Cannot prove that they suffered diabetes or a diabetes related condition, and/or Cannot prove that they used Seroquel within 1 year of their claimed injury, and/or c) Had a large number of known risk factors for diabetes before they started taking Seroquel. For example - obesity, family history, smoking, etc.Therefore, all cases whose injuries are limited to weight gain or high blood sugar and whose medical records will confirm that they were never diagnosed with diabetes or pancreatitis, should choose Track 1. Similarly, any claimed injury that occurred long after the last use of Seroquel should also choose Track 1. These cases are likely to receive a small award in Track II (likely less than $12,000) because it is extremely difficult to prove that these injuries were caused by Seroquel. Therefore, we suggest that if your case falls into this category you should choose Track 1. Additionally, payment of Track I settlement awards will be processed first once AstaZeneca waives its "walk away right". (See Section IV© below) Track II involves an in-depth review of the severity of the injury, the claimed use of Seroquel and its proximity to the injury as well the available proof found in the contemporaneous medical records. Additionally, Judge Corodemus will strongly consider many known risk factors for these injuries including but not limited to smoking, obesity and family history as well as the participation in the Zyprexa settlement for these same injuries. This model is very similar to the one used in the National Vioxx Settlement Program as well as dozens of other similar settlement programs which were successfully resolved in recent years. Judge Corodemus has established a points system and will consider all of the critical issues including but not limited to: - Nature of the injury - Severity of the injury - Age at the time of injury - Proximity of Seroquel use to the claimed injury - Changes in the Seroque11abel - Risk Factors including Smoking, Body Mass Index, etc. After carefully reviewing all of the medical records and the individual fact sheet, Judge Corodemus will assign a point value to each case. The more points a case is awarded based on the specific facts of the case, the larger the settlement will be. At this time, there is no way to predict with accuracy how many points an individual case may be awarded and it is even more difficult to determine how much money each point will receive. The exact value of each point will depend on the number of participants in Track II and the total number of points assigned. All cases in Track II will be eligible for a settlement award but Judge Corodemus could award LESS than $12,000 (what people will receive automatically by choosing Track 1) if the case lacks merit. In the interest of fairness, Judge Corodemus has committed to review each case in Track II very carefully and this process will take time to complete. Judge Corodemus has stated that she hopes to have this process completed by the end of 2011 but please be warned that it could take a little longer due to the amount of work that is involved. However, in order to get this settlement process moving forward and ultimately paid you must send us your signed Release form as soon as possible. If you choose Track I your settlement award of $12,000 is set. If you choose Track II, Judge Corodemus will review your claim and will issue an award. We expect that we will contact you in approximately November 2011 and notify you of your point award and the expected amount of your settlement. At that point, you will be given a choice to accept your award, appeal your award or withdraw from the settlement program. If you accept, we will forward your release to AstraZeneca for their review and approval. Please understand that this settlement is not official until we send AstraZeneca your signed Release Form, AstraZeneca approves it AND AstraZeneca waives its walk away right. In the interest of time, we are asking you to return your signed Release Form now so we can meet the tight deadlines associated with this settlement. If you are unhappy with your allocation amount and/or believe that your case involves "Extraordinary Injury or Circumstances" you have the right to appeal your award. Upon receipt of such an application, Judge Corodemus will re-review your records and make a final decision. Please be aware that there is no additional right of appeal (to Judge Corodemus or to any Court) once this final decision is made. If you decide to decline the settlement amount offered to you, you must notify us within ten days of your receipt of your allocation amount and your signed Release Form will no longer be valid. As in all settlements of this type, our agreement with the defendant depends on nearly full participation from all of our clients. Under the terms of our agreement, we must provide Qualifying Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once we reach this number, AstraZeneca's "walk away right" is officially waived. We strongly believe that our clients will agree that this settlement program offers the best possible terms and we expect that we will meet this requirement in the next 90-120 days. In order to meet this deadline we MUST have your complete cooperation and immediate response. Of course, if we do not meet this required number of responses, Astrazeneca can decide to withdraw its settlement offer to everyone whether one signed the Release Form or not. Therefore, time is of the essence. A. Release Form: Enclosed you will find a Release Form which you must sign in front of a notary in Order to participate in the settlement. If you have a spouse he/she must sign the Release Form as well. Attached to the Release Form will be an instruction sheet to guide you to ensure that this important form is signed the right way. A Release Form that is signed the wrong way or that is not witnessed (by a notary) is useless and will not be accepted by the defendants. The Release Form is your agreement to participate in the settlement program and at the same time discontinue your lawsuit in exchange for your settlement award. Please turn to Page 2 of the Release Form and complete the details of your Seroquel use. You may refer to Page 1 of the Brief Questionnaire which lists the Seroquel information that was found in your medical records or that you have previously provided to us. If this information is inaccurate, please cross it out and write in when you started and when you stopped taking Seroquel on BOTH the Release Form and the Brief Questionnaire. Due to the fast approaching deadlines, and our goal to get you your settlement processed and paid as quickly as possible, we MUST receive this signed release form back from you before August 31, 2011. Please use the envelope provided herein and return the signed and notarized release form today before you forget about it. Please note that once we submit your release form to AstraZeneca it can not be revoked. B. Track Selection Form: Enclosed you will find a "Track Selection Form" which is the form used to officially notify the Special Master which Track you want your case to follow. Please Note that there are 4 options on this form. You MUST check one of the Options. If you want to participate in this settlement, and we strongly think that you should, you must check either Track I OR Track II and you must sign the bottom of the form. Your Track selection cannot be changed and is considered final once the Judge's Allocations are made. In other words, a person who chooses Track II and is awarded less than $12,000 CANNOT then choose to go to Track 1 for a higher award. C. Brief Questionnaire: Enclosed you will find a 3 page Brief Questionnaire which has important information about your claim. For all claimants who choose to enter Track II, Judge Corodemus will be reviewing your medical records, your Fact Sheet and this Brief Questionnaire and will issue a point award. Judge Corodemus will consider the proof of your claim found in your medical records as well as the information that you provide in this Questionnaire. Therefore, it is important that you answer these questions honestly and completely and that they are consistent with what is found in your medical records. litigation and our conversations with our medical experts, it is clear that Seroquel lawsuits are very difficult to win, very expensive, and very time consuming to take through to trial, verdict and appeal. Over the past six years only I case (from W & L) of24,000 cases in the Country made it to and through trial. Countless other cases were prepared and then dismissed based on merit and/or inability to prove that Seroquel caused the injury. Just because an individual took Seroquel and suffered an injury like diabetes does not mean that such a case will win at trial. In order to succeed at trial, a plaintiff must prove both that Seroquel can cause such an injury in general AND that, within a reasonable degree of medical certainty, Seroquel caused this injury to this particular person (despite any individual risk factors such as smoking, weight, high blood sugar, family history etc.). We have told you in the past update letters that the Courts have consistently ruled in favor of the defendants on many of these issues and have prohibited medical experts from testifying because of a lack of scientific proof linking the plaintiff s injuries to his/her Seroquel use. It is also important to note that even if your case is able to advance past this judicial scrutiny, a trial of this magnitude will cost over $750,000 per case and many of these costs are reimbursed off of the top of a favorable verdict reducing the amount received by the plaintiff. Furthermore, any case that is won at trial will surely face a lengthy and hard-fought appeal. Finally, nearly all of the Seroquel cases are being handled by three judges. Even at an accelerated pace, the chances are slim that your case would be tried in the next 10 years if not longer. In taking all of these factors into consideration, and considering the issues of risk and reward, we believe that a settlement of this type offers you the most advantageous resolution possible. You will be notified once the Special Master issues your point award at which point you can appeal to the Special Master if you believe that your case involves extraordinary circumstances. Thereafter, the decision of the Special Master is final, binding and non-appealable. We have retained the Garretson Law Firm to negotiate any and all Federal and State liens (Medicare/Medicaid/SSI) that may be applicable in your case. The Garretson Firm is a specialist in this field and they have obtained excellent results in their negotiation of similar liens in other litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson Firm has already worked on thousands of other Seroquel cases and has been able to achieve excellent results in large part due to the volume of cases that they are able to include in a Global Resolution. At this time, the Garretson Firm has already negotiated with 44 individual states regarding Medicaid and they have reached an agreement to CAP Medicaid liens at a maximum of 20% of the settlement amount. Please see the enclosed blue booklet regarding governmental liens for more details. Additionally, please also be advised that if you or Weitz & Luxenberg are put on written notice of a private lien, for example from your medical provider, this lien must be resolved before any settlement proceeds can be distributed. If you have received any notice of a lien, please advise us immediately. The terms of your signed contingency fee agreement will be in effect. We have taken great effort to keep the case specific expenses as low as possible. Under the terms of your agreement, the contingency fee will be calculated after the expenses are deducted. Under the terms of our agreement with AstraZeneca, any interest earned on the settlement proceeds before allocation and payment to the individual clients will be used to offset the fixed costs of the Special Master and the Lien Administrator. Due to the low interest rates paid by all banks in this economy, we do not expect that there will be any leftover interest. However, in such a case, the leftover interest will be added to the settlement trust and will be distributed to all claimants as part of Judge Corodemus' allocation process. After careful analysis of the likelihood of success in the court system, as well as the cost and time elements involved, we strongly recommend that you AGREE to participate in this settlement. We are confident that this settlement is the best possible resolution of your claim especially in light of the history of this litigation. We expect that any case that does not agree to participate in this settlement will have a very difficult time navigating through the Court system and trial dates may not be set for many years. Moreover, as we have seen, these cases will be aggressively defended by AstraZeneca and we expect that we will receive motions to dismiss and unfavorable decisions from the Court on unsettled cases in the coming months. Moreover, if this settlement program is not successful (we fail to reach the 98% response rate) we highly doubt that we will ever obtain a settlement amount and terms as good as those contained in this program. While we hope that this letter and enclosures will help answer all of your questions, we understand that you may have additional questions for us. Please keep in mind that we are working very hard to evaluate each and every case individually and the many deadlines that are part of this settlement are fast approaching. Your case has been assigned to Judy Koenig. If you have an important question please call Judy Koenig at (800) 438-9786 and ask for extension 5860. If you reach a voice-mail, please leave a message and you will be called back as quickly as possible. Please do not leave multiple voicemail messages on the same day as that will slow down our ability to return your call. Additionally, if you have email access, please try to email your detailed questions to us at sqinfo@... and we will get back to you quickly. If this letter has successfully answered your questions, and you have decided to participate, please carefully follow the directions on the front page of the enclosed release form and send your signed and witnessed release formes), your Track Selection AND your Brief Questionnaire to us as soon as possible. If you still have questions after reviewing this letter and after speaking to us over the telephone and you would like to meet us in person, we will be happy to schedule a meeting in our office at your convenience. Finally, please remember that the detailed information regarding this settlement program is COMPLETELY CONFIDENTIAL and should not be shared or discussed with anyone. Sedgh, Esq Glenn Zuckerman, Esq.

[Guest guest]

"Awry," not "a rye" but I digress. This is exactly why I never urge anyone to sue. The deck is stacked against us in court and attorneys are looking for a quick and easy buck. No justice is to be had.TerrySent via BlackBerry by AT&TFrom: "jeremy9282" <jeremybryce1953@...>Sender: SSRI medications Date: Wed, 10 Aug 2011 12:02:28 -0000<SSRI medications >Reply SSRI medications Subject: SEROQUEL Law Firms have sold their clients down the river Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO REJECT this Insult on Top of Injury Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO REJECT this Insult on Top of InjuryI would like to thank a brave, courageous, and ethical anonymous source who has send in this letter correspondence they received from the law firm of Weitz & Luxenberg. This letter doesn't require a whole lot of commentary. It's obvious that Law Firms have sold their clients down the proverbial river while at the same time enriching themselves (who's best interest are you obligated too fulfill?). This settlement offer and the injured litigants legal representation has carried out a blatant miscarriage of justice, a forever horrible stain upon the American Justice system, and a orchestrated crime perpetrated upon victims of this well documented & evidenced unbridled & unregulated corporate criminal enterprise gone a rye.The time has now come for the victims to stand up to this criminal corporation "AstraZeneca" & their poison drug "Seroquel", to reject this horrible injustice and settlement offer. We want, what America & our Constitution promises us all, our day in court before a jury of our peers....____________________________________________________________Weitz & Luxenberg P.C.We are happy to report excellent news! After a long and hard fought legal battle, AstraZeneca has agreed to participate in a Settlement Program to resolve Weitz & Luxenberg ("W & L") Seroguel cases. Our patience and aggressive litigating has resulted in very favorable settlement terms for our clients which will be further outlined below. We have carefully reviewed all of the factors of this agreement and we believe that this settlement offers you the best, and very likely the only opportunity to receive a fair resolution of your lawsuit. Therefore, we strongly recommend that you sign and complete the enclosed "Release Form", "Track Selection Form" and "Brief Questionnaire" and AGREE to participate. As you know, we have engaged in a long legal battle with AstraZeneca over the past 6 years. Weitz & Luxenberg led the charge for the Plaintiffs around the Country. AstraZeneca put up a tremendous and expensive defense and they successfully were able to get a large number of cases to be permanently dismissed by the court. Weitz & Luxenberg is the only firm who took a case to trial anywhere in the Country. However, after a month-long trial, the jury unfortunately ruled in favor of the defendants. This loss did not affect the strength of our fight. Over the past year, even as almost every other plaintiffs firm settled their cases, Weitz & Luxenberg prepared two more cases for trial which was scheduled to begin this Summer. As a direct result of the endless and consistent pressure applied by the attorneys at Weitz & Luxenberg, we are happy to report that AstraZeneca has now agreed to participate in a favorable settlement program. Based on public reports regarding settlement programs reached with other plaintiff law firms we are confident that the settlement program outlined below has more favorable terms and for this reason we are recommending your participation.The defendants have argued that they refuse to pay anyone who cannot prove through medical records or via certification that they have used Seroquel. They also refuse to pay anyone whose case is not active in this litigation. We recently told you about the Order issued by the Court requiring you to confirm when you started taking Seroquel and when you stopped taking Seroquel. We cannot stress enough that you MUST read, complete and return this certification form to us immediately. The failure to return this form within the next 30 days will result in the permanent dismissal of your case. In order to protect your legal rights, to keep your case active and be permitted to participate in this Settlement Program you must take this Order very seriously and you must respond.Based on our experience in other litigations and having reviewed the media reports of the terms of other firms' Seroquel settlement programs, we know that the defendants are looking for a settlement program that includes all claimants (W & L Seroquel Plaintiffs) so that they will achieve complete closure of the entirYlitigation. Our goal in this negotiation was to obtain a settlement for the most amount of money using a fair method to pay our clients based upon the merits of their individual case. We also stressed our intentions that the case review and payment process be performed quickly yet fairly so that our clients can receive their settlements as soon as possible. A key part of this settlement program is that a claimant cannot be part of the settlement if their case is dismissed and unless they provide, at the very least, a certification that they in fact took Seroquel and suffered an injury. Therefore, please make sure that you return your certification form to us immediatelyWe have hired Hon.Marina Corodemus to act as the Special Master for the W & L Seroquel settlement program. Judge Corodemus previously ran the New Jersey Mass Tort Court and has a lot of experience in this field. She was appointed as a Special Master by the Vioxx State and Federal Court Judges to determine the appropriateness of Vioxx settlements and to resolve Vioxx appeals. She has also served as the Special Master in many other litigations such as Bextra and Celebrex which used similar settlement terms. We have met several times with Judge Corodemus and discussed the goals outlined above to get the most amount of money to the most amount of claimants in the fastest amount of time possible. We believe that Judge Corodemus is the perfect choice to create and oversee a settlement program in accordance with these goals. The W & L Seroquel Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only those clients with active cases (not dismissed as outlined above) can participate in this settlement program. Unlike other settlement programs that you may have read about in the media and internet, the W & L Settlement program does not award every case an equal settlement amount. The size of an individual's settlement will depend entirely on the merit of that individual's case. As a direct result of the large number of cases represented by W & L, and the merits of those cases, we are confident that we have obtained the best possible settlement for our clients. After complex negotiations, AstraZeneca has agreed to deposit $92.25 Million dollars into a trust account to be used for this Settlement Program. This amount is completely confidential and you should NOT discuss this with anyone. A settlement of this type is called an "Aggregate Settlement" where a fair and reasonable sum of money is obtained to resolve multiple cases. In order to maintain proper representation of each individual client, W & L is NOT involved in the allocation decision making, which will be handled exclusively by Judge Corodemus. W & L has reviewed the general framework of the settlement plan with Judge Corodemus and we strongly believe that it is fair and reasonable and offers each of our clients the best possible outcome under the circumstances of this litigation. Track I offers the Seroquel claimant a settlement of $12,000. This track involves a simple review of each case and will result in a quick approval by Judge Corodemus without an analysis of the specific details of the case such as injury, amount of Seroquel taken, how close the last Seroquel use was to the date of the injury or the individual claimant's risk factors. a) Cannot prove that they suffered diabetes or a diabetes related condition, and/or Cannot prove that they used Seroquel within 1 year of their claimed injury, and/or c) Had a large number of known risk factors for diabetes before they started taking Seroquel. For example - obesity, family history, smoking, etc.Therefore, all cases whose injuries are limited to weight gain or high blood sugar and whose medical records will confirm that they were never diagnosed with diabetes or pancreatitis, should choose Track 1. Similarly, any claimed injury that occurred long after the last use of Seroquel should also choose Track 1. These cases are likely to receive a small award in Track II (likely less than $12,000) because it is extremely difficult to prove that these injuries were caused by Seroquel. Therefore, we suggest that if your case falls into this category you should choose Track 1. Additionally, payment of Track I settlement awards will be processed first once AstaZeneca waives its "walk away right". (See Section IV© below) Track II involves an in-depth review of the severity of the injury, the claimed use of Seroquel and its proximity to the injury as well the available proof found in the contemporaneous medical records. Additionally, Judge Corodemus will strongly consider many known risk factors for these injuries including but not limited to smoking, obesity and family history as well as the participation in the Zyprexa settlement for these same injuries. This model is very similar to the one used in the National Vioxx Settlement Program as well as dozens of other similar settlement programs which were successfully resolved in recent years. Judge Corodemus has established a points system and will consider all of the critical issues including but not limited to: - Nature of the injury - Severity of the injury - Age at the time of injury - Proximity of Seroquel use to the claimed injury - Changes in the Seroque11abel - Risk Factors including Smoking, Body Mass Index, etc. After carefully reviewing all of the medical records and the individual fact sheet, Judge Corodemus will assign a point value to each case. The more points a case is awarded based on the specific facts of the case, the larger the settlement will be. At this time, there is no way to predict with accuracy how many points an individual case may be awarded and it is even more difficult to determine how much money each point will receive. The exact value of each point will depend on the number of participants in Track II and the total number of points assigned. All cases in Track II will be eligible for a settlement award but Judge Corodemus could award LESS than $12,000 (what people will receive automatically by choosing Track 1) if the case lacks merit. In the interest of fairness, Judge Corodemus has committed to review each case in Track II very carefully and this process will take time to complete. Judge Corodemus has stated that she hopes to have this process completed by the end of 2011 but please be warned that it could take a little longer due to the amount of work that is involved. However, in order to get this settlement process moving forward and ultimately paid you must send us your signed Release form as soon as possible. If you choose Track I your settlement award of $12,000 is set. If you choose Track II, Judge Corodemus will review your claim and will issue an award. We expect that we will contact you in approximately November 2011 and notify you of your point award and the expected amount of your settlement. At that point, you will be given a choice to accept your award, appeal your award or withdraw from the settlement program. If you accept, we will forward your release to AstraZeneca for their review and approval. Please understand that this settlement is not official until we send AstraZeneca your signed Release Form, AstraZeneca approves it AND AstraZeneca waives its walk away right. In the interest of time, we are asking you to return your signed Release Form now so we can meet the tight deadlines associated with this settlement. If you are unhappy with your allocation amount and/or believe that your case involves "Extraordinary Injury or Circumstances" you have the right to appeal your award. Upon receipt of such an application, Judge Corodemus will re-review your records and make a final decision. Please be aware that there is no additional right of appeal (to Judge Corodemus or to any Court) once this final decision is made. If you decide to decline the settlement amount offered to you, you must notify us within ten days of your receipt of your allocation amount and your signed Release Form will no longer be valid. As in all settlements of this type, our agreement with the defendant depends on nearly full participation from all of our clients. Under the terms of our agreement, we must provide Qualifying Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once we reach this number, AstraZeneca's "walk away right" is officially waived. We strongly believe that our clients will agree that this settlement program offers the best possible terms and we expect that we will meet this requirement in the next 90-120 days. In order to meet this deadline we MUST have your complete cooperation and immediate response. Of course, if we do not meet this required number of responses, Astrazeneca can decide to withdraw its settlement offer to everyone whether one signed the Release Form or not. Therefore, time is of the essence. A. Release Form: Enclosed you will find a Release Form which you must sign in front of a notary in Order to participate in the settlement. If you have a spouse he/she must sign the Release Form as well. Attached to the Release Form will be an instruction sheet to guide you to ensure that this important form is signed the right way. A Release Form that is signed the wrong way or that is not witnessed (by a notary) is useless and will not be accepted by the defendants. The Release Form is your agreement to participate in the settlement program and at the same time discontinue your lawsuit in exchange for your settlement award. Please turn to Page 2 of the Release Form and complete the details of your Seroquel use. You may refer to Page 1 of the Brief Questionnaire which lists the Seroquel information that was found in your medical records or that you have previously provided to us. If this information is inaccurate, please cross it out and write in when you started and when you stopped taking Seroquel on BOTH the Release Form and the Brief Questionnaire. Due to the fast approaching deadlines, and our goal to get you your settlement processed and paid as quickly as possible, we MUST receive this signed release form back from you before August 31, 2011. Please use the envelope provided herein and return the signed and notarized release form today before you forget about it. Please note that once we submit your release form to AstraZeneca it can not be revoked. B. Track Selection Form: Enclosed you will find a "Track Selection Form" which is the form used to officially notify the Special Master which Track you want your case to follow. Please Note that there are 4 options on this form. You MUST check one of the Options. If you want to participate in this settlement, and we strongly think that you should, you must check either Track I OR Track II and you must sign the bottom of the form. Your Track selection cannot be changed and is considered final once the Judge's Allocations are made. In other words, a person who chooses Track II and is awarded less than $12,000 CANNOT then choose to go to Track 1 for a higher award. C. Brief Questionnaire: Enclosed you will find a 3 page Brief Questionnaire which has important information about your claim. For all claimants who choose to enter Track II, Judge Corodemus will be reviewing your medical records, your Fact Sheet and this Brief Questionnaire and will issue a point award. Judge Corodemus will consider the proof of your claim found in your medical records as well as the information that you provide in this Questionnaire. Therefore, it is important that you answer these questions honestly and completely and that they are consistent with what is found in your medical records. litigation and our conversations with our medical experts, it is clear that Seroquel lawsuits are very difficult to win, very expensive, and very time consuming to take through to trial, verdict and appeal. Over the past six years only I case (from W & L) of24,000 cases in the Country made it to and through trial. Countless other cases were prepared and then dismissed based on merit and/or inability to prove that Seroquel caused the injury. Just because an individual took Seroquel and suffered an injury like diabetes does not mean that such a case will win at trial. In order to succeed at trial, a plaintiff must prove both that Seroquel can cause such an injury in general AND that, within a reasonable degree of medical certainty, Seroquel caused this injury to this particular person (despite any individual risk factors such as smoking, weight, high blood sugar, family history etc.). We have told you in the past update letters that the Courts have consistently ruled in favor of the defendants on many of these issues and have prohibited medical experts from testifying because of a lack of scientific proof linking the plaintiff s injuries to his/her Seroquel use. It is also important to note that even if your case is able to advance past this judicial scrutiny, a trial of this magnitude will cost over $750,000 per case and many of these costs are reimbursed off of the top of a favorable verdict reducing the amount received by the plaintiff. Furthermore, any case that is won at trial will surely face a lengthy and hard-fought appeal. Finally, nearly all of the Seroquel cases are being handled by three judges. Even at an accelerated pace, the chances are slim that your case would be tried in the next 10 years if not longer. In taking all of these factors into consideration, and considering the issues of risk and reward, we believe that a settlement of this type offers you the most advantageous resolution possible. You will be notified once the Special Master issues your point award at which point you can appeal to the Special Master if you believe that your case involves extraordinary circumstances. Thereafter, the decision of the Special Master is final, binding and non-appealable. We have retained the Garretson Law Firm to negotiate any and all Federal and State liens (Medicare/Medicaid/SSI) that may be applicable in your case. The Garretson Firm is a specialist in this field and they have obtained excellent results in their negotiation of similar liens in other litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson Firm has already worked on thousands of other Seroquel cases and has been able to achieve excellent results in large part due to the volume of cases that they are able to include in a Global Resolution. At this time, the Garretson Firm has already negotiated with 44 individual states regarding Medicaid and they have reached an agreement to CAP Medicaid liens at a maximum of 20% of the settlement amount. Please see the enclosed blue booklet regarding governmental liens for more details. Additionally, please also be advised that if you or Weitz & Luxenberg are put on written notice of a private lien, for example from your medical provider, this lien must be resolved before any settlement proceeds can be distributed. If you have received any notice of a lien, please advise us immediately. The terms of your signed contingency fee agreement will be in effect. We have taken great effort to keep the case specific expenses as low as possible. Under the terms of your agreement, the contingency fee will be calculated after the expenses are deducted. Under the terms of our agreement with AstraZeneca, any interest earned on the settlement proceeds before allocation and payment to the individual clients will be used to offset the fixed costs of the Special Master and the Lien Administrator. Due to the low interest rates paid by all banks in this economy, we do not expect that there will be any leftover interest. However, in such a case, the leftover interest will be added to the settlement trust and will be distributed to all claimants as part of Judge Corodemus' allocation process. After careful analysis of the likelihood of success in the court system, as well as the cost and time elements involved, we strongly recommend that you AGREE to participate in this settlement. We are confident that this settlement is the best possible resolution of your claim especially in light of the history of this litigation. We expect that any case that does not agree to participate in this settlement will have a very difficult time navigating through the Court system and trial dates may not be set for many years. Moreover, as we have seen, these cases will be aggressively defended by AstraZeneca and we expect that we will receive motions to dismiss and unfavorable decisions from the Court on unsettled cases in the coming months. Moreover, if this settlement program is not successful (we fail to reach the 98% response rate) we highly doubt that we will ever obtain a settlement amount and terms as good as those contained in this program. While we hope that this letter and enclosures will help answer all of your questions, we understand that you may have additional questions for us. Please keep in mind that we are working very hard to evaluate each and every case individually and the many deadlines that are part of this settlement are fast approaching. Your case has been assigned to Judy Koenig. If you have an important question please call Judy Koenig at (800) 438-9786 and ask for extension 5860. If you reach a voice-mail, please leave a message and you will be called back as quickly as possible. Please do not leave multiple voicemail messages on the same day as that will slow down our ability to return your call. Additionally, if you have email access, please try to email your detailed questions to us at sqinfo@... and we will get back to you quickly. If this letter has successfully answered your questions, and you have decided to participate, please carefully follow the directions on the front page of the enclosed release form and send your signed and witnessed release formes), your Track Selection AND your Brief Questionnaire to us as soon as possible. If you still have questions after reviewing this letter and after speaking to us over the telephone and you would like to meet us in person, we will be happy to schedule a meeting in our office at your convenience. Finally, please remember that the detailed information regarding this settlement program is COMPLETELY CONFIDENTIAL and should not be shared or discussed with anyone. Sedgh, Esq Glenn Zuckerman, Esq.

[Guest guest]

"Awry," not "a rye" but I digress. This is exactly why I never urge anyone to sue. The deck is stacked against us in court and attorneys are looking for a quick and easy buck. No justice is to be had.TerrySent via BlackBerry by AT&TFrom: "jeremy9282" <jeremybryce1953@...>Sender: SSRI medications Date: Wed, 10 Aug 2011 12:02:28 -0000<SSRI medications >Reply SSRI medications Subject: SEROQUEL Law Firms have sold their clients down the river Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO REJECT this Insult on Top of Injury Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO REJECT this Insult on Top of InjuryI would like to thank a brave, courageous, and ethical anonymous source who has send in this letter correspondence they received from the law firm of Weitz & Luxenberg. This letter doesn't require a whole lot of commentary. It's obvious that Law Firms have sold their clients down the proverbial river while at the same time enriching themselves (who's best interest are you obligated too fulfill?). This settlement offer and the injured litigants legal representation has carried out a blatant miscarriage of justice, a forever horrible stain upon the American Justice system, and a orchestrated crime perpetrated upon victims of this well documented & evidenced unbridled & unregulated corporate criminal enterprise gone a rye.The time has now come for the victims to stand up to this criminal corporation "AstraZeneca" & their poison drug "Seroquel", to reject this horrible injustice and settlement offer. We want, what America & our Constitution promises us all, our day in court before a jury of our peers....____________________________________________________________Weitz & Luxenberg P.C.We are happy to report excellent news! After a long and hard fought legal battle, AstraZeneca has agreed to participate in a Settlement Program to resolve Weitz & Luxenberg ("W & L") Seroguel cases. Our patience and aggressive litigating has resulted in very favorable settlement terms for our clients which will be further outlined below. We have carefully reviewed all of the factors of this agreement and we believe that this settlement offers you the best, and very likely the only opportunity to receive a fair resolution of your lawsuit. Therefore, we strongly recommend that you sign and complete the enclosed "Release Form", "Track Selection Form" and "Brief Questionnaire" and AGREE to participate. As you know, we have engaged in a long legal battle with AstraZeneca over the past 6 years. Weitz & Luxenberg led the charge for the Plaintiffs around the Country. AstraZeneca put up a tremendous and expensive defense and they successfully were able to get a large number of cases to be permanently dismissed by the court. Weitz & Luxenberg is the only firm who took a case to trial anywhere in the Country. However, after a month-long trial, the jury unfortunately ruled in favor of the defendants. This loss did not affect the strength of our fight. Over the past year, even as almost every other plaintiffs firm settled their cases, Weitz & Luxenberg prepared two more cases for trial which was scheduled to begin this Summer. As a direct result of the endless and consistent pressure applied by the attorneys at Weitz & Luxenberg, we are happy to report that AstraZeneca has now agreed to participate in a favorable settlement program. Based on public reports regarding settlement programs reached with other plaintiff law firms we are confident that the settlement program outlined below has more favorable terms and for this reason we are recommending your participation.The defendants have argued that they refuse to pay anyone who cannot prove through medical records or via certification that they have used Seroquel. They also refuse to pay anyone whose case is not active in this litigation. We recently told you about the Order issued by the Court requiring you to confirm when you started taking Seroquel and when you stopped taking Seroquel. We cannot stress enough that you MUST read, complete and return this certification form to us immediately. The failure to return this form within the next 30 days will result in the permanent dismissal of your case. In order to protect your legal rights, to keep your case active and be permitted to participate in this Settlement Program you must take this Order very seriously and you must respond.Based on our experience in other litigations and having reviewed the media reports of the terms of other firms' Seroquel settlement programs, we know that the defendants are looking for a settlement program that includes all claimants (W & L Seroquel Plaintiffs) so that they will achieve complete closure of the entirYlitigation. Our goal in this negotiation was to obtain a settlement for the most amount of money using a fair method to pay our clients based upon the merits of their individual case. We also stressed our intentions that the case review and payment process be performed quickly yet fairly so that our clients can receive their settlements as soon as possible. A key part of this settlement program is that a claimant cannot be part of the settlement if their case is dismissed and unless they provide, at the very least, a certification that they in fact took Seroquel and suffered an injury. Therefore, please make sure that you return your certification form to us immediatelyWe have hired Hon.Marina Corodemus to act as the Special Master for the W & L Seroquel settlement program. Judge Corodemus previously ran the New Jersey Mass Tort Court and has a lot of experience in this field. She was appointed as a Special Master by the Vioxx State and Federal Court Judges to determine the appropriateness of Vioxx settlements and to resolve Vioxx appeals. She has also served as the Special Master in many other litigations such as Bextra and Celebrex which used similar settlement terms. We have met several times with Judge Corodemus and discussed the goals outlined above to get the most amount of money to the most amount of claimants in the fastest amount of time possible. We believe that Judge Corodemus is the perfect choice to create and oversee a settlement program in accordance with these goals. The W & L Seroquel Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only those clients with active cases (not dismissed as outlined above) can participate in this settlement program. Unlike other settlement programs that you may have read about in the media and internet, the W & L Settlement program does not award every case an equal settlement amount. The size of an individual's settlement will depend entirely on the merit of that individual's case. As a direct result of the large number of cases represented by W & L, and the merits of those cases, we are confident that we have obtained the best possible settlement for our clients. After complex negotiations, AstraZeneca has agreed to deposit $92.25 Million dollars into a trust account to be used for this Settlement Program. This amount is completely confidential and you should NOT discuss this with anyone. A settlement of this type is called an "Aggregate Settlement" where a fair and reasonable sum of money is obtained to resolve multiple cases. In order to maintain proper representation of each individual client, W & L is NOT involved in the allocation decision making, which will be handled exclusively by Judge Corodemus. W & L has reviewed the general framework of the settlement plan with Judge Corodemus and we strongly believe that it is fair and reasonable and offers each of our clients the best possible outcome under the circumstances of this litigation. Track I offers the Seroquel claimant a settlement of $12,000. This track involves a simple review of each case and will result in a quick approval by Judge Corodemus without an analysis of the specific details of the case such as injury, amount of Seroquel taken, how close the last Seroquel use was to the date of the injury or the individual claimant's risk factors. a) Cannot prove that they suffered diabetes or a diabetes related condition, and/or Cannot prove that they used Seroquel within 1 year of their claimed injury, and/or c) Had a large number of known risk factors for diabetes before they started taking Seroquel. For example - obesity, family history, smoking, etc.Therefore, all cases whose injuries are limited to weight gain or high blood sugar and whose medical records will confirm that they were never diagnosed with diabetes or pancreatitis, should choose Track 1. Similarly, any claimed injury that occurred long after the last use of Seroquel should also choose Track 1. These cases are likely to receive a small award in Track II (likely less than $12,000) because it is extremely difficult to prove that these injuries were caused by Seroquel. Therefore, we suggest that if your case falls into this category you should choose Track 1. Additionally, payment of Track I settlement awards will be processed first once AstaZeneca waives its "walk away right". (See Section IV© below) Track II involves an in-depth review of the severity of the injury, the claimed use of Seroquel and its proximity to the injury as well the available proof found in the contemporaneous medical records. Additionally, Judge Corodemus will strongly consider many known risk factors for these injuries including but not limited to smoking, obesity and family history as well as the participation in the Zyprexa settlement for these same injuries. This model is very similar to the one used in the National Vioxx Settlement Program as well as dozens of other similar settlement programs which were successfully resolved in recent years. Judge Corodemus has established a points system and will consider all of the critical issues including but not limited to: - Nature of the injury - Severity of the injury - Age at the time of injury - Proximity of Seroquel use to the claimed injury - Changes in the Seroque11abel - Risk Factors including Smoking, Body Mass Index, etc. After carefully reviewing all of the medical records and the individual fact sheet, Judge Corodemus will assign a point value to each case. The more points a case is awarded based on the specific facts of the case, the larger the settlement will be. At this time, there is no way to predict with accuracy how many points an individual case may be awarded and it is even more difficult to determine how much money each point will receive. The exact value of each point will depend on the number of participants in Track II and the total number of points assigned. All cases in Track II will be eligible for a settlement award but Judge Corodemus could award LESS than $12,000 (what people will receive automatically by choosing Track 1) if the case lacks merit. In the interest of fairness, Judge Corodemus has committed to review each case in Track II very carefully and this process will take time to complete. Judge Corodemus has stated that she hopes to have this process completed by the end of 2011 but please be warned that it could take a little longer due to the amount of work that is involved. However, in order to get this settlement process moving forward and ultimately paid you must send us your signed Release form as soon as possible. If you choose Track I your settlement award of $12,000 is set. If you choose Track II, Judge Corodemus will review your claim and will issue an award. We expect that we will contact you in approximately November 2011 and notify you of your point award and the expected amount of your settlement. At that point, you will be given a choice to accept your award, appeal your award or withdraw from the settlement program. If you accept, we will forward your release to AstraZeneca for their review and approval. Please understand that this settlement is not official until we send AstraZeneca your signed Release Form, AstraZeneca approves it AND AstraZeneca waives its walk away right. In the interest of time, we are asking you to return your signed Release Form now so we can meet the tight deadlines associated with this settlement. If you are unhappy with your allocation amount and/or believe that your case involves "Extraordinary Injury or Circumstances" you have the right to appeal your award. Upon receipt of such an application, Judge Corodemus will re-review your records and make a final decision. Please be aware that there is no additional right of appeal (to Judge Corodemus or to any Court) once this final decision is made. If you decide to decline the settlement amount offered to you, you must notify us within ten days of your receipt of your allocation amount and your signed Release Form will no longer be valid. As in all settlements of this type, our agreement with the defendant depends on nearly full participation from all of our clients. Under the terms of our agreement, we must provide Qualifying Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once we reach this number, AstraZeneca's "walk away right" is officially waived. We strongly believe that our clients will agree that this settlement program offers the best possible terms and we expect that we will meet this requirement in the next 90-120 days. In order to meet this deadline we MUST have your complete cooperation and immediate response. Of course, if we do not meet this required number of responses, Astrazeneca can decide to withdraw its settlement offer to everyone whether one signed the Release Form or not. Therefore, time is of the essence. A. Release Form: Enclosed you will find a Release Form which you must sign in front of a notary in Order to participate in the settlement. If you have a spouse he/she must sign the Release Form as well. Attached to the Release Form will be an instruction sheet to guide you to ensure that this important form is signed the right way. A Release Form that is signed the wrong way or that is not witnessed (by a notary) is useless and will not be accepted by the defendants. The Release Form is your agreement to participate in the settlement program and at the same time discontinue your lawsuit in exchange for your settlement award. Please turn to Page 2 of the Release Form and complete the details of your Seroquel use. You may refer to Page 1 of the Brief Questionnaire which lists the Seroquel information that was found in your medical records or that you have previously provided to us. If this information is inaccurate, please cross it out and write in when you started and when you stopped taking Seroquel on BOTH the Release Form and the Brief Questionnaire. Due to the fast approaching deadlines, and our goal to get you your settlement processed and paid as quickly as possible, we MUST receive this signed release form back from you before August 31, 2011. Please use the envelope provided herein and return the signed and notarized release form today before you forget about it. Please note that once we submit your release form to AstraZeneca it can not be revoked. B. Track Selection Form: Enclosed you will find a "Track Selection Form" which is the form used to officially notify the Special Master which Track you want your case to follow. Please Note that there are 4 options on this form. You MUST check one of the Options. If you want to participate in this settlement, and we strongly think that you should, you must check either Track I OR Track II and you must sign the bottom of the form. Your Track selection cannot be changed and is considered final once the Judge's Allocations are made. In other words, a person who chooses Track II and is awarded less than $12,000 CANNOT then choose to go to Track 1 for a higher award. C. Brief Questionnaire: Enclosed you will find a 3 page Brief Questionnaire which has important information about your claim. For all claimants who choose to enter Track II, Judge Corodemus will be reviewing your medical records, your Fact Sheet and this Brief Questionnaire and will issue a point award. Judge Corodemus will consider the proof of your claim found in your medical records as well as the information that you provide in this Questionnaire. Therefore, it is important that you answer these questions honestly and completely and that they are consistent with what is found in your medical records. litigation and our conversations with our medical experts, it is clear that Seroquel lawsuits are very difficult to win, very expensive, and very time consuming to take through to trial, verdict and appeal. Over the past six years only I case (from W & L) of24,000 cases in the Country made it to and through trial. Countless other cases were prepared and then dismissed based on merit and/or inability to prove that Seroquel caused the injury. Just because an individual took Seroquel and suffered an injury like diabetes does not mean that such a case will win at trial. In order to succeed at trial, a plaintiff must prove both that Seroquel can cause such an injury in general AND that, within a reasonable degree of medical certainty, Seroquel caused this injury to this particular person (despite any individual risk factors such as smoking, weight, high blood sugar, family history etc.). We have told you in the past update letters that the Courts have consistently ruled in favor of the defendants on many of these issues and have prohibited medical experts from testifying because of a lack of scientific proof linking the plaintiff s injuries to his/her Seroquel use. It is also important to note that even if your case is able to advance past this judicial scrutiny, a trial of this magnitude will cost over $750,000 per case and many of these costs are reimbursed off of the top of a favorable verdict reducing the amount received by the plaintiff. Furthermore, any case that is won at trial will surely face a lengthy and hard-fought appeal. Finally, nearly all of the Seroquel cases are being handled by three judges. Even at an accelerated pace, the chances are slim that your case would be tried in the next 10 years if not longer. In taking all of these factors into consideration, and considering the issues of risk and reward, we believe that a settlement of this type offers you the most advantageous resolution possible. You will be notified once the Special Master issues your point award at which point you can appeal to the Special Master if you believe that your case involves extraordinary circumstances. Thereafter, the decision of the Special Master is final, binding and non-appealable. We have retained the Garretson Law Firm to negotiate any and all Federal and State liens (Medicare/Medicaid/SSI) that may be applicable in your case. The Garretson Firm is a specialist in this field and they have obtained excellent results in their negotiation of similar liens in other litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson Firm has already worked on thousands of other Seroquel cases and has been able to achieve excellent results in large part due to the volume of cases that they are able to include in a Global Resolution. At this time, the Garretson Firm has already negotiated with 44 individual states regarding Medicaid and they have reached an agreement to CAP Medicaid liens at a maximum of 20% of the settlement amount. Please see the enclosed blue booklet regarding governmental liens for more details. Additionally, please also be advised that if you or Weitz & Luxenberg are put on written notice of a private lien, for example from your medical provider, this lien must be resolved before any settlement proceeds can be distributed. If you have received any notice of a lien, please advise us immediately. The terms of your signed contingency fee agreement will be in effect. We have taken great effort to keep the case specific expenses as low as possible. Under the terms of your agreement, the contingency fee will be calculated after the expenses are deducted. Under the terms of our agreement with AstraZeneca, any interest earned on the settlement proceeds before allocation and payment to the individual clients will be used to offset the fixed costs of the Special Master and the Lien Administrator. Due to the low interest rates paid by all banks in this economy, we do not expect that there will be any leftover interest. However, in such a case, the leftover interest will be added to the settlement trust and will be distributed to all claimants as part of Judge Corodemus' allocation process. After careful analysis of the likelihood of success in the court system, as well as the cost and time elements involved, we strongly recommend that you AGREE to participate in this settlement. We are confident that this settlement is the best possible resolution of your claim especially in light of the history of this litigation. We expect that any case that does not agree to participate in this settlement will have a very difficult time navigating through the Court system and trial dates may not be set for many years. Moreover, as we have seen, these cases will be aggressively defended by AstraZeneca and we expect that we will receive motions to dismiss and unfavorable decisions from the Court on unsettled cases in the coming months. Moreover, if this settlement program is not successful (we fail to reach the 98% response rate) we highly doubt that we will ever obtain a settlement amount and terms as good as those contained in this program. While we hope that this letter and enclosures will help answer all of your questions, we understand that you may have additional questions for us. Please keep in mind that we are working very hard to evaluate each and every case individually and the many deadlines that are part of this settlement are fast approaching. Your case has been assigned to Judy Koenig. If you have an important question please call Judy Koenig at (800) 438-9786 and ask for extension 5860. If you reach a voice-mail, please leave a message and you will be called back as quickly as possible. Please do not leave multiple voicemail messages on the same day as that will slow down our ability to return your call. Additionally, if you have email access, please try to email your detailed questions to us at sqinfo@... and we will get back to you quickly. If this letter has successfully answered your questions, and you have decided to participate, please carefully follow the directions on the front page of the enclosed release form and send your signed and witnessed release formes), your Track Selection AND your Brief Questionnaire to us as soon as possible. If you still have questions after reviewing this letter and after speaking to us over the telephone and you would like to meet us in person, we will be happy to schedule a meeting in our office at your convenience. Finally, please remember that the detailed information regarding this settlement program is COMPLETELY CONFIDENTIAL and should not be shared or discussed with anyone. Sedgh, Esq Glenn Zuckerman, Esq.

[Guest guest]

"Awry," not "a rye" but I digress. This is exactly why I never urge anyone to sue. The deck is stacked against us in court and attorneys are looking for a quick and easy buck. No justice is to be had.TerrySent via BlackBerry by AT&TFrom: "jeremy9282" <jeremybryce1953@...>Sender: SSRI medications Date: Wed, 10 Aug 2011 12:02:28 -0000<SSRI medications >Reply SSRI medications Subject: SEROQUEL Law Firms have sold their clients down the river Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO REJECT this Insult on Top of Injury Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO REJECT this Insult on Top of InjuryI would like to thank a brave, courageous, and ethical anonymous source who has send in this letter correspondence they received from the law firm of Weitz & Luxenberg. This letter doesn't require a whole lot of commentary. It's obvious that Law Firms have sold their clients down the proverbial river while at the same time enriching themselves (who's best interest are you obligated too fulfill?). This settlement offer and the injured litigants legal representation has carried out a blatant miscarriage of justice, a forever horrible stain upon the American Justice system, and a orchestrated crime perpetrated upon victims of this well documented & evidenced unbridled & unregulated corporate criminal enterprise gone a rye.The time has now come for the victims to stand up to this criminal corporation "AstraZeneca" & their poison drug "Seroquel", to reject this horrible injustice and settlement offer. We want, what America & our Constitution promises us all, our day in court before a jury of our peers....____________________________________________________________Weitz & Luxenberg P.C.We are happy to report excellent news! After a long and hard fought legal battle, AstraZeneca has agreed to participate in a Settlement Program to resolve Weitz & Luxenberg ("W & L") Seroguel cases. Our patience and aggressive litigating has resulted in very favorable settlement terms for our clients which will be further outlined below. We have carefully reviewed all of the factors of this agreement and we believe that this settlement offers you the best, and very likely the only opportunity to receive a fair resolution of your lawsuit. Therefore, we strongly recommend that you sign and complete the enclosed "Release Form", "Track Selection Form" and "Brief Questionnaire" and AGREE to participate. As you know, we have engaged in a long legal battle with AstraZeneca over the past 6 years. Weitz & Luxenberg led the charge for the Plaintiffs around the Country. AstraZeneca put up a tremendous and expensive defense and they successfully were able to get a large number of cases to be permanently dismissed by the court. Weitz & Luxenberg is the only firm who took a case to trial anywhere in the Country. However, after a month-long trial, the jury unfortunately ruled in favor of the defendants. This loss did not affect the strength of our fight. Over the past year, even as almost every other plaintiffs firm settled their cases, Weitz & Luxenberg prepared two more cases for trial which was scheduled to begin this Summer. As a direct result of the endless and consistent pressure applied by the attorneys at Weitz & Luxenberg, we are happy to report that AstraZeneca has now agreed to participate in a favorable settlement program. Based on public reports regarding settlement programs reached with other plaintiff law firms we are confident that the settlement program outlined below has more favorable terms and for this reason we are recommending your participation.The defendants have argued that they refuse to pay anyone who cannot prove through medical records or via certification that they have used Seroquel. They also refuse to pay anyone whose case is not active in this litigation. We recently told you about the Order issued by the Court requiring you to confirm when you started taking Seroquel and when you stopped taking Seroquel. We cannot stress enough that you MUST read, complete and return this certification form to us immediately. The failure to return this form within the next 30 days will result in the permanent dismissal of your case. In order to protect your legal rights, to keep your case active and be permitted to participate in this Settlement Program you must take this Order very seriously and you must respond.Based on our experience in other litigations and having reviewed the media reports of the terms of other firms' Seroquel settlement programs, we know that the defendants are looking for a settlement program that includes all claimants (W & L Seroquel Plaintiffs) so that they will achieve complete closure of the entirYlitigation. Our goal in this negotiation was to obtain a settlement for the most amount of money using a fair method to pay our clients based upon the merits of their individual case. We also stressed our intentions that the case review and payment process be performed quickly yet fairly so that our clients can receive their settlements as soon as possible. A key part of this settlement program is that a claimant cannot be part of the settlement if their case is dismissed and unless they provide, at the very least, a certification that they in fact took Seroquel and suffered an injury. Therefore, please make sure that you return your certification form to us immediatelyWe have hired Hon.Marina Corodemus to act as the Special Master for the W & L Seroquel settlement program. Judge Corodemus previously ran the New Jersey Mass Tort Court and has a lot of experience in this field. She was appointed as a Special Master by the Vioxx State and Federal Court Judges to determine the appropriateness of Vioxx settlements and to resolve Vioxx appeals. She has also served as the Special Master in many other litigations such as Bextra and Celebrex which used similar settlement terms. We have met several times with Judge Corodemus and discussed the goals outlined above to get the most amount of money to the most amount of claimants in the fastest amount of time possible. We believe that Judge Corodemus is the perfect choice to create and oversee a settlement program in accordance with these goals. The W & L Seroquel Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only those clients with active cases (not dismissed as outlined above) can participate in this settlement program. Unlike other settlement programs that you may have read about in the media and internet, the W & L Settlement program does not award every case an equal settlement amount. The size of an individual's settlement will depend entirely on the merit of that individual's case. As a direct result of the large number of cases represented by W & L, and the merits of those cases, we are confident that we have obtained the best possible settlement for our clients. After complex negotiations, AstraZeneca has agreed to deposit $92.25 Million dollars into a trust account to be used for this Settlement Program. This amount is completely confidential and you should NOT discuss this with anyone. A settlement of this type is called an "Aggregate Settlement" where a fair and reasonable sum of money is obtained to resolve multiple cases. In order to maintain proper representation of each individual client, W & L is NOT involved in the allocation decision making, which will be handled exclusively by Judge Corodemus. W & L has reviewed the general framework of the settlement plan with Judge Corodemus and we strongly believe that it is fair and reasonable and offers each of our clients the best possible outcome under the circumstances of this litigation. Track I offers the Seroquel claimant a settlement of $12,000. This track involves a simple review of each case and will result in a quick approval by Judge Corodemus without an analysis of the specific details of the case such as injury, amount of Seroquel taken, how close the last Seroquel use was to the date of the injury or the individual claimant's risk factors. a) Cannot prove that they suffered diabetes or a diabetes related condition, and/or Cannot prove that they used Seroquel within 1 year of their claimed injury, and/or c) Had a large number of known risk factors for diabetes before they started taking Seroquel. For example - obesity, family history, smoking, etc.Therefore, all cases whose injuries are limited to weight gain or high blood sugar and whose medical records will confirm that they were never diagnosed with diabetes or pancreatitis, should choose Track 1. Similarly, any claimed injury that occurred long after the last use of Seroquel should also choose Track 1. These cases are likely to receive a small award in Track II (likely less than $12,000) because it is extremely difficult to prove that these injuries were caused by Seroquel. Therefore, we suggest that if your case falls into this category you should choose Track 1. Additionally, payment of Track I settlement awards will be processed first once AstaZeneca waives its "walk away right". (See Section IV© below) Track II involves an in-depth review of the severity of the injury, the claimed use of Seroquel and its proximity to the injury as well the available proof found in the contemporaneous medical records. Additionally, Judge Corodemus will strongly consider many known risk factors for these injuries including but not limited to smoking, obesity and family history as well as the participation in the Zyprexa settlement for these same injuries. This model is very similar to the one used in the National Vioxx Settlement Program as well as dozens of other similar settlement programs which were successfully resolved in recent years. Judge Corodemus has established a points system and will consider all of the critical issues including but not limited to: - Nature of the injury - Severity of the injury - Age at the time of injury - Proximity of Seroquel use to the claimed injury - Changes in the Seroque11abel - Risk Factors including Smoking, Body Mass Index, etc. After carefully reviewing all of the medical records and the individual fact sheet, Judge Corodemus will assign a point value to each case. The more points a case is awarded based on the specific facts of the case, the larger the settlement will be. At this time, there is no way to predict with accuracy how many points an individual case may be awarded and it is even more difficult to determine how much money each point will receive. The exact value of each point will depend on the number of participants in Track II and the total number of points assigned. All cases in Track II will be eligible for a settlement award but Judge Corodemus could award LESS than $12,000 (what people will receive automatically by choosing Track 1) if the case lacks merit. In the interest of fairness, Judge Corodemus has committed to review each case in Track II very carefully and this process will take time to complete. Judge Corodemus has stated that she hopes to have this process completed by the end of 2011 but please be warned that it could take a little longer due to the amount of work that is involved. However, in order to get this settlement process moving forward and ultimately paid you must send us your signed Release form as soon as possible. If you choose Track I your settlement award of $12,000 is set. If you choose Track II, Judge Corodemus will review your claim and will issue an award. We expect that we will contact you in approximately November 2011 and notify you of your point award and the expected amount of your settlement. At that point, you will be given a choice to accept your award, appeal your award or withdraw from the settlement program. If you accept, we will forward your release to AstraZeneca for their review and approval. Please understand that this settlement is not official until we send AstraZeneca your signed Release Form, AstraZeneca approves it AND AstraZeneca waives its walk away right. In the interest of time, we are asking you to return your signed Release Form now so we can meet the tight deadlines associated with this settlement. If you are unhappy with your allocation amount and/or believe that your case involves "Extraordinary Injury or Circumstances" you have the right to appeal your award. Upon receipt of such an application, Judge Corodemus will re-review your records and make a final decision. Please be aware that there is no additional right of appeal (to Judge Corodemus or to any Court) once this final decision is made. If you decide to decline the settlement amount offered to you, you must notify us within ten days of your receipt of your allocation amount and your signed Release Form will no longer be valid. As in all settlements of this type, our agreement with the defendant depends on nearly full participation from all of our clients. Under the terms of our agreement, we must provide Qualifying Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once we reach this number, AstraZeneca's "walk away right" is officially waived. We strongly believe that our clients will agree that this settlement program offers the best possible terms and we expect that we will meet this requirement in the next 90-120 days. In order to meet this deadline we MUST have your complete cooperation and immediate response. Of course, if we do not meet this required number of responses, Astrazeneca can decide to withdraw its settlement offer to everyone whether one signed the Release Form or not. Therefore, time is of the essence. A. Release Form: Enclosed you will find a Release Form which you must sign in front of a notary in Order to participate in the settlement. If you have a spouse he/she must sign the Release Form as well. Attached to the Release Form will be an instruction sheet to guide you to ensure that this important form is signed the right way. A Release Form that is signed the wrong way or that is not witnessed (by a notary) is useless and will not be accepted by the defendants. The Release Form is your agreement to participate in the settlement program and at the same time discontinue your lawsuit in exchange for your settlement award. Please turn to Page 2 of the Release Form and complete the details of your Seroquel use. You may refer to Page 1 of the Brief Questionnaire which lists the Seroquel information that was found in your medical records or that you have previously provided to us. If this information is inaccurate, please cross it out and write in when you started and when you stopped taking Seroquel on BOTH the Release Form and the Brief Questionnaire. Due to the fast approaching deadlines, and our goal to get you your settlement processed and paid as quickly as possible, we MUST receive this signed release form back from you before August 31, 2011. Please use the envelope provided herein and return the signed and notarized release form today before you forget about it. Please note that once we submit your release form to AstraZeneca it can not be revoked. B. Track Selection Form: Enclosed you will find a "Track Selection Form" which is the form used to officially notify the Special Master which Track you want your case to follow. Please Note that there are 4 options on this form. You MUST check one of the Options. If you want to participate in this settlement, and we strongly think that you should, you must check either Track I OR Track II and you must sign the bottom of the form. Your Track selection cannot be changed and is considered final once the Judge's Allocations are made. In other words, a person who chooses Track II and is awarded less than $12,000 CANNOT then choose to go to Track 1 for a higher award. C. Brief Questionnaire: Enclosed you will find a 3 page Brief Questionnaire which has important information about your claim. For all claimants who choose to enter Track II, Judge Corodemus will be reviewing your medical records, your Fact Sheet and this Brief Questionnaire and will issue a point award. Judge Corodemus will consider the proof of your claim found in your medical records as well as the information that you provide in this Questionnaire. Therefore, it is important that you answer these questions honestly and completely and that they are consistent with what is found in your medical records. litigation and our conversations with our medical experts, it is clear that Seroquel lawsuits are very difficult to win, very expensive, and very time consuming to take through to trial, verdict and appeal. Over the past six years only I case (from W & L) of24,000 cases in the Country made it to and through trial. Countless other cases were prepared and then dismissed based on merit and/or inability to prove that Seroquel caused the injury. Just because an individual took Seroquel and suffered an injury like diabetes does not mean that such a case will win at trial. In order to succeed at trial, a plaintiff must prove both that Seroquel can cause such an injury in general AND that, within a reasonable degree of medical certainty, Seroquel caused this injury to this particular person (despite any individual risk factors such as smoking, weight, high blood sugar, family history etc.). We have told you in the past update letters that the Courts have consistently ruled in favor of the defendants on many of these issues and have prohibited medical experts from testifying because of a lack of scientific proof linking the plaintiff s injuries to his/her Seroquel use. It is also important to note that even if your case is able to advance past this judicial scrutiny, a trial of this magnitude will cost over $750,000 per case and many of these costs are reimbursed off of the top of a favorable verdict reducing the amount received by the plaintiff. Furthermore, any case that is won at trial will surely face a lengthy and hard-fought appeal. Finally, nearly all of the Seroquel cases are being handled by three judges. Even at an accelerated pace, the chances are slim that your case would be tried in the next 10 years if not longer. In taking all of these factors into consideration, and considering the issues of risk and reward, we believe that a settlement of this type offers you the most advantageous resolution possible. You will be notified once the Special Master issues your point award at which point you can appeal to the Special Master if you believe that your case involves extraordinary circumstances. Thereafter, the decision of the Special Master is final, binding and non-appealable. We have retained the Garretson Law Firm to negotiate any and all Federal and State liens (Medicare/Medicaid/SSI) that may be applicable in your case. The Garretson Firm is a specialist in this field and they have obtained excellent results in their negotiation of similar liens in other litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson Firm has already worked on thousands of other Seroquel cases and has been able to achieve excellent results in large part due to the volume of cases that they are able to include in a Global Resolution. At this time, the Garretson Firm has already negotiated with 44 individual states regarding Medicaid and they have reached an agreement to CAP Medicaid liens at a maximum of 20% of the settlement amount. Please see the enclosed blue booklet regarding governmental liens for more details. Additionally, please also be advised that if you or Weitz & Luxenberg are put on written notice of a private lien, for example from your medical provider, this lien must be resolved before any settlement proceeds can be distributed. If you have received any notice of a lien, please advise us immediately. The terms of your signed contingency fee agreement will be in effect. We have taken great effort to keep the case specific expenses as low as possible. Under the terms of your agreement, the contingency fee will be calculated after the expenses are deducted. Under the terms of our agreement with AstraZeneca, any interest earned on the settlement proceeds before allocation and payment to the individual clients will be used to offset the fixed costs of the Special Master and the Lien Administrator. Due to the low interest rates paid by all banks in this economy, we do not expect that there will be any leftover interest. However, in such a case, the leftover interest will be added to the settlement trust and will be distributed to all claimants as part of Judge Corodemus' allocation process. After careful analysis of the likelihood of success in the court system, as well as the cost and time elements involved, we strongly recommend that you AGREE to participate in this settlement. We are confident that this settlement is the best possible resolution of your claim especially in light of the history of this litigation. We expect that any case that does not agree to participate in this settlement will have a very difficult time navigating through the Court system and trial dates may not be set for many years. Moreover, as we have seen, these cases will be aggressively defended by AstraZeneca and we expect that we will receive motions to dismiss and unfavorable decisions from the Court on unsettled cases in the coming months. Moreover, if this settlement program is not successful (we fail to reach the 98% response rate) we highly doubt that we will ever obtain a settlement amount and terms as good as those contained in this program. While we hope that this letter and enclosures will help answer all of your questions, we understand that you may have additional questions for us. Please keep in mind that we are working very hard to evaluate each and every case individually and the many deadlines that are part of this settlement are fast approaching. Your case has been assigned to Judy Koenig. If you have an important question please call Judy Koenig at (800) 438-9786 and ask for extension 5860. If you reach a voice-mail, please leave a message and you will be called back as quickly as possible. Please do not leave multiple voicemail messages on the same day as that will slow down our ability to return your call. Additionally, if you have email access, please try to email your detailed questions to us at sqinfo@... and we will get back to you quickly. If this letter has successfully answered your questions, and you have decided to participate, please carefully follow the directions on the front page of the enclosed release form and send your signed and witnessed release formes), your Track Selection AND your Brief Questionnaire to us as soon as possible. If you still have questions after reviewing this letter and after speaking to us over the telephone and you would like to meet us in person, we will be happy to schedule a meeting in our office at your convenience. Finally, please remember that the detailed information regarding this settlement program is COMPLETELY CONFIDENTIAL and should not be shared or discussed with anyone. Sedgh, Esq Glenn Zuckerman, Esq.

[Guest guest]

I wonder whether individual suits are more effective than class action suits?

Those are known to be mostly for the benefit of the lawyers, in any field of

injury, not just pharmaceuticals. Cate

>

> " Awry, " not " a rye " but I digress. This is exactly why I never urge anyone to

sue. The deck is stacked against us in court and attorneys are looking for a

quick and easy buck. No justice is to be had.

>

> Terry

> Sent via BlackBerry by AT & T

>

> SEROQUEL Law Firms have sold their clients down the

river

>

> Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO

> REJECT this Insult on Top of Injury

> [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

> ElFTkSuQmCC]

>

>

>

> Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO

> REJECT this Insult on Top of Injury

> I would like to thank a brave, courageous, and ethical anonymous source

> who has send in this letter correspondence they received from the law

> firm of Weitz & Luxenberg. This letter doesn't require a whole lot of

> commentary.

> It's obvious that Law Firms have sold their clients down the proverbial

> river while at the same time enriching themselves (who's best interest

> are you obligated too fulfill?). This settlement offer and the injured

> litigants legal representation has carried out a blatant miscarriage of

> justice, a forever horrible stain upon the American Justice system, and

> a orchestrated crime perpetrated upon victims of this well documented &

> evidenced unbridled & unregulated corporate criminal enterprise gone a

> rye.

> The time has now come for the victims to stand up to this criminal

> corporation " AstraZeneca " & their poison drug " Seroquel " , to reject this

> horrible injustice and settlement offer. We want, what America & our

> Constitution promises us all, our day in court before a jury of our

> peers....

> ____________________________________________________________

>

> Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> We are happy to report excellent news! After a long and hard fought

> legal battle, AstraZeneca has agreed to participate in a Settlement

> Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> patience and aggressive litigating has resulted in very favorable

> settlement terms for our clients which will be further outlined below.

> We have carefully reviewed all of the factors of this agreement and we

> believe that this settlement offers you the best, and very likely the

> only opportunity to receive a fair resolution of your lawsuit.

> Therefore, we strongly recommend that you sign and complete the enclosed

> " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> AGREE to participate.

> As you know, we have engaged in a long legal battle with AstraZeneca

> over the past 6 years. Weitz & Luxenberg led the charge for the

> Plaintiffs around the Country. AstraZeneca put up a tremendous and

> expensive defense and they successfully were able to get a large number

> of cases to be permanently dismissed by the court. Weitz & Luxenberg is

> the only firm who took a case to trial anywhere in the Country. However,

> after a month-long trial, the jury unfortunately ruled in favor of the

> defendants. This loss did not affect the strength of our fight. Over the

> past year, even as almost every other plaintiffs firm settled their

> cases, Weitz & Luxenberg prepared two more cases for trial which was

> scheduled to begin this Summer. As a direct result of the endless and

> consistent pressure applied by the attorneys at Weitz & Luxenberg, we

> are happy to report that AstraZeneca has now agreed to participate in a

> favorable settlement program. Based on public reports regarding

> settlement programs reached with other plaintiff law firms we are

> confident that the settlement program outlined below has more favorable

> terms and for this reason we are recommending your participation.

> The defendants have argued that they refuse to pay anyone who cannot

> prove through medical records or via certification that they have used

> Seroquel. They also refuse to pay anyone whose case is not active in

> this litigation. We recently told you about the Order issued by the

> Court requiring you to confirm when you started taking Seroquel and when

> you stopped taking Seroquel. We cannot stress enough that you MUST read,

> complete and return this certification form to us immediately. The

> failure to return this form within the next 30 days will result in the

> permanent dismissal of your case. In order to protect your legal rights,

> to keep your case active and be permitted to participate in this

> Settlement Program you must take this Order very seriously and you must

> respond.

> Based on our experience in other litigations and having reviewed the

> media reports of the terms of other firms' Seroquel settlement programs,

> we know that the defendants are looking for a settlement program that

> includes all claimants (W & L Seroquel Plaintiffs) so that they will

> achieve complete closure of the entirYlitigation. Our goal in this

> negotiation was to obtain a settlement for the most amount of money

> using a fair method to pay our clients based upon the merits of their

> individual case. We also stressed our intentions that the case review

> and payment process be performed quickly yet fairly so that our clients

> can receive their settlements as soon as possible. A key part of this

> settlement program is that a claimant cannot be part of the settlement

> if their case is dismissed and unless they provide, at the very least, a

> certification that they in fact took Seroquel and suffered an injury.

> Therefore, please make sure that you return your certification form to

> us immediately

>

> We have hired Hon.Marina Corodemus to act as the Special Master for the

> W & L Seroquel settlement program. Judge Corodemus previously ran the New

> Jersey Mass Tort Court and has a lot of experience in this field. She

> was appointed as a Special Master by the Vioxx State and Federal Court

> Judges to determine the appropriateness of Vioxx settlements and to

> resolve Vioxx appeals. She has also served as the Special Master in many

> other litigations such as Bextra and Celebrex which used similar

> settlement terms. We have met several times with Judge Corodemus and

> discussed the goals outlined above to get the most amount of money to

> the most amount of claimants in the fastest amount of time possible. We

> believe that Judge Corodemus is the perfect choice to create and oversee

> a settlement program in accordance with these goals. The W & L Seroquel

> Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> those clients with active cases (not dismissed as outlined above) can

> participate in this settlement program. Unlike other settlement programs

> that you may have read about in the media and internet, the W & L

> Settlement program does not award every case an equal settlement amount.

> The size of an individual's settlement will depend entirely on the merit

> of that individual's case. As a direct result of the large number of

> cases represented by W & L, and the merits of those cases, we are

> confident that we have obtained the best possible settlement for our

> clients. After complex negotiations, AstraZeneca

> has agreed to deposit $92.25 Million dollars into a trust account to be

> used for this Settlement Program. This amount is completely confidential

> and you should NOT discuss this with anyone. A settlement of this type

> is called an " Aggregate Settlement " where a fair and reasonable sum of

> money is obtained to resolve multiple cases. In order to maintain proper

> representation of each individual client, W & L is NOT involved in the

> allocation decision making, which will be handled exclusively by Judge

> Corodemus. W & L has reviewed the general framework of the settlement

> plan with Judge Corodemus and we strongly believe that it is fair and

> reasonable and offers each of our clients the best possible outcome

> under the circumstances of this litigation. Track I offers the Seroquel

> claimant a settlement of $12,000. This track involves a simple review of

> each case and will result in a quick approval by Judge Corodemus without

> an analysis of the specific details of the case such as injury, amount

> of Seroquel taken, how close the last Seroquel use was to the date of

> the injury or the individual claimant's risk factors. a) Cannot

> prove that they suffered diabetes or a diabetes related condition,

> and/or Cannot prove that they used Seroquel within 1 year of

> their claimed injury, and/or c) Had a large number of known

> risk factors for diabetes before they started taking Seroquel. For

> example - obesity, family history, smoking, etc.

>

> Therefore, all cases whose injuries are limited to weight gain or high

> blood sugar and whose medical records will confirm that they were never

> diagnosed with diabetes or pancreatitis, should choose Track 1.

> Similarly, any claimed injury that occurred long after the last use of

> Seroquel should also choose Track 1. These cases are likely to receive a

> small award in Track II (likely less than $12,000) because it is

> extremely difficult to prove that these injuries were caused by

> Seroquel. Therefore, we suggest that if your case falls into this

> category you should choose Track 1. Additionally, payment of Track I

> settlement awards will be processed first once AstaZeneca waives its

> " walk away right " . (See Section IV© below) Track II involves an

> in-depth review of the severity of the injury, the claimed use of

> Seroquel and its proximity to the injury as well the available proof

> found in the contemporaneous medical records. Additionally, Judge

> Corodemus will strongly consider many known risk factors for these

> injuries including but not limited to smoking, obesity and family

> history as well as the participation in the Zyprexa settlement for these

> same injuries. This model is very similar to the one used in the

> National Vioxx Settlement Program as well as dozens of other similar

> settlement programs which were successfully resolved in recent years.

> Judge Corodemus has established a points system and will consider all of

> the critical issues including but not limited to:

> - Nature of the injury - Severity of the injury - Age at the time of

> injury - Proximity of Seroquel use to the claimed injury - Changes in

> the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> etc. After carefully reviewing all of the medical records and the

> individual fact sheet, Judge Corodemus will assign a point value to each

> case. The more points a case is awarded based on the specific facts of

> the case, the larger the settlement will be. At this time, there is no

> way to predict with accuracy how many points an individual case may be

> awarded and it is even more difficult to determine how much money each

> point will receive. The exact value of each point will depend on the

> number of participants in Track II and the total number of points

> assigned. All cases in Track II will be eligible for a settlement award

> but Judge Corodemus could award LESS than $12,000 (what people will

> receive automatically by choosing Track 1) if the case lacks merit. In

> the interest of fairness, Judge Corodemus has committed to review each

> case in Track II very carefully and this process will take time to

> complete. Judge Corodemus has stated that she hopes to have this process

> completed by the end of 2011 but please be warned that it could take a

> little longer due to the amount of work that is involved. However, in

> order to get this settlement process moving forward and ultimately paid

> you must send us your signed Release form as soon as possible. If you

> choose Track I your settlement award of $12,000 is set. If you choose

> Track II, Judge Corodemus will review your claim and will issue an

> award. We expect that we will contact you in approximately November 2011

> and notify you of your point award and the expected amount of your

> settlement. At that point, you will be given a choice to accept your

> award, appeal your award or withdraw from the settlement program. If you

> accept, we will forward your release to AstraZeneca for their review and

> approval. Please understand that this settlement is not official until

> we send AstraZeneca your signed Release Form, AstraZeneca approves it

> AND AstraZeneca waives its walk away right. In the interest of time, we

> are asking you to return your signed Release Form now so we can meet the

> tight deadlines associated with this settlement. If you are unhappy with

> your allocation amount and/or believe that your case involves

> " Extraordinary Injury or Circumstances " you have the right to appeal

> your award. Upon receipt of such an application, Judge Corodemus will

> re-review your records and make a final decision. Please be aware that

> there is no additional right of appeal (to Judge Corodemus or to any

> Court) once this final decision is made. If you decide to decline the

> settlement amount offered to you, you must notify us within ten days of

> your receipt of your allocation amount and your signed Release Form will

> no longer be valid. As in all settlements of this type, our agreement

> with the defendant depends on nearly full participation from all of our

> clients. Under the terms of our agreement, we must provide Qualifying

> Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once

> we reach this number, AstraZeneca's " walk away right " is officially

> waived. We strongly believe that our clients will agree that this

> settlement program offers the best possible terms and we expect that we

> will meet this requirement in the next 90-120 days. In order to meet

> this deadline we MUST have your complete

> cooperation and immediate response. Of course, if we do not meet this

> required number of responses, Astrazeneca can decide to withdraw its

> settlement offer to everyone whether one signed the Release Form or not.

> Therefore, time is of the essence. A. Release Form: Enclosed you will

> find a Release Form which you must sign in front of a notary in Order to

> participate in the settlement. If you have a spouse he/she must sign the

> Release Form as well. Attached to the Release Form will be an

> instruction sheet to guide you to ensure that this important form is

> signed the right way. A Release Form that is signed the wrong way or

> that is not witnessed (by a notary) is useless and will not be accepted

> by the defendants. The Release Form is your agreement to participate in

> the settlement program and at the same time discontinue your lawsuit in

> exchange for your settlement award. Please turn to Page 2 of the Release

> Form and complete the details of your Seroquel use. You may refer to

> Page 1 of the Brief Questionnaire which lists the Seroquel information

> that was found in your medical records or that you have previously

> provided to us. If this information is inaccurate, please cross it out

> and write in when you started and when you stopped taking Seroquel on

> BOTH the Release Form and the Brief Questionnaire. Due to the fast

> approaching deadlines, and our goal to get you your settlement processed

> and paid as quickly as possible, we MUST receive this signed release

> form back from you before August 31, 2011. Please use the envelope

> provided herein and return the signed and notarized release form today

> before you forget about it. Please note that once we submit your release

> form to AstraZeneca it can not be revoked. B. Track Selection Form:

> Enclosed you will find a " Track Selection Form " which is the form used

> to officially notify the Special Master which Track you want your case

> to follow. Please Note that there are 4 options on this form. You MUST

> check one of the Options. If you want to participate in this settlement,

> and we strongly think that you should, you must check either Track I OR

> Track II and you must sign the bottom of the form. Your Track selection

> cannot be changed and is considered final once the Judge's Allocations

> are made. In other words, a person who chooses Track II and is awarded

> less than $12,000 CANNOT then choose to go to Track 1 for a higher

> award. C. Brief Questionnaire: Enclosed you will find a 3

> page Brief Questionnaire which has important information about your

> claim. For all claimants who choose to enter Track II, Judge Corodemus

> will be reviewing your medical records, your Fact Sheet and this Brief

> Questionnaire and will issue a point award. Judge Corodemus will

> consider the proof of your claim found in your medical records as well

> as the information that you provide in this Questionnaire. Therefore, it

> is important that you answer these questions honestly and completely and

> that they are consistent with what is found in your medical records.

> litigation and our conversations with our medical experts, it is clear

> that Seroquel lawsuits are very difficult to win, very expensive, and

> very time consuming to take through to trial, verdict and appeal. Over

> the past six years only I case (from W & L) of24,000 cases in the Country

> made it to and through trial. Countless other cases were prepared and

> then dismissed based on merit and/or inability to prove that Seroquel

> caused the injury. Just because an individual took Seroquel and suffered

> an injury like diabetes does not mean that such a case will win at

> trial. In order to succeed at trial, a plaintiff must prove both that

> Seroquel can cause such an injury in general AND that, within a

> reasonable degree of medical certainty, Seroquel caused this injury to

> this particular person (despite any individual risk factors such as

> smoking, weight, high blood sugar, family history etc.). We have told

> you in the past update letters that the Courts have consistently ruled

> in favor of the defendants on many of these issues and have prohibited

> medical experts from testifying because of a lack of scientific proof

> linking the plaintiff s injuries to his/her Seroquel use. It is also

> important to note that even if your case is able to advance past this

> judicial scrutiny, a trial of this magnitude will cost over $750,000 per

> case and many of these costs are reimbursed off of the top of a

> favorable verdict reducing the amount received by the plaintiff.

> Furthermore, any case that is won at trial will surely face a lengthy

> and hard-fought appeal. Finally, nearly all of the Seroquel cases are

> being handled by three judges. Even at an accelerated pace, the chances

> are slim that your case would be tried in the next 10 years if not

> longer. In taking all of these factors into consideration, and

> considering the issues of risk and reward, we believe that a settlement

> of this type offers you the most advantageous resolution possible. You

> will be notified once the Special Master issues your point award at

> which point you can appeal to the Special Master if you believe that

> your case involves extraordinary circumstances. Thereafter, the decision

> of the Special Master is final, binding and non-appealable. We have

> retained the Garretson Law Firm to negotiate any and all Federal and

> State liens (Medicare/Medicaid/SSI) that may be applicable in your case.

> The Garretson Firm is a specialist in this field and they have obtained

> excellent results in their negotiation of similar liens in other

> litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson

> Firm has already worked on thousands of other Seroquel cases and has

> been able to achieve excellent results in large part due to the volume

> of cases that they are able to include in a Global Resolution. At this

> time, the Garretson Firm has already negotiated with 44 individual

> states regarding Medicaid and they have reached an agreement to CAP

> Medicaid liens at a maximum of 20% of the settlement amount. Please see

> the enclosed blue booklet regarding governmental liens for more details.

> Additionally, please also be advised that if you or Weitz & Luxenberg

> are put on written notice of a private lien, for example from your

> medical provider, this lien must be resolved before any settlement

> proceeds can be distributed. If you have received any notice of a lien,

> please advise us immediately. The terms of your signed contingency fee

> agreement will be in effect. We have taken great effort to keep the case

> specific expenses as low as possible. Under the terms of your agreement,

> the

> contingency fee will be calculated after the expenses are deducted.

> Under the terms of our agreement with AstraZeneca, any interest earned

> on the settlement proceeds before allocation and payment to the

> individual clients will be used to offset the fixed costs of the Special

> Master and the Lien Administrator. Due to the low interest rates paid by

> all banks in this economy, we do not expect that there will be any

> leftover interest. However, in such a case, the leftover interest will

> be added to the settlement trust and will be distributed to all

> claimants as part of Judge Corodemus' allocation process. After careful

> analysis of the likelihood of success in the court system, as well as

> the cost and time elements involved, we strongly recommend that you

> AGREE to participate in this settlement. We are confident that this

> settlement is the best possible resolution of your claim especially in

> light of the history of this litigation. We expect that any case that

> does not agree to participate in this settlement will have a very

> difficult time navigating through the Court system and trial dates may

> not be set for many years. Moreover, as we have seen, these cases will

> be aggressively defended by AstraZeneca and we expect that we will

> receive motions to dismiss and unfavorable decisions from the Court on

> unsettled cases in the coming months. Moreover, if this settlement

> program is not successful (we fail to reach the 98% response rate) we

> highly doubt that we will ever obtain a settlement amount and terms as

> good as those contained in this program. While we hope that this letter

> and enclosures will help answer all of your questions, we understand

> that you may have additional questions for us. Please keep in mind that

> we are working very hard to evaluate each and every case individually

> and the many deadlines that are part of this settlement are fast

> approaching. Your case has been assigned to Judy Koenig. If you have an

> important question please call Judy Koenig at (800) 438-9786 and ask for

> extension 5860. If you reach a voice-mail, please leave a message and

> you will be called back as quickly as possible. Please do not leave

> multiple voicemail messages on the same day as that will slow down our

> ability to return your call. Additionally, if you have email access,

> please try to email your detailed questions to us at sqinfo@...

> <mailto:sqinfo@...> and we will get back to you quickly. If

> this letter has successfully answered your questions, and you have

> decided to participate, please carefully follow the directions on the

> front page of the enclosed release form and send your signed and

> witnessed release formes), your Track Selection AND your Brief

> Questionnaire to us as soon as possible. If you still have questions

> after reviewing this letter and after speaking to us over the telephone

> and you would like to meet us in person, we will be happy to schedule a

> meeting in our office at your convenience. Finally, please remember that

> the detailed information regarding this settlement program is COMPLETELY

> CONFIDENTIAL and should not be shared or discussed with anyone.

> Sedgh, Esq Glenn Zuckerman, Esq.

>

[Guest guest]

I wonder whether individual suits are more effective than class action suits?

Those are known to be mostly for the benefit of the lawyers, in any field of

injury, not just pharmaceuticals. Cate

>

> " Awry, " not " a rye " but I digress. This is exactly why I never urge anyone to

sue. The deck is stacked against us in court and attorneys are looking for a

quick and easy buck. No justice is to be had.

>

> Terry

> Sent via BlackBerry by AT & T

>

> SEROQUEL Law Firms have sold their clients down the

river

>

> Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO

> REJECT this Insult on Top of Injury

> [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

> ElFTkSuQmCC]

>

>

>

> Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO

> REJECT this Insult on Top of Injury

> I would like to thank a brave, courageous, and ethical anonymous source

> who has send in this letter correspondence they received from the law

> firm of Weitz & Luxenberg. This letter doesn't require a whole lot of

> commentary.

> It's obvious that Law Firms have sold their clients down the proverbial

> river while at the same time enriching themselves (who's best interest

> are you obligated too fulfill?). This settlement offer and the injured

> litigants legal representation has carried out a blatant miscarriage of

> justice, a forever horrible stain upon the American Justice system, and

> a orchestrated crime perpetrated upon victims of this well documented &

> evidenced unbridled & unregulated corporate criminal enterprise gone a

> rye.

> The time has now come for the victims to stand up to this criminal

> corporation " AstraZeneca " & their poison drug " Seroquel " , to reject this

> horrible injustice and settlement offer. We want, what America & our

> Constitution promises us all, our day in court before a jury of our

> peers....

> ____________________________________________________________

>

> Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> We are happy to report excellent news! After a long and hard fought

> legal battle, AstraZeneca has agreed to participate in a Settlement

> Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> patience and aggressive litigating has resulted in very favorable

> settlement terms for our clients which will be further outlined below.

> We have carefully reviewed all of the factors of this agreement and we

> believe that this settlement offers you the best, and very likely the

> only opportunity to receive a fair resolution of your lawsuit.

> Therefore, we strongly recommend that you sign and complete the enclosed

> " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> AGREE to participate.

> As you know, we have engaged in a long legal battle with AstraZeneca

> over the past 6 years. Weitz & Luxenberg led the charge for the

> Plaintiffs around the Country. AstraZeneca put up a tremendous and

> expensive defense and they successfully were able to get a large number

> of cases to be permanently dismissed by the court. Weitz & Luxenberg is

> the only firm who took a case to trial anywhere in the Country. However,

> after a month-long trial, the jury unfortunately ruled in favor of the

> defendants. This loss did not affect the strength of our fight. Over the

> past year, even as almost every other plaintiffs firm settled their

> cases, Weitz & Luxenberg prepared two more cases for trial which was

> scheduled to begin this Summer. As a direct result of the endless and

> consistent pressure applied by the attorneys at Weitz & Luxenberg, we

> are happy to report that AstraZeneca has now agreed to participate in a

> favorable settlement program. Based on public reports regarding

> settlement programs reached with other plaintiff law firms we are

> confident that the settlement program outlined below has more favorable

> terms and for this reason we are recommending your participation.

> The defendants have argued that they refuse to pay anyone who cannot

> prove through medical records or via certification that they have used

> Seroquel. They also refuse to pay anyone whose case is not active in

> this litigation. We recently told you about the Order issued by the

> Court requiring you to confirm when you started taking Seroquel and when

> you stopped taking Seroquel. We cannot stress enough that you MUST read,

> complete and return this certification form to us immediately. The

> failure to return this form within the next 30 days will result in the

> permanent dismissal of your case. In order to protect your legal rights,

> to keep your case active and be permitted to participate in this

> Settlement Program you must take this Order very seriously and you must

> respond.

> Based on our experience in other litigations and having reviewed the

> media reports of the terms of other firms' Seroquel settlement programs,

> we know that the defendants are looking for a settlement program that

> includes all claimants (W & L Seroquel Plaintiffs) so that they will

> achieve complete closure of the entirYlitigation. Our goal in this

> negotiation was to obtain a settlement for the most amount of money

> using a fair method to pay our clients based upon the merits of their

> individual case. We also stressed our intentions that the case review

> and payment process be performed quickly yet fairly so that our clients

> can receive their settlements as soon as possible. A key part of this

> settlement program is that a claimant cannot be part of the settlement

> if their case is dismissed and unless they provide, at the very least, a

> certification that they in fact took Seroquel and suffered an injury.

> Therefore, please make sure that you return your certification form to

> us immediately

>

> We have hired Hon.Marina Corodemus to act as the Special Master for the

> W & L Seroquel settlement program. Judge Corodemus previously ran the New

> Jersey Mass Tort Court and has a lot of experience in this field. She

> was appointed as a Special Master by the Vioxx State and Federal Court

> Judges to determine the appropriateness of Vioxx settlements and to

> resolve Vioxx appeals. She has also served as the Special Master in many

> other litigations such as Bextra and Celebrex which used similar

> settlement terms. We have met several times with Judge Corodemus and

> discussed the goals outlined above to get the most amount of money to

> the most amount of claimants in the fastest amount of time possible. We

> believe that Judge Corodemus is the perfect choice to create and oversee

> a settlement program in accordance with these goals. The W & L Seroquel

> Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> those clients with active cases (not dismissed as outlined above) can

> participate in this settlement program. Unlike other settlement programs

> that you may have read about in the media and internet, the W & L

> Settlement program does not award every case an equal settlement amount.

> The size of an individual's settlement will depend entirely on the merit

> of that individual's case. As a direct result of the large number of

> cases represented by W & L, and the merits of those cases, we are

> confident that we have obtained the best possible settlement for our

> clients. After complex negotiations, AstraZeneca

> has agreed to deposit $92.25 Million dollars into a trust account to be

> used for this Settlement Program. This amount is completely confidential

> and you should NOT discuss this with anyone. A settlement of this type

> is called an " Aggregate Settlement " where a fair and reasonable sum of

> money is obtained to resolve multiple cases. In order to maintain proper

> representation of each individual client, W & L is NOT involved in the

> allocation decision making, which will be handled exclusively by Judge

> Corodemus. W & L has reviewed the general framework of the settlement

> plan with Judge Corodemus and we strongly believe that it is fair and

> reasonable and offers each of our clients the best possible outcome

> under the circumstances of this litigation. Track I offers the Seroquel

> claimant a settlement of $12,000. This track involves a simple review of

> each case and will result in a quick approval by Judge Corodemus without

> an analysis of the specific details of the case such as injury, amount

> of Seroquel taken, how close the last Seroquel use was to the date of

> the injury or the individual claimant's risk factors. a) Cannot

> prove that they suffered diabetes or a diabetes related condition,

> and/or Cannot prove that they used Seroquel within 1 year of

> their claimed injury, and/or c) Had a large number of known

> risk factors for diabetes before they started taking Seroquel. For

> example - obesity, family history, smoking, etc.

>

> Therefore, all cases whose injuries are limited to weight gain or high

> blood sugar and whose medical records will confirm that they were never

> diagnosed with diabetes or pancreatitis, should choose Track 1.

> Similarly, any claimed injury that occurred long after the last use of

> Seroquel should also choose Track 1. These cases are likely to receive a

> small award in Track II (likely less than $12,000) because it is

> extremely difficult to prove that these injuries were caused by

> Seroquel. Therefore, we suggest that if your case falls into this

> category you should choose Track 1. Additionally, payment of Track I

> settlement awards will be processed first once AstaZeneca waives its

> " walk away right " . (See Section IV© below) Track II involves an

> in-depth review of the severity of the injury, the claimed use of

> Seroquel and its proximity to the injury as well the available proof

> found in the contemporaneous medical records. Additionally, Judge

> Corodemus will strongly consider many known risk factors for these

> injuries including but not limited to smoking, obesity and family

> history as well as the participation in the Zyprexa settlement for these

> same injuries. This model is very similar to the one used in the

> National Vioxx Settlement Program as well as dozens of other similar

> settlement programs which were successfully resolved in recent years.

> Judge Corodemus has established a points system and will consider all of

> the critical issues including but not limited to:

> - Nature of the injury - Severity of the injury - Age at the time of

> injury - Proximity of Seroquel use to the claimed injury - Changes in

> the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> etc. After carefully reviewing all of the medical records and the

> individual fact sheet, Judge Corodemus will assign a point value to each

> case. The more points a case is awarded based on the specific facts of

> the case, the larger the settlement will be. At this time, there is no

> way to predict with accuracy how many points an individual case may be

> awarded and it is even more difficult to determine how much money each

> point will receive. The exact value of each point will depend on the

> number of participants in Track II and the total number of points

> assigned. All cases in Track II will be eligible for a settlement award

> but Judge Corodemus could award LESS than $12,000 (what people will

> receive automatically by choosing Track 1) if the case lacks merit. In

> the interest of fairness, Judge Corodemus has committed to review each

> case in Track II very carefully and this process will take time to

> complete. Judge Corodemus has stated that she hopes to have this process

> completed by the end of 2011 but please be warned that it could take a

> little longer due to the amount of work that is involved. However, in

> order to get this settlement process moving forward and ultimately paid

> you must send us your signed Release form as soon as possible. If you

> choose Track I your settlement award of $12,000 is set. If you choose

> Track II, Judge Corodemus will review your claim and will issue an

> award. We expect that we will contact you in approximately November 2011

> and notify you of your point award and the expected amount of your

> settlement. At that point, you will be given a choice to accept your

> award, appeal your award or withdraw from the settlement program. If you

> accept, we will forward your release to AstraZeneca for their review and

> approval. Please understand that this settlement is not official until

> we send AstraZeneca your signed Release Form, AstraZeneca approves it

> AND AstraZeneca waives its walk away right. In the interest of time, we

> are asking you to return your signed Release Form now so we can meet the

> tight deadlines associated with this settlement. If you are unhappy with

> your allocation amount and/or believe that your case involves

> " Extraordinary Injury or Circumstances " you have the right to appeal

> your award. Upon receipt of such an application, Judge Corodemus will

> re-review your records and make a final decision. Please be aware that

> there is no additional right of appeal (to Judge Corodemus or to any

> Court) once this final decision is made. If you decide to decline the

> settlement amount offered to you, you must notify us within ten days of

> your receipt of your allocation amount and your signed Release Form will

> no longer be valid. As in all settlements of this type, our agreement

> with the defendant depends on nearly full participation from all of our

> clients. Under the terms of our agreement, we must provide Qualifying

> Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once

> we reach this number, AstraZeneca's " walk away right " is officially

> waived. We strongly believe that our clients will agree that this

> settlement program offers the best possible terms and we expect that we

> will meet this requirement in the next 90-120 days. In order to meet

> this deadline we MUST have your complete

> cooperation and immediate response. Of course, if we do not meet this

> required number of responses, Astrazeneca can decide to withdraw its

> settlement offer to everyone whether one signed the Release Form or not.

> Therefore, time is of the essence. A. Release Form: Enclosed you will

> find a Release Form which you must sign in front of a notary in Order to

> participate in the settlement. If you have a spouse he/she must sign the

> Release Form as well. Attached to the Release Form will be an

> instruction sheet to guide you to ensure that this important form is

> signed the right way. A Release Form that is signed the wrong way or

> that is not witnessed (by a notary) is useless and will not be accepted

> by the defendants. The Release Form is your agreement to participate in

> the settlement program and at the same time discontinue your lawsuit in

> exchange for your settlement award. Please turn to Page 2 of the Release

> Form and complete the details of your Seroquel use. You may refer to

> Page 1 of the Brief Questionnaire which lists the Seroquel information

> that was found in your medical records or that you have previously

> provided to us. If this information is inaccurate, please cross it out

> and write in when you started and when you stopped taking Seroquel on

> BOTH the Release Form and the Brief Questionnaire. Due to the fast

> approaching deadlines, and our goal to get you your settlement processed

> and paid as quickly as possible, we MUST receive this signed release

> form back from you before August 31, 2011. Please use the envelope

> provided herein and return the signed and notarized release form today

> before you forget about it. Please note that once we submit your release

> form to AstraZeneca it can not be revoked. B. Track Selection Form:

> Enclosed you will find a " Track Selection Form " which is the form used

> to officially notify the Special Master which Track you want your case

> to follow. Please Note that there are 4 options on this form. You MUST

> check one of the Options. If you want to participate in this settlement,

> and we strongly think that you should, you must check either Track I OR

> Track II and you must sign the bottom of the form. Your Track selection

> cannot be changed and is considered final once the Judge's Allocations

> are made. In other words, a person who chooses Track II and is awarded

> less than $12,000 CANNOT then choose to go to Track 1 for a higher

> award. C. Brief Questionnaire: Enclosed you will find a 3

> page Brief Questionnaire which has important information about your

> claim. For all claimants who choose to enter Track II, Judge Corodemus

> will be reviewing your medical records, your Fact Sheet and this Brief

> Questionnaire and will issue a point award. Judge Corodemus will

> consider the proof of your claim found in your medical records as well

> as the information that you provide in this Questionnaire. Therefore, it

> is important that you answer these questions honestly and completely and

> that they are consistent with what is found in your medical records.

> litigation and our conversations with our medical experts, it is clear

> that Seroquel lawsuits are very difficult to win, very expensive, and

> very time consuming to take through to trial, verdict and appeal. Over

> the past six years only I case (from W & L) of24,000 cases in the Country

> made it to and through trial. Countless other cases were prepared and

> then dismissed based on merit and/or inability to prove that Seroquel

> caused the injury. Just because an individual took Seroquel and suffered

> an injury like diabetes does not mean that such a case will win at

> trial. In order to succeed at trial, a plaintiff must prove both that

> Seroquel can cause such an injury in general AND that, within a

> reasonable degree of medical certainty, Seroquel caused this injury to

> this particular person (despite any individual risk factors such as

> smoking, weight, high blood sugar, family history etc.). We have told

> you in the past update letters that the Courts have consistently ruled

> in favor of the defendants on many of these issues and have prohibited

> medical experts from testifying because of a lack of scientific proof

> linking the plaintiff s injuries to his/her Seroquel use. It is also

> important to note that even if your case is able to advance past this

> judicial scrutiny, a trial of this magnitude will cost over $750,000 per

> case and many of these costs are reimbursed off of the top of a

> favorable verdict reducing the amount received by the plaintiff.

> Furthermore, any case that is won at trial will surely face a lengthy

> and hard-fought appeal. Finally, nearly all of the Seroquel cases are

> being handled by three judges. Even at an accelerated pace, the chances

> are slim that your case would be tried in the next 10 years if not

> longer. In taking all of these factors into consideration, and

> considering the issues of risk and reward, we believe that a settlement

> of this type offers you the most advantageous resolution possible. You

> will be notified once the Special Master issues your point award at

> which point you can appeal to the Special Master if you believe that

> your case involves extraordinary circumstances. Thereafter, the decision

> of the Special Master is final, binding and non-appealable. We have

> retained the Garretson Law Firm to negotiate any and all Federal and

> State liens (Medicare/Medicaid/SSI) that may be applicable in your case.

> The Garretson Firm is a specialist in this field and they have obtained

> excellent results in their negotiation of similar liens in other

> litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson

> Firm has already worked on thousands of other Seroquel cases and has

> been able to achieve excellent results in large part due to the volume

> of cases that they are able to include in a Global Resolution. At this

> time, the Garretson Firm has already negotiated with 44 individual

> states regarding Medicaid and they have reached an agreement to CAP

> Medicaid liens at a maximum of 20% of the settlement amount. Please see

> the enclosed blue booklet regarding governmental liens for more details.

> Additionally, please also be advised that if you or Weitz & Luxenberg

> are put on written notice of a private lien, for example from your

> medical provider, this lien must be resolved before any settlement

> proceeds can be distributed. If you have received any notice of a lien,

> please advise us immediately. The terms of your signed contingency fee

> agreement will be in effect. We have taken great effort to keep the case

> specific expenses as low as possible. Under the terms of your agreement,

> the

> contingency fee will be calculated after the expenses are deducted.

> Under the terms of our agreement with AstraZeneca, any interest earned

> on the settlement proceeds before allocation and payment to the

> individual clients will be used to offset the fixed costs of the Special

> Master and the Lien Administrator. Due to the low interest rates paid by

> all banks in this economy, we do not expect that there will be any

> leftover interest. However, in such a case, the leftover interest will

> be added to the settlement trust and will be distributed to all

> claimants as part of Judge Corodemus' allocation process. After careful

> analysis of the likelihood of success in the court system, as well as

> the cost and time elements involved, we strongly recommend that you

> AGREE to participate in this settlement. We are confident that this

> settlement is the best possible resolution of your claim especially in

> light of the history of this litigation. We expect that any case that

> does not agree to participate in this settlement will have a very

> difficult time navigating through the Court system and trial dates may

> not be set for many years. Moreover, as we have seen, these cases will

> be aggressively defended by AstraZeneca and we expect that we will

> receive motions to dismiss and unfavorable decisions from the Court on

> unsettled cases in the coming months. Moreover, if this settlement

> program is not successful (we fail to reach the 98% response rate) we

> highly doubt that we will ever obtain a settlement amount and terms as

> good as those contained in this program. While we hope that this letter

> and enclosures will help answer all of your questions, we understand

> that you may have additional questions for us. Please keep in mind that

> we are working very hard to evaluate each and every case individually

> and the many deadlines that are part of this settlement are fast

> approaching. Your case has been assigned to Judy Koenig. If you have an

> important question please call Judy Koenig at (800) 438-9786 and ask for

> extension 5860. If you reach a voice-mail, please leave a message and

> you will be called back as quickly as possible. Please do not leave

> multiple voicemail messages on the same day as that will slow down our

> ability to return your call. Additionally, if you have email access,

> please try to email your detailed questions to us at sqinfo@...

> <mailto:sqinfo@...> and we will get back to you quickly. If

> this letter has successfully answered your questions, and you have

> decided to participate, please carefully follow the directions on the

> front page of the enclosed release form and send your signed and

> witnessed release formes), your Track Selection AND your Brief

> Questionnaire to us as soon as possible. If you still have questions

> after reviewing this letter and after speaking to us over the telephone

> and you would like to meet us in person, we will be happy to schedule a

> meeting in our office at your convenience. Finally, please remember that

> the detailed information regarding this settlement program is COMPLETELY

> CONFIDENTIAL and should not be shared or discussed with anyone.

> Sedgh, Esq Glenn Zuckerman, Esq.

>

[Guest guest]

I wonder whether individual suits are more effective than class action suits?

Those are known to be mostly for the benefit of the lawyers, in any field of

injury, not just pharmaceuticals. Cate

>

> " Awry, " not " a rye " but I digress. This is exactly why I never urge anyone to

sue. The deck is stacked against us in court and attorneys are looking for a

quick and easy buck. No justice is to be had.

>

> Terry

> Sent via BlackBerry by AT & T

>

> SEROQUEL Law Firms have sold their clients down the

river

>

> Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO

> REJECT this Insult on Top of Injury

> [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

> ElFTkSuQmCC]

>

>

>

> Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO

> REJECT this Insult on Top of Injury

> I would like to thank a brave, courageous, and ethical anonymous source

> who has send in this letter correspondence they received from the law

> firm of Weitz & Luxenberg. This letter doesn't require a whole lot of

> commentary.

> It's obvious that Law Firms have sold their clients down the proverbial

> river while at the same time enriching themselves (who's best interest

> are you obligated too fulfill?). This settlement offer and the injured

> litigants legal representation has carried out a blatant miscarriage of

> justice, a forever horrible stain upon the American Justice system, and

> a orchestrated crime perpetrated upon victims of this well documented &

> evidenced unbridled & unregulated corporate criminal enterprise gone a

> rye.

> The time has now come for the victims to stand up to this criminal

> corporation " AstraZeneca " & their poison drug " Seroquel " , to reject this

> horrible injustice and settlement offer. We want, what America & our

> Constitution promises us all, our day in court before a jury of our

> peers....

> ____________________________________________________________

>

> Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> We are happy to report excellent news! After a long and hard fought

> legal battle, AstraZeneca has agreed to participate in a Settlement

> Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> patience and aggressive litigating has resulted in very favorable

> settlement terms for our clients which will be further outlined below.

> We have carefully reviewed all of the factors of this agreement and we

> believe that this settlement offers you the best, and very likely the

> only opportunity to receive a fair resolution of your lawsuit.

> Therefore, we strongly recommend that you sign and complete the enclosed

> " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> AGREE to participate.

> As you know, we have engaged in a long legal battle with AstraZeneca

> over the past 6 years. Weitz & Luxenberg led the charge for the

> Plaintiffs around the Country. AstraZeneca put up a tremendous and

> expensive defense and they successfully were able to get a large number

> of cases to be permanently dismissed by the court. Weitz & Luxenberg is

> the only firm who took a case to trial anywhere in the Country. However,

> after a month-long trial, the jury unfortunately ruled in favor of the

> defendants. This loss did not affect the strength of our fight. Over the

> past year, even as almost every other plaintiffs firm settled their

> cases, Weitz & Luxenberg prepared two more cases for trial which was

> scheduled to begin this Summer. As a direct result of the endless and

> consistent pressure applied by the attorneys at Weitz & Luxenberg, we

> are happy to report that AstraZeneca has now agreed to participate in a

> favorable settlement program. Based on public reports regarding

> settlement programs reached with other plaintiff law firms we are

> confident that the settlement program outlined below has more favorable

> terms and for this reason we are recommending your participation.

> The defendants have argued that they refuse to pay anyone who cannot

> prove through medical records or via certification that they have used

> Seroquel. They also refuse to pay anyone whose case is not active in

> this litigation. We recently told you about the Order issued by the

> Court requiring you to confirm when you started taking Seroquel and when

> you stopped taking Seroquel. We cannot stress enough that you MUST read,

> complete and return this certification form to us immediately. The

> failure to return this form within the next 30 days will result in the

> permanent dismissal of your case. In order to protect your legal rights,

> to keep your case active and be permitted to participate in this

> Settlement Program you must take this Order very seriously and you must

> respond.

> Based on our experience in other litigations and having reviewed the

> media reports of the terms of other firms' Seroquel settlement programs,

> we know that the defendants are looking for a settlement program that

> includes all claimants (W & L Seroquel Plaintiffs) so that they will

> achieve complete closure of the entirYlitigation. Our goal in this

> negotiation was to obtain a settlement for the most amount of money

> using a fair method to pay our clients based upon the merits of their

> individual case. We also stressed our intentions that the case review

> and payment process be performed quickly yet fairly so that our clients

> can receive their settlements as soon as possible. A key part of this

> settlement program is that a claimant cannot be part of the settlement

> if their case is dismissed and unless they provide, at the very least, a

> certification that they in fact took Seroquel and suffered an injury.

> Therefore, please make sure that you return your certification form to

> us immediately

>

> We have hired Hon.Marina Corodemus to act as the Special Master for the

> W & L Seroquel settlement program. Judge Corodemus previously ran the New

> Jersey Mass Tort Court and has a lot of experience in this field. She

> was appointed as a Special Master by the Vioxx State and Federal Court

> Judges to determine the appropriateness of Vioxx settlements and to

> resolve Vioxx appeals. She has also served as the Special Master in many

> other litigations such as Bextra and Celebrex which used similar

> settlement terms. We have met several times with Judge Corodemus and

> discussed the goals outlined above to get the most amount of money to

> the most amount of claimants in the fastest amount of time possible. We

> believe that Judge Corodemus is the perfect choice to create and oversee

> a settlement program in accordance with these goals. The W & L Seroquel

> Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> those clients with active cases (not dismissed as outlined above) can

> participate in this settlement program. Unlike other settlement programs

> that you may have read about in the media and internet, the W & L

> Settlement program does not award every case an equal settlement amount.

> The size of an individual's settlement will depend entirely on the merit

> of that individual's case. As a direct result of the large number of

> cases represented by W & L, and the merits of those cases, we are

> confident that we have obtained the best possible settlement for our

> clients. After complex negotiations, AstraZeneca

> has agreed to deposit $92.25 Million dollars into a trust account to be

> used for this Settlement Program. This amount is completely confidential

> and you should NOT discuss this with anyone. A settlement of this type

> is called an " Aggregate Settlement " where a fair and reasonable sum of

> money is obtained to resolve multiple cases. In order to maintain proper

> representation of each individual client, W & L is NOT involved in the

> allocation decision making, which will be handled exclusively by Judge

> Corodemus. W & L has reviewed the general framework of the settlement

> plan with Judge Corodemus and we strongly believe that it is fair and

> reasonable and offers each of our clients the best possible outcome

> under the circumstances of this litigation. Track I offers the Seroquel

> claimant a settlement of $12,000. This track involves a simple review of

> each case and will result in a quick approval by Judge Corodemus without

> an analysis of the specific details of the case such as injury, amount

> of Seroquel taken, how close the last Seroquel use was to the date of

> the injury or the individual claimant's risk factors. a) Cannot

> prove that they suffered diabetes or a diabetes related condition,

> and/or Cannot prove that they used Seroquel within 1 year of

> their claimed injury, and/or c) Had a large number of known

> risk factors for diabetes before they started taking Seroquel. For

> example - obesity, family history, smoking, etc.

>

> Therefore, all cases whose injuries are limited to weight gain or high

> blood sugar and whose medical records will confirm that they were never

> diagnosed with diabetes or pancreatitis, should choose Track 1.

> Similarly, any claimed injury that occurred long after the last use of

> Seroquel should also choose Track 1. These cases are likely to receive a

> small award in Track II (likely less than $12,000) because it is

> extremely difficult to prove that these injuries were caused by

> Seroquel. Therefore, we suggest that if your case falls into this

> category you should choose Track 1. Additionally, payment of Track I

> settlement awards will be processed first once AstaZeneca waives its

> " walk away right " . (See Section IV© below) Track II involves an

> in-depth review of the severity of the injury, the claimed use of

> Seroquel and its proximity to the injury as well the available proof

> found in the contemporaneous medical records. Additionally, Judge

> Corodemus will strongly consider many known risk factors for these

> injuries including but not limited to smoking, obesity and family

> history as well as the participation in the Zyprexa settlement for these

> same injuries. This model is very similar to the one used in the

> National Vioxx Settlement Program as well as dozens of other similar

> settlement programs which were successfully resolved in recent years.

> Judge Corodemus has established a points system and will consider all of

> the critical issues including but not limited to:

> - Nature of the injury - Severity of the injury - Age at the time of

> injury - Proximity of Seroquel use to the claimed injury - Changes in

> the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> etc. After carefully reviewing all of the medical records and the

> individual fact sheet, Judge Corodemus will assign a point value to each

> case. The more points a case is awarded based on the specific facts of

> the case, the larger the settlement will be. At this time, there is no

> way to predict with accuracy how many points an individual case may be

> awarded and it is even more difficult to determine how much money each

> point will receive. The exact value of each point will depend on the

> number of participants in Track II and the total number of points

> assigned. All cases in Track II will be eligible for a settlement award

> but Judge Corodemus could award LESS than $12,000 (what people will

> receive automatically by choosing Track 1) if the case lacks merit. In

> the interest of fairness, Judge Corodemus has committed to review each

> case in Track II very carefully and this process will take time to

> complete. Judge Corodemus has stated that she hopes to have this process

> completed by the end of 2011 but please be warned that it could take a

> little longer due to the amount of work that is involved. However, in

> order to get this settlement process moving forward and ultimately paid

> you must send us your signed Release form as soon as possible. If you

> choose Track I your settlement award of $12,000 is set. If you choose

> Track II, Judge Corodemus will review your claim and will issue an

> award. We expect that we will contact you in approximately November 2011

> and notify you of your point award and the expected amount of your

> settlement. At that point, you will be given a choice to accept your

> award, appeal your award or withdraw from the settlement program. If you

> accept, we will forward your release to AstraZeneca for their review and

> approval. Please understand that this settlement is not official until

> we send AstraZeneca your signed Release Form, AstraZeneca approves it

> AND AstraZeneca waives its walk away right. In the interest of time, we

> are asking you to return your signed Release Form now so we can meet the

> tight deadlines associated with this settlement. If you are unhappy with

> your allocation amount and/or believe that your case involves

> " Extraordinary Injury or Circumstances " you have the right to appeal

> your award. Upon receipt of such an application, Judge Corodemus will

> re-review your records and make a final decision. Please be aware that

> there is no additional right of appeal (to Judge Corodemus or to any

> Court) once this final decision is made. If you decide to decline the

> settlement amount offered to you, you must notify us within ten days of

> your receipt of your allocation amount and your signed Release Form will

> no longer be valid. As in all settlements of this type, our agreement

> with the defendant depends on nearly full participation from all of our

> clients. Under the terms of our agreement, we must provide Qualifying

> Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once

> we reach this number, AstraZeneca's " walk away right " is officially

> waived. We strongly believe that our clients will agree that this

> settlement program offers the best possible terms and we expect that we

> will meet this requirement in the next 90-120 days. In order to meet

> this deadline we MUST have your complete

> cooperation and immediate response. Of course, if we do not meet this

> required number of responses, Astrazeneca can decide to withdraw its

> settlement offer to everyone whether one signed the Release Form or not.

> Therefore, time is of the essence. A. Release Form: Enclosed you will

> find a Release Form which you must sign in front of a notary in Order to

> participate in the settlement. If you have a spouse he/she must sign the

> Release Form as well. Attached to the Release Form will be an

> instruction sheet to guide you to ensure that this important form is

> signed the right way. A Release Form that is signed the wrong way or

> that is not witnessed (by a notary) is useless and will not be accepted

> by the defendants. The Release Form is your agreement to participate in

> the settlement program and at the same time discontinue your lawsuit in

> exchange for your settlement award. Please turn to Page 2 of the Release

> Form and complete the details of your Seroquel use. You may refer to

> Page 1 of the Brief Questionnaire which lists the Seroquel information

> that was found in your medical records or that you have previously

> provided to us. If this information is inaccurate, please cross it out

> and write in when you started and when you stopped taking Seroquel on

> BOTH the Release Form and the Brief Questionnaire. Due to the fast

> approaching deadlines, and our goal to get you your settlement processed

> and paid as quickly as possible, we MUST receive this signed release

> form back from you before August 31, 2011. Please use the envelope

> provided herein and return the signed and notarized release form today

> before you forget about it. Please note that once we submit your release

> form to AstraZeneca it can not be revoked. B. Track Selection Form:

> Enclosed you will find a " Track Selection Form " which is the form used

> to officially notify the Special Master which Track you want your case

> to follow. Please Note that there are 4 options on this form. You MUST

> check one of the Options. If you want to participate in this settlement,

> and we strongly think that you should, you must check either Track I OR

> Track II and you must sign the bottom of the form. Your Track selection

> cannot be changed and is considered final once the Judge's Allocations

> are made. In other words, a person who chooses Track II and is awarded

> less than $12,000 CANNOT then choose to go to Track 1 for a higher

> award. C. Brief Questionnaire: Enclosed you will find a 3

> page Brief Questionnaire which has important information about your

> claim. For all claimants who choose to enter Track II, Judge Corodemus

> will be reviewing your medical records, your Fact Sheet and this Brief

> Questionnaire and will issue a point award. Judge Corodemus will

> consider the proof of your claim found in your medical records as well

> as the information that you provide in this Questionnaire. Therefore, it

> is important that you answer these questions honestly and completely and

> that they are consistent with what is found in your medical records.

> litigation and our conversations with our medical experts, it is clear

> that Seroquel lawsuits are very difficult to win, very expensive, and

> very time consuming to take through to trial, verdict and appeal. Over

> the past six years only I case (from W & L) of24,000 cases in the Country

> made it to and through trial. Countless other cases were prepared and

> then dismissed based on merit and/or inability to prove that Seroquel

> caused the injury. Just because an individual took Seroquel and suffered

> an injury like diabetes does not mean that such a case will win at

> trial. In order to succeed at trial, a plaintiff must prove both that

> Seroquel can cause such an injury in general AND that, within a

> reasonable degree of medical certainty, Seroquel caused this injury to

> this particular person (despite any individual risk factors such as

> smoking, weight, high blood sugar, family history etc.). We have told

> you in the past update letters that the Courts have consistently ruled

> in favor of the defendants on many of these issues and have prohibited

> medical experts from testifying because of a lack of scientific proof

> linking the plaintiff s injuries to his/her Seroquel use. It is also

> important to note that even if your case is able to advance past this

> judicial scrutiny, a trial of this magnitude will cost over $750,000 per

> case and many of these costs are reimbursed off of the top of a

> favorable verdict reducing the amount received by the plaintiff.

> Furthermore, any case that is won at trial will surely face a lengthy

> and hard-fought appeal. Finally, nearly all of the Seroquel cases are

> being handled by three judges. Even at an accelerated pace, the chances

> are slim that your case would be tried in the next 10 years if not

> longer. In taking all of these factors into consideration, and

> considering the issues of risk and reward, we believe that a settlement

> of this type offers you the most advantageous resolution possible. You

> will be notified once the Special Master issues your point award at

> which point you can appeal to the Special Master if you believe that

> your case involves extraordinary circumstances. Thereafter, the decision

> of the Special Master is final, binding and non-appealable. We have

> retained the Garretson Law Firm to negotiate any and all Federal and

> State liens (Medicare/Medicaid/SSI) that may be applicable in your case.

> The Garretson Firm is a specialist in this field and they have obtained

> excellent results in their negotiation of similar liens in other

> litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson

> Firm has already worked on thousands of other Seroquel cases and has

> been able to achieve excellent results in large part due to the volume

> of cases that they are able to include in a Global Resolution. At this

> time, the Garretson Firm has already negotiated with 44 individual

> states regarding Medicaid and they have reached an agreement to CAP

> Medicaid liens at a maximum of 20% of the settlement amount. Please see

> the enclosed blue booklet regarding governmental liens for more details.

> Additionally, please also be advised that if you or Weitz & Luxenberg

> are put on written notice of a private lien, for example from your

> medical provider, this lien must be resolved before any settlement

> proceeds can be distributed. If you have received any notice of a lien,

> please advise us immediately. The terms of your signed contingency fee

> agreement will be in effect. We have taken great effort to keep the case

> specific expenses as low as possible. Under the terms of your agreement,

> the

> contingency fee will be calculated after the expenses are deducted.

> Under the terms of our agreement with AstraZeneca, any interest earned

> on the settlement proceeds before allocation and payment to the

> individual clients will be used to offset the fixed costs of the Special

> Master and the Lien Administrator. Due to the low interest rates paid by

> all banks in this economy, we do not expect that there will be any

> leftover interest. However, in such a case, the leftover interest will

> be added to the settlement trust and will be distributed to all

> claimants as part of Judge Corodemus' allocation process. After careful

> analysis of the likelihood of success in the court system, as well as

> the cost and time elements involved, we strongly recommend that you

> AGREE to participate in this settlement. We are confident that this

> settlement is the best possible resolution of your claim especially in

> light of the history of this litigation. We expect that any case that

> does not agree to participate in this settlement will have a very

> difficult time navigating through the Court system and trial dates may

> not be set for many years. Moreover, as we have seen, these cases will

> be aggressively defended by AstraZeneca and we expect that we will

> receive motions to dismiss and unfavorable decisions from the Court on

> unsettled cases in the coming months. Moreover, if this settlement

> program is not successful (we fail to reach the 98% response rate) we

> highly doubt that we will ever obtain a settlement amount and terms as

> good as those contained in this program. While we hope that this letter

> and enclosures will help answer all of your questions, we understand

> that you may have additional questions for us. Please keep in mind that

> we are working very hard to evaluate each and every case individually

> and the many deadlines that are part of this settlement are fast

> approaching. Your case has been assigned to Judy Koenig. If you have an

> important question please call Judy Koenig at (800) 438-9786 and ask for

> extension 5860. If you reach a voice-mail, please leave a message and

> you will be called back as quickly as possible. Please do not leave

> multiple voicemail messages on the same day as that will slow down our

> ability to return your call. Additionally, if you have email access,

> please try to email your detailed questions to us at sqinfo@...

> <mailto:sqinfo@...> and we will get back to you quickly. If

> this letter has successfully answered your questions, and you have

> decided to participate, please carefully follow the directions on the

> front page of the enclosed release form and send your signed and

> witnessed release formes), your Track Selection AND your Brief

> Questionnaire to us as soon as possible. If you still have questions

> after reviewing this letter and after speaking to us over the telephone

> and you would like to meet us in person, we will be happy to schedule a

> meeting in our office at your convenience. Finally, please remember that

> the detailed information regarding this settlement program is COMPLETELY

> CONFIDENTIAL and should not be shared or discussed with anyone.

> Sedgh, Esq Glenn Zuckerman, Esq.

>

[Guest guest]

I wonder whether individual suits are more effective than class action suits?

Those are known to be mostly for the benefit of the lawyers, in any field of

injury, not just pharmaceuticals. Cate

>

> " Awry, " not " a rye " but I digress. This is exactly why I never urge anyone to

sue. The deck is stacked against us in court and attorneys are looking for a

quick and easy buck. No justice is to be had.

>

> Terry

> Sent via BlackBerry by AT & T

>

> SEROQUEL Law Firms have sold their clients down the

river

>

> Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO

> REJECT this Insult on Top of Injury

> [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

> ElFTkSuQmCC]

>

>

>

> Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO

> REJECT this Insult on Top of Injury

> I would like to thank a brave, courageous, and ethical anonymous source

> who has send in this letter correspondence they received from the law

> firm of Weitz & Luxenberg. This letter doesn't require a whole lot of

> commentary.

> It's obvious that Law Firms have sold their clients down the proverbial

> river while at the same time enriching themselves (who's best interest

> are you obligated too fulfill?). This settlement offer and the injured

> litigants legal representation has carried out a blatant miscarriage of

> justice, a forever horrible stain upon the American Justice system, and

> a orchestrated crime perpetrated upon victims of this well documented &

> evidenced unbridled & unregulated corporate criminal enterprise gone a

> rye.

> The time has now come for the victims to stand up to this criminal

> corporation " AstraZeneca " & their poison drug " Seroquel " , to reject this

> horrible injustice and settlement offer. We want, what America & our

> Constitution promises us all, our day in court before a jury of our

> peers....

> ____________________________________________________________

>

> Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> We are happy to report excellent news! After a long and hard fought

> legal battle, AstraZeneca has agreed to participate in a Settlement

> Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> patience and aggressive litigating has resulted in very favorable

> settlement terms for our clients which will be further outlined below.

> We have carefully reviewed all of the factors of this agreement and we

> believe that this settlement offers you the best, and very likely the

> only opportunity to receive a fair resolution of your lawsuit.

> Therefore, we strongly recommend that you sign and complete the enclosed

> " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> AGREE to participate.

> As you know, we have engaged in a long legal battle with AstraZeneca

> over the past 6 years. Weitz & Luxenberg led the charge for the

> Plaintiffs around the Country. AstraZeneca put up a tremendous and

> expensive defense and they successfully were able to get a large number

> of cases to be permanently dismissed by the court. Weitz & Luxenberg is

> the only firm who took a case to trial anywhere in the Country. However,

> after a month-long trial, the jury unfortunately ruled in favor of the

> defendants. This loss did not affect the strength of our fight. Over the

> past year, even as almost every other plaintiffs firm settled their

> cases, Weitz & Luxenberg prepared two more cases for trial which was

> scheduled to begin this Summer. As a direct result of the endless and

> consistent pressure applied by the attorneys at Weitz & Luxenberg, we

> are happy to report that AstraZeneca has now agreed to participate in a

> favorable settlement program. Based on public reports regarding

> settlement programs reached with other plaintiff law firms we are

> confident that the settlement program outlined below has more favorable

> terms and for this reason we are recommending your participation.

> The defendants have argued that they refuse to pay anyone who cannot

> prove through medical records or via certification that they have used

> Seroquel. They also refuse to pay anyone whose case is not active in

> this litigation. We recently told you about the Order issued by the

> Court requiring you to confirm when you started taking Seroquel and when

> you stopped taking Seroquel. We cannot stress enough that you MUST read,

> complete and return this certification form to us immediately. The

> failure to return this form within the next 30 days will result in the

> permanent dismissal of your case. In order to protect your legal rights,

> to keep your case active and be permitted to participate in this

> Settlement Program you must take this Order very seriously and you must

> respond.

> Based on our experience in other litigations and having reviewed the

> media reports of the terms of other firms' Seroquel settlement programs,

> we know that the defendants are looking for a settlement program that

> includes all claimants (W & L Seroquel Plaintiffs) so that they will

> achieve complete closure of the entirYlitigation. Our goal in this

> negotiation was to obtain a settlement for the most amount of money

> using a fair method to pay our clients based upon the merits of their

> individual case. We also stressed our intentions that the case review

> and payment process be performed quickly yet fairly so that our clients

> can receive their settlements as soon as possible. A key part of this

> settlement program is that a claimant cannot be part of the settlement

> if their case is dismissed and unless they provide, at the very least, a

> certification that they in fact took Seroquel and suffered an injury.

> Therefore, please make sure that you return your certification form to

> us immediately

>

> We have hired Hon.Marina Corodemus to act as the Special Master for the

> W & L Seroquel settlement program. Judge Corodemus previously ran the New

> Jersey Mass Tort Court and has a lot of experience in this field. She

> was appointed as a Special Master by the Vioxx State and Federal Court

> Judges to determine the appropriateness of Vioxx settlements and to

> resolve Vioxx appeals. She has also served as the Special Master in many

> other litigations such as Bextra and Celebrex which used similar

> settlement terms. We have met several times with Judge Corodemus and

> discussed the goals outlined above to get the most amount of money to

> the most amount of claimants in the fastest amount of time possible. We

> believe that Judge Corodemus is the perfect choice to create and oversee

> a settlement program in accordance with these goals. The W & L Seroquel

> Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> those clients with active cases (not dismissed as outlined above) can

> participate in this settlement program. Unlike other settlement programs

> that you may have read about in the media and internet, the W & L

> Settlement program does not award every case an equal settlement amount.

> The size of an individual's settlement will depend entirely on the merit

> of that individual's case. As a direct result of the large number of

> cases represented by W & L, and the merits of those cases, we are

> confident that we have obtained the best possible settlement for our

> clients. After complex negotiations, AstraZeneca

> has agreed to deposit $92.25 Million dollars into a trust account to be

> used for this Settlement Program. This amount is completely confidential

> and you should NOT discuss this with anyone. A settlement of this type

> is called an " Aggregate Settlement " where a fair and reasonable sum of

> money is obtained to resolve multiple cases. In order to maintain proper

> representation of each individual client, W & L is NOT involved in the

> allocation decision making, which will be handled exclusively by Judge

> Corodemus. W & L has reviewed the general framework of the settlement

> plan with Judge Corodemus and we strongly believe that it is fair and

> reasonable and offers each of our clients the best possible outcome

> under the circumstances of this litigation. Track I offers the Seroquel

> claimant a settlement of $12,000. This track involves a simple review of

> each case and will result in a quick approval by Judge Corodemus without

> an analysis of the specific details of the case such as injury, amount

> of Seroquel taken, how close the last Seroquel use was to the date of

> the injury or the individual claimant's risk factors. a) Cannot

> prove that they suffered diabetes or a diabetes related condition,

> and/or Cannot prove that they used Seroquel within 1 year of

> their claimed injury, and/or c) Had a large number of known

> risk factors for diabetes before they started taking Seroquel. For

> example - obesity, family history, smoking, etc.

>

> Therefore, all cases whose injuries are limited to weight gain or high

> blood sugar and whose medical records will confirm that they were never

> diagnosed with diabetes or pancreatitis, should choose Track 1.

> Similarly, any claimed injury that occurred long after the last use of

> Seroquel should also choose Track 1. These cases are likely to receive a

> small award in Track II (likely less than $12,000) because it is

> extremely difficult to prove that these injuries were caused by

> Seroquel. Therefore, we suggest that if your case falls into this

> category you should choose Track 1. Additionally, payment of Track I

> settlement awards will be processed first once AstaZeneca waives its

> " walk away right " . (See Section IV© below) Track II involves an

> in-depth review of the severity of the injury, the claimed use of

> Seroquel and its proximity to the injury as well the available proof

> found in the contemporaneous medical records. Additionally, Judge

> Corodemus will strongly consider many known risk factors for these

> injuries including but not limited to smoking, obesity and family

> history as well as the participation in the Zyprexa settlement for these

> same injuries. This model is very similar to the one used in the

> National Vioxx Settlement Program as well as dozens of other similar

> settlement programs which were successfully resolved in recent years.

> Judge Corodemus has established a points system and will consider all of

> the critical issues including but not limited to:

> - Nature of the injury - Severity of the injury - Age at the time of

> injury - Proximity of Seroquel use to the claimed injury - Changes in

> the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> etc. After carefully reviewing all of the medical records and the

> individual fact sheet, Judge Corodemus will assign a point value to each

> case. The more points a case is awarded based on the specific facts of

> the case, the larger the settlement will be. At this time, there is no

> way to predict with accuracy how many points an individual case may be

> awarded and it is even more difficult to determine how much money each

> point will receive. The exact value of each point will depend on the

> number of participants in Track II and the total number of points

> assigned. All cases in Track II will be eligible for a settlement award

> but Judge Corodemus could award LESS than $12,000 (what people will

> receive automatically by choosing Track 1) if the case lacks merit. In

> the interest of fairness, Judge Corodemus has committed to review each

> case in Track II very carefully and this process will take time to

> complete. Judge Corodemus has stated that she hopes to have this process

> completed by the end of 2011 but please be warned that it could take a

> little longer due to the amount of work that is involved. However, in

> order to get this settlement process moving forward and ultimately paid

> you must send us your signed Release form as soon as possible. If you

> choose Track I your settlement award of $12,000 is set. If you choose

> Track II, Judge Corodemus will review your claim and will issue an

> award. We expect that we will contact you in approximately November 2011

> and notify you of your point award and the expected amount of your

> settlement. At that point, you will be given a choice to accept your

> award, appeal your award or withdraw from the settlement program. If you

> accept, we will forward your release to AstraZeneca for their review and

> approval. Please understand that this settlement is not official until

> we send AstraZeneca your signed Release Form, AstraZeneca approves it

> AND AstraZeneca waives its walk away right. In the interest of time, we

> are asking you to return your signed Release Form now so we can meet the

> tight deadlines associated with this settlement. If you are unhappy with

> your allocation amount and/or believe that your case involves

> " Extraordinary Injury or Circumstances " you have the right to appeal

> your award. Upon receipt of such an application, Judge Corodemus will

> re-review your records and make a final decision. Please be aware that

> there is no additional right of appeal (to Judge Corodemus or to any

> Court) once this final decision is made. If you decide to decline the

> settlement amount offered to you, you must notify us within ten days of

> your receipt of your allocation amount and your signed Release Form will

> no longer be valid. As in all settlements of this type, our agreement

> with the defendant depends on nearly full participation from all of our

> clients. Under the terms of our agreement, we must provide Qualifying

> Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once

> we reach this number, AstraZeneca's " walk away right " is officially

> waived. We strongly believe that our clients will agree that this

> settlement program offers the best possible terms and we expect that we

> will meet this requirement in the next 90-120 days. In order to meet

> this deadline we MUST have your complete

> cooperation and immediate response. Of course, if we do not meet this

> required number of responses, Astrazeneca can decide to withdraw its

> settlement offer to everyone whether one signed the Release Form or not.

> Therefore, time is of the essence. A. Release Form: Enclosed you will

> find a Release Form which you must sign in front of a notary in Order to

> participate in the settlement. If you have a spouse he/she must sign the

> Release Form as well. Attached to the Release Form will be an

> instruction sheet to guide you to ensure that this important form is

> signed the right way. A Release Form that is signed the wrong way or

> that is not witnessed (by a notary) is useless and will not be accepted

> by the defendants. The Release Form is your agreement to participate in

> the settlement program and at the same time discontinue your lawsuit in

> exchange for your settlement award. Please turn to Page 2 of the Release

> Form and complete the details of your Seroquel use. You may refer to

> Page 1 of the Brief Questionnaire which lists the Seroquel information

> that was found in your medical records or that you have previously

> provided to us. If this information is inaccurate, please cross it out

> and write in when you started and when you stopped taking Seroquel on

> BOTH the Release Form and the Brief Questionnaire. Due to the fast

> approaching deadlines, and our goal to get you your settlement processed

> and paid as quickly as possible, we MUST receive this signed release

> form back from you before August 31, 2011. Please use the envelope

> provided herein and return the signed and notarized release form today

> before you forget about it. Please note that once we submit your release

> form to AstraZeneca it can not be revoked. B. Track Selection Form:

> Enclosed you will find a " Track Selection Form " which is the form used

> to officially notify the Special Master which Track you want your case

> to follow. Please Note that there are 4 options on this form. You MUST

> check one of the Options. If you want to participate in this settlement,

> and we strongly think that you should, you must check either Track I OR

> Track II and you must sign the bottom of the form. Your Track selection

> cannot be changed and is considered final once the Judge's Allocations

> are made. In other words, a person who chooses Track II and is awarded

> less than $12,000 CANNOT then choose to go to Track 1 for a higher

> award. C. Brief Questionnaire: Enclosed you will find a 3

> page Brief Questionnaire which has important information about your

> claim. For all claimants who choose to enter Track II, Judge Corodemus

> will be reviewing your medical records, your Fact Sheet and this Brief

> Questionnaire and will issue a point award. Judge Corodemus will

> consider the proof of your claim found in your medical records as well

> as the information that you provide in this Questionnaire. Therefore, it

> is important that you answer these questions honestly and completely and

> that they are consistent with what is found in your medical records.

> litigation and our conversations with our medical experts, it is clear

> that Seroquel lawsuits are very difficult to win, very expensive, and

> very time consuming to take through to trial, verdict and appeal. Over

> the past six years only I case (from W & L) of24,000 cases in the Country

> made it to and through trial. Countless other cases were prepared and

> then dismissed based on merit and/or inability to prove that Seroquel

> caused the injury. Just because an individual took Seroquel and suffered

> an injury like diabetes does not mean that such a case will win at

> trial. In order to succeed at trial, a plaintiff must prove both that

> Seroquel can cause such an injury in general AND that, within a

> reasonable degree of medical certainty, Seroquel caused this injury to

> this particular person (despite any individual risk factors such as

> smoking, weight, high blood sugar, family history etc.). We have told

> you in the past update letters that the Courts have consistently ruled

> in favor of the defendants on many of these issues and have prohibited

> medical experts from testifying because of a lack of scientific proof

> linking the plaintiff s injuries to his/her Seroquel use. It is also

> important to note that even if your case is able to advance past this

> judicial scrutiny, a trial of this magnitude will cost over $750,000 per

> case and many of these costs are reimbursed off of the top of a

> favorable verdict reducing the amount received by the plaintiff.

> Furthermore, any case that is won at trial will surely face a lengthy

> and hard-fought appeal. Finally, nearly all of the Seroquel cases are

> being handled by three judges. Even at an accelerated pace, the chances

> are slim that your case would be tried in the next 10 years if not

> longer. In taking all of these factors into consideration, and

> considering the issues of risk and reward, we believe that a settlement

> of this type offers you the most advantageous resolution possible. You

> will be notified once the Special Master issues your point award at

> which point you can appeal to the Special Master if you believe that

> your case involves extraordinary circumstances. Thereafter, the decision

> of the Special Master is final, binding and non-appealable. We have

> retained the Garretson Law Firm to negotiate any and all Federal and

> State liens (Medicare/Medicaid/SSI) that may be applicable in your case.

> The Garretson Firm is a specialist in this field and they have obtained

> excellent results in their negotiation of similar liens in other

> litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson

> Firm has already worked on thousands of other Seroquel cases and has

> been able to achieve excellent results in large part due to the volume

> of cases that they are able to include in a Global Resolution. At this

> time, the Garretson Firm has already negotiated with 44 individual

> states regarding Medicaid and they have reached an agreement to CAP

> Medicaid liens at a maximum of 20% of the settlement amount. Please see

> the enclosed blue booklet regarding governmental liens for more details.

> Additionally, please also be advised that if you or Weitz & Luxenberg

> are put on written notice of a private lien, for example from your

> medical provider, this lien must be resolved before any settlement

> proceeds can be distributed. If you have received any notice of a lien,

> please advise us immediately. The terms of your signed contingency fee

> agreement will be in effect. We have taken great effort to keep the case

> specific expenses as low as possible. Under the terms of your agreement,

> the

> contingency fee will be calculated after the expenses are deducted.

> Under the terms of our agreement with AstraZeneca, any interest earned

> on the settlement proceeds before allocation and payment to the

> individual clients will be used to offset the fixed costs of the Special

> Master and the Lien Administrator. Due to the low interest rates paid by

> all banks in this economy, we do not expect that there will be any

> leftover interest. However, in such a case, the leftover interest will

> be added to the settlement trust and will be distributed to all

> claimants as part of Judge Corodemus' allocation process. After careful

> analysis of the likelihood of success in the court system, as well as

> the cost and time elements involved, we strongly recommend that you

> AGREE to participate in this settlement. We are confident that this

> settlement is the best possible resolution of your claim especially in

> light of the history of this litigation. We expect that any case that

> does not agree to participate in this settlement will have a very

> difficult time navigating through the Court system and trial dates may

> not be set for many years. Moreover, as we have seen, these cases will

> be aggressively defended by AstraZeneca and we expect that we will

> receive motions to dismiss and unfavorable decisions from the Court on

> unsettled cases in the coming months. Moreover, if this settlement

> program is not successful (we fail to reach the 98% response rate) we

> highly doubt that we will ever obtain a settlement amount and terms as

> good as those contained in this program. While we hope that this letter

> and enclosures will help answer all of your questions, we understand

> that you may have additional questions for us. Please keep in mind that

> we are working very hard to evaluate each and every case individually

> and the many deadlines that are part of this settlement are fast

> approaching. Your case has been assigned to Judy Koenig. If you have an

> important question please call Judy Koenig at (800) 438-9786 and ask for

> extension 5860. If you reach a voice-mail, please leave a message and

> you will be called back as quickly as possible. Please do not leave

> multiple voicemail messages on the same day as that will slow down our

> ability to return your call. Additionally, if you have email access,

> please try to email your detailed questions to us at sqinfo@...

> <mailto:sqinfo@...> and we will get back to you quickly. If

> this letter has successfully answered your questions, and you have

> decided to participate, please carefully follow the directions on the

> front page of the enclosed release form and send your signed and

> witnessed release formes), your Track Selection AND your Brief

> Questionnaire to us as soon as possible. If you still have questions

> after reviewing this letter and after speaking to us over the telephone

> and you would like to meet us in person, we will be happy to schedule a

> meeting in our office at your convenience. Finally, please remember that

> the detailed information regarding this settlement program is COMPLETELY

> CONFIDENTIAL and should not be shared or discussed with anyone.

> Sedgh, Esq Glenn Zuckerman, Esq.

>

[Guest guest]

Been there. Been dragged through hell. Had every aspect of our lives, and our son's life, put under a microscope. Had lawsuit dismissed "with prejudice" due to pre-emption. To hell with lawsuits.T.Sent via BlackBerry by AT&TFrom: "Cate" <ccsh@...>Sender: SSRI medications Date: Fri, 26 Aug 2011 20:31:48 -0000<SSRI medications >Reply SSRI medications Subject: Re: SEROQUEL Law Firms have sold their clients down the river I wonder whether individual suits are more effective than class action suits? Those are known to be mostly for the benefit of the lawyers, in any field of injury, not just pharmaceuticals. Cate>> " Awry, " not " a rye " but I digress. This is exactly why I never urge anyone to sue. The deck is stacked against us in court and attorneys are looking for a quick and easy buck. No justice is to be had.> > Terry> Sent via BlackBerry by AT & T> > SEROQUEL Law Firms have sold their clients down the river> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO> REJECT this Insult on Top of Injury > [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\> ElFTkSuQmCC]> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO> REJECT this Insult on Top of Injury> I would like to thank a brave, courageous, and ethical anonymous source> who has send in this letter correspondence they received from the law> firm of Weitz & Luxenberg. This letter doesn't require a whole lot of> commentary.> It's obvious that Law Firms have sold their clients down the proverbial> river while at the same time enriching themselves (who's best interest> are you obligated too fulfill?). This settlement offer and the injured> litigants legal representation has carried out a blatant miscarriage of> justice, a forever horrible stain upon the American Justice system, and> a orchestrated crime perpetrated upon victims of this well documented & > evidenced unbridled & unregulated corporate criminal enterprise gone a> rye.> The time has now come for the victims to stand up to this criminal> corporation " AstraZeneca " & their poison drug " Seroquel " , to reject this> horrible injustice and settlement offer. We want, what America & our> Constitution promises us all, our day in court before a jury of our> peers....> __________________________________________________________> > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>> We are happy to report excellent news! After a long and hard fought> legal battle, AstraZeneca has agreed to participate in a Settlement> Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our> patience and aggressive litigating has resulted in very favorable> settlement terms for our clients which will be further outlined below.> We have carefully reviewed all of the factors of this agreement and we> believe that this settlement offers you the best, and very likely the> only opportunity to receive a fair resolution of your lawsuit.> Therefore, we strongly recommend that you sign and complete the enclosed> " Release Form " , " Track Selection Form " and " Brief Questionnaire " and> AGREE to participate.> As you know, we have engaged in a long legal battle with AstraZeneca> over the past 6 years. Weitz & Luxenberg led the charge for the> Plaintiffs around the Country. AstraZeneca put up a tremendous and> expensive defense and they successfully were able to get a large number> of cases to be permanently dismissed by the court. Weitz & Luxenberg is> the only firm who took a case to trial anywhere in the Country. However,> after a month-long trial, the jury unfortunately ruled in favor of the> defendants. This loss did not affect the strength of our fight. Over the> past year, even as almost every other plaintiffs firm settled their> cases, Weitz & Luxenberg prepared two more cases for trial which was> scheduled to begin this Summer. As a direct result of the endless and> consistent pressure applied by the attorneys at Weitz & Luxenberg, we> are happy to report that AstraZeneca has now agreed to participate in a> favorable settlement program. Based on public reports regarding> settlement programs reached with other plaintiff law firms we are> confident that the settlement program outlined below has more favorable> terms and for this reason we are recommending your participation.> The defendants have argued that they refuse to pay anyone who cannot> prove through medical records or via certification that they have used> Seroquel. They also refuse to pay anyone whose case is not active in> this litigation. We recently told you about the Order issued by the> Court requiring you to confirm when you started taking Seroquel and when> you stopped taking Seroquel. We cannot stress enough that you MUST read,> complete and return this certification form to us immediately. The> failure to return this form within the next 30 days will result in the> permanent dismissal of your case. In order to protect your legal rights,> to keep your case active and be permitted to participate in this> Settlement Program you must take this Order very seriously and you must> respond.> Based on our experience in other litigations and having reviewed the> media reports of the terms of other firms' Seroquel settlement programs,> we know that the defendants are looking for a settlement program that> includes all claimants (W & L Seroquel Plaintiffs) so that they will> achieve complete closure of the entirYlitigation. Our goal in this> negotiation was to obtain a settlement for the most amount of money> using a fair method to pay our clients based upon the merits of their> individual case. We also stressed our intentions that the case review> and payment process be performed quickly yet fairly so that our clients> can receive their settlements as soon as possible. A key part of this> settlement program is that a claimant cannot be part of the settlement> if their case is dismissed and unless they provide, at the very least, a> certification that they in fact took Seroquel and suffered an injury.> Therefore, please make sure that you return your certification form to> us immediately> > We have hired Hon.Marina Corodemus to act as the Special Master for the> W & L Seroquel settlement program. Judge Corodemus previously ran the New> Jersey Mass Tort Court and has a lot of experience in this field. She> was appointed as a Special Master by the Vioxx State and Federal Court> Judges to determine the appropriateness of Vioxx settlements and to> resolve Vioxx appeals. She has also served as the Special Master in many> other litigations such as Bextra and Celebrex which used similar> settlement terms. We have met several times with Judge Corodemus and> discussed the goals outlined above to get the most amount of money to> the most amount of claimants in the fastest amount of time possible. We> believe that Judge Corodemus is the perfect choice to create and oversee> a settlement program in accordance with these goals. The W & L Seroquel> Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only> those clients with active cases (not dismissed as outlined above) can> participate in this settlement program. Unlike other settlement programs> that you may have read about in the media and internet, the W & L> Settlement program does not award every case an equal settlement amount.> The size of an individual's settlement will depend entirely on the merit> of that individual's case. As a direct result of the large number of> cases represented by W & L, and the merits of those cases, we are> confident that we have obtained the best possible settlement for our> clients. After complex negotiations, AstraZeneca> has agreed to deposit $92.25 Million dollars into a trust account to be> used for this Settlement Program. This amount is completely confidential> and you should NOT discuss this with anyone. A settlement of this type> is called an " Aggregate Settlement " where a fair and reasonable sum of> money is obtained to resolve multiple cases. In order to maintain proper> representation of each individual client, W & L is NOT involved in the> allocation decision making, which will be handled exclusively by Judge> Corodemus. W & L has reviewed the general framework of the settlement> plan with Judge Corodemus and we strongly believe that it is fair and> reasonable and offers each of our clients the best possible outcome> under the circumstances of this litigation. Track I offers the Seroquel> claimant a settlement of $12,000. This track involves a simple review of> each case and will result in a quick approval by Judge Corodemus without> an analysis of the specific details of the case such as injury, amount> of Seroquel taken, how close the last Seroquel use was to the date of> the injury or the individual claimant's risk factors. a) Cannot> prove that they suffered diabetes or a diabetes related condition,> and/or Cannot prove that they used Seroquel within 1 year of> their claimed injury, and/or c) Had a large number of known> risk factors for diabetes before they started taking Seroquel. For> example - obesity, family history, smoking, etc.> > Therefore, all cases whose injuries are limited to weight gain or high> blood sugar and whose medical records will confirm that they were never> diagnosed with diabetes or pancreatitis, should choose Track 1.> Similarly, any claimed injury that occurred long after the last use of> Seroquel should also choose Track 1. These cases are likely to receive a> small award in Track II (likely less than $12,000) because it is> extremely difficult to prove that these injuries were caused by> Seroquel. Therefore, we suggest that if your case falls into this> category you should choose Track 1. Additionally, payment of Track I> settlement awards will be processed first once AstaZeneca waives its> " walk away right " . (See Section IV© below) Track II involves an> in-depth review of the severity of the injury, the claimed use of> Seroquel and its proximity to the injury as well the available proof> found in the contemporaneous medical records. Additionally, Judge> Corodemus will strongly consider many known risk factors for these> injuries including but not limited to smoking, obesity and family> history as well as the participation in the Zyprexa settlement for these> same injuries. This model is very similar to the one used in the> National Vioxx Settlement Program as well as dozens of other similar> settlement programs which were successfully resolved in recent years.> Judge Corodemus has established a points system and will consider all of> the critical issues including but not limited to:> - Nature of the injury - Severity of the injury - Age at the time of> injury - Proximity of Seroquel use to the claimed injury - Changes in> the Seroque11abel - Risk Factors including Smoking, Body Mass Index,> etc. After carefully reviewing all of the medical records and the> individual fact sheet, Judge Corodemus will assign a point value to each> case. The more points a case is awarded based on the specific facts of> the case, the larger the settlement will be. At this time, there is no> way to predict with accuracy how many points an individual case may be> awarded and it is even more difficult to determine how much money each> point will receive. The exact value of each point will depend on the> number of participants in Track II and the total number of points> assigned. All cases in Track II will be eligible for a settlement award> but Judge Corodemus could award LESS than $12,000 (what people will> receive automatically by choosing Track 1) if the case lacks merit. In> the interest of fairness, Judge Corodemus has committed to review each> case in Track II very carefully and this process will take time to> complete. Judge Corodemus has stated that she hopes to have this process> completed by the end of 2011 but please be warned that it could take a> little longer due to the amount of work that is involved. However, in> order to get this settlement process moving forward and ultimately paid> you must send us your signed Release form as soon as possible. If you> choose Track I your settlement award of $12,000 is set. If you choose> Track II, Judge Corodemus will review your claim and will issue an> award. We expect that we will contact you in approximately November 2011> and notify you of your point award and the expected amount of your> settlement. At that point, you will be given a choice to accept your> award, appeal your award or withdraw from the settlement program. If you> accept, we will forward your release to AstraZeneca for their review and> approval. Please understand that this settlement is not official until> we send AstraZeneca your signed Release Form, AstraZeneca approves it> AND AstraZeneca waives its walk away right. In the interest of time, we> are asking you to return your signed Release Form now so we can meet the> tight deadlines associated with this settlement. If you are unhappy with> your allocation amount and/or believe that your case involves> " Extraordinary Injury or Circumstances " you have the right to appeal> your award. Upon receipt of such an application, Judge Corodemus will> re-review your records and make a final decision. Please be aware that> there is no additional right of appeal (to Judge Corodemus or to any> Court) once this final decision is made. If you decide to decline the> settlement amount offered to you, you must notify us within ten days of> your receipt of your allocation amount and your signed Release Form will> no longer be valid. As in all settlements of this type, our agreement> with the defendant depends on nearly full participation from all of our> clients. Under the terms of our agreement, we must provide Qualifying> Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once> we reach this number, AstraZeneca's " walk away right " is officially> waived. We strongly believe that our clients will agree that this> settlement program offers the best possible terms and we expect that we> will meet this requirement in the next 90-120 days. In order to meet> this deadline we MUST have your complete> cooperation and immediate response. Of course, if we do not meet this> required number of responses, Astrazeneca can decide to withdraw its> settlement offer to everyone whether one signed the Release Form or not.> Therefore, time is of the essence. A. Release Form: Enclosed you will> find a Release Form which you must sign in front of a notary in Order to> participate in the settlement. If you have a spouse he/she must sign the> Release Form as well. Attached to the Release Form will be an> instruction sheet to guide you to ensure that this important form is> signed the right way. A Release Form that is signed the wrong way or> that is not witnessed (by a notary) is useless and will not be accepted> by the defendants. The Release Form is your agreement to participate in> the settlement program and at the same time discontinue your lawsuit in> exchange for your settlement award. Please turn to Page 2 of the Release> Form and complete the details of your Seroquel use. You may refer to> Page 1 of the Brief Questionnaire which lists the Seroquel information> that was found in your medical records or that you have previously> provided to us. If this information is inaccurate, please cross it out> and write in when you started and when you stopped taking Seroquel on> BOTH the Release Form and the Brief Questionnaire. Due to the fast> approaching deadlines, and our goal to get you your settlement processed> and paid as quickly as possible, we MUST receive this signed release> form back from you before August 31, 2011. Please use the envelope> provided herein and return the signed and notarized release form today> before you forget about it. Please note that once we submit your release> form to AstraZeneca it can not be revoked. B. Track Selection Form:> Enclosed you will find a " Track Selection Form " which is the form used> to officially notify the Special Master which Track you want your case> to follow. Please Note that there are 4 options on this form. You MUST> check one of the Options. If you want to participate in this settlement,> and we strongly think that you should, you must check either Track I OR> Track II and you must sign the bottom of the form. Your Track selection> cannot be changed and is considered final once the Judge's Allocations> are made. In other words, a person who chooses Track II and is awarded> less than $12,000 CANNOT then choose to go to Track 1 for a higher> award. C. Brief Questionnaire: Enclosed you will find a 3> page Brief Questionnaire which has important information about your> claim. For all claimants who choose to enter Track II, Judge Corodemus> will be reviewing your medical records, your Fact Sheet and this Brief> Questionnaire and will issue a point award. Judge Corodemus will> consider the proof of your claim found in your medical records as well> as the information that you provide in this Questionnaire. Therefore, it> is important that you answer these questions honestly and completely and> that they are consistent with what is found in your medical records.> litigation and our conversations with our medical experts, it is clear> that Seroquel lawsuits are very difficult to win, very expensive, and> very time consuming to take through to trial, verdict and appeal. Over> the past six years only I case (from W & L) of24,000 cases in the Country> made it to and through trial. Countless other cases were prepared and> then dismissed based on merit and/or inability to prove that Seroquel> caused the injury. Just because an individual took Seroquel and suffered> an injury like diabetes does not mean that such a case will win at> trial. In order to succeed at trial, a plaintiff must prove both that> Seroquel can cause such an injury in general AND that, within a> reasonable degree of medical certainty, Seroquel caused this injury to> this particular person (despite any individual risk factors such as> smoking, weight, high blood sugar, family history etc.). We have told> you in the past update letters that the Courts have consistently ruled> in favor of the defendants on many of these issues and have prohibited> medical experts from testifying because of a lack of scientific proof> linking the plaintiff s injuries to his/her Seroquel use. It is also> important to note that even if your case is able to advance past this> judicial scrutiny, a trial of this magnitude will cost over $750,000 per> case and many of these costs are reimbursed off of the top of a> favorable verdict reducing the amount received by the plaintiff.> Furthermore, any case that is won at trial will surely face a lengthy> and hard-fought appeal. Finally, nearly all of the Seroquel cases are> being handled by three judges. Even at an accelerated pace, the chances> are slim that your case would be tried in the next 10 years if not> longer. In taking all of these factors into consideration, and> considering the issues of risk and reward, we believe that a settlement> of this type offers you the most advantageous resolution possible. You> will be notified once the Special Master issues your point award at> which point you can appeal to the Special Master if you believe that> your case involves extraordinary circumstances. Thereafter, the decision> of the Special Master is final, binding and non-appealable. We have> retained the Garretson Law Firm to negotiate any and all Federal and> State liens (Medicare/Medicaid/SSI) that may be applicable in your case.> The Garretson Firm is a specialist in this field and they have obtained> excellent results in their negotiation of similar liens in other> litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson> Firm has already worked on thousands of other Seroquel cases and has> been able to achieve excellent results in large part due to the volume> of cases that they are able to include in a Global Resolution. At this> time, the Garretson Firm has already negotiated with 44 individual> states regarding Medicaid and they have reached an agreement to CAP> Medicaid liens at a maximum of 20% of the settlement amount. Please see> the enclosed blue booklet regarding governmental liens for more details.> Additionally, please also be advised that if you or Weitz & Luxenberg> are put on written notice of a private lien, for example from your> medical provider, this lien must be resolved before any settlement> proceeds can be distributed. If you have received any notice of a lien,> please advise us immediately. The terms of your signed contingency fee> agreement will be in effect. We have taken great effort to keep the case> specific expenses as low as possible. Under the terms of your agreement,> the> contingency fee will be calculated after the expenses are deducted.> Under the terms of our agreement with AstraZeneca, any interest earned> on the settlement proceeds before allocation and payment to the> individual clients will be used to offset the fixed costs of the Special> Master and the Lien Administrator. Due to the low interest rates paid by> all banks in this economy, we do not expect that there will be any> leftover interest. However, in such a case, the leftover interest will> be added to the settlement trust and will be distributed to all> claimants as part of Judge Corodemus' allocation process. After careful> analysis of the likelihood of success in the court system, as well as> the cost and time elements involved, we strongly recommend that you> AGREE to participate in this settlement. We are confident that this> settlement is the best possible resolution of your claim especially in> light of the history of this litigation. We expect that any case that> does not agree to participate in this settlement will have a very> difficult time navigating through the Court system and trial dates may> not be set for many years. Moreover, as we have seen, these cases will> be aggressively defended by AstraZeneca and we expect that we will> receive motions to dismiss and unfavorable decisions from the Court on> unsettled cases in the coming months. Moreover, if this settlement> program is not successful (we fail to reach the 98% response rate) we> highly doubt that we will ever obtain a settlement amount and terms as> good as those contained in this program. While we hope that this letter> and enclosures will help answer all of your questions, we understand> that you may have additional questions for us. Please keep in mind that> we are working very hard to evaluate each and every case individually> and the many deadlines that are part of this settlement are fast> approaching. Your case has been assigned to Judy Koenig. If you have an> important question please call Judy Koenig at (800) 438-9786 and ask for> extension 5860. If you reach a voice-mail, please leave a message and> you will be called back as quickly as possible. Please do not leave> multiple voicemail messages on the same day as that will slow down our> ability to return your call. Additionally, if you have email access,> please try to email your detailed questions to us at sqinfo@...> <mailto:sqinfo@...> and we will get back to you quickly. If> this letter has successfully answered your questions, and you have> decided to participate, please carefully follow the directions on the> front page of the enclosed release form and send your signed and> witnessed release formes), your Track Selection AND your Brief> Questionnaire to us as soon as possible. If you still have questions> after reviewing this letter and after speaking to us over the telephone> and you would like to meet us in person, we will be happy to schedule a> meeting in our office at your convenience. Finally, please remember that> the detailed information regarding this settlement program is COMPLETELY> CONFIDENTIAL and should not be shared or discussed with anyone. > Sedgh, Esq Glenn Zuckerman, Esq.>

[Guest guest]

Been there. Been dragged through hell. Had every aspect of our lives, and our son's life, put under a microscope. Had lawsuit dismissed "with prejudice" due to pre-emption. To hell with lawsuits.T.Sent via BlackBerry by AT&TFrom: "Cate" <ccsh@...>Sender: SSRI medications Date: Fri, 26 Aug 2011 20:31:48 -0000<SSRI medications >Reply SSRI medications Subject: Re: SEROQUEL Law Firms have sold their clients down the river I wonder whether individual suits are more effective than class action suits? Those are known to be mostly for the benefit of the lawyers, in any field of injury, not just pharmaceuticals. Cate>> " Awry, " not " a rye " but I digress. This is exactly why I never urge anyone to sue. The deck is stacked against us in court and attorneys are looking for a quick and easy buck. No justice is to be had.> > Terry> Sent via BlackBerry by AT & T> > SEROQUEL Law Firms have sold their clients down the river> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO> REJECT this Insult on Top of Injury > [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\> ElFTkSuQmCC]> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO> REJECT this Insult on Top of Injury> I would like to thank a brave, courageous, and ethical anonymous source> who has send in this letter correspondence they received from the law> firm of Weitz & Luxenberg. This letter doesn't require a whole lot of> commentary.> It's obvious that Law Firms have sold their clients down the proverbial> river while at the same time enriching themselves (who's best interest> are you obligated too fulfill?). This settlement offer and the injured> litigants legal representation has carried out a blatant miscarriage of> justice, a forever horrible stain upon the American Justice system, and> a orchestrated crime perpetrated upon victims of this well documented & > evidenced unbridled & unregulated corporate criminal enterprise gone a> rye.> The time has now come for the victims to stand up to this criminal> corporation " AstraZeneca " & their poison drug " Seroquel " , to reject this> horrible injustice and settlement offer. We want, what America & our> Constitution promises us all, our day in court before a jury of our> peers....> __________________________________________________________> > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>> We are happy to report excellent news! After a long and hard fought> legal battle, AstraZeneca has agreed to participate in a Settlement> Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our> patience and aggressive litigating has resulted in very favorable> settlement terms for our clients which will be further outlined below.> We have carefully reviewed all of the factors of this agreement and we> believe that this settlement offers you the best, and very likely the> only opportunity to receive a fair resolution of your lawsuit.> Therefore, we strongly recommend that you sign and complete the enclosed> " Release Form " , " Track Selection Form " and " Brief Questionnaire " and> AGREE to participate.> As you know, we have engaged in a long legal battle with AstraZeneca> over the past 6 years. Weitz & Luxenberg led the charge for the> Plaintiffs around the Country. AstraZeneca put up a tremendous and> expensive defense and they successfully were able to get a large number> of cases to be permanently dismissed by the court. Weitz & Luxenberg is> the only firm who took a case to trial anywhere in the Country. However,> after a month-long trial, the jury unfortunately ruled in favor of the> defendants. This loss did not affect the strength of our fight. Over the> past year, even as almost every other plaintiffs firm settled their> cases, Weitz & Luxenberg prepared two more cases for trial which was> scheduled to begin this Summer. As a direct result of the endless and> consistent pressure applied by the attorneys at Weitz & Luxenberg, we> are happy to report that AstraZeneca has now agreed to participate in a> favorable settlement program. Based on public reports regarding> settlement programs reached with other plaintiff law firms we are> confident that the settlement program outlined below has more favorable> terms and for this reason we are recommending your participation.> The defendants have argued that they refuse to pay anyone who cannot> prove through medical records or via certification that they have used> Seroquel. They also refuse to pay anyone whose case is not active in> this litigation. We recently told you about the Order issued by the> Court requiring you to confirm when you started taking Seroquel and when> you stopped taking Seroquel. We cannot stress enough that you MUST read,> complete and return this certification form to us immediately. The> failure to return this form within the next 30 days will result in the> permanent dismissal of your case. In order to protect your legal rights,> to keep your case active and be permitted to participate in this> Settlement Program you must take this Order very seriously and you must> respond.> Based on our experience in other litigations and having reviewed the> media reports of the terms of other firms' Seroquel settlement programs,> we know that the defendants are looking for a settlement program that> includes all claimants (W & L Seroquel Plaintiffs) so that they will> achieve complete closure of the entirYlitigation. Our goal in this> negotiation was to obtain a settlement for the most amount of money> using a fair method to pay our clients based upon the merits of their> individual case. We also stressed our intentions that the case review> and payment process be performed quickly yet fairly so that our clients> can receive their settlements as soon as possible. A key part of this> settlement program is that a claimant cannot be part of the settlement> if their case is dismissed and unless they provide, at the very least, a> certification that they in fact took Seroquel and suffered an injury.> Therefore, please make sure that you return your certification form to> us immediately> > We have hired Hon.Marina Corodemus to act as the Special Master for the> W & L Seroquel settlement program. Judge Corodemus previously ran the New> Jersey Mass Tort Court and has a lot of experience in this field. She> was appointed as a Special Master by the Vioxx State and Federal Court> Judges to determine the appropriateness of Vioxx settlements and to> resolve Vioxx appeals. She has also served as the Special Master in many> other litigations such as Bextra and Celebrex which used similar> settlement terms. We have met several times with Judge Corodemus and> discussed the goals outlined above to get the most amount of money to> the most amount of claimants in the fastest amount of time possible. We> believe that Judge Corodemus is the perfect choice to create and oversee> a settlement program in accordance with these goals. The W & L Seroquel> Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only> those clients with active cases (not dismissed as outlined above) can> participate in this settlement program. Unlike other settlement programs> that you may have read about in the media and internet, the W & L> Settlement program does not award every case an equal settlement amount.> The size of an individual's settlement will depend entirely on the merit> of that individual's case. As a direct result of the large number of> cases represented by W & L, and the merits of those cases, we are> confident that we have obtained the best possible settlement for our> clients. After complex negotiations, AstraZeneca> has agreed to deposit $92.25 Million dollars into a trust account to be> used for this Settlement Program. This amount is completely confidential> and you should NOT discuss this with anyone. A settlement of this type> is called an " Aggregate Settlement " where a fair and reasonable sum of> money is obtained to resolve multiple cases. In order to maintain proper> representation of each individual client, W & L is NOT involved in the> allocation decision making, which will be handled exclusively by Judge> Corodemus. W & L has reviewed the general framework of the settlement> plan with Judge Corodemus and we strongly believe that it is fair and> reasonable and offers each of our clients the best possible outcome> under the circumstances of this litigation. Track I offers the Seroquel> claimant a settlement of $12,000. This track involves a simple review of> each case and will result in a quick approval by Judge Corodemus without> an analysis of the specific details of the case such as injury, amount> of Seroquel taken, how close the last Seroquel use was to the date of> the injury or the individual claimant's risk factors. a) Cannot> prove that they suffered diabetes or a diabetes related condition,> and/or Cannot prove that they used Seroquel within 1 year of> their claimed injury, and/or c) Had a large number of known> risk factors for diabetes before they started taking Seroquel. For> example - obesity, family history, smoking, etc.> > Therefore, all cases whose injuries are limited to weight gain or high> blood sugar and whose medical records will confirm that they were never> diagnosed with diabetes or pancreatitis, should choose Track 1.> Similarly, any claimed injury that occurred long after the last use of> Seroquel should also choose Track 1. These cases are likely to receive a> small award in Track II (likely less than $12,000) because it is> extremely difficult to prove that these injuries were caused by> Seroquel. Therefore, we suggest that if your case falls into this> category you should choose Track 1. Additionally, payment of Track I> settlement awards will be processed first once AstaZeneca waives its> " walk away right " . (See Section IV© below) Track II involves an> in-depth review of the severity of the injury, the claimed use of> Seroquel and its proximity to the injury as well the available proof> found in the contemporaneous medical records. Additionally, Judge> Corodemus will strongly consider many known risk factors for these> injuries including but not limited to smoking, obesity and family> history as well as the participation in the Zyprexa settlement for these> same injuries. This model is very similar to the one used in the> National Vioxx Settlement Program as well as dozens of other similar> settlement programs which were successfully resolved in recent years.> Judge Corodemus has established a points system and will consider all of> the critical issues including but not limited to:> - Nature of the injury - Severity of the injury - Age at the time of> injury - Proximity of Seroquel use to the claimed injury - Changes in> the Seroque11abel - Risk Factors including Smoking, Body Mass Index,> etc. After carefully reviewing all of the medical records and the> individual fact sheet, Judge Corodemus will assign a point value to each> case. The more points a case is awarded based on the specific facts of> the case, the larger the settlement will be. At this time, there is no> way to predict with accuracy how many points an individual case may be> awarded and it is even more difficult to determine how much money each> point will receive. The exact value of each point will depend on the> number of participants in Track II and the total number of points> assigned. All cases in Track II will be eligible for a settlement award> but Judge Corodemus could award LESS than $12,000 (what people will> receive automatically by choosing Track 1) if the case lacks merit. In> the interest of fairness, Judge Corodemus has committed to review each> case in Track II very carefully and this process will take time to> complete. Judge Corodemus has stated that she hopes to have this process> completed by the end of 2011 but please be warned that it could take a> little longer due to the amount of work that is involved. However, in> order to get this settlement process moving forward and ultimately paid> you must send us your signed Release form as soon as possible. If you> choose Track I your settlement award of $12,000 is set. If you choose> Track II, Judge Corodemus will review your claim and will issue an> award. We expect that we will contact you in approximately November 2011> and notify you of your point award and the expected amount of your> settlement. At that point, you will be given a choice to accept your> award, appeal your award or withdraw from the settlement program. If you> accept, we will forward your release to AstraZeneca for their review and> approval. Please understand that this settlement is not official until> we send AstraZeneca your signed Release Form, AstraZeneca approves it> AND AstraZeneca waives its walk away right. In the interest of time, we> are asking you to return your signed Release Form now so we can meet the> tight deadlines associated with this settlement. If you are unhappy with> your allocation amount and/or believe that your case involves> " Extraordinary Injury or Circumstances " you have the right to appeal> your award. Upon receipt of such an application, Judge Corodemus will> re-review your records and make a final decision. Please be aware that> there is no additional right of appeal (to Judge Corodemus or to any> Court) once this final decision is made. If you decide to decline the> settlement amount offered to you, you must notify us within ten days of> your receipt of your allocation amount and your signed Release Form will> no longer be valid. As in all settlements of this type, our agreement> with the defendant depends on nearly full participation from all of our> clients. Under the terms of our agreement, we must provide Qualifying> Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once> we reach this number, AstraZeneca's " walk away right " is officially> waived. We strongly believe that our clients will agree that this> settlement program offers the best possible terms and we expect that we> will meet this requirement in the next 90-120 days. In order to meet> this deadline we MUST have your complete> cooperation and immediate response. Of course, if we do not meet this> required number of responses, Astrazeneca can decide to withdraw its> settlement offer to everyone whether one signed the Release Form or not.> Therefore, time is of the essence. A. Release Form: Enclosed you will> find a Release Form which you must sign in front of a notary in Order to> participate in the settlement. If you have a spouse he/she must sign the> Release Form as well. Attached to the Release Form will be an> instruction sheet to guide you to ensure that this important form is> signed the right way. A Release Form that is signed the wrong way or> that is not witnessed (by a notary) is useless and will not be accepted> by the defendants. The Release Form is your agreement to participate in> the settlement program and at the same time discontinue your lawsuit in> exchange for your settlement award. Please turn to Page 2 of the Release> Form and complete the details of your Seroquel use. You may refer to> Page 1 of the Brief Questionnaire which lists the Seroquel information> that was found in your medical records or that you have previously> provided to us. If this information is inaccurate, please cross it out> and write in when you started and when you stopped taking Seroquel on> BOTH the Release Form and the Brief Questionnaire. Due to the fast> approaching deadlines, and our goal to get you your settlement processed> and paid as quickly as possible, we MUST receive this signed release> form back from you before August 31, 2011. Please use the envelope> provided herein and return the signed and notarized release form today> before you forget about it. Please note that once we submit your release> form to AstraZeneca it can not be revoked. B. Track Selection Form:> Enclosed you will find a " Track Selection Form " which is the form used> to officially notify the Special Master which Track you want your case> to follow. Please Note that there are 4 options on this form. You MUST> check one of the Options. If you want to participate in this settlement,> and we strongly think that you should, you must check either Track I OR> Track II and you must sign the bottom of the form. Your Track selection> cannot be changed and is considered final once the Judge's Allocations> are made. In other words, a person who chooses Track II and is awarded> less than $12,000 CANNOT then choose to go to Track 1 for a higher> award. C. Brief Questionnaire: Enclosed you will find a 3> page Brief Questionnaire which has important information about your> claim. For all claimants who choose to enter Track II, Judge Corodemus> will be reviewing your medical records, your Fact Sheet and this Brief> Questionnaire and will issue a point award. Judge Corodemus will> consider the proof of your claim found in your medical records as well> as the information that you provide in this Questionnaire. Therefore, it> is important that you answer these questions honestly and completely and> that they are consistent with what is found in your medical records.> litigation and our conversations with our medical experts, it is clear> that Seroquel lawsuits are very difficult to win, very expensive, and> very time consuming to take through to trial, verdict and appeal. Over> the past six years only I case (from W & L) of24,000 cases in the Country> made it to and through trial. Countless other cases were prepared and> then dismissed based on merit and/or inability to prove that Seroquel> caused the injury. Just because an individual took Seroquel and suffered> an injury like diabetes does not mean that such a case will win at> trial. In order to succeed at trial, a plaintiff must prove both that> Seroquel can cause such an injury in general AND that, within a> reasonable degree of medical certainty, Seroquel caused this injury to> this particular person (despite any individual risk factors such as> smoking, weight, high blood sugar, family history etc.). We have told> you in the past update letters that the Courts have consistently ruled> in favor of the defendants on many of these issues and have prohibited> medical experts from testifying because of a lack of scientific proof> linking the plaintiff s injuries to his/her Seroquel use. It is also> important to note that even if your case is able to advance past this> judicial scrutiny, a trial of this magnitude will cost over $750,000 per> case and many of these costs are reimbursed off of the top of a> favorable verdict reducing the amount received by the plaintiff.> Furthermore, any case that is won at trial will surely face a lengthy> and hard-fought appeal. Finally, nearly all of the Seroquel cases are> being handled by three judges. Even at an accelerated pace, the chances> are slim that your case would be tried in the next 10 years if not> longer. In taking all of these factors into consideration, and> considering the issues of risk and reward, we believe that a settlement> of this type offers you the most advantageous resolution possible. You> will be notified once the Special Master issues your point award at> which point you can appeal to the Special Master if you believe that> your case involves extraordinary circumstances. Thereafter, the decision> of the Special Master is final, binding and non-appealable. We have> retained the Garretson Law Firm to negotiate any and all Federal and> State liens (Medicare/Medicaid/SSI) that may be applicable in your case.> The Garretson Firm is a specialist in this field and they have obtained> excellent results in their negotiation of similar liens in other> litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson> Firm has already worked on thousands of other Seroquel cases and has> been able to achieve excellent results in large part due to the volume> of cases that they are able to include in a Global Resolution. At this> time, the Garretson Firm has already negotiated with 44 individual> states regarding Medicaid and they have reached an agreement to CAP> Medicaid liens at a maximum of 20% of the settlement amount. Please see> the enclosed blue booklet regarding governmental liens for more details.> Additionally, please also be advised that if you or Weitz & Luxenberg> are put on written notice of a private lien, for example from your> medical provider, this lien must be resolved before any settlement> proceeds can be distributed. If you have received any notice of a lien,> please advise us immediately. The terms of your signed contingency fee> agreement will be in effect. We have taken great effort to keep the case> specific expenses as low as possible. Under the terms of your agreement,> the> contingency fee will be calculated after the expenses are deducted.> Under the terms of our agreement with AstraZeneca, any interest earned> on the settlement proceeds before allocation and payment to the> individual clients will be used to offset the fixed costs of the Special> Master and the Lien Administrator. Due to the low interest rates paid by> all banks in this economy, we do not expect that there will be any> leftover interest. However, in such a case, the leftover interest will> be added to the settlement trust and will be distributed to all> claimants as part of Judge Corodemus' allocation process. After careful> analysis of the likelihood of success in the court system, as well as> the cost and time elements involved, we strongly recommend that you> AGREE to participate in this settlement. We are confident that this> settlement is the best possible resolution of your claim especially in> light of the history of this litigation. We expect that any case that> does not agree to participate in this settlement will have a very> difficult time navigating through the Court system and trial dates may> not be set for many years. Moreover, as we have seen, these cases will> be aggressively defended by AstraZeneca and we expect that we will> receive motions to dismiss and unfavorable decisions from the Court on> unsettled cases in the coming months. Moreover, if this settlement> program is not successful (we fail to reach the 98% response rate) we> highly doubt that we will ever obtain a settlement amount and terms as> good as those contained in this program. While we hope that this letter> and enclosures will help answer all of your questions, we understand> that you may have additional questions for us. Please keep in mind that> we are working very hard to evaluate each and every case individually> and the many deadlines that are part of this settlement are fast> approaching. Your case has been assigned to Judy Koenig. If you have an> important question please call Judy Koenig at (800) 438-9786 and ask for> extension 5860. If you reach a voice-mail, please leave a message and> you will be called back as quickly as possible. Please do not leave> multiple voicemail messages on the same day as that will slow down our> ability to return your call. Additionally, if you have email access,> please try to email your detailed questions to us at sqinfo@...> <mailto:sqinfo@...> and we will get back to you quickly. If> this letter has successfully answered your questions, and you have> decided to participate, please carefully follow the directions on the> front page of the enclosed release form and send your signed and> witnessed release formes), your Track Selection AND your Brief> Questionnaire to us as soon as possible. If you still have questions> after reviewing this letter and after speaking to us over the telephone> and you would like to meet us in person, we will be happy to schedule a> meeting in our office at your convenience. Finally, please remember that> the detailed information regarding this settlement program is COMPLETELY> CONFIDENTIAL and should not be shared or discussed with anyone. > Sedgh, Esq Glenn Zuckerman, Esq.>

[Guest guest]

Been there. Been dragged through hell. Had every aspect of our lives, and our son's life, put under a microscope. Had lawsuit dismissed "with prejudice" due to pre-emption. To hell with lawsuits.T.Sent via BlackBerry by AT&TFrom: "Cate" <ccsh@...>Sender: SSRI medications Date: Fri, 26 Aug 2011 20:31:48 -0000<SSRI medications >Reply SSRI medications Subject: Re: SEROQUEL Law Firms have sold their clients down the river I wonder whether individual suits are more effective than class action suits? Those are known to be mostly for the benefit of the lawyers, in any field of injury, not just pharmaceuticals. Cate>> " Awry, " not " a rye " but I digress. This is exactly why I never urge anyone to sue. The deck is stacked against us in court and attorneys are looking for a quick and easy buck. No justice is to be had.> > Terry> Sent via BlackBerry by AT & T> > SEROQUEL Law Firms have sold their clients down the river> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO> REJECT this Insult on Top of Injury > [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\> ElFTkSuQmCC]> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO> REJECT this Insult on Top of Injury> I would like to thank a brave, courageous, and ethical anonymous source> who has send in this letter correspondence they received from the law> firm of Weitz & Luxenberg. This letter doesn't require a whole lot of> commentary.> It's obvious that Law Firms have sold their clients down the proverbial> river while at the same time enriching themselves (who's best interest> are you obligated too fulfill?). This settlement offer and the injured> litigants legal representation has carried out a blatant miscarriage of> justice, a forever horrible stain upon the American Justice system, and> a orchestrated crime perpetrated upon victims of this well documented & > evidenced unbridled & unregulated corporate criminal enterprise gone a> rye.> The time has now come for the victims to stand up to this criminal> corporation " AstraZeneca " & their poison drug " Seroquel " , to reject this> horrible injustice and settlement offer. We want, what America & our> Constitution promises us all, our day in court before a jury of our> peers....> __________________________________________________________> > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>> We are happy to report excellent news! After a long and hard fought> legal battle, AstraZeneca has agreed to participate in a Settlement> Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our> patience and aggressive litigating has resulted in very favorable> settlement terms for our clients which will be further outlined below.> We have carefully reviewed all of the factors of this agreement and we> believe that this settlement offers you the best, and very likely the> only opportunity to receive a fair resolution of your lawsuit.> Therefore, we strongly recommend that you sign and complete the enclosed> " Release Form " , " Track Selection Form " and " Brief Questionnaire " and> AGREE to participate.> As you know, we have engaged in a long legal battle with AstraZeneca> over the past 6 years. Weitz & Luxenberg led the charge for the> Plaintiffs around the Country. AstraZeneca put up a tremendous and> expensive defense and they successfully were able to get a large number> of cases to be permanently dismissed by the court. Weitz & Luxenberg is> the only firm who took a case to trial anywhere in the Country. However,> after a month-long trial, the jury unfortunately ruled in favor of the> defendants. This loss did not affect the strength of our fight. Over the> past year, even as almost every other plaintiffs firm settled their> cases, Weitz & Luxenberg prepared two more cases for trial which was> scheduled to begin this Summer. As a direct result of the endless and> consistent pressure applied by the attorneys at Weitz & Luxenberg, we> are happy to report that AstraZeneca has now agreed to participate in a> favorable settlement program. Based on public reports regarding> settlement programs reached with other plaintiff law firms we are> confident that the settlement program outlined below has more favorable> terms and for this reason we are recommending your participation.> The defendants have argued that they refuse to pay anyone who cannot> prove through medical records or via certification that they have used> Seroquel. They also refuse to pay anyone whose case is not active in> this litigation. We recently told you about the Order issued by the> Court requiring you to confirm when you started taking Seroquel and when> you stopped taking Seroquel. We cannot stress enough that you MUST read,> complete and return this certification form to us immediately. The> failure to return this form within the next 30 days will result in the> permanent dismissal of your case. In order to protect your legal rights,> to keep your case active and be permitted to participate in this> Settlement Program you must take this Order very seriously and you must> respond.> Based on our experience in other litigations and having reviewed the> media reports of the terms of other firms' Seroquel settlement programs,> we know that the defendants are looking for a settlement program that> includes all claimants (W & L Seroquel Plaintiffs) so that they will> achieve complete closure of the entirYlitigation. Our goal in this> negotiation was to obtain a settlement for the most amount of money> using a fair method to pay our clients based upon the merits of their> individual case. We also stressed our intentions that the case review> and payment process be performed quickly yet fairly so that our clients> can receive their settlements as soon as possible. A key part of this> settlement program is that a claimant cannot be part of the settlement> if their case is dismissed and unless they provide, at the very least, a> certification that they in fact took Seroquel and suffered an injury.> Therefore, please make sure that you return your certification form to> us immediately> > We have hired Hon.Marina Corodemus to act as the Special Master for the> W & L Seroquel settlement program. Judge Corodemus previously ran the New> Jersey Mass Tort Court and has a lot of experience in this field. She> was appointed as a Special Master by the Vioxx State and Federal Court> Judges to determine the appropriateness of Vioxx settlements and to> resolve Vioxx appeals. She has also served as the Special Master in many> other litigations such as Bextra and Celebrex which used similar> settlement terms. We have met several times with Judge Corodemus and> discussed the goals outlined above to get the most amount of money to> the most amount of claimants in the fastest amount of time possible. We> believe that Judge Corodemus is the perfect choice to create and oversee> a settlement program in accordance with these goals. The W & L Seroquel> Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only> those clients with active cases (not dismissed as outlined above) can> participate in this settlement program. Unlike other settlement programs> that you may have read about in the media and internet, the W & L> Settlement program does not award every case an equal settlement amount.> The size of an individual's settlement will depend entirely on the merit> of that individual's case. As a direct result of the large number of> cases represented by W & L, and the merits of those cases, we are> confident that we have obtained the best possible settlement for our> clients. After complex negotiations, AstraZeneca> has agreed to deposit $92.25 Million dollars into a trust account to be> used for this Settlement Program. This amount is completely confidential> and you should NOT discuss this with anyone. A settlement of this type> is called an " Aggregate Settlement " where a fair and reasonable sum of> money is obtained to resolve multiple cases. In order to maintain proper> representation of each individual client, W & L is NOT involved in the> allocation decision making, which will be handled exclusively by Judge> Corodemus. W & L has reviewed the general framework of the settlement> plan with Judge Corodemus and we strongly believe that it is fair and> reasonable and offers each of our clients the best possible outcome> under the circumstances of this litigation. Track I offers the Seroquel> claimant a settlement of $12,000. This track involves a simple review of> each case and will result in a quick approval by Judge Corodemus without> an analysis of the specific details of the case such as injury, amount> of Seroquel taken, how close the last Seroquel use was to the date of> the injury or the individual claimant's risk factors. a) Cannot> prove that they suffered diabetes or a diabetes related condition,> and/or Cannot prove that they used Seroquel within 1 year of> their claimed injury, and/or c) Had a large number of known> risk factors for diabetes before they started taking Seroquel. For> example - obesity, family history, smoking, etc.> > Therefore, all cases whose injuries are limited to weight gain or high> blood sugar and whose medical records will confirm that they were never> diagnosed with diabetes or pancreatitis, should choose Track 1.> Similarly, any claimed injury that occurred long after the last use of> Seroquel should also choose Track 1. These cases are likely to receive a> small award in Track II (likely less than $12,000) because it is> extremely difficult to prove that these injuries were caused by> Seroquel. Therefore, we suggest that if your case falls into this> category you should choose Track 1. Additionally, payment of Track I> settlement awards will be processed first once AstaZeneca waives its> " walk away right " . (See Section IV© below) Track II involves an> in-depth review of the severity of the injury, the claimed use of> Seroquel and its proximity to the injury as well the available proof> found in the contemporaneous medical records. Additionally, Judge> Corodemus will strongly consider many known risk factors for these> injuries including but not limited to smoking, obesity and family> history as well as the participation in the Zyprexa settlement for these> same injuries. This model is very similar to the one used in the> National Vioxx Settlement Program as well as dozens of other similar> settlement programs which were successfully resolved in recent years.> Judge Corodemus has established a points system and will consider all of> the critical issues including but not limited to:> - Nature of the injury - Severity of the injury - Age at the time of> injury - Proximity of Seroquel use to the claimed injury - Changes in> the Seroque11abel - Risk Factors including Smoking, Body Mass Index,> etc. After carefully reviewing all of the medical records and the> individual fact sheet, Judge Corodemus will assign a point value to each> case. The more points a case is awarded based on the specific facts of> the case, the larger the settlement will be. At this time, there is no> way to predict with accuracy how many points an individual case may be> awarded and it is even more difficult to determine how much money each> point will receive. The exact value of each point will depend on the> number of participants in Track II and the total number of points> assigned. All cases in Track II will be eligible for a settlement award> but Judge Corodemus could award LESS than $12,000 (what people will> receive automatically by choosing Track 1) if the case lacks merit. In> the interest of fairness, Judge Corodemus has committed to review each> case in Track II very carefully and this process will take time to> complete. Judge Corodemus has stated that she hopes to have this process> completed by the end of 2011 but please be warned that it could take a> little longer due to the amount of work that is involved. However, in> order to get this settlement process moving forward and ultimately paid> you must send us your signed Release form as soon as possible. If you> choose Track I your settlement award of $12,000 is set. If you choose> Track II, Judge Corodemus will review your claim and will issue an> award. We expect that we will contact you in approximately November 2011> and notify you of your point award and the expected amount of your> settlement. At that point, you will be given a choice to accept your> award, appeal your award or withdraw from the settlement program. If you> accept, we will forward your release to AstraZeneca for their review and> approval. Please understand that this settlement is not official until> we send AstraZeneca your signed Release Form, AstraZeneca approves it> AND AstraZeneca waives its walk away right. In the interest of time, we> are asking you to return your signed Release Form now so we can meet the> tight deadlines associated with this settlement. If you are unhappy with> your allocation amount and/or believe that your case involves> " Extraordinary Injury or Circumstances " you have the right to appeal> your award. Upon receipt of such an application, Judge Corodemus will> re-review your records and make a final decision. Please be aware that> there is no additional right of appeal (to Judge Corodemus or to any> Court) once this final decision is made. If you decide to decline the> settlement amount offered to you, you must notify us within ten days of> your receipt of your allocation amount and your signed Release Form will> no longer be valid. As in all settlements of this type, our agreement> with the defendant depends on nearly full participation from all of our> clients. Under the terms of our agreement, we must provide Qualifying> Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once> we reach this number, AstraZeneca's " walk away right " is officially> waived. We strongly believe that our clients will agree that this> settlement program offers the best possible terms and we expect that we> will meet this requirement in the next 90-120 days. In order to meet> this deadline we MUST have your complete> cooperation and immediate response. Of course, if we do not meet this> required number of responses, Astrazeneca can decide to withdraw its> settlement offer to everyone whether one signed the Release Form or not.> Therefore, time is of the essence. A. Release Form: Enclosed you will> find a Release Form which you must sign in front of a notary in Order to> participate in the settlement. If you have a spouse he/she must sign the> Release Form as well. Attached to the Release Form will be an> instruction sheet to guide you to ensure that this important form is> signed the right way. A Release Form that is signed the wrong way or> that is not witnessed (by a notary) is useless and will not be accepted> by the defendants. The Release Form is your agreement to participate in> the settlement program and at the same time discontinue your lawsuit in> exchange for your settlement award. Please turn to Page 2 of the Release> Form and complete the details of your Seroquel use. You may refer to> Page 1 of the Brief Questionnaire which lists the Seroquel information> that was found in your medical records or that you have previously> provided to us. If this information is inaccurate, please cross it out> and write in when you started and when you stopped taking Seroquel on> BOTH the Release Form and the Brief Questionnaire. Due to the fast> approaching deadlines, and our goal to get you your settlement processed> and paid as quickly as possible, we MUST receive this signed release> form back from you before August 31, 2011. Please use the envelope> provided herein and return the signed and notarized release form today> before you forget about it. Please note that once we submit your release> form to AstraZeneca it can not be revoked. B. Track Selection Form:> Enclosed you will find a " Track Selection Form " which is the form used> to officially notify the Special Master which Track you want your case> to follow. Please Note that there are 4 options on this form. You MUST> check one of the Options. If you want to participate in this settlement,> and we strongly think that you should, you must check either Track I OR> Track II and you must sign the bottom of the form. Your Track selection> cannot be changed and is considered final once the Judge's Allocations> are made. In other words, a person who chooses Track II and is awarded> less than $12,000 CANNOT then choose to go to Track 1 for a higher> award. C. Brief Questionnaire: Enclosed you will find a 3> page Brief Questionnaire which has important information about your> claim. For all claimants who choose to enter Track II, Judge Corodemus> will be reviewing your medical records, your Fact Sheet and this Brief> Questionnaire and will issue a point award. Judge Corodemus will> consider the proof of your claim found in your medical records as well> as the information that you provide in this Questionnaire. Therefore, it> is important that you answer these questions honestly and completely and> that they are consistent with what is found in your medical records.> litigation and our conversations with our medical experts, it is clear> that Seroquel lawsuits are very difficult to win, very expensive, and> very time consuming to take through to trial, verdict and appeal. Over> the past six years only I case (from W & L) of24,000 cases in the Country> made it to and through trial. Countless other cases were prepared and> then dismissed based on merit and/or inability to prove that Seroquel> caused the injury. Just because an individual took Seroquel and suffered> an injury like diabetes does not mean that such a case will win at> trial. In order to succeed at trial, a plaintiff must prove both that> Seroquel can cause such an injury in general AND that, within a> reasonable degree of medical certainty, Seroquel caused this injury to> this particular person (despite any individual risk factors such as> smoking, weight, high blood sugar, family history etc.). We have told> you in the past update letters that the Courts have consistently ruled> in favor of the defendants on many of these issues and have prohibited> medical experts from testifying because of a lack of scientific proof> linking the plaintiff s injuries to his/her Seroquel use. It is also> important to note that even if your case is able to advance past this> judicial scrutiny, a trial of this magnitude will cost over $750,000 per> case and many of these costs are reimbursed off of the top of a> favorable verdict reducing the amount received by the plaintiff.> Furthermore, any case that is won at trial will surely face a lengthy> and hard-fought appeal. Finally, nearly all of the Seroquel cases are> being handled by three judges. Even at an accelerated pace, the chances> are slim that your case would be tried in the next 10 years if not> longer. In taking all of these factors into consideration, and> considering the issues of risk and reward, we believe that a settlement> of this type offers you the most advantageous resolution possible. You> will be notified once the Special Master issues your point award at> which point you can appeal to the Special Master if you believe that> your case involves extraordinary circumstances. Thereafter, the decision> of the Special Master is final, binding and non-appealable. We have> retained the Garretson Law Firm to negotiate any and all Federal and> State liens (Medicare/Medicaid/SSI) that may be applicable in your case.> The Garretson Firm is a specialist in this field and they have obtained> excellent results in their negotiation of similar liens in other> litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson> Firm has already worked on thousands of other Seroquel cases and has> been able to achieve excellent results in large part due to the volume> of cases that they are able to include in a Global Resolution. At this> time, the Garretson Firm has already negotiated with 44 individual> states regarding Medicaid and they have reached an agreement to CAP> Medicaid liens at a maximum of 20% of the settlement amount. Please see> the enclosed blue booklet regarding governmental liens for more details.> Additionally, please also be advised that if you or Weitz & Luxenberg> are put on written notice of a private lien, for example from your> medical provider, this lien must be resolved before any settlement> proceeds can be distributed. If you have received any notice of a lien,> please advise us immediately. The terms of your signed contingency fee> agreement will be in effect. We have taken great effort to keep the case> specific expenses as low as possible. Under the terms of your agreement,> the> contingency fee will be calculated after the expenses are deducted.> Under the terms of our agreement with AstraZeneca, any interest earned> on the settlement proceeds before allocation and payment to the> individual clients will be used to offset the fixed costs of the Special> Master and the Lien Administrator. Due to the low interest rates paid by> all banks in this economy, we do not expect that there will be any> leftover interest. However, in such a case, the leftover interest will> be added to the settlement trust and will be distributed to all> claimants as part of Judge Corodemus' allocation process. After careful> analysis of the likelihood of success in the court system, as well as> the cost and time elements involved, we strongly recommend that you> AGREE to participate in this settlement. We are confident that this> settlement is the best possible resolution of your claim especially in> light of the history of this litigation. We expect that any case that> does not agree to participate in this settlement will have a very> difficult time navigating through the Court system and trial dates may> not be set for many years. Moreover, as we have seen, these cases will> be aggressively defended by AstraZeneca and we expect that we will> receive motions to dismiss and unfavorable decisions from the Court on> unsettled cases in the coming months. Moreover, if this settlement> program is not successful (we fail to reach the 98% response rate) we> highly doubt that we will ever obtain a settlement amount and terms as> good as those contained in this program. While we hope that this letter> and enclosures will help answer all of your questions, we understand> that you may have additional questions for us. Please keep in mind that> we are working very hard to evaluate each and every case individually> and the many deadlines that are part of this settlement are fast> approaching. Your case has been assigned to Judy Koenig. If you have an> important question please call Judy Koenig at (800) 438-9786 and ask for> extension 5860. If you reach a voice-mail, please leave a message and> you will be called back as quickly as possible. Please do not leave> multiple voicemail messages on the same day as that will slow down our> ability to return your call. Additionally, if you have email access,> please try to email your detailed questions to us at sqinfo@...> <mailto:sqinfo@...> and we will get back to you quickly. If> this letter has successfully answered your questions, and you have> decided to participate, please carefully follow the directions on the> front page of the enclosed release form and send your signed and> witnessed release formes), your Track Selection AND your Brief> Questionnaire to us as soon as possible. If you still have questions> after reviewing this letter and after speaking to us over the telephone> and you would like to meet us in person, we will be happy to schedule a> meeting in our office at your convenience. Finally, please remember that> the detailed information regarding this settlement program is COMPLETELY> CONFIDENTIAL and should not be shared or discussed with anyone. > Sedgh, Esq Glenn Zuckerman, Esq.>

[Guest guest]

Been there. Been dragged through hell. Had every aspect of our lives, and our son's life, put under a microscope. Had lawsuit dismissed "with prejudice" due to pre-emption. To hell with lawsuits.T.Sent via BlackBerry by AT&TFrom: "Cate" <ccsh@...>Sender: SSRI medications Date: Fri, 26 Aug 2011 20:31:48 -0000<SSRI medications >Reply SSRI medications Subject: Re: SEROQUEL Law Firms have sold their clients down the river I wonder whether individual suits are more effective than class action suits? Those are known to be mostly for the benefit of the lawyers, in any field of injury, not just pharmaceuticals. Cate>> " Awry, " not " a rye " but I digress. This is exactly why I never urge anyone to sue. The deck is stacked against us in court and attorneys are looking for a quick and easy buck. No justice is to be had.> > Terry> Sent via BlackBerry by AT & T> > SEROQUEL Law Firms have sold their clients down the river> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO> REJECT this Insult on Top of Injury > [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\> ElFTkSuQmCC]> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME TO> REJECT this Insult on Top of Injury> I would like to thank a brave, courageous, and ethical anonymous source> who has send in this letter correspondence they received from the law> firm of Weitz & Luxenberg. This letter doesn't require a whole lot of> commentary.> It's obvious that Law Firms have sold their clients down the proverbial> river while at the same time enriching themselves (who's best interest> are you obligated too fulfill?). This settlement offer and the injured> litigants legal representation has carried out a blatant miscarriage of> justice, a forever horrible stain upon the American Justice system, and> a orchestrated crime perpetrated upon victims of this well documented & > evidenced unbridled & unregulated corporate criminal enterprise gone a> rye.> The time has now come for the victims to stand up to this criminal> corporation " AstraZeneca " & their poison drug " Seroquel " , to reject this> horrible injustice and settlement offer. We want, what America & our> Constitution promises us all, our day in court before a jury of our> peers....> __________________________________________________________> > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>> We are happy to report excellent news! After a long and hard fought> legal battle, AstraZeneca has agreed to participate in a Settlement> Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our> patience and aggressive litigating has resulted in very favorable> settlement terms for our clients which will be further outlined below.> We have carefully reviewed all of the factors of this agreement and we> believe that this settlement offers you the best, and very likely the> only opportunity to receive a fair resolution of your lawsuit.> Therefore, we strongly recommend that you sign and complete the enclosed> " Release Form " , " Track Selection Form " and " Brief Questionnaire " and> AGREE to participate.> As you know, we have engaged in a long legal battle with AstraZeneca> over the past 6 years. Weitz & Luxenberg led the charge for the> Plaintiffs around the Country. AstraZeneca put up a tremendous and> expensive defense and they successfully were able to get a large number> of cases to be permanently dismissed by the court. Weitz & Luxenberg is> the only firm who took a case to trial anywhere in the Country. However,> after a month-long trial, the jury unfortunately ruled in favor of the> defendants. This loss did not affect the strength of our fight. Over the> past year, even as almost every other plaintiffs firm settled their> cases, Weitz & Luxenberg prepared two more cases for trial which was> scheduled to begin this Summer. As a direct result of the endless and> consistent pressure applied by the attorneys at Weitz & Luxenberg, we> are happy to report that AstraZeneca has now agreed to participate in a> favorable settlement program. Based on public reports regarding> settlement programs reached with other plaintiff law firms we are> confident that the settlement program outlined below has more favorable> terms and for this reason we are recommending your participation.> The defendants have argued that they refuse to pay anyone who cannot> prove through medical records or via certification that they have used> Seroquel. They also refuse to pay anyone whose case is not active in> this litigation. We recently told you about the Order issued by the> Court requiring you to confirm when you started taking Seroquel and when> you stopped taking Seroquel. We cannot stress enough that you MUST read,> complete and return this certification form to us immediately. The> failure to return this form within the next 30 days will result in the> permanent dismissal of your case. In order to protect your legal rights,> to keep your case active and be permitted to participate in this> Settlement Program you must take this Order very seriously and you must> respond.> Based on our experience in other litigations and having reviewed the> media reports of the terms of other firms' Seroquel settlement programs,> we know that the defendants are looking for a settlement program that> includes all claimants (W & L Seroquel Plaintiffs) so that they will> achieve complete closure of the entirYlitigation. Our goal in this> negotiation was to obtain a settlement for the most amount of money> using a fair method to pay our clients based upon the merits of their> individual case. We also stressed our intentions that the case review> and payment process be performed quickly yet fairly so that our clients> can receive their settlements as soon as possible. A key part of this> settlement program is that a claimant cannot be part of the settlement> if their case is dismissed and unless they provide, at the very least, a> certification that they in fact took Seroquel and suffered an injury.> Therefore, please make sure that you return your certification form to> us immediately> > We have hired Hon.Marina Corodemus to act as the Special Master for the> W & L Seroquel settlement program. Judge Corodemus previously ran the New> Jersey Mass Tort Court and has a lot of experience in this field. She> was appointed as a Special Master by the Vioxx State and Federal Court> Judges to determine the appropriateness of Vioxx settlements and to> resolve Vioxx appeals. She has also served as the Special Master in many> other litigations such as Bextra and Celebrex which used similar> settlement terms. We have met several times with Judge Corodemus and> discussed the goals outlined above to get the most amount of money to> the most amount of claimants in the fastest amount of time possible. We> believe that Judge Corodemus is the perfect choice to create and oversee> a settlement program in accordance with these goals. The W & L Seroquel> Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only> those clients with active cases (not dismissed as outlined above) can> participate in this settlement program. Unlike other settlement programs> that you may have read about in the media and internet, the W & L> Settlement program does not award every case an equal settlement amount.> The size of an individual's settlement will depend entirely on the merit> of that individual's case. As a direct result of the large number of> cases represented by W & L, and the merits of those cases, we are> confident that we have obtained the best possible settlement for our> clients. After complex negotiations, AstraZeneca> has agreed to deposit $92.25 Million dollars into a trust account to be> used for this Settlement Program. This amount is completely confidential> and you should NOT discuss this with anyone. A settlement of this type> is called an " Aggregate Settlement " where a fair and reasonable sum of> money is obtained to resolve multiple cases. In order to maintain proper> representation of each individual client, W & L is NOT involved in the> allocation decision making, which will be handled exclusively by Judge> Corodemus. W & L has reviewed the general framework of the settlement> plan with Judge Corodemus and we strongly believe that it is fair and> reasonable and offers each of our clients the best possible outcome> under the circumstances of this litigation. Track I offers the Seroquel> claimant a settlement of $12,000. This track involves a simple review of> each case and will result in a quick approval by Judge Corodemus without> an analysis of the specific details of the case such as injury, amount> of Seroquel taken, how close the last Seroquel use was to the date of> the injury or the individual claimant's risk factors. a) Cannot> prove that they suffered diabetes or a diabetes related condition,> and/or Cannot prove that they used Seroquel within 1 year of> their claimed injury, and/or c) Had a large number of known> risk factors for diabetes before they started taking Seroquel. For> example - obesity, family history, smoking, etc.> > Therefore, all cases whose injuries are limited to weight gain or high> blood sugar and whose medical records will confirm that they were never> diagnosed with diabetes or pancreatitis, should choose Track 1.> Similarly, any claimed injury that occurred long after the last use of> Seroquel should also choose Track 1. These cases are likely to receive a> small award in Track II (likely less than $12,000) because it is> extremely difficult to prove that these injuries were caused by> Seroquel. Therefore, we suggest that if your case falls into this> category you should choose Track 1. Additionally, payment of Track I> settlement awards will be processed first once AstaZeneca waives its> " walk away right " . (See Section IV© below) Track II involves an> in-depth review of the severity of the injury, the claimed use of> Seroquel and its proximity to the injury as well the available proof> found in the contemporaneous medical records. Additionally, Judge> Corodemus will strongly consider many known risk factors for these> injuries including but not limited to smoking, obesity and family> history as well as the participation in the Zyprexa settlement for these> same injuries. This model is very similar to the one used in the> National Vioxx Settlement Program as well as dozens of other similar> settlement programs which were successfully resolved in recent years.> Judge Corodemus has established a points system and will consider all of> the critical issues including but not limited to:> - Nature of the injury - Severity of the injury - Age at the time of> injury - Proximity of Seroquel use to the claimed injury - Changes in> the Seroque11abel - Risk Factors including Smoking, Body Mass Index,> etc. After carefully reviewing all of the medical records and the> individual fact sheet, Judge Corodemus will assign a point value to each> case. The more points a case is awarded based on the specific facts of> the case, the larger the settlement will be. At this time, there is no> way to predict with accuracy how many points an individual case may be> awarded and it is even more difficult to determine how much money each> point will receive. The exact value of each point will depend on the> number of participants in Track II and the total number of points> assigned. All cases in Track II will be eligible for a settlement award> but Judge Corodemus could award LESS than $12,000 (what people will> receive automatically by choosing Track 1) if the case lacks merit. In> the interest of fairness, Judge Corodemus has committed to review each> case in Track II very carefully and this process will take time to> complete. Judge Corodemus has stated that she hopes to have this process> completed by the end of 2011 but please be warned that it could take a> little longer due to the amount of work that is involved. However, in> order to get this settlement process moving forward and ultimately paid> you must send us your signed Release form as soon as possible. If you> choose Track I your settlement award of $12,000 is set. If you choose> Track II, Judge Corodemus will review your claim and will issue an> award. We expect that we will contact you in approximately November 2011> and notify you of your point award and the expected amount of your> settlement. At that point, you will be given a choice to accept your> award, appeal your award or withdraw from the settlement program. If you> accept, we will forward your release to AstraZeneca for their review and> approval. Please understand that this settlement is not official until> we send AstraZeneca your signed Release Form, AstraZeneca approves it> AND AstraZeneca waives its walk away right. In the interest of time, we> are asking you to return your signed Release Form now so we can meet the> tight deadlines associated with this settlement. If you are unhappy with> your allocation amount and/or believe that your case involves> " Extraordinary Injury or Circumstances " you have the right to appeal> your award. Upon receipt of such an application, Judge Corodemus will> re-review your records and make a final decision. Please be aware that> there is no additional right of appeal (to Judge Corodemus or to any> Court) once this final decision is made. If you decide to decline the> settlement amount offered to you, you must notify us within ten days of> your receipt of your allocation amount and your signed Release Form will> no longer be valid. As in all settlements of this type, our agreement> with the defendant depends on nearly full participation from all of our> clients. Under the terms of our agreement, we must provide Qualifying> Materials (Release Form and/or Dismissal) for 2,260 of our clients. Once> we reach this number, AstraZeneca's " walk away right " is officially> waived. We strongly believe that our clients will agree that this> settlement program offers the best possible terms and we expect that we> will meet this requirement in the next 90-120 days. In order to meet> this deadline we MUST have your complete> cooperation and immediate response. Of course, if we do not meet this> required number of responses, Astrazeneca can decide to withdraw its> settlement offer to everyone whether one signed the Release Form or not.> Therefore, time is of the essence. A. Release Form: Enclosed you will> find a Release Form which you must sign in front of a notary in Order to> participate in the settlement. If you have a spouse he/she must sign the> Release Form as well. Attached to the Release Form will be an> instruction sheet to guide you to ensure that this important form is> signed the right way. A Release Form that is signed the wrong way or> that is not witnessed (by a notary) is useless and will not be accepted> by the defendants. The Release Form is your agreement to participate in> the settlement program and at the same time discontinue your lawsuit in> exchange for your settlement award. Please turn to Page 2 of the Release> Form and complete the details of your Seroquel use. You may refer to> Page 1 of the Brief Questionnaire which lists the Seroquel information> that was found in your medical records or that you have previously> provided to us. If this information is inaccurate, please cross it out> and write in when you started and when you stopped taking Seroquel on> BOTH the Release Form and the Brief Questionnaire. Due to the fast> approaching deadlines, and our goal to get you your settlement processed> and paid as quickly as possible, we MUST receive this signed release> form back from you before August 31, 2011. Please use the envelope> provided herein and return the signed and notarized release form today> before you forget about it. Please note that once we submit your release> form to AstraZeneca it can not be revoked. B. Track Selection Form:> Enclosed you will find a " Track Selection Form " which is the form used> to officially notify the Special Master which Track you want your case> to follow. Please Note that there are 4 options on this form. You MUST> check one of the Options. If you want to participate in this settlement,> and we strongly think that you should, you must check either Track I OR> Track II and you must sign the bottom of the form. Your Track selection> cannot be changed and is considered final once the Judge's Allocations> are made. In other words, a person who chooses Track II and is awarded> less than $12,000 CANNOT then choose to go to Track 1 for a higher> award. C. Brief Questionnaire: Enclosed you will find a 3> page Brief Questionnaire which has important information about your> claim. For all claimants who choose to enter Track II, Judge Corodemus> will be reviewing your medical records, your Fact Sheet and this Brief> Questionnaire and will issue a point award. Judge Corodemus will> consider the proof of your claim found in your medical records as well> as the information that you provide in this Questionnaire. Therefore, it> is important that you answer these questions honestly and completely and> that they are consistent with what is found in your medical records.> litigation and our conversations with our medical experts, it is clear> that Seroquel lawsuits are very difficult to win, very expensive, and> very time consuming to take through to trial, verdict and appeal. Over> the past six years only I case (from W & L) of24,000 cases in the Country> made it to and through trial. Countless other cases were prepared and> then dismissed based on merit and/or inability to prove that Seroquel> caused the injury. Just because an individual took Seroquel and suffered> an injury like diabetes does not mean that such a case will win at> trial. In order to succeed at trial, a plaintiff must prove both that> Seroquel can cause such an injury in general AND that, within a> reasonable degree of medical certainty, Seroquel caused this injury to> this particular person (despite any individual risk factors such as> smoking, weight, high blood sugar, family history etc.). We have told> you in the past update letters that the Courts have consistently ruled> in favor of the defendants on many of these issues and have prohibited> medical experts from testifying because of a lack of scientific proof> linking the plaintiff s injuries to his/her Seroquel use. It is also> important to note that even if your case is able to advance past this> judicial scrutiny, a trial of this magnitude will cost over $750,000 per> case and many of these costs are reimbursed off of the top of a> favorable verdict reducing the amount received by the plaintiff.> Furthermore, any case that is won at trial will surely face a lengthy> and hard-fought appeal. Finally, nearly all of the Seroquel cases are> being handled by three judges. Even at an accelerated pace, the chances> are slim that your case would be tried in the next 10 years if not> longer. In taking all of these factors into consideration, and> considering the issues of risk and reward, we believe that a settlement> of this type offers you the most advantageous resolution possible. You> will be notified once the Special Master issues your point award at> which point you can appeal to the Special Master if you believe that> your case involves extraordinary circumstances. Thereafter, the decision> of the Special Master is final, binding and non-appealable. We have> retained the Garretson Law Firm to negotiate any and all Federal and> State liens (Medicare/Medicaid/SSI) that may be applicable in your case.> The Garretson Firm is a specialist in this field and they have obtained> excellent results in their negotiation of similar liens in other> litigations like Vioxx, Bextra, and Celebrex. Moreover, the Garretson> Firm has already worked on thousands of other Seroquel cases and has> been able to achieve excellent results in large part due to the volume> of cases that they are able to include in a Global Resolution. At this> time, the Garretson Firm has already negotiated with 44 individual> states regarding Medicaid and they have reached an agreement to CAP> Medicaid liens at a maximum of 20% of the settlement amount. Please see> the enclosed blue booklet regarding governmental liens for more details.> Additionally, please also be advised that if you or Weitz & Luxenberg> are put on written notice of a private lien, for example from your> medical provider, this lien must be resolved before any settlement> proceeds can be distributed. If you have received any notice of a lien,> please advise us immediately. The terms of your signed contingency fee> agreement will be in effect. We have taken great effort to keep the case> specific expenses as low as possible. Under the terms of your agreement,> the> contingency fee will be calculated after the expenses are deducted.> Under the terms of our agreement with AstraZeneca, any interest earned> on the settlement proceeds before allocation and payment to the> individual clients will be used to offset the fixed costs of the Special> Master and the Lien Administrator. Due to the low interest rates paid by> all banks in this economy, we do not expect that there will be any> leftover interest. However, in such a case, the leftover interest will> be added to the settlement trust and will be distributed to all> claimants as part of Judge Corodemus' allocation process. After careful> analysis of the likelihood of success in the court system, as well as> the cost and time elements involved, we strongly recommend that you> AGREE to participate in this settlement. We are confident that this> settlement is the best possible resolution of your claim especially in> light of the history of this litigation. We expect that any case that> does not agree to participate in this settlement will have a very> difficult time navigating through the Court system and trial dates may> not be set for many years. Moreover, as we have seen, these cases will> be aggressively defended by AstraZeneca and we expect that we will> receive motions to dismiss and unfavorable decisions from the Court on> unsettled cases in the coming months. Moreover, if this settlement> program is not successful (we fail to reach the 98% response rate) we> highly doubt that we will ever obtain a settlement amount and terms as> good as those contained in this program. While we hope that this letter> and enclosures will help answer all of your questions, we understand> that you may have additional questions for us. Please keep in mind that> we are working very hard to evaluate each and every case individually> and the many deadlines that are part of this settlement are fast> approaching. Your case has been assigned to Judy Koenig. If you have an> important question please call Judy Koenig at (800) 438-9786 and ask for> extension 5860. If you reach a voice-mail, please leave a message and> you will be called back as quickly as possible. Please do not leave> multiple voicemail messages on the same day as that will slow down our> ability to return your call. Additionally, if you have email access,> please try to email your detailed questions to us at sqinfo@...> <mailto:sqinfo@...> and we will get back to you quickly. If> this letter has successfully answered your questions, and you have> decided to participate, please carefully follow the directions on the> front page of the enclosed release form and send your signed and> witnessed release formes), your Track Selection AND your Brief> Questionnaire to us as soon as possible. If you still have questions> after reviewing this letter and after speaking to us over the telephone> and you would like to meet us in person, we will be happy to schedule a> meeting in our office at your convenience. Finally, please remember that> the detailed information regarding this settlement program is COMPLETELY> CONFIDENTIAL and should not be shared or discussed with anyone. > Sedgh, Esq Glenn Zuckerman, Esq.>

[Guest guest]

Cate

The evidence is clear ..............the suits don't work for the

litigants, all they seem to do is line the pockets of the lawyers many

of whom have clear links back to Scientology / CCHR

We must be careful not to be duped twice, first by pharma & then by the

class action lawyers and their rabble -rousers

> >

> > " Awry, " not " a rye " but I digress. This is exactly why I never urge

anyone to sue. The deck is stacked against us in court and attorneys are

looking for a quick and easy buck. No justice is to be had.

> >

> > Terry

> > Sent via BlackBerry by AT & T

> >

> > SEROQUEL Law Firms have sold their clients

down the river

> >

> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

TO

> > REJECT this Insult on Top of Injury

> >

[data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

\

> >

ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

\

> >

A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

\

> >

oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

\

> >

3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

\

> >

DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

\

> >

HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

\

> >

oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

\

> >

1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

\

> >

EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

\

> >

VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

\

> >

2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

\

> >

IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

\

> >

kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

\

> >

/jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

\

> >

9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

\

> >

CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

\

> >

ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

\

> >

zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

\

> >

T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

\

> >

N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

\

> >

HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

\

> >

gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

\

> >

w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

\

> >

3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

\

> >

wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

\

> >

TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

\

> >

Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

\

> >

NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

\

> >

LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

\

> >

yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

\

> >

rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

\

> >

pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

\

> >

5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

\

> >

bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

\

> >

rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

\

> >

XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

\

> >

AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

\

> >

sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

\

> >

uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

\

> >

9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

\

> >

aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

\

> >

83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

\

> >

mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

\

> >

0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

\

> >

A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

\

> >

QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

\

> >

UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

\

> >

ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

\

> >

/p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

\

> >

i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

\

> >

Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

\

> >

DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

\

> >

8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

\

> >

zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

\

> >

hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

\

> >

i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

\

> >

gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

\

> >

m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

\

> >

VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

\

> >

Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

\

> >

bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

\

> >

MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

\

> >

RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

\

> >

RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

\

> >

4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

\

> >

AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

\

> >

jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

\

> >

okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

\

> >

kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

\

> >

HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

\

> >

cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

\

> >

tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

\

> >

YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

\

> >

+EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

\

> >

sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

\

> >

9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

\

> >

QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

\

> >

kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

\

> >

Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

\

> >

Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

\

> >

QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

\

> >

t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

\

> >

MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

\

> >

VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

\

> >

nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

\

> >

SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

\

> >

tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

\

> >

8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

\

> >

ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

\

> >

J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

\

> >

m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

\

> >

6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

\

> >

76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

\

> >

9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

\

> >

zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

\

> >

9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

\

> >

5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

\

> >

oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

\

> >

hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

\

> >

5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

\

> >

vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

\

> >

fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

\

> >

aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

\

> >

+sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

\

> >

HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

\

> >

aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

\

> >

jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

\

> >

7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

\

> >

/Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

\

> >

G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

\

> >

GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

\

> >

+AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

\

> >

kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

\

> >

h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

\

> >

NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

\

> >

rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

\

> >

T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

\

> >

C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

\

> >

at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

\

> >

7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

\

> >

X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

\

> >

kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

\

> >

PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

\

> >

tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

\

> >

2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

\

> >

ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

\

> >

DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

\

> >

cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

\

> >

Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

\

> >

qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

\

> >

wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

\

> >

aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

\

> >

zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

\

> >

KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

\

> >

BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

\

> >

XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

\

> >

fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

\

> >

R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

\

> >

xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

\

> >

SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

\

> >

BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

\

> >

BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

\

> >

iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

\

> >

Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

\

> >

Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

\

> >

dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

\

> >

BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

\

> >

whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

\

> >

Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

\

> >

NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

\

> >

4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

\

> >

4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

\

> >

D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

\

> >

amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

\

> >

UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

\

> >

n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

\

> >

nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

\

> >

3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

\

> >

e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

\

> >

nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

\

> >

CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

\

> >

1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

\

> >

MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

\

> >

X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

\

> >

9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

\

> >

qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

\

> >

e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

\

> >

oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

\

> >

CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

\

> >

62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

\

> >

GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

\

> >

ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

\

> >

Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

\

> >

AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

\

> >

ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

\

> >

vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

\

> >

+2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

\

> >

kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

\

> >

e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

\

> >

hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

\

> >

6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

\

> >

DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

\

> >

ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

\

> >

suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

\

> >

6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

\

> >

yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

\

> >

c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

\

> >

rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

\

> >

FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

\

> >

2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

\

> >

GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

\

> >

UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

\

> >

I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

\

> >

xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

\

> >

IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

\

> >

EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

\

> >

Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

\

> >

S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

\

> >

WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

\

> >

mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

\

> >

Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

\

> >

QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

\

> >

IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

\

> >

9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

\

> >

FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

\

> >

FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

\

> >

lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

\

> >

Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

\

> >

Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

\

> >

+fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

\

> >

aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

\

> >

Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

\

> >

wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

\

> >

yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

\

> >

QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

\

> >

CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

\

> >

kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

\

> >

Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

\

> >

6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

\

> >

AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

\

> >

eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

\

> >

sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

\

> >

gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

\

> >

9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

\

> >

hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

\

> >

KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

\

> >

1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

\

> >

/m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

\

> >

9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

\

> >

qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

\

> >

LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

\

> >

iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

\

> >

wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

\

> >

A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

\

> >

A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

\

> >

1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

\

> >

h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

\

> >

X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

\

> >

TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

\

> >

kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

\

> >

SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

\

> >

mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

\

> >

7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

\

> >

XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

\

> >

U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

\

> >

+d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

\

> >

SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

\

> >

WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

\

> >

gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

\

> >

YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

\

> >

tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

\

> >

HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

\

> >

bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

\

> >

ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

\

> >

IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

\

> >

HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

\

> >

wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

\

> >

NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

\

> >

1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

\

> >

n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

\

> >

kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

\

> >

X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

\

> >

rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

\

> >

x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

\

> >

Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

\

> >

tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

\

> >

Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

\

> >

fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

\

> >

UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

\

> >

xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

\

> >

IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

\

> >

0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

\

> >

fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

\

> >

Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

\

> >

9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

\

> >

iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

\

> >

oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

\

> >

KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

\

> >

6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

\

> >

RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

\

> > ElFTkSuQmCC]

> >

> >

> >

> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

TO

> > REJECT this Insult on Top of Injury

> > I would like to thank a brave, courageous, and ethical anonymous

source

> > who has send in this letter correspondence they received from the

law

> > firm of Weitz & Luxenberg. This letter doesn't require a whole lot

of

> > commentary.

> > It's obvious that Law Firms have sold their clients down the

proverbial

> > river while at the same time enriching themselves (who's best

interest

> > are you obligated too fulfill?). This settlement offer and the

injured

> > litigants legal representation has carried out a blatant miscarriage

of

> > justice, a forever horrible stain upon the American Justice system,

and

> > a orchestrated crime perpetrated upon victims of this well

documented &

> > evidenced unbridled & unregulated corporate criminal enterprise gone

a

> > rye.

> > The time has now come for the victims to stand up to this criminal

> > corporation " AstraZeneca " & their poison drug " Seroquel " , to reject

this

> > horrible injustice and settlement offer. We want, what America & our

> > Constitution promises us all, our day in court before a jury of our

> > peers....

> > ____________________________________________________________

> >

> > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> > We are happy to report excellent news! After a long and hard fought

> > legal battle, AstraZeneca has agreed to participate in a Settlement

> > Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> > patience and aggressive litigating has resulted in very favorable

> > settlement terms for our clients which will be further outlined

below.

> > We have carefully reviewed all of the factors of this agreement and

we

> > believe that this settlement offers you the best, and very likely

the

> > only opportunity to receive a fair resolution of your lawsuit.

> > Therefore, we strongly recommend that you sign and complete the

enclosed

> > " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> > AGREE to participate.

> > As you know, we have engaged in a long legal battle with AstraZeneca

> > over the past 6 years. Weitz & Luxenberg led the charge for the

> > Plaintiffs around the Country. AstraZeneca put up a tremendous and

> > expensive defense and they successfully were able to get a large

number

> > of cases to be permanently dismissed by the court. Weitz & Luxenberg

is

> > the only firm who took a case to trial anywhere in the Country.

However,

> > after a month-long trial, the jury unfortunately ruled in favor of

the

> > defendants. This loss did not affect the strength of our fight. Over

the

> > past year, even as almost every other plaintiffs firm settled their

> > cases, Weitz & Luxenberg prepared two more cases for trial which was

> > scheduled to begin this Summer. As a direct result of the endless

and

> > consistent pressure applied by the attorneys at Weitz & Luxenberg,

we

> > are happy to report that AstraZeneca has now agreed to participate

in a

> > favorable settlement program. Based on public reports regarding

> > settlement programs reached with other plaintiff law firms we are

> > confident that the settlement program outlined below has more

favorable

> > terms and for this reason we are recommending your participation.

> > The defendants have argued that they refuse to pay anyone who cannot

> > prove through medical records or via certification that they have

used

> > Seroquel. They also refuse to pay anyone whose case is not active in

> > this litigation. We recently told you about the Order issued by the

> > Court requiring you to confirm when you started taking Seroquel and

when

> > you stopped taking Seroquel. We cannot stress enough that you MUST

read,

> > complete and return this certification form to us immediately. The

> > failure to return this form within the next 30 days will result in

the

> > permanent dismissal of your case. In order to protect your legal

rights,

> > to keep your case active and be permitted to participate in this

> > Settlement Program you must take this Order very seriously and you

must

> > respond.

> > Based on our experience in other litigations and having reviewed the

> > media reports of the terms of other firms' Seroquel settlement

programs,

> > we know that the defendants are looking for a settlement program

that

> > includes all claimants (W & L Seroquel Plaintiffs) so that they will

> > achieve complete closure of the entirYlitigation. Our goal in this

> > negotiation was to obtain a settlement for the most amount of money

> > using a fair method to pay our clients based upon the merits of

their

> > individual case. We also stressed our intentions that the case

review

> > and payment process be performed quickly yet fairly so that our

clients

> > can receive their settlements as soon as possible. A key part of

this

> > settlement program is that a claimant cannot be part of the

settlement

> > if their case is dismissed and unless they provide, at the very

least, a

> > certification that they in fact took Seroquel and suffered an

injury.

> > Therefore, please make sure that you return your certification form

to

> > us immediately

> >

> > We have hired Hon.Marina Corodemus to act as the Special Master for

the

> > W & L Seroquel settlement program. Judge Corodemus previously ran the

New

> > Jersey Mass Tort Court and has a lot of experience in this field.

She

> > was appointed as a Special Master by the Vioxx State and Federal

Court

> > Judges to determine the appropriateness of Vioxx settlements and to

> > resolve Vioxx appeals. She has also served as the Special Master in

many

> > other litigations such as Bextra and Celebrex which used similar

> > settlement terms. We have met several times with Judge Corodemus and

> > discussed the goals outlined above to get the most amount of money

to

> > the most amount of claimants in the fastest amount of time possible.

We

> > believe that Judge Corodemus is the perfect choice to create and

oversee

> > a settlement program in accordance with these goals. The W & L

Seroquel

> > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> > those clients with active cases (not dismissed as outlined above)

can

> > participate in this settlement program. Unlike other settlement

programs

> > that you may have read about in the media and internet, the W & L

> > Settlement program does not award every case an equal settlement

amount.

> > The size of an individual's settlement will depend entirely on the

merit

> > of that individual's case. As a direct result of the large number of

> > cases represented by W & L, and the merits of those cases, we are

> > confident that we have obtained the best possible settlement for our

> > clients. After complex negotiations, AstraZeneca

> > has agreed to deposit $92.25 Million dollars into a trust account to

be

> > used for this Settlement Program. This amount is completely

confidential

> > and you should NOT discuss this with anyone. A settlement of this

type

> > is called an " Aggregate Settlement " where a fair and reasonable sum

of

> > money is obtained to resolve multiple cases. In order to maintain

proper

> > representation of each individual client, W & L is NOT involved in

the

> > allocation decision making, which will be handled exclusively by

Judge

> > Corodemus. W & L has reviewed the general framework of the settlement

> > plan with Judge Corodemus and we strongly believe that it is fair

and

> > reasonable and offers each of our clients the best possible outcome

> > under the circumstances of this litigation. Track I offers the

Seroquel

> > claimant a settlement of $12,000. This track involves a simple

review of

> > each case and will result in a quick approval by Judge Corodemus

without

> > an analysis of the specific details of the case such as injury,

amount

> > of Seroquel taken, how close the last Seroquel use was to the date

of

> > the injury or the individual claimant's risk factors. a) Cannot

> > prove that they suffered diabetes or a diabetes related condition,

> > and/or Cannot prove that they used Seroquel within 1 year of

> > their claimed injury, and/or c) Had a large number of known

> > risk factors for diabetes before they started taking Seroquel. For

> > example - obesity, family history, smoking, etc.

> >

> > Therefore, all cases whose injuries are limited to weight gain or

high

> > blood sugar and whose medical records will confirm that they were

never

> > diagnosed with diabetes or pancreatitis, should choose Track 1.

> > Similarly, any claimed injury that occurred long after the last use

of

> > Seroquel should also choose Track 1. These cases are likely to

receive a

> > small award in Track II (likely less than $12,000) because it is

> > extremely difficult to prove that these injuries were caused by

> > Seroquel. Therefore, we suggest that if your case falls into this

> > category you should choose Track 1. Additionally, payment of Track I

> > settlement awards will be processed first once AstaZeneca waives its

> > " walk away right " . (See Section IV© below) Track II involves an

> > in-depth review of the severity of the injury, the claimed use of

> > Seroquel and its proximity to the injury as well the available proof

> > found in the contemporaneous medical records. Additionally, Judge

> > Corodemus will strongly consider many known risk factors for these

> > injuries including but not limited to smoking, obesity and family

> > history as well as the participation in the Zyprexa settlement for

these

> > same injuries. This model is very similar to the one used in the

> > National Vioxx Settlement Program as well as dozens of other similar

> > settlement programs which were successfully resolved in recent

years.

> > Judge Corodemus has established a points system and will consider

all of

> > the critical issues including but not limited to:

> > - Nature of the injury - Severity of the injury - Age at the time of

> > injury - Proximity of Seroquel use to the claimed injury - Changes

in

> > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> > etc. After carefully reviewing all of the medical records and the

> > individual fact sheet, Judge Corodemus will assign a point value to

each

> > case. The more points a case is awarded based on the specific facts

of

> > the case, the larger the settlement will be. At this time, there is

no

> > way to predict with accuracy how many points an individual case may

be

> > awarded and it is even more difficult to determine how much money

each

> > point will receive. The exact value of each point will depend on the

> > number of participants in Track II and the total number of points

> > assigned. All cases in Track II will be eligible for a settlement

award

> > but Judge Corodemus could award LESS than $12,000 (what people will

> > receive automatically by choosing Track 1) if the case lacks merit.

In

> > the interest of fairness, Judge Corodemus has committed to review

each

> > case in Track II very carefully and this process will take time to

> > complete. Judge Corodemus has stated that she hopes to have this

process

> > completed by the end of 2011 but please be warned that it could take

a

> > little longer due to the amount of work that is involved. However,

in

> > order to get this settlement process moving forward and ultimately

paid

> > you must send us your signed Release form as soon as possible. If

you

> > choose Track I your settlement award of $12,000 is set. If you

choose

> > Track II, Judge Corodemus will review your claim and will issue an

> > award. We expect that we will contact you in approximately November

2011

> > and notify you of your point award and the expected amount of your

> > settlement. At that point, you will be given a choice to accept your

> > award, appeal your award or withdraw from the settlement program. If

you

> > accept, we will forward your release to AstraZeneca for their review

and

> > approval. Please understand that this settlement is not official

until

> > we send AstraZeneca your signed Release Form, AstraZeneca approves

it

> > AND AstraZeneca waives its walk away right. In the interest of time,

we

> > are asking you to return your signed Release Form now so we can meet

the

> > tight deadlines associated with this settlement. If you are unhappy

with

> > your allocation amount and/or believe that your case involves

> > " Extraordinary Injury or Circumstances " you have the right to appeal

> > your award. Upon receipt of such an application, Judge Corodemus

will

> > re-review your records and make a final decision. Please be aware

that

> > there is no additional right of appeal (to Judge Corodemus or to any

> > Court) once this final decision is made. If you decide to decline

the

> > settlement amount offered to you, you must notify us within ten days

of

> > your receipt of your allocation amount and your signed Release Form

will

> > no longer be valid. As in all settlements of this type, our

agreement

> > with the defendant depends on nearly full participation from all of

our

> > clients. Under the terms of our agreement, we must provide

Qualifying

> > Materials (Release Form and/or Dismissal) for 2,260 of our clients.

Once

> > we reach this number, AstraZeneca's " walk away right " is officially

> > waived. We strongly believe that our clients will agree that this

> > settlement program offers the best possible terms and we expect that

we

> > will meet this requirement in the next 90-120 days. In order to meet

> > this deadline we MUST have your complete

> > cooperation and immediate response. Of course, if we do not meet

this

> > required number of responses, Astrazeneca can decide to withdraw its

> > settlement offer to everyone whether one signed the Release Form or

not.

> > Therefore, time is of the essence. A. Release Form: Enclosed you

will

> > find a Release Form which you must sign in front of a notary in

Order to

> > participate in the settlement. If you have a spouse he/she must sign

the

> > Release Form as well. Attached to the Release Form will be an

> > instruction sheet to guide you to ensure that this important form is

> > signed the right way. A Release Form that is signed the wrong way or

> > that is not witnessed (by a notary) is useless and will not be

accepted

> > by the defendants. The Release Form is your agreement to participate

in

> > the settlement program and at the same time discontinue your lawsuit

in

> > exchange for your settlement award. Please turn to Page 2 of the

Release

> > Form and complete the details of your Seroquel use. You may refer to

> > Page 1 of the Brief Questionnaire which lists the Seroquel

information

> > that was found in your medical records or that you have previously

> > provided to us. If this information is inaccurate, please cross it

out

> > and write in when you started and when you stopped taking Seroquel

on

> > BOTH the Release Form and the Brief Questionnaire. Due to the fast

> > approaching deadlines, and our goal to get you your settlement

processed

> > and paid as quickly as possible, we MUST receive this signed release

> > form back from you before August 31, 2011. Please use the envelope

> > provided herein and return the signed and notarized release form

today

> > before you forget about it. Please note that once we submit your

release

> > form to AstraZeneca it can not be revoked. B. Track Selection Form:

> > Enclosed you will find a " Track Selection Form " which is the form

used

> > to officially notify the Special Master which Track you want your

case

> > to follow. Please Note that there are 4 options on this form. You

MUST

> > check one of the Options. If you want to participate in this

settlement,

> > and we strongly think that you should, you must check either Track I

OR

> > Track II and you must sign the bottom of the form. Your Track

selection

> > cannot be changed and is considered final once the Judge's

Allocations

> > are made. In other words, a person who chooses Track II and is

awarded

> > less than $12,000 CANNOT then choose to go to Track 1 for a higher

> > award. C. Brief Questionnaire: Enclosed you will find a 3

> > page Brief Questionnaire which has important information about your

> > claim. For all claimants who choose to enter Track II, Judge

Corodemus

> > will be reviewing your medical records, your Fact Sheet and this

Brief

> > Questionnaire and will issue a point award. Judge Corodemus will

> > consider the proof of your claim found in your medical records as

well

> > as the information that you provide in this Questionnaire.

Therefore, it

> > is important that you answer these questions honestly and completely

and

> > that they are consistent with what is found in your medical records.

> > litigation and our conversations with our medical experts, it is

clear

> > that Seroquel lawsuits are very difficult to win, very expensive,

and

> > very time consuming to take through to trial, verdict and appeal.

Over

> > the past six years only I case (from W & L) of24,000 cases in the

Country

> > made it to and through trial. Countless other cases were prepared

and

> > then dismissed based on merit and/or inability to prove that

Seroquel

> > caused the injury. Just because an individual took Seroquel and

suffered

> > an injury like diabetes does not mean that such a case will win at

> > trial. In order to succeed at trial, a plaintiff must prove both

that

> > Seroquel can cause such an injury in general AND that, within a

> > reasonable degree of medical certainty, Seroquel caused this injury

to

> > this particular person (despite any individual risk factors such as

> > smoking, weight, high blood sugar, family history etc.). We have

told

> > you in the past update letters that the Courts have consistently

ruled

> > in favor of the defendants on many of these issues and have

prohibited

> > medical experts from testifying because of a lack of scientific

proof

> > linking the plaintiff s injuries to his/her Seroquel use. It is also

> > important to note that even if your case is able to advance past

this

> > judicial scrutiny, a trial of this magnitude will cost over $750,000

per

> > case and many of these costs are reimbursed off of the top of a

> > favorable verdict reducing the amount received by the plaintiff.

> > Furthermore, any case that is won at trial will surely face a

lengthy

> > and hard-fought appeal. Finally, nearly all of the Seroquel cases

are

> > being handled by three judges. Even at an accelerated pace, the

chances

> > are slim that your case would be tried in the next 10 years if not

> > longer. In taking all of these factors into consideration, and

> > considering the issues of risk and reward, we believe that a

settlement

> > of this type offers you the most advantageous resolution possible.

You

> > will be notified once the Special Master issues your point award at

> > which point you can appeal to the Special Master if you believe that

> > your case involves extraordinary circumstances. Thereafter, the

decision

> > of the Special Master is final, binding and non-appealable. We have

> > retained the Garretson Law Firm to negotiate any and all Federal and

> > State liens (Medicare/Medicaid/SSI) that may be applicable in your

case.

> > The Garretson Firm is a specialist in this field and they have

obtained

> > excellent results in their negotiation of similar liens in other

> > litigations like Vioxx, Bextra, and Celebrex. Moreover, the

Garretson

> > Firm has already worked on thousands of other Seroquel cases and has

> > been able to achieve excellent results in large part due to the

volume

> > of cases that they are able to include in a Global Resolution. At

this

> > time, the Garretson Firm has already negotiated with 44 individual

> > states regarding Medicaid and they have reached an agreement to CAP

> > Medicaid liens at a maximum of 20% of the settlement amount. Please

see

> > the enclosed blue booklet regarding governmental liens for more

details.

> > Additionally, please also be advised that if you or Weitz &

Luxenberg

> > are put on written notice of a private lien, for example from your

> > medical provider, this lien must be resolved before any settlement

> > proceeds can be distributed. If you have received any notice of a

lien,

> > please advise us immediately. The terms of your signed contingency

fee

> > agreement will be in effect. We have taken great effort to keep the

case

> > specific expenses as low as possible. Under the terms of your

agreement,

> > the

> > contingency fee will be calculated after the expenses are deducted.

> > Under the terms of our agreement with AstraZeneca, any interest

earned

> > on the settlement proceeds before allocation and payment to the

> > individual clients will be used to offset the fixed costs of the

Special

> > Master and the Lien Administrator. Due to the low interest rates

paid by

> > all banks in this economy, we do not expect that there will be any

> > leftover interest. However, in such a case, the leftover interest

will

> > be added to the settlement trust and will be distributed to all

> > claimants as part of Judge Corodemus' allocation process. After

careful

> > analysis of the likelihood of success in the court system, as well

as

> > the cost and time elements involved, we strongly recommend that you

> > AGREE to participate in this settlement. We are confident that this

> > settlement is the best possible resolution of your claim especially

in

> > light of the history of this litigation. We expect that any case

that

> > does not agree to participate in this settlement will have a very

> > difficult time navigating through the Court system and trial dates

may

> > not be set for many years. Moreover, as we have seen, these cases

will

> > be aggressively defended by AstraZeneca and we expect that we will

> > receive motions to dismiss and unfavorable decisions from the Court

on

> > unsettled cases in the coming months. Moreover, if this settlement

> > program is not successful (we fail to reach the 98% response rate)

we

> > highly doubt that we will ever obtain a settlement amount and terms

as

> > good as those contained in this program. While we hope that this

letter

> > and enclosures will help answer all of your questions, we understand

> > that you may have additional questions for us. Please keep in mind

that

> > we are working very hard to evaluate each and every case

individually

> > and the many deadlines that are part of this settlement are fast

> > approaching. Your case has been assigned to Judy Koenig. If you have

an

> > important question please call Judy Koenig at (800) 438-9786 and ask

for

> > extension 5860. If you reach a voice-mail, please leave a message

and

> > you will be called back as quickly as possible. Please do not leave

> > multiple voicemail messages on the same day as that will slow down

our

> > ability to return your call. Additionally, if you have email access,

> > please try to email your detailed questions to us at sqinfo@

> > <mailto:sqinfo@ and we will get back to you quickly. If

> > this letter has successfully answered your questions, and you have

> > decided to participate, please carefully follow the directions on

the

> > front page of the enclosed release form and send your signed and

> > witnessed release formes), your Track Selection AND your Brief

> > Questionnaire to us as soon as possible. If you still have questions

> > after reviewing this letter and after speaking to us over the

telephone

> > and you would like to meet us in person, we will be happy to

schedule a

> > meeting in our office at your convenience. Finally, please remember

that

> > the detailed information regarding this settlement program is

COMPLETELY

> > CONFIDENTIAL and should not be shared or discussed with anyone.

> > Sedgh, Esq Glenn Zuckerman, Esq.

> >

>

[Guest guest]

Cate

The evidence is clear ..............the suits don't work for the

litigants, all they seem to do is line the pockets of the lawyers many

of whom have clear links back to Scientology / CCHR

We must be careful not to be duped twice, first by pharma & then by the

class action lawyers and their rabble -rousers

> >

> > " Awry, " not " a rye " but I digress. This is exactly why I never urge

anyone to sue. The deck is stacked against us in court and attorneys are

looking for a quick and easy buck. No justice is to be had.

> >

> > Terry

> > Sent via BlackBerry by AT & T

> >

> > SEROQUEL Law Firms have sold their clients

down the river

> >

> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

TO

> > REJECT this Insult on Top of Injury

> >

[data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

\

> >

ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

\

> >

A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

\

> >

oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

\

> >

3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

\

> >

DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

\

> >

HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

\

> >

oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

\

> >

1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

\

> >

EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

\

> >

VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

\

> >

2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

\

> >

IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

\

> >

kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

\

> >

/jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

\

> >

9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

\

> >

CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

\

> >

ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

\

> >

zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

\

> >

T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

\

> >

N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

\

> >

HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

\

> >

gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

\

> >

w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

\

> >

3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

\

> >

wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

\

> >

TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

\

> >

Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

\

> >

NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

\

> >

LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

\

> >

yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

\

> >

rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

\

> >

pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

\

> >

5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

\

> >

bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

\

> >

rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

\

> >

XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

\

> >

AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

\

> >

sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

\

> >

uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

\

> >

9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

\

> >

aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

\

> >

83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

\

> >

mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

\

> >

0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

\

> >

A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

\

> >

QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

\

> >

UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

\

> >

ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

\

> >

/p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

\

> >

i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

\

> >

Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

\

> >

DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

\

> >

8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

\

> >

zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

\

> >

hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

\

> >

i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

\

> >

gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

\

> >

m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

\

> >

VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

\

> >

Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

\

> >

bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

\

> >

MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

\

> >

RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

\

> >

RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

\

> >

4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

\

> >

AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

\

> >

jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

\

> >

okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

\

> >

kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

\

> >

HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

\

> >

cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

\

> >

tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

\

> >

YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

\

> >

+EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

\

> >

sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

\

> >

9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

\

> >

QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

\

> >

kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

\

> >

Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

\

> >

Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

\

> >

QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

\

> >

t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

\

> >

MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

\

> >

VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

\

> >

nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

\

> >

SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

\

> >

tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

\

> >

8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

\

> >

ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

\

> >

J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

\

> >

m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

\

> >

6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

\

> >

76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

\

> >

9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

\

> >

zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

\

> >

9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

\

> >

5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

\

> >

oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

\

> >

hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

\

> >

5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

\

> >

vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

\

> >

fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

\

> >

aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

\

> >

+sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

\

> >

HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

\

> >

aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

\

> >

jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

\

> >

7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

\

> >

/Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

\

> >

G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

\

> >

GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

\

> >

+AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

\

> >

kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

\

> >

h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

\

> >

NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

\

> >

rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

\

> >

T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

\

> >

C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

\

> >

at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

\

> >

7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

\

> >

X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

\

> >

kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

\

> >

PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

\

> >

tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

\

> >

2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

\

> >

ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

\

> >

DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

\

> >

cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

\

> >

Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

\

> >

qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

\

> >

wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

\

> >

aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

\

> >

zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

\

> >

KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

\

> >

BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

\

> >

XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

\

> >

fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

\

> >

R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

\

> >

xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

\

> >

SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

\

> >

BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

\

> >

BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

\

> >

iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

\

> >

Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

\

> >

Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

\

> >

dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

\

> >

BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

\

> >

whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

\

> >

Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

\

> >

NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

\

> >

4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

\

> >

4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

\

> >

D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

\

> >

amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

\

> >

UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

\

> >

n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

\

> >

nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

\

> >

3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

\

> >

e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

\

> >

nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

\

> >

CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

\

> >

1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

\

> >

MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

\

> >

X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

\

> >

9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

\

> >

qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

\

> >

e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

\

> >

oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

\

> >

CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

\

> >

62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

\

> >

GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

\

> >

ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

\

> >

Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

\

> >

AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

\

> >

ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

\

> >

vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

\

> >

+2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

\

> >

kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

\

> >

e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

\

> >

hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

\

> >

6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

\

> >

DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

\

> >

ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

\

> >

suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

\

> >

6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

\

> >

yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

\

> >

c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

\

> >

rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

\

> >

FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

\

> >

2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

\

> >

GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

\

> >

UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

\

> >

I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

\

> >

xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

\

> >

IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

\

> >

EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

\

> >

Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

\

> >

S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

\

> >

WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

\

> >

mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

\

> >

Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

\

> >

QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

\

> >

IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

\

> >

9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

\

> >

FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

\

> >

FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

\

> >

lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

\

> >

Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

\

> >

Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

\

> >

+fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

\

> >

aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

\

> >

Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

\

> >

wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

\

> >

yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

\

> >

QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

\

> >

CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

\

> >

kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

\

> >

Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

\

> >

6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

\

> >

AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

\

> >

eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

\

> >

sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

\

> >

gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

\

> >

9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

\

> >

hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

\

> >

KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

\

> >

1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

\

> >

/m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

\

> >

9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

\

> >

qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

\

> >

LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

\

> >

iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

\

> >

wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

\

> >

A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

\

> >

A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

\

> >

1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

\

> >

h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

\

> >

X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

\

> >

TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

\

> >

kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

\

> >

SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

\

> >

mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

\

> >

7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

\

> >

XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

\

> >

U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

\

> >

+d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

\

> >

SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

\

> >

WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

\

> >

gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

\

> >

YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

\

> >

tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

\

> >

HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

\

> >

bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

\

> >

ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

\

> >

IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

\

> >

HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

\

> >

wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

\

> >

NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

\

> >

1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

\

> >

n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

\

> >

kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

\

> >

X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

\

> >

rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

\

> >

x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

\

> >

Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

\

> >

tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

\

> >

Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

\

> >

fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

\

> >

UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

\

> >

xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

\

> >

IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

\

> >

0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

\

> >

fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

\

> >

Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

\

> >

9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

\

> >

iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

\

> >

oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

\

> >

KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

\

> >

6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

\

> >

RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

\

> > ElFTkSuQmCC]

> >

> >

> >

> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

TO

> > REJECT this Insult on Top of Injury

> > I would like to thank a brave, courageous, and ethical anonymous

source

> > who has send in this letter correspondence they received from the

law

> > firm of Weitz & Luxenberg. This letter doesn't require a whole lot

of

> > commentary.

> > It's obvious that Law Firms have sold their clients down the

proverbial

> > river while at the same time enriching themselves (who's best

interest

> > are you obligated too fulfill?). This settlement offer and the

injured

> > litigants legal representation has carried out a blatant miscarriage

of

> > justice, a forever horrible stain upon the American Justice system,

and

> > a orchestrated crime perpetrated upon victims of this well

documented &

> > evidenced unbridled & unregulated corporate criminal enterprise gone

a

> > rye.

> > The time has now come for the victims to stand up to this criminal

> > corporation " AstraZeneca " & their poison drug " Seroquel " , to reject

this

> > horrible injustice and settlement offer. We want, what America & our

> > Constitution promises us all, our day in court before a jury of our

> > peers....

> > ____________________________________________________________

> >

> > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> > We are happy to report excellent news! After a long and hard fought

> > legal battle, AstraZeneca has agreed to participate in a Settlement

> > Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> > patience and aggressive litigating has resulted in very favorable

> > settlement terms for our clients which will be further outlined

below.

> > We have carefully reviewed all of the factors of this agreement and

we

> > believe that this settlement offers you the best, and very likely

the

> > only opportunity to receive a fair resolution of your lawsuit.

> > Therefore, we strongly recommend that you sign and complete the

enclosed

> > " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> > AGREE to participate.

> > As you know, we have engaged in a long legal battle with AstraZeneca

> > over the past 6 years. Weitz & Luxenberg led the charge for the

> > Plaintiffs around the Country. AstraZeneca put up a tremendous and

> > expensive defense and they successfully were able to get a large

number

> > of cases to be permanently dismissed by the court. Weitz & Luxenberg

is

> > the only firm who took a case to trial anywhere in the Country.

However,

> > after a month-long trial, the jury unfortunately ruled in favor of

the

> > defendants. This loss did not affect the strength of our fight. Over

the

> > past year, even as almost every other plaintiffs firm settled their

> > cases, Weitz & Luxenberg prepared two more cases for trial which was

> > scheduled to begin this Summer. As a direct result of the endless

and

> > consistent pressure applied by the attorneys at Weitz & Luxenberg,

we

> > are happy to report that AstraZeneca has now agreed to participate

in a

> > favorable settlement program. Based on public reports regarding

> > settlement programs reached with other plaintiff law firms we are

> > confident that the settlement program outlined below has more

favorable

> > terms and for this reason we are recommending your participation.

> > The defendants have argued that they refuse to pay anyone who cannot

> > prove through medical records or via certification that they have

used

> > Seroquel. They also refuse to pay anyone whose case is not active in

> > this litigation. We recently told you about the Order issued by the

> > Court requiring you to confirm when you started taking Seroquel and

when

> > you stopped taking Seroquel. We cannot stress enough that you MUST

read,

> > complete and return this certification form to us immediately. The

> > failure to return this form within the next 30 days will result in

the

> > permanent dismissal of your case. In order to protect your legal

rights,

> > to keep your case active and be permitted to participate in this

> > Settlement Program you must take this Order very seriously and you

must

> > respond.

> > Based on our experience in other litigations and having reviewed the

> > media reports of the terms of other firms' Seroquel settlement

programs,

> > we know that the defendants are looking for a settlement program

that

> > includes all claimants (W & L Seroquel Plaintiffs) so that they will

> > achieve complete closure of the entirYlitigation. Our goal in this

> > negotiation was to obtain a settlement for the most amount of money

> > using a fair method to pay our clients based upon the merits of

their

> > individual case. We also stressed our intentions that the case

review

> > and payment process be performed quickly yet fairly so that our

clients

> > can receive their settlements as soon as possible. A key part of

this

> > settlement program is that a claimant cannot be part of the

settlement

> > if their case is dismissed and unless they provide, at the very

least, a

> > certification that they in fact took Seroquel and suffered an

injury.

> > Therefore, please make sure that you return your certification form

to

> > us immediately

> >

> > We have hired Hon.Marina Corodemus to act as the Special Master for

the

> > W & L Seroquel settlement program. Judge Corodemus previously ran the

New

> > Jersey Mass Tort Court and has a lot of experience in this field.

She

> > was appointed as a Special Master by the Vioxx State and Federal

Court

> > Judges to determine the appropriateness of Vioxx settlements and to

> > resolve Vioxx appeals. She has also served as the Special Master in

many

> > other litigations such as Bextra and Celebrex which used similar

> > settlement terms. We have met several times with Judge Corodemus and

> > discussed the goals outlined above to get the most amount of money

to

> > the most amount of claimants in the fastest amount of time possible.

We

> > believe that Judge Corodemus is the perfect choice to create and

oversee

> > a settlement program in accordance with these goals. The W & L

Seroquel

> > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> > those clients with active cases (not dismissed as outlined above)

can

> > participate in this settlement program. Unlike other settlement

programs

> > that you may have read about in the media and internet, the W & L

> > Settlement program does not award every case an equal settlement

amount.

> > The size of an individual's settlement will depend entirely on the

merit

> > of that individual's case. As a direct result of the large number of

> > cases represented by W & L, and the merits of those cases, we are

> > confident that we have obtained the best possible settlement for our

> > clients. After complex negotiations, AstraZeneca

> > has agreed to deposit $92.25 Million dollars into a trust account to

be

> > used for this Settlement Program. This amount is completely

confidential

> > and you should NOT discuss this with anyone. A settlement of this

type

> > is called an " Aggregate Settlement " where a fair and reasonable sum

of

> > money is obtained to resolve multiple cases. In order to maintain

proper

> > representation of each individual client, W & L is NOT involved in

the

> > allocation decision making, which will be handled exclusively by

Judge

> > Corodemus. W & L has reviewed the general framework of the settlement

> > plan with Judge Corodemus and we strongly believe that it is fair

and

> > reasonable and offers each of our clients the best possible outcome

> > under the circumstances of this litigation. Track I offers the

Seroquel

> > claimant a settlement of $12,000. This track involves a simple

review of

> > each case and will result in a quick approval by Judge Corodemus

without

> > an analysis of the specific details of the case such as injury,

amount

> > of Seroquel taken, how close the last Seroquel use was to the date

of

> > the injury or the individual claimant's risk factors. a) Cannot

> > prove that they suffered diabetes or a diabetes related condition,

> > and/or Cannot prove that they used Seroquel within 1 year of

> > their claimed injury, and/or c) Had a large number of known

> > risk factors for diabetes before they started taking Seroquel. For

> > example - obesity, family history, smoking, etc.

> >

> > Therefore, all cases whose injuries are limited to weight gain or

high

> > blood sugar and whose medical records will confirm that they were

never

> > diagnosed with diabetes or pancreatitis, should choose Track 1.

> > Similarly, any claimed injury that occurred long after the last use

of

> > Seroquel should also choose Track 1. These cases are likely to

receive a

> > small award in Track II (likely less than $12,000) because it is

> > extremely difficult to prove that these injuries were caused by

> > Seroquel. Therefore, we suggest that if your case falls into this

> > category you should choose Track 1. Additionally, payment of Track I

> > settlement awards will be processed first once AstaZeneca waives its

> > " walk away right " . (See Section IV© below) Track II involves an

> > in-depth review of the severity of the injury, the claimed use of

> > Seroquel and its proximity to the injury as well the available proof

> > found in the contemporaneous medical records. Additionally, Judge

> > Corodemus will strongly consider many known risk factors for these

> > injuries including but not limited to smoking, obesity and family

> > history as well as the participation in the Zyprexa settlement for

these

> > same injuries. This model is very similar to the one used in the

> > National Vioxx Settlement Program as well as dozens of other similar

> > settlement programs which were successfully resolved in recent

years.

> > Judge Corodemus has established a points system and will consider

all of

> > the critical issues including but not limited to:

> > - Nature of the injury - Severity of the injury - Age at the time of

> > injury - Proximity of Seroquel use to the claimed injury - Changes

in

> > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> > etc. After carefully reviewing all of the medical records and the

> > individual fact sheet, Judge Corodemus will assign a point value to

each

> > case. The more points a case is awarded based on the specific facts

of

> > the case, the larger the settlement will be. At this time, there is

no

> > way to predict with accuracy how many points an individual case may

be

> > awarded and it is even more difficult to determine how much money

each

> > point will receive. The exact value of each point will depend on the

> > number of participants in Track II and the total number of points

> > assigned. All cases in Track II will be eligible for a settlement

award

> > but Judge Corodemus could award LESS than $12,000 (what people will

> > receive automatically by choosing Track 1) if the case lacks merit.

In

> > the interest of fairness, Judge Corodemus has committed to review

each

> > case in Track II very carefully and this process will take time to

> > complete. Judge Corodemus has stated that she hopes to have this

process

> > completed by the end of 2011 but please be warned that it could take

a

> > little longer due to the amount of work that is involved. However,

in

> > order to get this settlement process moving forward and ultimately

paid

> > you must send us your signed Release form as soon as possible. If

you

> > choose Track I your settlement award of $12,000 is set. If you

choose

> > Track II, Judge Corodemus will review your claim and will issue an

> > award. We expect that we will contact you in approximately November

2011

> > and notify you of your point award and the expected amount of your

> > settlement. At that point, you will be given a choice to accept your

> > award, appeal your award or withdraw from the settlement program. If

you

> > accept, we will forward your release to AstraZeneca for their review

and

> > approval. Please understand that this settlement is not official

until

> > we send AstraZeneca your signed Release Form, AstraZeneca approves

it

> > AND AstraZeneca waives its walk away right. In the interest of time,

we

> > are asking you to return your signed Release Form now so we can meet

the

> > tight deadlines associated with this settlement. If you are unhappy

with

> > your allocation amount and/or believe that your case involves

> > " Extraordinary Injury or Circumstances " you have the right to appeal

> > your award. Upon receipt of such an application, Judge Corodemus

will

> > re-review your records and make a final decision. Please be aware

that

> > there is no additional right of appeal (to Judge Corodemus or to any

> > Court) once this final decision is made. If you decide to decline

the

> > settlement amount offered to you, you must notify us within ten days

of

> > your receipt of your allocation amount and your signed Release Form

will

> > no longer be valid. As in all settlements of this type, our

agreement

> > with the defendant depends on nearly full participation from all of

our

> > clients. Under the terms of our agreement, we must provide

Qualifying

> > Materials (Release Form and/or Dismissal) for 2,260 of our clients.

Once

> > we reach this number, AstraZeneca's " walk away right " is officially

> > waived. We strongly believe that our clients will agree that this

> > settlement program offers the best possible terms and we expect that

we

> > will meet this requirement in the next 90-120 days. In order to meet

> > this deadline we MUST have your complete

> > cooperation and immediate response. Of course, if we do not meet

this

> > required number of responses, Astrazeneca can decide to withdraw its

> > settlement offer to everyone whether one signed the Release Form or

not.

> > Therefore, time is of the essence. A. Release Form: Enclosed you

will

> > find a Release Form which you must sign in front of a notary in

Order to

> > participate in the settlement. If you have a spouse he/she must sign

the

> > Release Form as well. Attached to the Release Form will be an

> > instruction sheet to guide you to ensure that this important form is

> > signed the right way. A Release Form that is signed the wrong way or

> > that is not witnessed (by a notary) is useless and will not be

accepted

> > by the defendants. The Release Form is your agreement to participate

in

> > the settlement program and at the same time discontinue your lawsuit

in

> > exchange for your settlement award. Please turn to Page 2 of the

Release

> > Form and complete the details of your Seroquel use. You may refer to

> > Page 1 of the Brief Questionnaire which lists the Seroquel

information

> > that was found in your medical records or that you have previously

> > provided to us. If this information is inaccurate, please cross it

out

> > and write in when you started and when you stopped taking Seroquel

on

> > BOTH the Release Form and the Brief Questionnaire. Due to the fast

> > approaching deadlines, and our goal to get you your settlement

processed

> > and paid as quickly as possible, we MUST receive this signed release

> > form back from you before August 31, 2011. Please use the envelope

> > provided herein and return the signed and notarized release form

today

> > before you forget about it. Please note that once we submit your

release

> > form to AstraZeneca it can not be revoked. B. Track Selection Form:

> > Enclosed you will find a " Track Selection Form " which is the form

used

> > to officially notify the Special Master which Track you want your

case

> > to follow. Please Note that there are 4 options on this form. You

MUST

> > check one of the Options. If you want to participate in this

settlement,

> > and we strongly think that you should, you must check either Track I

OR

> > Track II and you must sign the bottom of the form. Your Track

selection

> > cannot be changed and is considered final once the Judge's

Allocations

> > are made. In other words, a person who chooses Track II and is

awarded

> > less than $12,000 CANNOT then choose to go to Track 1 for a higher

> > award. C. Brief Questionnaire: Enclosed you will find a 3

> > page Brief Questionnaire which has important information about your

> > claim. For all claimants who choose to enter Track II, Judge

Corodemus

> > will be reviewing your medical records, your Fact Sheet and this

Brief

> > Questionnaire and will issue a point award. Judge Corodemus will

> > consider the proof of your claim found in your medical records as

well

> > as the information that you provide in this Questionnaire.

Therefore, it

> > is important that you answer these questions honestly and completely

and

> > that they are consistent with what is found in your medical records.

> > litigation and our conversations with our medical experts, it is

clear

> > that Seroquel lawsuits are very difficult to win, very expensive,

and

> > very time consuming to take through to trial, verdict and appeal.

Over

> > the past six years only I case (from W & L) of24,000 cases in the

Country

> > made it to and through trial. Countless other cases were prepared

and

> > then dismissed based on merit and/or inability to prove that

Seroquel

> > caused the injury. Just because an individual took Seroquel and

suffered

> > an injury like diabetes does not mean that such a case will win at

> > trial. In order to succeed at trial, a plaintiff must prove both

that

> > Seroquel can cause such an injury in general AND that, within a

> > reasonable degree of medical certainty, Seroquel caused this injury

to

> > this particular person (despite any individual risk factors such as

> > smoking, weight, high blood sugar, family history etc.). We have

told

> > you in the past update letters that the Courts have consistently

ruled

> > in favor of the defendants on many of these issues and have

prohibited

> > medical experts from testifying because of a lack of scientific

proof

> > linking the plaintiff s injuries to his/her Seroquel use. It is also

> > important to note that even if your case is able to advance past

this

> > judicial scrutiny, a trial of this magnitude will cost over $750,000

per

> > case and many of these costs are reimbursed off of the top of a

> > favorable verdict reducing the amount received by the plaintiff.

> > Furthermore, any case that is won at trial will surely face a

lengthy

> > and hard-fought appeal. Finally, nearly all of the Seroquel cases

are

> > being handled by three judges. Even at an accelerated pace, the

chances

> > are slim that your case would be tried in the next 10 years if not

> > longer. In taking all of these factors into consideration, and

> > considering the issues of risk and reward, we believe that a

settlement

> > of this type offers you the most advantageous resolution possible.

You

> > will be notified once the Special Master issues your point award at

> > which point you can appeal to the Special Master if you believe that

> > your case involves extraordinary circumstances. Thereafter, the

decision

> > of the Special Master is final, binding and non-appealable. We have

> > retained the Garretson Law Firm to negotiate any and all Federal and

> > State liens (Medicare/Medicaid/SSI) that may be applicable in your

case.

> > The Garretson Firm is a specialist in this field and they have

obtained

> > excellent results in their negotiation of similar liens in other

> > litigations like Vioxx, Bextra, and Celebrex. Moreover, the

Garretson

> > Firm has already worked on thousands of other Seroquel cases and has

> > been able to achieve excellent results in large part due to the

volume

> > of cases that they are able to include in a Global Resolution. At

this

> > time, the Garretson Firm has already negotiated with 44 individual

> > states regarding Medicaid and they have reached an agreement to CAP

> > Medicaid liens at a maximum of 20% of the settlement amount. Please

see

> > the enclosed blue booklet regarding governmental liens for more

details.

> > Additionally, please also be advised that if you or Weitz &

Luxenberg

> > are put on written notice of a private lien, for example from your

> > medical provider, this lien must be resolved before any settlement

> > proceeds can be distributed. If you have received any notice of a

lien,

> > please advise us immediately. The terms of your signed contingency

fee

> > agreement will be in effect. We have taken great effort to keep the

case

> > specific expenses as low as possible. Under the terms of your

agreement,

> > the

> > contingency fee will be calculated after the expenses are deducted.

> > Under the terms of our agreement with AstraZeneca, any interest

earned

> > on the settlement proceeds before allocation and payment to the

> > individual clients will be used to offset the fixed costs of the

Special

> > Master and the Lien Administrator. Due to the low interest rates

paid by

> > all banks in this economy, we do not expect that there will be any

> > leftover interest. However, in such a case, the leftover interest

will

> > be added to the settlement trust and will be distributed to all

> > claimants as part of Judge Corodemus' allocation process. After

careful

> > analysis of the likelihood of success in the court system, as well

as

> > the cost and time elements involved, we strongly recommend that you

> > AGREE to participate in this settlement. We are confident that this

> > settlement is the best possible resolution of your claim especially

in

> > light of the history of this litigation. We expect that any case

that

> > does not agree to participate in this settlement will have a very

> > difficult time navigating through the Court system and trial dates

may

> > not be set for many years. Moreover, as we have seen, these cases

will

> > be aggressively defended by AstraZeneca and we expect that we will

> > receive motions to dismiss and unfavorable decisions from the Court

on

> > unsettled cases in the coming months. Moreover, if this settlement

> > program is not successful (we fail to reach the 98% response rate)

we

> > highly doubt that we will ever obtain a settlement amount and terms

as

> > good as those contained in this program. While we hope that this

letter

> > and enclosures will help answer all of your questions, we understand

> > that you may have additional questions for us. Please keep in mind

that

> > we are working very hard to evaluate each and every case

individually

> > and the many deadlines that are part of this settlement are fast

> > approaching. Your case has been assigned to Judy Koenig. If you have

an

> > important question please call Judy Koenig at (800) 438-9786 and ask

for

> > extension 5860. If you reach a voice-mail, please leave a message

and

> > you will be called back as quickly as possible. Please do not leave

> > multiple voicemail messages on the same day as that will slow down

our

> > ability to return your call. Additionally, if you have email access,

> > please try to email your detailed questions to us at sqinfo@

> > <mailto:sqinfo@ and we will get back to you quickly. If

> > this letter has successfully answered your questions, and you have

> > decided to participate, please carefully follow the directions on

the

> > front page of the enclosed release form and send your signed and

> > witnessed release formes), your Track Selection AND your Brief

> > Questionnaire to us as soon as possible. If you still have questions

> > after reviewing this letter and after speaking to us over the

telephone

> > and you would like to meet us in person, we will be happy to

schedule a

> > meeting in our office at your convenience. Finally, please remember

that

> > the detailed information regarding this settlement program is

COMPLETELY

> > CONFIDENTIAL and should not be shared or discussed with anyone.

> > Sedgh, Esq Glenn Zuckerman, Esq.

> >

>

[Guest guest]

Cate

The evidence is clear ..............the suits don't work for the

litigants, all they seem to do is line the pockets of the lawyers many

of whom have clear links back to Scientology / CCHR

We must be careful not to be duped twice, first by pharma & then by the

class action lawyers and their rabble -rousers

> >

> > " Awry, " not " a rye " but I digress. This is exactly why I never urge

anyone to sue. The deck is stacked against us in court and attorneys are

looking for a quick and easy buck. No justice is to be had.

> >

> > Terry

> > Sent via BlackBerry by AT & T

> >

> > SEROQUEL Law Firms have sold their clients

down the river

> >

> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

TO

> > REJECT this Insult on Top of Injury

> >

[data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

\

> >

ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

\

> >

A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

\

> >

oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

\

> >

3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

\

> >

DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

\

> >

HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

\

> >

oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

\

> >

1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

\

> >

EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

\

> >

VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

\

> >

2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

\

> >

IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

\

> >

kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

\

> >

/jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

\

> >

9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

\

> >

CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

\

> >

ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

\

> >

zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

\

> >

T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

\

> >

N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

\

> >

HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

\

> >

gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

\

> >

w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

\

> >

3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

\

> >

wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

\

> >

TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

\

> >

Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

\

> >

NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

\

> >

LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

\

> >

yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

\

> >

rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

\

> >

pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

\

> >

5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

\

> >

bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

\

> >

rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

\

> >

XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

\

> >

AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

\

> >

sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

\

> >

uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

\

> >

9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

\

> >

aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

\

> >

83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

\

> >

mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

\

> >

0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

\

> >

A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

\

> >

QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

\

> >

UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

\

> >

ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

\

> >

/p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

\

> >

i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

\

> >

Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

\

> >

DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

\

> >

8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

\

> >

zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

\

> >

hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

\

> >

i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

\

> >

gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

\

> >

m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

\

> >

VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

\

> >

Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

\

> >

bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

\

> >

MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

\

> >

RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

\

> >

RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

\

> >

4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

\

> >

AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

\

> >

jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

\

> >

okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

\

> >

kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

\

> >

HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

\

> >

cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

\

> >

tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

\

> >

YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

\

> >

+EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

\

> >

sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

\

> >

9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

\

> >

QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

\

> >

kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

\

> >

Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

\

> >

Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

\

> >

QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

\

> >

t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

\

> >

MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

\

> >

VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

\

> >

nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

\

> >

SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

\

> >

tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

\

> >

8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

\

> >

ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

\

> >

J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

\

> >

m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

\

> >

6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

\

> >

76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

\

> >

9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

\

> >

zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

\

> >

9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

\

> >

5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

\

> >

oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

\

> >

hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

\

> >

5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

\

> >

vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

\

> >

fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

\

> >

aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

\

> >

+sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

\

> >

HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

\

> >

aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

\

> >

jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

\

> >

7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

\

> >

/Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

\

> >

G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

\

> >

GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

\

> >

+AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

\

> >

kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

\

> >

h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

\

> >

NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

\

> >

rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

\

> >

T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

\

> >

C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

\

> >

at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

\

> >

7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

\

> >

X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

\

> >

kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

\

> >

PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

\

> >

tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

\

> >

2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

\

> >

ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

\

> >

DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

\

> >

cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

\

> >

Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

\

> >

qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

\

> >

wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

\

> >

aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

\

> >

zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

\

> >

KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

\

> >

BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

\

> >

XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

\

> >

fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

\

> >

R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

\

> >

xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

\

> >

SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

\

> >

BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

\

> >

BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

\

> >

iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

\

> >

Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

\

> >

Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

\

> >

dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

\

> >

BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

\

> >

whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

\

> >

Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

\

> >

NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

\

> >

4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

\

> >

4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

\

> >

D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

\

> >

amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

\

> >

UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

\

> >

n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

\

> >

nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

\

> >

3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

\

> >

e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

\

> >

nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

\

> >

CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

\

> >

1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

\

> >

MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

\

> >

X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

\

> >

9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

\

> >

qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

\

> >

e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

\

> >

oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

\

> >

CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

\

> >

62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

\

> >

GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

\

> >

ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

\

> >

Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

\

> >

AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

\

> >

ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

\

> >

vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

\

> >

+2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

\

> >

kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

\

> >

e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

\

> >

hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

\

> >

6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

\

> >

DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

\

> >

ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

\

> >

suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

\

> >

6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

\

> >

yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

\

> >

c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

\

> >

rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

\

> >

FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

\

> >

2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

\

> >

GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

\

> >

UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

\

> >

I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

\

> >

xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

\

> >

IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

\

> >

EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

\

> >

Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

\

> >

S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

\

> >

WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

\

> >

mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

\

> >

Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

\

> >

QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

\

> >

IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

\

> >

9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

\

> >

FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

\

> >

FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

\

> >

lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

\

> >

Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

\

> >

Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

\

> >

+fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

\

> >

aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

\

> >

Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

\

> >

wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

\

> >

yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

\

> >

QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

\

> >

CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

\

> >

kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

\

> >

Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

\

> >

6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

\

> >

AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

\

> >

eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

\

> >

sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

\

> >

gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

\

> >

9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

\

> >

hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

\

> >

KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

\

> >

1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

\

> >

/m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

\

> >

9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

\

> >

qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

\

> >

LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

\

> >

iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

\

> >

wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

\

> >

A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

\

> >

A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

\

> >

1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

\

> >

h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

\

> >

X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

\

> >

TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

\

> >

kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

\

> >

SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

\

> >

mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

\

> >

7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

\

> >

XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

\

> >

U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

\

> >

+d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

\

> >

SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

\

> >

WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

\

> >

gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

\

> >

YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

\

> >

tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

\

> >

HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

\

> >

bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

\

> >

ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

\

> >

IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

\

> >

HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

\

> >

wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

\

> >

NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

\

> >

1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

\

> >

n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

\

> >

kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

\

> >

X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

\

> >

rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

\

> >

x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

\

> >

Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

\

> >

tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

\

> >

Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

\

> >

fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

\

> >

UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

\

> >

xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

\

> >

IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

\

> >

0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

\

> >

fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

\

> >

Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

\

> >

9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

\

> >

iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

\

> >

oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

\

> >

KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

\

> >

6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

\

> >

RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

\

> > ElFTkSuQmCC]

> >

> >

> >

> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

TO

> > REJECT this Insult on Top of Injury

> > I would like to thank a brave, courageous, and ethical anonymous

source

> > who has send in this letter correspondence they received from the

law

> > firm of Weitz & Luxenberg. This letter doesn't require a whole lot

of

> > commentary.

> > It's obvious that Law Firms have sold their clients down the

proverbial

> > river while at the same time enriching themselves (who's best

interest

> > are you obligated too fulfill?). This settlement offer and the

injured

> > litigants legal representation has carried out a blatant miscarriage

of

> > justice, a forever horrible stain upon the American Justice system,

and

> > a orchestrated crime perpetrated upon victims of this well

documented &

> > evidenced unbridled & unregulated corporate criminal enterprise gone

a

> > rye.

> > The time has now come for the victims to stand up to this criminal

> > corporation " AstraZeneca " & their poison drug " Seroquel " , to reject

this

> > horrible injustice and settlement offer. We want, what America & our

> > Constitution promises us all, our day in court before a jury of our

> > peers....

> > ____________________________________________________________

> >

> > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> > We are happy to report excellent news! After a long and hard fought

> > legal battle, AstraZeneca has agreed to participate in a Settlement

> > Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> > patience and aggressive litigating has resulted in very favorable

> > settlement terms for our clients which will be further outlined

below.

> > We have carefully reviewed all of the factors of this agreement and

we

> > believe that this settlement offers you the best, and very likely

the

> > only opportunity to receive a fair resolution of your lawsuit.

> > Therefore, we strongly recommend that you sign and complete the

enclosed

> > " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> > AGREE to participate.

> > As you know, we have engaged in a long legal battle with AstraZeneca

> > over the past 6 years. Weitz & Luxenberg led the charge for the

> > Plaintiffs around the Country. AstraZeneca put up a tremendous and

> > expensive defense and they successfully were able to get a large

number

> > of cases to be permanently dismissed by the court. Weitz & Luxenberg

is

> > the only firm who took a case to trial anywhere in the Country.

However,

> > after a month-long trial, the jury unfortunately ruled in favor of

the

> > defendants. This loss did not affect the strength of our fight. Over

the

> > past year, even as almost every other plaintiffs firm settled their

> > cases, Weitz & Luxenberg prepared two more cases for trial which was

> > scheduled to begin this Summer. As a direct result of the endless

and

> > consistent pressure applied by the attorneys at Weitz & Luxenberg,

we

> > are happy to report that AstraZeneca has now agreed to participate

in a

> > favorable settlement program. Based on public reports regarding

> > settlement programs reached with other plaintiff law firms we are

> > confident that the settlement program outlined below has more

favorable

> > terms and for this reason we are recommending your participation.

> > The defendants have argued that they refuse to pay anyone who cannot

> > prove through medical records or via certification that they have

used

> > Seroquel. They also refuse to pay anyone whose case is not active in

> > this litigation. We recently told you about the Order issued by the

> > Court requiring you to confirm when you started taking Seroquel and

when

> > you stopped taking Seroquel. We cannot stress enough that you MUST

read,

> > complete and return this certification form to us immediately. The

> > failure to return this form within the next 30 days will result in

the

> > permanent dismissal of your case. In order to protect your legal

rights,

> > to keep your case active and be permitted to participate in this

> > Settlement Program you must take this Order very seriously and you

must

> > respond.

> > Based on our experience in other litigations and having reviewed the

> > media reports of the terms of other firms' Seroquel settlement

programs,

> > we know that the defendants are looking for a settlement program

that

> > includes all claimants (W & L Seroquel Plaintiffs) so that they will

> > achieve complete closure of the entirYlitigation. Our goal in this

> > negotiation was to obtain a settlement for the most amount of money

> > using a fair method to pay our clients based upon the merits of

their

> > individual case. We also stressed our intentions that the case

review

> > and payment process be performed quickly yet fairly so that our

clients

> > can receive their settlements as soon as possible. A key part of

this

> > settlement program is that a claimant cannot be part of the

settlement

> > if their case is dismissed and unless they provide, at the very

least, a

> > certification that they in fact took Seroquel and suffered an

injury.

> > Therefore, please make sure that you return your certification form

to

> > us immediately

> >

> > We have hired Hon.Marina Corodemus to act as the Special Master for

the

> > W & L Seroquel settlement program. Judge Corodemus previously ran the

New

> > Jersey Mass Tort Court and has a lot of experience in this field.

She

> > was appointed as a Special Master by the Vioxx State and Federal

Court

> > Judges to determine the appropriateness of Vioxx settlements and to

> > resolve Vioxx appeals. She has also served as the Special Master in

many

> > other litigations such as Bextra and Celebrex which used similar

> > settlement terms. We have met several times with Judge Corodemus and

> > discussed the goals outlined above to get the most amount of money

to

> > the most amount of claimants in the fastest amount of time possible.

We

> > believe that Judge Corodemus is the perfect choice to create and

oversee

> > a settlement program in accordance with these goals. The W & L

Seroquel

> > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> > those clients with active cases (not dismissed as outlined above)

can

> > participate in this settlement program. Unlike other settlement

programs

> > that you may have read about in the media and internet, the W & L

> > Settlement program does not award every case an equal settlement

amount.

> > The size of an individual's settlement will depend entirely on the

merit

> > of that individual's case. As a direct result of the large number of

> > cases represented by W & L, and the merits of those cases, we are

> > confident that we have obtained the best possible settlement for our

> > clients. After complex negotiations, AstraZeneca

> > has agreed to deposit $92.25 Million dollars into a trust account to

be

> > used for this Settlement Program. This amount is completely

confidential

> > and you should NOT discuss this with anyone. A settlement of this

type

> > is called an " Aggregate Settlement " where a fair and reasonable sum

of

> > money is obtained to resolve multiple cases. In order to maintain

proper

> > representation of each individual client, W & L is NOT involved in

the

> > allocation decision making, which will be handled exclusively by

Judge

> > Corodemus. W & L has reviewed the general framework of the settlement

> > plan with Judge Corodemus and we strongly believe that it is fair

and

> > reasonable and offers each of our clients the best possible outcome

> > under the circumstances of this litigation. Track I offers the

Seroquel

> > claimant a settlement of $12,000. This track involves a simple

review of

> > each case and will result in a quick approval by Judge Corodemus

without

> > an analysis of the specific details of the case such as injury,

amount

> > of Seroquel taken, how close the last Seroquel use was to the date

of

> > the injury or the individual claimant's risk factors. a) Cannot

> > prove that they suffered diabetes or a diabetes related condition,

> > and/or Cannot prove that they used Seroquel within 1 year of

> > their claimed injury, and/or c) Had a large number of known

> > risk factors for diabetes before they started taking Seroquel. For

> > example - obesity, family history, smoking, etc.

> >

> > Therefore, all cases whose injuries are limited to weight gain or

high

> > blood sugar and whose medical records will confirm that they were

never

> > diagnosed with diabetes or pancreatitis, should choose Track 1.

> > Similarly, any claimed injury that occurred long after the last use

of

> > Seroquel should also choose Track 1. These cases are likely to

receive a

> > small award in Track II (likely less than $12,000) because it is

> > extremely difficult to prove that these injuries were caused by

> > Seroquel. Therefore, we suggest that if your case falls into this

> > category you should choose Track 1. Additionally, payment of Track I

> > settlement awards will be processed first once AstaZeneca waives its

> > " walk away right " . (See Section IV© below) Track II involves an

> > in-depth review of the severity of the injury, the claimed use of

> > Seroquel and its proximity to the injury as well the available proof

> > found in the contemporaneous medical records. Additionally, Judge

> > Corodemus will strongly consider many known risk factors for these

> > injuries including but not limited to smoking, obesity and family

> > history as well as the participation in the Zyprexa settlement for

these

> > same injuries. This model is very similar to the one used in the

> > National Vioxx Settlement Program as well as dozens of other similar

> > settlement programs which were successfully resolved in recent

years.

> > Judge Corodemus has established a points system and will consider

all of

> > the critical issues including but not limited to:

> > - Nature of the injury - Severity of the injury - Age at the time of

> > injury - Proximity of Seroquel use to the claimed injury - Changes

in

> > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> > etc. After carefully reviewing all of the medical records and the

> > individual fact sheet, Judge Corodemus will assign a point value to

each

> > case. The more points a case is awarded based on the specific facts

of

> > the case, the larger the settlement will be. At this time, there is

no

> > way to predict with accuracy how many points an individual case may

be

> > awarded and it is even more difficult to determine how much money

each

> > point will receive. The exact value of each point will depend on the

> > number of participants in Track II and the total number of points

> > assigned. All cases in Track II will be eligible for a settlement

award

> > but Judge Corodemus could award LESS than $12,000 (what people will

> > receive automatically by choosing Track 1) if the case lacks merit.

In

> > the interest of fairness, Judge Corodemus has committed to review

each

> > case in Track II very carefully and this process will take time to

> > complete. Judge Corodemus has stated that she hopes to have this

process

> > completed by the end of 2011 but please be warned that it could take

a

> > little longer due to the amount of work that is involved. However,

in

> > order to get this settlement process moving forward and ultimately

paid

> > you must send us your signed Release form as soon as possible. If

you

> > choose Track I your settlement award of $12,000 is set. If you

choose

> > Track II, Judge Corodemus will review your claim and will issue an

> > award. We expect that we will contact you in approximately November

2011

> > and notify you of your point award and the expected amount of your

> > settlement. At that point, you will be given a choice to accept your

> > award, appeal your award or withdraw from the settlement program. If

you

> > accept, we will forward your release to AstraZeneca for their review

and

> > approval. Please understand that this settlement is not official

until

> > we send AstraZeneca your signed Release Form, AstraZeneca approves

it

> > AND AstraZeneca waives its walk away right. In the interest of time,

we

> > are asking you to return your signed Release Form now so we can meet

the

> > tight deadlines associated with this settlement. If you are unhappy

with

> > your allocation amount and/or believe that your case involves

> > " Extraordinary Injury or Circumstances " you have the right to appeal

> > your award. Upon receipt of such an application, Judge Corodemus

will

> > re-review your records and make a final decision. Please be aware

that

> > there is no additional right of appeal (to Judge Corodemus or to any

> > Court) once this final decision is made. If you decide to decline

the

> > settlement amount offered to you, you must notify us within ten days

of

> > your receipt of your allocation amount and your signed Release Form

will

> > no longer be valid. As in all settlements of this type, our

agreement

> > with the defendant depends on nearly full participation from all of

our

> > clients. Under the terms of our agreement, we must provide

Qualifying

> > Materials (Release Form and/or Dismissal) for 2,260 of our clients.

Once

> > we reach this number, AstraZeneca's " walk away right " is officially

> > waived. We strongly believe that our clients will agree that this

> > settlement program offers the best possible terms and we expect that

we

> > will meet this requirement in the next 90-120 days. In order to meet

> > this deadline we MUST have your complete

> > cooperation and immediate response. Of course, if we do not meet

this

> > required number of responses, Astrazeneca can decide to withdraw its

> > settlement offer to everyone whether one signed the Release Form or

not.

> > Therefore, time is of the essence. A. Release Form: Enclosed you

will

> > find a Release Form which you must sign in front of a notary in

Order to

> > participate in the settlement. If you have a spouse he/she must sign

the

> > Release Form as well. Attached to the Release Form will be an

> > instruction sheet to guide you to ensure that this important form is

> > signed the right way. A Release Form that is signed the wrong way or

> > that is not witnessed (by a notary) is useless and will not be

accepted

> > by the defendants. The Release Form is your agreement to participate

in

> > the settlement program and at the same time discontinue your lawsuit

in

> > exchange for your settlement award. Please turn to Page 2 of the

Release

> > Form and complete the details of your Seroquel use. You may refer to

> > Page 1 of the Brief Questionnaire which lists the Seroquel

information

> > that was found in your medical records or that you have previously

> > provided to us. If this information is inaccurate, please cross it

out

> > and write in when you started and when you stopped taking Seroquel

on

> > BOTH the Release Form and the Brief Questionnaire. Due to the fast

> > approaching deadlines, and our goal to get you your settlement

processed

> > and paid as quickly as possible, we MUST receive this signed release

> > form back from you before August 31, 2011. Please use the envelope

> > provided herein and return the signed and notarized release form

today

> > before you forget about it. Please note that once we submit your

release

> > form to AstraZeneca it can not be revoked. B. Track Selection Form:

> > Enclosed you will find a " Track Selection Form " which is the form

used

> > to officially notify the Special Master which Track you want your

case

> > to follow. Please Note that there are 4 options on this form. You

MUST

> > check one of the Options. If you want to participate in this

settlement,

> > and we strongly think that you should, you must check either Track I

OR

> > Track II and you must sign the bottom of the form. Your Track

selection

> > cannot be changed and is considered final once the Judge's

Allocations

> > are made. In other words, a person who chooses Track II and is

awarded

> > less than $12,000 CANNOT then choose to go to Track 1 for a higher

> > award. C. Brief Questionnaire: Enclosed you will find a 3

> > page Brief Questionnaire which has important information about your

> > claim. For all claimants who choose to enter Track II, Judge

Corodemus

> > will be reviewing your medical records, your Fact Sheet and this

Brief

> > Questionnaire and will issue a point award. Judge Corodemus will

> > consider the proof of your claim found in your medical records as

well

> > as the information that you provide in this Questionnaire.

Therefore, it

> > is important that you answer these questions honestly and completely

and

> > that they are consistent with what is found in your medical records.

> > litigation and our conversations with our medical experts, it is

clear

> > that Seroquel lawsuits are very difficult to win, very expensive,

and

> > very time consuming to take through to trial, verdict and appeal.

Over

> > the past six years only I case (from W & L) of24,000 cases in the

Country

> > made it to and through trial. Countless other cases were prepared

and

> > then dismissed based on merit and/or inability to prove that

Seroquel

> > caused the injury. Just because an individual took Seroquel and

suffered

> > an injury like diabetes does not mean that such a case will win at

> > trial. In order to succeed at trial, a plaintiff must prove both

that

> > Seroquel can cause such an injury in general AND that, within a

> > reasonable degree of medical certainty, Seroquel caused this injury

to

> > this particular person (despite any individual risk factors such as

> > smoking, weight, high blood sugar, family history etc.). We have

told

> > you in the past update letters that the Courts have consistently

ruled

> > in favor of the defendants on many of these issues and have

prohibited

> > medical experts from testifying because of a lack of scientific

proof

> > linking the plaintiff s injuries to his/her Seroquel use. It is also

> > important to note that even if your case is able to advance past

this

> > judicial scrutiny, a trial of this magnitude will cost over $750,000

per

> > case and many of these costs are reimbursed off of the top of a

> > favorable verdict reducing the amount received by the plaintiff.

> > Furthermore, any case that is won at trial will surely face a

lengthy

> > and hard-fought appeal. Finally, nearly all of the Seroquel cases

are

> > being handled by three judges. Even at an accelerated pace, the

chances

> > are slim that your case would be tried in the next 10 years if not

> > longer. In taking all of these factors into consideration, and

> > considering the issues of risk and reward, we believe that a

settlement

> > of this type offers you the most advantageous resolution possible.

You

> > will be notified once the Special Master issues your point award at

> > which point you can appeal to the Special Master if you believe that

> > your case involves extraordinary circumstances. Thereafter, the

decision

> > of the Special Master is final, binding and non-appealable. We have

> > retained the Garretson Law Firm to negotiate any and all Federal and

> > State liens (Medicare/Medicaid/SSI) that may be applicable in your

case.

> > The Garretson Firm is a specialist in this field and they have

obtained

> > excellent results in their negotiation of similar liens in other

> > litigations like Vioxx, Bextra, and Celebrex. Moreover, the

Garretson

> > Firm has already worked on thousands of other Seroquel cases and has

> > been able to achieve excellent results in large part due to the

volume

> > of cases that they are able to include in a Global Resolution. At

this

> > time, the Garretson Firm has already negotiated with 44 individual

> > states regarding Medicaid and they have reached an agreement to CAP

> > Medicaid liens at a maximum of 20% of the settlement amount. Please

see

> > the enclosed blue booklet regarding governmental liens for more

details.

> > Additionally, please also be advised that if you or Weitz &

Luxenberg

> > are put on written notice of a private lien, for example from your

> > medical provider, this lien must be resolved before any settlement

> > proceeds can be distributed. If you have received any notice of a

lien,

> > please advise us immediately. The terms of your signed contingency

fee

> > agreement will be in effect. We have taken great effort to keep the

case

> > specific expenses as low as possible. Under the terms of your

agreement,

> > the

> > contingency fee will be calculated after the expenses are deducted.

> > Under the terms of our agreement with AstraZeneca, any interest

earned

> > on the settlement proceeds before allocation and payment to the

> > individual clients will be used to offset the fixed costs of the

Special

> > Master and the Lien Administrator. Due to the low interest rates

paid by

> > all banks in this economy, we do not expect that there will be any

> > leftover interest. However, in such a case, the leftover interest

will

> > be added to the settlement trust and will be distributed to all

> > claimants as part of Judge Corodemus' allocation process. After

careful

> > analysis of the likelihood of success in the court system, as well

as

> > the cost and time elements involved, we strongly recommend that you

> > AGREE to participate in this settlement. We are confident that this

> > settlement is the best possible resolution of your claim especially

in

> > light of the history of this litigation. We expect that any case

that

> > does not agree to participate in this settlement will have a very

> > difficult time navigating through the Court system and trial dates

may

> > not be set for many years. Moreover, as we have seen, these cases

will

> > be aggressively defended by AstraZeneca and we expect that we will

> > receive motions to dismiss and unfavorable decisions from the Court

on

> > unsettled cases in the coming months. Moreover, if this settlement

> > program is not successful (we fail to reach the 98% response rate)

we

> > highly doubt that we will ever obtain a settlement amount and terms

as

> > good as those contained in this program. While we hope that this

letter

> > and enclosures will help answer all of your questions, we understand

> > that you may have additional questions for us. Please keep in mind

that

> > we are working very hard to evaluate each and every case

individually

> > and the many deadlines that are part of this settlement are fast

> > approaching. Your case has been assigned to Judy Koenig. If you have

an

> > important question please call Judy Koenig at (800) 438-9786 and ask

for

> > extension 5860. If you reach a voice-mail, please leave a message

and

> > you will be called back as quickly as possible. Please do not leave

> > multiple voicemail messages on the same day as that will slow down

our

> > ability to return your call. Additionally, if you have email access,

> > please try to email your detailed questions to us at sqinfo@

> > <mailto:sqinfo@ and we will get back to you quickly. If

> > this letter has successfully answered your questions, and you have

> > decided to participate, please carefully follow the directions on

the

> > front page of the enclosed release form and send your signed and

> > witnessed release formes), your Track Selection AND your Brief

> > Questionnaire to us as soon as possible. If you still have questions

> > after reviewing this letter and after speaking to us over the

telephone

> > and you would like to meet us in person, we will be happy to

schedule a

> > meeting in our office at your convenience. Finally, please remember

that

> > the detailed information regarding this settlement program is

COMPLETELY

> > CONFIDENTIAL and should not be shared or discussed with anyone.

> > Sedgh, Esq Glenn Zuckerman, Esq.

> >

>

[Guest guest]

Cate

The evidence is clear ..............the suits don't work for the

litigants, all they seem to do is line the pockets of the lawyers many

of whom have clear links back to Scientology / CCHR

We must be careful not to be duped twice, first by pharma & then by the

class action lawyers and their rabble -rousers

> >

> > " Awry, " not " a rye " but I digress. This is exactly why I never urge

anyone to sue. The deck is stacked against us in court and attorneys are

looking for a quick and easy buck. No justice is to be had.

> >

> > Terry

> > Sent via BlackBerry by AT & T

> >

> > SEROQUEL Law Firms have sold their clients

down the river

> >

> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

TO

> > REJECT this Insult on Top of Injury

> >

[data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

\

> >

ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

\

> >

A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

\

> >

oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

\

> >

3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

\

> >

DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

\

> >

HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

\

> >

oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

\

> >

1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

\

> >

EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

\

> >

VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

\

> >

2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

\

> >

IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

\

> >

kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

\

> >

/jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

\

> >

9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

\

> >

CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

\

> >

ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

\

> >

zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

\

> >

T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

\

> >

N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

\

> >

HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

\

> >

gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

\

> >

w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

\

> >

3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

\

> >

wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

\

> >

TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

\

> >

Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

\

> >

NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

\

> >

LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

\

> >

yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

\

> >

rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

\

> >

pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

\

> >

5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

\

> >

bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

\

> >

rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

\

> >

XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

\

> >

AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

\

> >

sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

\

> >

uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

\

> >

9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

\

> >

aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

\

> >

83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

\

> >

mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

\

> >

0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

\

> >

A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

\

> >

QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

\

> >

UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

\

> >

ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

\

> >

/p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

\

> >

i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

\

> >

Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

\

> >

DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

\

> >

8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

\

> >

zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

\

> >

hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

\

> >

i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

\

> >

gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

\

> >

m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

\

> >

VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

\

> >

Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

\

> >

bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

\

> >

MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

\

> >

RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

\

> >

RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

\

> >

4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

\

> >

AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

\

> >

jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

\

> >

okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

\

> >

kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

\

> >

HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

\

> >

cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

\

> >

tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

\

> >

YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

\

> >

+EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

\

> >

sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

\

> >

9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

\

> >

QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

\

> >

kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

\

> >

Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

\

> >

Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

\

> >

QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

\

> >

t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

\

> >

MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

\

> >

VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

\

> >

nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

\

> >

SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

\

> >

tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

\

> >

8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

\

> >

ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

\

> >

J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

\

> >

m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

\

> >

6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

\

> >

76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

\

> >

9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

\

> >

zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

\

> >

9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

\

> >

5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

\

> >

oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

\

> >

hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

\

> >

5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

\

> >

vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

\

> >

fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

\

> >

aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

\

> >

+sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

\

> >

HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

\

> >

aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

\

> >

jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

\

> >

7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

\

> >

/Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

\

> >

G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

\

> >

GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

\

> >

+AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

\

> >

kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

\

> >

h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

\

> >

NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

\

> >

rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

\

> >

T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

\

> >

C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

\

> >

at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

\

> >

7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

\

> >

X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

\

> >

kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

\

> >

PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

\

> >

tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

\

> >

2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

\

> >

ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

\

> >

DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

\

> >

cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

\

> >

Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

\

> >

qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

\

> >

wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

\

> >

aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

\

> >

zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

\

> >

KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

\

> >

BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

\

> >

XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

\

> >

fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

\

> >

R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

\

> >

xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

\

> >

SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

\

> >

BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

\

> >

BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

\

> >

iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

\

> >

Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

\

> >

Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

\

> >

dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

\

> >

BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

\

> >

whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

\

> >

Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

\

> >

NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

\

> >

4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

\

> >

4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

\

> >

D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

\

> >

amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

\

> >

UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

\

> >

n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

\

> >

nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

\

> >

3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

\

> >

e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

\

> >

nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

\

> >

CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

\

> >

1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

\

> >

MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

\

> >

X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

\

> >

9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

\

> >

qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

\

> >

e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

\

> >

oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

\

> >

CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

\

> >

62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

\

> >

GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

\

> >

ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

\

> >

Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

\

> >

AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

\

> >

ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

\

> >

vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

\

> >

+2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

\

> >

kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

\

> >

e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

\

> >

hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

\

> >

6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

\

> >

DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

\

> >

ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

\

> >

suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

\

> >

6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

\

> >

yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

\

> >

c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

\

> >

rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

\

> >

FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

\

> >

2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

\

> >

GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

\

> >

UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

\

> >

I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

\

> >

xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

\

> >

IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

\

> >

EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

\

> >

Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

\

> >

S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

\

> >

WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

\

> >

mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

\

> >

Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

\

> >

QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

\

> >

IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

\

> >

9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

\

> >

FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

\

> >

FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

\

> >

lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

\

> >

Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

\

> >

Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

\

> >

+fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

\

> >

aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

\

> >

Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

\

> >

wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

\

> >

yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

\

> >

QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

\

> >

CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

\

> >

kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

\

> >

Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

\

> >

6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

\

> >

AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

\

> >

eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

\

> >

sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

\

> >

gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

\

> >

9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

\

> >

hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

\

> >

KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

\

> >

1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

\

> >

/m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

\

> >

9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

\

> >

qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

\

> >

LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

\

> >

iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

\

> >

wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

\

> >

A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

\

> >

A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

\

> >

1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

\

> >

h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

\

> >

X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

\

> >

TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

\

> >

kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

\

> >

SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

\

> >

mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

\

> >

7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

\

> >

XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

\

> >

U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

\

> >

+d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

\

> >

SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

\

> >

WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

\

> >

gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

\

> >

YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

\

> >

tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

\

> >

HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

\

> >

bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

\

> >

ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

\

> >

IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

\

> >

HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

\

> >

wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

\

> >

NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

\

> >

1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

\

> >

n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

\

> >

kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

\

> >

X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

\

> >

rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

\

> >

x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

\

> >

Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

\

> >

tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

\

> >

Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

\

> >

fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

\

> >

UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

\

> >

xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

\

> >

IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

\

> >

0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

\

> >

fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

\

> >

Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

\

> >

9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

\

> >

iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

\

> >

oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

\

> >

KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

\

> >

6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

\

> >

RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

\

> > ElFTkSuQmCC]

> >

> >

> >

> > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

TO

> > REJECT this Insult on Top of Injury

> > I would like to thank a brave, courageous, and ethical anonymous

source

> > who has send in this letter correspondence they received from the

law

> > firm of Weitz & Luxenberg. This letter doesn't require a whole lot

of

> > commentary.

> > It's obvious that Law Firms have sold their clients down the

proverbial

> > river while at the same time enriching themselves (who's best

interest

> > are you obligated too fulfill?). This settlement offer and the

injured

> > litigants legal representation has carried out a blatant miscarriage

of

> > justice, a forever horrible stain upon the American Justice system,

and

> > a orchestrated crime perpetrated upon victims of this well

documented &

> > evidenced unbridled & unregulated corporate criminal enterprise gone

a

> > rye.

> > The time has now come for the victims to stand up to this criminal

> > corporation " AstraZeneca " & their poison drug " Seroquel " , to reject

this

> > horrible injustice and settlement offer. We want, what America & our

> > Constitution promises us all, our day in court before a jury of our

> > peers....

> > ____________________________________________________________

> >

> > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> > We are happy to report excellent news! After a long and hard fought

> > legal battle, AstraZeneca has agreed to participate in a Settlement

> > Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> > patience and aggressive litigating has resulted in very favorable

> > settlement terms for our clients which will be further outlined

below.

> > We have carefully reviewed all of the factors of this agreement and

we

> > believe that this settlement offers you the best, and very likely

the

> > only opportunity to receive a fair resolution of your lawsuit.

> > Therefore, we strongly recommend that you sign and complete the

enclosed

> > " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> > AGREE to participate.

> > As you know, we have engaged in a long legal battle with AstraZeneca

> > over the past 6 years. Weitz & Luxenberg led the charge for the

> > Plaintiffs around the Country. AstraZeneca put up a tremendous and

> > expensive defense and they successfully were able to get a large

number

> > of cases to be permanently dismissed by the court. Weitz & Luxenberg

is

> > the only firm who took a case to trial anywhere in the Country.

However,

> > after a month-long trial, the jury unfortunately ruled in favor of

the

> > defendants. This loss did not affect the strength of our fight. Over

the

> > past year, even as almost every other plaintiffs firm settled their

> > cases, Weitz & Luxenberg prepared two more cases for trial which was

> > scheduled to begin this Summer. As a direct result of the endless

and

> > consistent pressure applied by the attorneys at Weitz & Luxenberg,

we

> > are happy to report that AstraZeneca has now agreed to participate

in a

> > favorable settlement program. Based on public reports regarding

> > settlement programs reached with other plaintiff law firms we are

> > confident that the settlement program outlined below has more

favorable

> > terms and for this reason we are recommending your participation.

> > The defendants have argued that they refuse to pay anyone who cannot

> > prove through medical records or via certification that they have

used

> > Seroquel. They also refuse to pay anyone whose case is not active in

> > this litigation. We recently told you about the Order issued by the

> > Court requiring you to confirm when you started taking Seroquel and

when

> > you stopped taking Seroquel. We cannot stress enough that you MUST

read,

> > complete and return this certification form to us immediately. The

> > failure to return this form within the next 30 days will result in

the

> > permanent dismissal of your case. In order to protect your legal

rights,

> > to keep your case active and be permitted to participate in this

> > Settlement Program you must take this Order very seriously and you

must

> > respond.

> > Based on our experience in other litigations and having reviewed the

> > media reports of the terms of other firms' Seroquel settlement

programs,

> > we know that the defendants are looking for a settlement program

that

> > includes all claimants (W & L Seroquel Plaintiffs) so that they will

> > achieve complete closure of the entirYlitigation. Our goal in this

> > negotiation was to obtain a settlement for the most amount of money

> > using a fair method to pay our clients based upon the merits of

their

> > individual case. We also stressed our intentions that the case

review

> > and payment process be performed quickly yet fairly so that our

clients

> > can receive their settlements as soon as possible. A key part of

this

> > settlement program is that a claimant cannot be part of the

settlement

> > if their case is dismissed and unless they provide, at the very

least, a

> > certification that they in fact took Seroquel and suffered an

injury.

> > Therefore, please make sure that you return your certification form

to

> > us immediately

> >

> > We have hired Hon.Marina Corodemus to act as the Special Master for

the

> > W & L Seroquel settlement program. Judge Corodemus previously ran the

New

> > Jersey Mass Tort Court and has a lot of experience in this field.

She

> > was appointed as a Special Master by the Vioxx State and Federal

Court

> > Judges to determine the appropriateness of Vioxx settlements and to

> > resolve Vioxx appeals. She has also served as the Special Master in

many

> > other litigations such as Bextra and Celebrex which used similar

> > settlement terms. We have met several times with Judge Corodemus and

> > discussed the goals outlined above to get the most amount of money

to

> > the most amount of claimants in the fastest amount of time possible.

We

> > believe that Judge Corodemus is the perfect choice to create and

oversee

> > a settlement program in accordance with these goals. The W & L

Seroquel

> > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> > those clients with active cases (not dismissed as outlined above)

can

> > participate in this settlement program. Unlike other settlement

programs

> > that you may have read about in the media and internet, the W & L

> > Settlement program does not award every case an equal settlement

amount.

> > The size of an individual's settlement will depend entirely on the

merit

> > of that individual's case. As a direct result of the large number of

> > cases represented by W & L, and the merits of those cases, we are

> > confident that we have obtained the best possible settlement for our

> > clients. After complex negotiations, AstraZeneca

> > has agreed to deposit $92.25 Million dollars into a trust account to

be

> > used for this Settlement Program. This amount is completely

confidential

> > and you should NOT discuss this with anyone. A settlement of this

type

> > is called an " Aggregate Settlement " where a fair and reasonable sum

of

> > money is obtained to resolve multiple cases. In order to maintain

proper

> > representation of each individual client, W & L is NOT involved in

the

> > allocation decision making, which will be handled exclusively by

Judge

> > Corodemus. W & L has reviewed the general framework of the settlement

> > plan with Judge Corodemus and we strongly believe that it is fair

and

> > reasonable and offers each of our clients the best possible outcome

> > under the circumstances of this litigation. Track I offers the

Seroquel

> > claimant a settlement of $12,000. This track involves a simple

review of

> > each case and will result in a quick approval by Judge Corodemus

without

> > an analysis of the specific details of the case such as injury,

amount

> > of Seroquel taken, how close the last Seroquel use was to the date

of

> > the injury or the individual claimant's risk factors. a) Cannot

> > prove that they suffered diabetes or a diabetes related condition,

> > and/or Cannot prove that they used Seroquel within 1 year of

> > their claimed injury, and/or c) Had a large number of known

> > risk factors for diabetes before they started taking Seroquel. For

> > example - obesity, family history, smoking, etc.

> >

> > Therefore, all cases whose injuries are limited to weight gain or

high

> > blood sugar and whose medical records will confirm that they were

never

> > diagnosed with diabetes or pancreatitis, should choose Track 1.

> > Similarly, any claimed injury that occurred long after the last use

of

> > Seroquel should also choose Track 1. These cases are likely to

receive a

> > small award in Track II (likely less than $12,000) because it is

> > extremely difficult to prove that these injuries were caused by

> > Seroquel. Therefore, we suggest that if your case falls into this

> > category you should choose Track 1. Additionally, payment of Track I

> > settlement awards will be processed first once AstaZeneca waives its

> > " walk away right " . (See Section IV© below) Track II involves an

> > in-depth review of the severity of the injury, the claimed use of

> > Seroquel and its proximity to the injury as well the available proof

> > found in the contemporaneous medical records. Additionally, Judge

> > Corodemus will strongly consider many known risk factors for these

> > injuries including but not limited to smoking, obesity and family

> > history as well as the participation in the Zyprexa settlement for

these

> > same injuries. This model is very similar to the one used in the

> > National Vioxx Settlement Program as well as dozens of other similar

> > settlement programs which were successfully resolved in recent

years.

> > Judge Corodemus has established a points system and will consider

all of

> > the critical issues including but not limited to:

> > - Nature of the injury - Severity of the injury - Age at the time of

> > injury - Proximity of Seroquel use to the claimed injury - Changes

in

> > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> > etc. After carefully reviewing all of the medical records and the

> > individual fact sheet, Judge Corodemus will assign a point value to

each

> > case. The more points a case is awarded based on the specific facts

of

> > the case, the larger the settlement will be. At this time, there is

no

> > way to predict with accuracy how many points an individual case may

be

> > awarded and it is even more difficult to determine how much money

each

> > point will receive. The exact value of each point will depend on the

> > number of participants in Track II and the total number of points

> > assigned. All cases in Track II will be eligible for a settlement

award

> > but Judge Corodemus could award LESS than $12,000 (what people will

> > receive automatically by choosing Track 1) if the case lacks merit.

In

> > the interest of fairness, Judge Corodemus has committed to review

each

> > case in Track II very carefully and this process will take time to

> > complete. Judge Corodemus has stated that she hopes to have this

process

> > completed by the end of 2011 but please be warned that it could take

a

> > little longer due to the amount of work that is involved. However,

in

> > order to get this settlement process moving forward and ultimately

paid

> > you must send us your signed Release form as soon as possible. If

you

> > choose Track I your settlement award of $12,000 is set. If you

choose

> > Track II, Judge Corodemus will review your claim and will issue an

> > award. We expect that we will contact you in approximately November

2011

> > and notify you of your point award and the expected amount of your

> > settlement. At that point, you will be given a choice to accept your

> > award, appeal your award or withdraw from the settlement program. If

you

> > accept, we will forward your release to AstraZeneca for their review

and

> > approval. Please understand that this settlement is not official

until

> > we send AstraZeneca your signed Release Form, AstraZeneca approves

it

> > AND AstraZeneca waives its walk away right. In the interest of time,

we

> > are asking you to return your signed Release Form now so we can meet

the

> > tight deadlines associated with this settlement. If you are unhappy

with

> > your allocation amount and/or believe that your case involves

> > " Extraordinary Injury or Circumstances " you have the right to appeal

> > your award. Upon receipt of such an application, Judge Corodemus

will

> > re-review your records and make a final decision. Please be aware

that

> > there is no additional right of appeal (to Judge Corodemus or to any

> > Court) once this final decision is made. If you decide to decline

the

> > settlement amount offered to you, you must notify us within ten days

of

> > your receipt of your allocation amount and your signed Release Form

will

> > no longer be valid. As in all settlements of this type, our

agreement

> > with the defendant depends on nearly full participation from all of

our

> > clients. Under the terms of our agreement, we must provide

Qualifying

> > Materials (Release Form and/or Dismissal) for 2,260 of our clients.

Once

> > we reach this number, AstraZeneca's " walk away right " is officially

> > waived. We strongly believe that our clients will agree that this

> > settlement program offers the best possible terms and we expect that

we

> > will meet this requirement in the next 90-120 days. In order to meet

> > this deadline we MUST have your complete

> > cooperation and immediate response. Of course, if we do not meet

this

> > required number of responses, Astrazeneca can decide to withdraw its

> > settlement offer to everyone whether one signed the Release Form or

not.

> > Therefore, time is of the essence. A. Release Form: Enclosed you

will

> > find a Release Form which you must sign in front of a notary in

Order to

> > participate in the settlement. If you have a spouse he/she must sign

the

> > Release Form as well. Attached to the Release Form will be an

> > instruction sheet to guide you to ensure that this important form is

> > signed the right way. A Release Form that is signed the wrong way or

> > that is not witnessed (by a notary) is useless and will not be

accepted

> > by the defendants. The Release Form is your agreement to participate

in

> > the settlement program and at the same time discontinue your lawsuit

in

> > exchange for your settlement award. Please turn to Page 2 of the

Release

> > Form and complete the details of your Seroquel use. You may refer to

> > Page 1 of the Brief Questionnaire which lists the Seroquel

information

> > that was found in your medical records or that you have previously

> > provided to us. If this information is inaccurate, please cross it

out

> > and write in when you started and when you stopped taking Seroquel

on

> > BOTH the Release Form and the Brief Questionnaire. Due to the fast

> > approaching deadlines, and our goal to get you your settlement

processed

> > and paid as quickly as possible, we MUST receive this signed release

> > form back from you before August 31, 2011. Please use the envelope

> > provided herein and return the signed and notarized release form

today

> > before you forget about it. Please note that once we submit your

release

> > form to AstraZeneca it can not be revoked. B. Track Selection Form:

> > Enclosed you will find a " Track Selection Form " which is the form

used

> > to officially notify the Special Master which Track you want your

case

> > to follow. Please Note that there are 4 options on this form. You

MUST

> > check one of the Options. If you want to participate in this

settlement,

> > and we strongly think that you should, you must check either Track I

OR

> > Track II and you must sign the bottom of the form. Your Track

selection

> > cannot be changed and is considered final once the Judge's

Allocations

> > are made. In other words, a person who chooses Track II and is

awarded

> > less than $12,000 CANNOT then choose to go to Track 1 for a higher

> > award. C. Brief Questionnaire: Enclosed you will find a 3

> > page Brief Questionnaire which has important information about your

> > claim. For all claimants who choose to enter Track II, Judge

Corodemus

> > will be reviewing your medical records, your Fact Sheet and this

Brief

> > Questionnaire and will issue a point award. Judge Corodemus will

> > consider the proof of your claim found in your medical records as

well

> > as the information that you provide in this Questionnaire.

Therefore, it

> > is important that you answer these questions honestly and completely

and

> > that they are consistent with what is found in your medical records.

> > litigation and our conversations with our medical experts, it is

clear

> > that Seroquel lawsuits are very difficult to win, very expensive,

and

> > very time consuming to take through to trial, verdict and appeal.

Over

> > the past six years only I case (from W & L) of24,000 cases in the

Country

> > made it to and through trial. Countless other cases were prepared

and

> > then dismissed based on merit and/or inability to prove that

Seroquel

> > caused the injury. Just because an individual took Seroquel and

suffered

> > an injury like diabetes does not mean that such a case will win at

> > trial. In order to succeed at trial, a plaintiff must prove both

that

> > Seroquel can cause such an injury in general AND that, within a

> > reasonable degree of medical certainty, Seroquel caused this injury

to

> > this particular person (despite any individual risk factors such as

> > smoking, weight, high blood sugar, family history etc.). We have

told

> > you in the past update letters that the Courts have consistently

ruled

> > in favor of the defendants on many of these issues and have

prohibited

> > medical experts from testifying because of a lack of scientific

proof

> > linking the plaintiff s injuries to his/her Seroquel use. It is also

> > important to note that even if your case is able to advance past

this

> > judicial scrutiny, a trial of this magnitude will cost over $750,000

per

> > case and many of these costs are reimbursed off of the top of a

> > favorable verdict reducing the amount received by the plaintiff.

> > Furthermore, any case that is won at trial will surely face a

lengthy

> > and hard-fought appeal. Finally, nearly all of the Seroquel cases

are

> > being handled by three judges. Even at an accelerated pace, the

chances

> > are slim that your case would be tried in the next 10 years if not

> > longer. In taking all of these factors into consideration, and

> > considering the issues of risk and reward, we believe that a

settlement

> > of this type offers you the most advantageous resolution possible.

You

> > will be notified once the Special Master issues your point award at

> > which point you can appeal to the Special Master if you believe that

> > your case involves extraordinary circumstances. Thereafter, the

decision

> > of the Special Master is final, binding and non-appealable. We have

> > retained the Garretson Law Firm to negotiate any and all Federal and

> > State liens (Medicare/Medicaid/SSI) that may be applicable in your

case.

> > The Garretson Firm is a specialist in this field and they have

obtained

> > excellent results in their negotiation of similar liens in other

> > litigations like Vioxx, Bextra, and Celebrex. Moreover, the

Garretson

> > Firm has already worked on thousands of other Seroquel cases and has

> > been able to achieve excellent results in large part due to the

volume

> > of cases that they are able to include in a Global Resolution. At

this

> > time, the Garretson Firm has already negotiated with 44 individual

> > states regarding Medicaid and they have reached an agreement to CAP

> > Medicaid liens at a maximum of 20% of the settlement amount. Please

see

> > the enclosed blue booklet regarding governmental liens for more

details.

> > Additionally, please also be advised that if you or Weitz &

Luxenberg

> > are put on written notice of a private lien, for example from your

> > medical provider, this lien must be resolved before any settlement

> > proceeds can be distributed. If you have received any notice of a

lien,

> > please advise us immediately. The terms of your signed contingency

fee

> > agreement will be in effect. We have taken great effort to keep the

case

> > specific expenses as low as possible. Under the terms of your

agreement,

> > the

> > contingency fee will be calculated after the expenses are deducted.

> > Under the terms of our agreement with AstraZeneca, any interest

earned

> > on the settlement proceeds before allocation and payment to the

> > individual clients will be used to offset the fixed costs of the

Special

> > Master and the Lien Administrator. Due to the low interest rates

paid by

> > all banks in this economy, we do not expect that there will be any

> > leftover interest. However, in such a case, the leftover interest

will

> > be added to the settlement trust and will be distributed to all

> > claimants as part of Judge Corodemus' allocation process. After

careful

> > analysis of the likelihood of success in the court system, as well

as

> > the cost and time elements involved, we strongly recommend that you

> > AGREE to participate in this settlement. We are confident that this

> > settlement is the best possible resolution of your claim especially

in

> > light of the history of this litigation. We expect that any case

that

> > does not agree to participate in this settlement will have a very

> > difficult time navigating through the Court system and trial dates

may

> > not be set for many years. Moreover, as we have seen, these cases

will

> > be aggressively defended by AstraZeneca and we expect that we will

> > receive motions to dismiss and unfavorable decisions from the Court

on

> > unsettled cases in the coming months. Moreover, if this settlement

> > program is not successful (we fail to reach the 98% response rate)

we

> > highly doubt that we will ever obtain a settlement amount and terms

as

> > good as those contained in this program. While we hope that this

letter

> > and enclosures will help answer all of your questions, we understand

> > that you may have additional questions for us. Please keep in mind

that

> > we are working very hard to evaluate each and every case

individually

> > and the many deadlines that are part of this settlement are fast

> > approaching. Your case has been assigned to Judy Koenig. If you have

an

> > important question please call Judy Koenig at (800) 438-9786 and ask

for

> > extension 5860. If you reach a voice-mail, please leave a message

and

> > you will be called back as quickly as possible. Please do not leave

> > multiple voicemail messages on the same day as that will slow down

our

> > ability to return your call. Additionally, if you have email access,

> > please try to email your detailed questions to us at sqinfo@

> > <mailto:sqinfo@ and we will get back to you quickly. If

> > this letter has successfully answered your questions, and you have

> > decided to participate, please carefully follow the directions on

the

> > front page of the enclosed release form and send your signed and

> > witnessed release formes), your Track Selection AND your Brief

> > Questionnaire to us as soon as possible. If you still have questions

> > after reviewing this letter and after speaking to us over the

telephone

> > and you would like to meet us in person, we will be happy to

schedule a

> > meeting in our office at your convenience. Finally, please remember

that

> > the detailed information regarding this settlement program is

COMPLETELY

> > CONFIDENTIAL and should not be shared or discussed with anyone.

> > Sedgh, Esq Glenn Zuckerman, Esq.

> >

>

[Guest guest]

That's interesting that you say the class-action lawyers are linked to CCHR --

years ago, the Scientologists were among the few who would speak out against

this mass drugging with SSRIs and other psychiatric drugs. I have been away for

several years from actice involvement in the issues, but I know a friend of

mine, many years ago, told a shrink that she found the side effects of Prozac

worrisome, and he told her not to listen to the Scientologists (she had never

heard of the Scientologists, that was just his way of throwing mud on the

windscreen, so to speak.)

> > >

> > > " Awry, " not " a rye " but I digress. This is exactly why I never urge

> anyone to sue. The deck is stacked against us in court and attorneys are

> looking for a quick and easy buck. No justice is to be had.

> > >

> > > Terry

> > > Sent via BlackBerry by AT & T

> > >

> > > SEROQUEL Law Firms have sold their clients

> down the river

> > >

> > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

> TO

> > > REJECT this Insult on Top of Injury

> > >

> [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

> \

> > >

> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

> \

> > >

> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

> \

> > >

> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

> \

> > >

> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

> \

> > >

> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

> \

> > >

> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

> \

> > >

> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

> \

> > >

> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

> \

> > >

> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

> \

> > >

> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

> \

> > >

> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

> \

> > >

> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

> \

> > >

> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

> \

> > >

> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

> \

> > >

> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

> \

> > >

> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

> \

> > >

> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

> \

> > >

> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

> \

> > >

> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

> \

> > >

> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

> \

> > >

> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

> \

> > >

> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

> \

> > >

> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

> \

> > >

> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

> \

> > >

> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

> \

> > >

> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

> \

> > >

> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

> \

> > >

> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

> \

> > >

> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

> \

> > >

> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

> \

> > >

> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

> \

> > >

> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

> \

> > >

> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

> \

> > >

> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

> \

> > >

> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

> \

> > >

> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

> \

> > >

> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

> \

> > >

> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

> \

> > >

> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

> \

> > >

> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

> \

> > >

> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

> \

> > >

> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

> \

> > >

> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

> \

> > >

> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

> \

> > >

> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

> \

> > >

> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

> \

> > >

> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

> \

> > >

> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

> \

> > >

> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

> \

> > >

> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

> \

> > >

> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

> \

> > >

> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

> \

> > >

> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

> \

> > >

> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

> \

> > >

> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

> \

> > >

> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

> \

> > >

> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

> \

> > >

> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

> \

> > >

> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

> \

> > >

> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

> \

> > >

> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

> \

> > >

> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

> \

> > >

> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

> \

> > >

> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

> \

> > >

> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

> \

> > >

> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

> \

> > >

> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

> \

> > >

> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

> \

> > >

> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

> \

> > >

> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

> \

> > >

> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

> \

> > >

> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

> \

> > >

> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

> \

> > >

> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

> \

> > >

> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

> \

> > >

> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

> \

> > >

> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

> \

> > >

> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

> \

> > >

> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

> \

> > >

> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

> \

> > >

> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

> \

> > >

> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

> \

> > >

> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

> \

> > >

> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

> \

> > >

> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

> \

> > >

> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

> \

> > >

> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

> \

> > >

> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

> \

> > >

> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

> \

> > >

> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

> \

> > >

> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

> \

> > >

> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

> \

> > >

> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

> \

> > >

> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

> \

> > >

> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

> \

> > >

> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

> \

> > >

> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

> \

> > >

> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

> \

> > >

> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

> \

> > >

> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

> \

> > >

> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

> \

> > >

> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

> \

> > >

> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

> \

> > >

> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

> \

> > >

> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

> \

> > >

> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

> \

> > >

> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

> \

> > >

> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

> \

> > >

> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

> \

> > >

> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

> \

> > >

> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

> \

> > >

> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

> \

> > >

> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

> \

> > >

> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

> \

> > >

> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

> \

> > >

> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

> \

> > >

> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

> \

> > >

> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

> \

> > >

> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

> \

> > >

> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

> \

> > >

> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

> \

> > >

> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

> \

> > >

> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

> \

> > >

> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

> \

> > >

> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

> \

> > >

> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

> \

> > >

> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

> \

> > >

> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

> \

> > >

> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

> \

> > >

> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

> \

> > >

> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

> \

> > >

> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

> \

> > >

> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

> \

> > >

> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

> \

> > >

> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

> \

> > >

> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

> \

> > >

> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

> \

> > >

> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

> \

> > >

> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

> \

> > >

> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

> \

> > >

> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

> \

> > >

> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

> \

> > >

> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

> \

> > >

> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

> \

> > >

> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

> \

> > >

> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

> \

> > >

> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

> \

> > >

> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

> \

> > >

> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

> \

> > >

> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

> \

> > >

> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

> \

> > >

> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

> \

> > >

> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

> \

> > >

> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

> \

> > >

> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

> \

> > >

> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

> \

> > >

> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

> \

> > >

> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

> \

> > >

> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

> \

> > >

> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

> \

> > >

> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

> \

> > >

> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

> \

> > >

> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

> \

> > >

> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

> \

> > >

> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

> \

> > >

> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

> \

> > >

> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

> \

> > >

> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

> \

> > >

> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

> \

> > >

> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

> \

> > >

> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

> \

> > >

> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

> \

> > >

> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

> \

> > >

> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

> \

> > >

> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

> \

> > >

> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

> \

> > >

> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

> \

> > >

> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

> \

> > >

> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

> \

> > >

> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

> \

> > >

> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

> \

> > >

> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

> \

> > >

> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

> \

> > >

> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

> \

> > >

> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

> \

> > >

> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

> \

> > >

> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

> \

> > >

> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

> \

> > >

> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

> \

> > >

> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

> \

> > >

> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

> \

> > >

> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

> \

> > >

> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

> \

> > >

> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

> \

> > >

> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

> \

> > >

> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

> \

> > >

> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

> \

> > >

> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

> \

> > >

> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

> \

> > >

> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

> \

> > >

> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

> \

> > >

> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

> \

> > >

> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

> \

> > >

> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

> \

> > >

> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

> \

> > >

> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

> \

> > >

> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

> \

> > >

> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

> \

> > >

> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

> \

> > >

> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

> \

> > >

> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

> \

> > >

> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

> \

> > >

> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

> \

> > >

> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

> \

> > >

> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

> \

> > >

> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

> \

> > >

> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

> \

> > >

> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

> \

> > >

> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

> \

> > >

> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

> \

> > >

> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

> \

> > >

> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

> \

> > >

> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

> \

> > >

> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

> \

> > >

> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

> \

> > >

> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

> \

> > >

> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

> \

> > >

> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

> \

> > >

> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

> \

> > >

> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

> \

> > >

> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

> \

> > >

> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

> \

> > >

> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

> \

> > >

> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

> \

> > >

> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

> \

> > >

> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

> \

> > >

> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

> \

> > >

> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

> \

> > >

> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

> \

> > >

> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

> \

> > >

> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

> \

> > >

> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

> \

> > >

> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

> \

> > >

> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

> \

> > >

> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

> \

> > >

> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

> \

> > >

> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

> \

> > >

> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

> \

> > >

> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

> \

> > >

> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

> \

> > >

> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

> \

> > >

> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

> \

> > >

> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

> \

> > >

> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

> \

> > >

> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

> \

> > >

> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

> \

> > >

> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

> \

> > >

> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

> \

> > >

> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

> \

> > >

> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

> \

> > >

> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

> \

> > >

> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

> \

> > >

> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

> \

> > >

> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

> \

> > >

> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

> \

> > >

> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

> \

> > >

> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

> \

> > >

> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

> \

> > >

> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

> \

> > >

> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

> \

> > >

> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

> \

> > >

> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

> \

> > >

> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

> \

> > >

> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

> \

> > >

> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

> \

> > >

> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

> \

> > >

> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

> \

> > >

> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

> \

> > >

> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

> \

> > >

> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

> \

> > > ElFTkSuQmCC]

> > >

> > >

> > >

> > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

> TO

> > > REJECT this Insult on Top of Injury

> > > I would like to thank a brave, courageous, and ethical anonymous

> source

> > > who has send in this letter correspondence they received from the

> law

> > > firm of Weitz & Luxenberg. This letter doesn't require a whole lot

> of

> > > commentary.

> > > It's obvious that Law Firms have sold their clients down the

> proverbial

> > > river while at the same time enriching themselves (who's best

> interest

> > > are you obligated too fulfill?). This settlement offer and the

> injured

> > > litigants legal representation has carried out a blatant miscarriage

> of

> > > justice, a forever horrible stain upon the American Justice system,

> and

> > > a orchestrated crime perpetrated upon victims of this well

> documented &

> > > evidenced unbridled & unregulated corporate criminal enterprise gone

> a

> > > rye.

> > > The time has now come for the victims to stand up to this criminal

> > > corporation " AstraZeneca " & their poison drug " Seroquel " , to reject

> this

> > > horrible injustice and settlement offer. We want, what America & our

> > > Constitution promises us all, our day in court before a jury of our

> > > peers....

> > > ____________________________________________________________

> > >

> > > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> > > We are happy to report excellent news! After a long and hard fought

> > > legal battle, AstraZeneca has agreed to participate in a Settlement

> > > Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> > > patience and aggressive litigating has resulted in very favorable

> > > settlement terms for our clients which will be further outlined

> below.

> > > We have carefully reviewed all of the factors of this agreement and

> we

> > > believe that this settlement offers you the best, and very likely

> the

> > > only opportunity to receive a fair resolution of your lawsuit.

> > > Therefore, we strongly recommend that you sign and complete the

> enclosed

> > > " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> > > AGREE to participate.

> > > As you know, we have engaged in a long legal battle with AstraZeneca

> > > over the past 6 years. Weitz & Luxenberg led the charge for the

> > > Plaintiffs around the Country. AstraZeneca put up a tremendous and

> > > expensive defense and they successfully were able to get a large

> number

> > > of cases to be permanently dismissed by the court. Weitz & Luxenberg

> is

> > > the only firm who took a case to trial anywhere in the Country.

> However,

> > > after a month-long trial, the jury unfortunately ruled in favor of

> the

> > > defendants. This loss did not affect the strength of our fight. Over

> the

> > > past year, even as almost every other plaintiffs firm settled their

> > > cases, Weitz & Luxenberg prepared two more cases for trial which was

> > > scheduled to begin this Summer. As a direct result of the endless

> and

> > > consistent pressure applied by the attorneys at Weitz & Luxenberg,

> we

> > > are happy to report that AstraZeneca has now agreed to participate

> in a

> > > favorable settlement program. Based on public reports regarding

> > > settlement programs reached with other plaintiff law firms we are

> > > confident that the settlement program outlined below has more

> favorable

> > > terms and for this reason we are recommending your participation.

> > > The defendants have argued that they refuse to pay anyone who cannot

> > > prove through medical records or via certification that they have

> used

> > > Seroquel. They also refuse to pay anyone whose case is not active in

> > > this litigation. We recently told you about the Order issued by the

> > > Court requiring you to confirm when you started taking Seroquel and

> when

> > > you stopped taking Seroquel. We cannot stress enough that you MUST

> read,

> > > complete and return this certification form to us immediately. The

> > > failure to return this form within the next 30 days will result in

> the

> > > permanent dismissal of your case. In order to protect your legal

> rights,

> > > to keep your case active and be permitted to participate in this

> > > Settlement Program you must take this Order very seriously and you

> must

> > > respond.

> > > Based on our experience in other litigations and having reviewed the

> > > media reports of the terms of other firms' Seroquel settlement

> programs,

> > > we know that the defendants are looking for a settlement program

> that

> > > includes all claimants (W & L Seroquel Plaintiffs) so that they will

> > > achieve complete closure of the entirYlitigation. Our goal in this

> > > negotiation was to obtain a settlement for the most amount of money

> > > using a fair method to pay our clients based upon the merits of

> their

> > > individual case. We also stressed our intentions that the case

> review

> > > and payment process be performed quickly yet fairly so that our

> clients

> > > can receive their settlements as soon as possible. A key part of

> this

> > > settlement program is that a claimant cannot be part of the

> settlement

> > > if their case is dismissed and unless they provide, at the very

> least, a

> > > certification that they in fact took Seroquel and suffered an

> injury.

> > > Therefore, please make sure that you return your certification form

> to

> > > us immediately

> > >

> > > We have hired Hon.Marina Corodemus to act as the Special Master for

> the

> > > W & L Seroquel settlement program. Judge Corodemus previously ran the

> New

> > > Jersey Mass Tort Court and has a lot of experience in this field.

> She

> > > was appointed as a Special Master by the Vioxx State and Federal

> Court

> > > Judges to determine the appropriateness of Vioxx settlements and to

> > > resolve Vioxx appeals. She has also served as the Special Master in

> many

> > > other litigations such as Bextra and Celebrex which used similar

> > > settlement terms. We have met several times with Judge Corodemus and

> > > discussed the goals outlined above to get the most amount of money

> to

> > > the most amount of claimants in the fastest amount of time possible.

> We

> > > believe that Judge Corodemus is the perfect choice to create and

> oversee

> > > a settlement program in accordance with these goals. The W & L

> Seroquel

> > > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> > > those clients with active cases (not dismissed as outlined above)

> can

> > > participate in this settlement program. Unlike other settlement

> programs

> > > that you may have read about in the media and internet, the W & L

> > > Settlement program does not award every case an equal settlement

> amount.

> > > The size of an individual's settlement will depend entirely on the

> merit

> > > of that individual's case. As a direct result of the large number of

> > > cases represented by W & L, and the merits of those cases, we are

> > > confident that we have obtained the best possible settlement for our

> > > clients. After complex negotiations, AstraZeneca

> > > has agreed to deposit $92.25 Million dollars into a trust account to

> be

> > > used for this Settlement Program. This amount is completely

> confidential

> > > and you should NOT discuss this with anyone. A settlement of this

> type

> > > is called an " Aggregate Settlement " where a fair and reasonable sum

> of

> > > money is obtained to resolve multiple cases. In order to maintain

> proper

> > > representation of each individual client, W & L is NOT involved in

> the

> > > allocation decision making, which will be handled exclusively by

> Judge

> > > Corodemus. W & L has reviewed the general framework of the settlement

> > > plan with Judge Corodemus and we strongly believe that it is fair

> and

> > > reasonable and offers each of our clients the best possible outcome

> > > under the circumstances of this litigation. Track I offers the

> Seroquel

> > > claimant a settlement of $12,000. This track involves a simple

> review of

> > > each case and will result in a quick approval by Judge Corodemus

> without

> > > an analysis of the specific details of the case such as injury,

> amount

> > > of Seroquel taken, how close the last Seroquel use was to the date

> of

> > > the injury or the individual claimant's risk factors. a) Cannot

> > > prove that they suffered diabetes or a diabetes related condition,

> > > and/or Cannot prove that they used Seroquel within 1 year of

> > > their claimed injury, and/or c) Had a large number of known

> > > risk factors for diabetes before they started taking Seroquel. For

> > > example - obesity, family history, smoking, etc.

> > >

> > > Therefore, all cases whose injuries are limited to weight gain or

> high

> > > blood sugar and whose medical records will confirm that they were

> never

> > > diagnosed with diabetes or pancreatitis, should choose Track 1.

> > > Similarly, any claimed injury that occurred long after the last use

> of

> > > Seroquel should also choose Track 1. These cases are likely to

> receive a

> > > small award in Track II (likely less than $12,000) because it is

> > > extremely difficult to prove that these injuries were caused by

> > > Seroquel. Therefore, we suggest that if your case falls into this

> > > category you should choose Track 1. Additionally, payment of Track I

> > > settlement awards will be processed first once AstaZeneca waives its

> > > " walk away right " . (See Section IV© below) Track II involves an

> > > in-depth review of the severity of the injury, the claimed use of

> > > Seroquel and its proximity to the injury as well the available proof

> > > found in the contemporaneous medical records. Additionally, Judge

> > > Corodemus will strongly consider many known risk factors for these

> > > injuries including but not limited to smoking, obesity and family

> > > history as well as the participation in the Zyprexa settlement for

> these

> > > same injuries. This model is very similar to the one used in the

> > > National Vioxx Settlement Program as well as dozens of other similar

> > > settlement programs which were successfully resolved in recent

> years.

> > > Judge Corodemus has established a points system and will consider

> all of

> > > the critical issues including but not limited to:

> > > - Nature of the injury - Severity of the injury - Age at the time of

> > > injury - Proximity of Seroquel use to the claimed injury - Changes

> in

> > > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> > > etc. After carefully reviewing all of the medical records and the

> > > individual fact sheet, Judge Corodemus will assign a point value to

> each

> > > case. The more points a case is awarded based on the specific facts

> of

> > > the case, the larger the settlement will be. At this time, there is

> no

> > > way to predict with accuracy how many points an individual case may

> be

> > > awarded and it is even more difficult to determine how much money

> each

> > > point will receive. The exact value of each point will depend on the

> > > number of participants in Track II and the total number of points

> > > assigned. All cases in Track II will be eligible for a settlement

> award

> > > but Judge Corodemus could award LESS than $12,000 (what people will

> > > receive automatically by choosing Track 1) if the case lacks merit.

> In

> > > the interest of fairness, Judge Corodemus has committed to review

> each

> > > case in Track II very carefully and this process will take time to

> > > complete. Judge Corodemus has stated that she hopes to have this

> process

> > > completed by the end of 2011 but please be warned that it could take

> a

> > > little longer due to the amount of work that is involved. However,

> in

> > > order to get this settlement process moving forward and ultimately

> paid

> > > you must send us your signed Release form as soon as possible. If

> you

> > > choose Track I your settlement award of $12,000 is set. If you

> choose

> > > Track II, Judge Corodemus will review your claim and will issue an

> > > award. We expect that we will contact you in approximately November

> 2011

> > > and notify you of your point award and the expected amount of your

> > > settlement. At that point, you will be given a choice to accept your

> > > award, appeal your award or withdraw from the settlement program. If

> you

> > > accept, we will forward your release to AstraZeneca for their review

> and

> > > approval. Please understand that this settlement is not official

> until

> > > we send AstraZeneca your signed Release Form, AstraZeneca approves

> it

> > > AND AstraZeneca waives its walk away right. In the interest of time,

> we

> > > are asking you to return your signed Release Form now so we can meet

> the

> > > tight deadlines associated with this settlement. If you are unhappy

> with

> > > your allocation amount and/or believe that your case involves

> > > " Extraordinary Injury or Circumstances " you have the right to appeal

> > > your award. Upon receipt of such an application, Judge Corodemus

> will

> > > re-review your records and make a final decision. Please be aware

> that

> > > there is no additional right of appeal (to Judge Corodemus or to any

> > > Court) once this final decision is made. If you decide to decline

> the

> > > settlement amount offered to you, you must notify us within ten days

> of

> > > your receipt of your allocation amount and your signed Release Form

> will

> > > no longer be valid. As in all settlements of this type, our

> agreement

> > > with the defendant depends on nearly full participation from all of

> our

> > > clients. Under the terms of our agreement, we must provide

> Qualifying

> > > Materials (Release Form and/or Dismissal) for 2,260 of our clients.

> Once

> > > we reach this number, AstraZeneca's " walk away right " is officially

> > > waived. We strongly believe that our clients will agree that this

> > > settlement program offers the best possible terms and we expect that

> we

> > > will meet this requirement in the next 90-120 days. In order to meet

> > > this deadline we MUST have your complete

> > > cooperation and immediate response. Of course, if we do not meet

> this

> > > required number of responses, Astrazeneca can decide to withdraw its

> > > settlement offer to everyone whether one signed the Release Form or

> not.

> > > Therefore, time is of the essence. A. Release Form: Enclosed you

> will

> > > find a Release Form which you must sign in front of a notary in

> Order to

> > > participate in the settlement. If you have a spouse he/she must sign

> the

> > > Release Form as well. Attached to the Release Form will be an

> > > instruction sheet to guide you to ensure that this important form is

> > > signed the right way. A Release Form that is signed the wrong way or

> > > that is not witnessed (by a notary) is useless and will not be

> accepted

> > > by the defendants. The Release Form is your agreement to participate

> in

> > > the settlement program and at the same time discontinue your lawsuit

> in

> > > exchange for your settlement award. Please turn to Page 2 of the

> Release

> > > Form and complete the details of your Seroquel use. You may refer to

> > > Page 1 of the Brief Questionnaire which lists the Seroquel

> information

> > > that was found in your medical records or that you have previously

> > > provided to us. If this information is inaccurate, please cross it

> out

> > > and write in when you started and when you stopped taking Seroquel

> on

> > > BOTH the Release Form and the Brief Questionnaire. Due to the fast

> > > approaching deadlines, and our goal to get you your settlement

> processed

> > > and paid as quickly as possible, we MUST receive this signed release

> > > form back from you before August 31, 2011. Please use the envelope

> > > provided herein and return the signed and notarized release form

> today

> > > before you forget about it. Please note that once we submit your

> release

> > > form to AstraZeneca it can not be revoked. B. Track Selection Form:

> > > Enclosed you will find a " Track Selection Form " which is the form

> used

> > > to officially notify the Special Master which Track you want your

> case

> > > to follow. Please Note that there are 4 options on this form. You

> MUST

> > > check one of the Options. If you want to participate in this

> settlement,

> > > and we strongly think that you should, you must check either Track I

> OR

> > > Track II and you must sign the bottom of the form. Your Track

> selection

> > > cannot be changed and is considered final once the Judge's

> Allocations

> > > are made. In other words, a person who chooses Track II and is

> awarded

> > > less than $12,000 CANNOT then choose to go to Track 1 for a higher

> > > award. C. Brief Questionnaire: Enclosed you will find a 3

> > > page Brief Questionnaire which has important information about your

> > > claim. For all claimants who choose to enter Track II, Judge

> Corodemus

> > > will be reviewing your medical records, your Fact Sheet and this

> Brief

> > > Questionnaire and will issue a point award. Judge Corodemus will

> > > consider the proof of your claim found in your medical records as

> well

> > > as the information that you provide in this Questionnaire.

> Therefore, it

> > > is important that you answer these questions honestly and completely

> and

> > > that they are consistent with what is found in your medical records.

> > > litigation and our conversations with our medical experts, it is

> clear

> > > that Seroquel lawsuits are very difficult to win, very expensive,

> and

> > > very time consuming to take through to trial, verdict and appeal.

> Over

> > > the past six years only I case (from W & L) of24,000 cases in the

> Country

> > > made it to and through trial. Countless other cases were prepared

> and

> > > then dismissed based on merit and/or inability to prove that

> Seroquel

> > > caused the injury. Just because an individual took Seroquel and

> suffered

> > > an injury like diabetes does not mean that such a case will win at

> > > trial. In order to succeed at trial, a plaintiff must prove both

> that

> > > Seroquel can cause such an injury in general AND that, within a

> > > reasonable degree of medical certainty, Seroquel caused this injury

> to

> > > this particular person (despite any individual risk factors such as

> > > smoking, weight, high blood sugar, family history etc.). We have

> told

> > > you in the past update letters that the Courts have consistently

> ruled

> > > in favor of the defendants on many of these issues and have

> prohibited

> > > medical experts from testifying because of a lack of scientific

> proof

> > > linking the plaintiff s injuries to his/her Seroquel use. It is also

> > > important to note that even if your case is able to advance past

> this

> > > judicial scrutiny, a trial of this magnitude will cost over $750,000

> per

> > > case and many of these costs are reimbursed off of the top of a

> > > favorable verdict reducing the amount received by the plaintiff.

> > > Furthermore, any case that is won at trial will surely face a

> lengthy

> > > and hard-fought appeal. Finally, nearly all of the Seroquel cases

> are

> > > being handled by three judges. Even at an accelerated pace, the

> chances

> > > are slim that your case would be tried in the next 10 years if not

> > > longer. In taking all of these factors into consideration, and

> > > considering the issues of risk and reward, we believe that a

> settlement

> > > of this type offers you the most advantageous resolution possible.

> You

> > > will be notified once the Special Master issues your point award at

> > > which point you can appeal to the Special Master if you believe that

> > > your case involves extraordinary circumstances. Thereafter, the

> decision

> > > of the Special Master is final, binding and non-appealable. We have

> > > retained the Garretson Law Firm to negotiate any and all Federal and

> > > State liens (Medicare/Medicaid/SSI) that may be applicable in your

> case.

> > > The Garretson Firm is a specialist in this field and they have

> obtained

> > > excellent results in their negotiation of similar liens in other

> > > litigations like Vioxx, Bextra, and Celebrex. Moreover, the

> Garretson

> > > Firm has already worked on thousands of other Seroquel cases and has

> > > been able to achieve excellent results in large part due to the

> volume

> > > of cases that they are able to include in a Global Resolution. At

> this

> > > time, the Garretson Firm has already negotiated with 44 individual

> > > states regarding Medicaid and they have reached an agreement to CAP

> > > Medicaid liens at a maximum of 20% of the settlement amount. Please

> see

> > > the enclosed blue booklet regarding governmental liens for more

> details.

> > > Additionally, please also be advised that if you or Weitz &

> Luxenberg

> > > are put on written notice of a private lien, for example from your

> > > medical provider, this lien must be resolved before any settlement

> > > proceeds can be distributed. If you have received any notice of a

> lien,

> > > please advise us immediately. The terms of your signed contingency

> fee

> > > agreement will be in effect. We have taken great effort to keep the

> case

> > > specific expenses as low as possible. Under the terms of your

> agreement,

> > > the

> > > contingency fee will be calculated after the expenses are deducted.

> > > Under the terms of our agreement with AstraZeneca, any interest

> earned

> > > on the settlement proceeds before allocation and payment to the

> > > individual clients will be used to offset the fixed costs of the

> Special

> > > Master and the Lien Administrator. Due to the low interest rates

> paid by

> > > all banks in this economy, we do not expect that there will be any

> > > leftover interest. However, in such a case, the leftover interest

> will

> > > be added to the settlement trust and will be distributed to all

> > > claimants as part of Judge Corodemus' allocation process. After

> careful

> > > analysis of the likelihood of success in the court system, as well

> as

> > > the cost and time elements involved, we strongly recommend that you

> > > AGREE to participate in this settlement. We are confident that this

> > > settlement is the best possible resolution of your claim especially

> in

> > > light of the history of this litigation. We expect that any case

> that

> > > does not agree to participate in this settlement will have a very

> > > difficult time navigating through the Court system and trial dates

> may

> > > not be set for many years. Moreover, as we have seen, these cases

> will

> > > be aggressively defended by AstraZeneca and we expect that we will

> > > receive motions to dismiss and unfavorable decisions from the Court

> on

> > > unsettled cases in the coming months. Moreover, if this settlement

> > > program is not successful (we fail to reach the 98% response rate)

> we

> > > highly doubt that we will ever obtain a settlement amount and terms

> as

> > > good as those contained in this program. While we hope that this

> letter

> > > and enclosures will help answer all of your questions, we understand

> > > that you may have additional questions for us. Please keep in mind

> that

> > > we are working very hard to evaluate each and every case

> individually

> > > and the many deadlines that are part of this settlement are fast

> > > approaching. Your case has been assigned to Judy Koenig. If you have

> an

> > > important question please call Judy Koenig at (800) 438-9786 and ask

> for

> > > extension 5860. If you reach a voice-mail, please leave a message

> and

> > > you will be called back as quickly as possible. Please do not leave

> > > multiple voicemail messages on the same day as that will slow down

> our

> > > ability to return your call. Additionally, if you have email access,

> > > please try to email your detailed questions to us at sqinfo@

> > > <mailto:sqinfo@ and we will get back to you quickly. If

> > > this letter has successfully answered your questions, and you have

> > > decided to participate, please carefully follow the directions on

> the

> > > front page of the enclosed release form and send your signed and

> > > witnessed release formes), your Track Selection AND your Brief

> > > Questionnaire to us as soon as possible. If you still have questions

> > > after reviewing this letter and after speaking to us over the

> telephone

> > > and you would like to meet us in person, we will be happy to

> schedule a

> > > meeting in our office at your convenience. Finally, please remember

> that

> > > the detailed information regarding this settlement program is

> COMPLETELY

> > > CONFIDENTIAL and should not be shared or discussed with anyone.

>

> > > Sedgh, Esq Glenn Zuckerman, Esq.

> > >

> >

>

[Guest guest]

That's interesting that you say the class-action lawyers are linked to CCHR --

years ago, the Scientologists were among the few who would speak out against

this mass drugging with SSRIs and other psychiatric drugs. I have been away for

several years from actice involvement in the issues, but I know a friend of

mine, many years ago, told a shrink that she found the side effects of Prozac

worrisome, and he told her not to listen to the Scientologists (she had never

heard of the Scientologists, that was just his way of throwing mud on the

windscreen, so to speak.)

> > >

> > > " Awry, " not " a rye " but I digress. This is exactly why I never urge

> anyone to sue. The deck is stacked against us in court and attorneys are

> looking for a quick and easy buck. No justice is to be had.

> > >

> > > Terry

> > > Sent via BlackBerry by AT & T

> > >

> > > SEROQUEL Law Firms have sold their clients

> down the river

> > >

> > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

> TO

> > > REJECT this Insult on Top of Injury

> > >

> [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

> \

> > >

> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

> \

> > >

> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

> \

> > >

> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

> \

> > >

> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

> \

> > >

> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

> \

> > >

> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

> \

> > >

> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

> \

> > >

> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

> \

> > >

> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

> \

> > >

> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

> \

> > >

> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

> \

> > >

> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

> \

> > >

> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

> \

> > >

> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

> \

> > >

> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

> \

> > >

> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

> \

> > >

> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

> \

> > >

> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

> \

> > >

> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

> \

> > >

> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

> \

> > >

> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

> \

> > >

> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

> \

> > >

> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

> \

> > >

> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

> \

> > >

> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

> \

> > >

> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

> \

> > >

> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

> \

> > >

> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

> \

> > >

> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

> \

> > >

> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

> \

> > >

> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

> \

> > >

> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

> \

> > >

> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

> \

> > >

> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

> \

> > >

> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

> \

> > >

> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

> \

> > >

> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

> \

> > >

> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

> \

> > >

> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

> \

> > >

> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

> \

> > >

> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

> \

> > >

> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

> \

> > >

> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

> \

> > >

> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

> \

> > >

> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

> \

> > >

> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

> \

> > >

> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

> \

> > >

> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

> \

> > >

> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

> \

> > >

> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

> \

> > >

> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

> \

> > >

> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

> \

> > >

> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

> \

> > >

> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

> \

> > >

> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

> \

> > >

> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

> \

> > >

> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

> \

> > >

> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

> \

> > >

> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

> \

> > >

> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

> \

> > >

> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

> \

> > >

> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

> \

> > >

> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

> \

> > >

> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

> \

> > >

> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

> \

> > >

> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

> \

> > >

> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

> \

> > >

> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

> \

> > >

> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

> \

> > >

> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

> \

> > >

> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

> \

> > >

> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

> \

> > >

> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

> \

> > >

> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

> \

> > >

> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

> \

> > >

> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

> \

> > >

> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

> \

> > >

> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

> \

> > >

> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

> \

> > >

> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

> \

> > >

> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

> \

> > >

> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

> \

> > >

> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

> \

> > >

> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

> \

> > >

> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

> \

> > >

> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

> \

> > >

> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

> \

> > >

> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

> \

> > >

> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

> \

> > >

> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

> \

> > >

> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

> \

> > >

> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

> \

> > >

> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

> \

> > >

> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

> \

> > >

> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

> \

> > >

> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

> \

> > >

> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

> \

> > >

> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

> \

> > >

> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

> \

> > >

> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

> \

> > >

> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

> \

> > >

> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

> \

> > >

> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

> \

> > >

> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

> \

> > >

> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

> \

> > >

> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

> \

> > >

> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

> \

> > >

> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

> \

> > >

> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

> \

> > >

> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

> \

> > >

> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

> \

> > >

> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

> \

> > >

> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

> \

> > >

> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

> \

> > >

> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

> \

> > >

> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

> \

> > >

> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

> \

> > >

> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

> \

> > >

> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

> \

> > >

> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

> \

> > >

> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

> \

> > >

> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

> \

> > >

> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

> \

> > >

> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

> \

> > >

> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

> \

> > >

> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

> \

> > >

> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

> \

> > >

> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

> \

> > >

> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

> \

> > >

> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

> \

> > >

> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

> \

> > >

> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

> \

> > >

> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

> \

> > >

> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

> \

> > >

> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

> \

> > >

> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

> \

> > >

> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

> \

> > >

> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

> \

> > >

> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

> \

> > >

> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

> \

> > >

> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

> \

> > >

> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

> \

> > >

> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

> \

> > >

> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

> \

> > >

> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

> \

> > >

> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

> \

> > >

> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

> \

> > >

> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

> \

> > >

> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

> \

> > >

> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

> \

> > >

> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

> \

> > >

> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

> \

> > >

> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

> \

> > >

> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

> \

> > >

> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

> \

> > >

> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

> \

> > >

> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

> \

> > >

> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

> \

> > >

> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

> \

> > >

> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

> \

> > >

> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

> \

> > >

> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

> \

> > >

> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

> \

> > >

> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

> \

> > >

> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

> \

> > >

> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

> \

> > >

> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

> \

> > >

> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

> \

> > >

> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

> \

> > >

> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

> \

> > >

> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

> \

> > >

> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

> \

> > >

> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

> \

> > >

> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

> \

> > >

> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

> \

> > >

> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

> \

> > >

> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

> \

> > >

> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

> \

> > >

> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

> \

> > >

> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

> \

> > >

> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

> \

> > >

> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

> \

> > >

> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

> \

> > >

> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

> \

> > >

> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

> \

> > >

> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

> \

> > >

> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

> \

> > >

> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

> \

> > >

> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

> \

> > >

> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

> \

> > >

> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

> \

> > >

> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

> \

> > >

> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

> \

> > >

> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

> \

> > >

> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

> \

> > >

> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

> \

> > >

> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

> \

> > >

> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

> \

> > >

> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

> \

> > >

> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

> \

> > >

> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

> \

> > >

> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

> \

> > >

> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

> \

> > >

> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

> \

> > >

> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

> \

> > >

> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

> \

> > >

> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

> \

> > >

> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

> \

> > >

> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

> \

> > >

> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

> \

> > >

> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

> \

> > >

> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

> \

> > >

> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

> \

> > >

> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

> \

> > >

> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

> \

> > >

> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

> \

> > >

> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

> \

> > >

> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

> \

> > >

> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

> \

> > >

> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

> \

> > >

> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

> \

> > >

> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

> \

> > >

> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

> \

> > >

> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

> \

> > >

> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

> \

> > >

> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

> \

> > >

> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

> \

> > >

> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

> \

> > >

> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

> \

> > >

> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

> \

> > >

> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

> \

> > >

> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

> \

> > >

> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

> \

> > >

> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

> \

> > >

> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

> \

> > >

> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

> \

> > >

> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

> \

> > >

> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

> \

> > >

> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

> \

> > >

> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

> \

> > >

> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

> \

> > >

> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

> \

> > >

> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

> \

> > >

> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

> \

> > >

> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

> \

> > >

> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

> \

> > >

> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

> \

> > >

> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

> \

> > >

> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

> \

> > >

> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

> \

> > >

> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

> \

> > >

> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

> \

> > >

> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

> \

> > >

> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

> \

> > >

> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

> \

> > >

> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

> \

> > >

> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

> \

> > >

> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

> \

> > >

> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

> \

> > >

> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

> \

> > >

> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

> \

> > >

> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

> \

> > >

> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

> \

> > >

> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

> \

> > >

> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

> \

> > >

> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

> \

> > >

> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

> \

> > >

> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

> \

> > >

> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

> \

> > >

> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

> \

> > >

> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

> \

> > >

> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

> \

> > >

> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

> \

> > >

> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

> \

> > >

> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

> \

> > >

> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

> \

> > >

> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

> \

> > >

> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

> \

> > >

> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

> \

> > >

> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

> \

> > > ElFTkSuQmCC]

> > >

> > >

> > >

> > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

> TO

> > > REJECT this Insult on Top of Injury

> > > I would like to thank a brave, courageous, and ethical anonymous

> source

> > > who has send in this letter correspondence they received from the

> law

> > > firm of Weitz & Luxenberg. This letter doesn't require a whole lot

> of

> > > commentary.

> > > It's obvious that Law Firms have sold their clients down the

> proverbial

> > > river while at the same time enriching themselves (who's best

> interest

> > > are you obligated too fulfill?). This settlement offer and the

> injured

> > > litigants legal representation has carried out a blatant miscarriage

> of

> > > justice, a forever horrible stain upon the American Justice system,

> and

> > > a orchestrated crime perpetrated upon victims of this well

> documented &

> > > evidenced unbridled & unregulated corporate criminal enterprise gone

> a

> > > rye.

> > > The time has now come for the victims to stand up to this criminal

> > > corporation " AstraZeneca " & their poison drug " Seroquel " , to reject

> this

> > > horrible injustice and settlement offer. We want, what America & our

> > > Constitution promises us all, our day in court before a jury of our

> > > peers....

> > > ____________________________________________________________

> > >

> > > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> > > We are happy to report excellent news! After a long and hard fought

> > > legal battle, AstraZeneca has agreed to participate in a Settlement

> > > Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> > > patience and aggressive litigating has resulted in very favorable

> > > settlement terms for our clients which will be further outlined

> below.

> > > We have carefully reviewed all of the factors of this agreement and

> we

> > > believe that this settlement offers you the best, and very likely

> the

> > > only opportunity to receive a fair resolution of your lawsuit.

> > > Therefore, we strongly recommend that you sign and complete the

> enclosed

> > > " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> > > AGREE to participate.

> > > As you know, we have engaged in a long legal battle with AstraZeneca

> > > over the past 6 years. Weitz & Luxenberg led the charge for the

> > > Plaintiffs around the Country. AstraZeneca put up a tremendous and

> > > expensive defense and they successfully were able to get a large

> number

> > > of cases to be permanently dismissed by the court. Weitz & Luxenberg

> is

> > > the only firm who took a case to trial anywhere in the Country.

> However,

> > > after a month-long trial, the jury unfortunately ruled in favor of

> the

> > > defendants. This loss did not affect the strength of our fight. Over

> the

> > > past year, even as almost every other plaintiffs firm settled their

> > > cases, Weitz & Luxenberg prepared two more cases for trial which was

> > > scheduled to begin this Summer. As a direct result of the endless

> and

> > > consistent pressure applied by the attorneys at Weitz & Luxenberg,

> we

> > > are happy to report that AstraZeneca has now agreed to participate

> in a

> > > favorable settlement program. Based on public reports regarding

> > > settlement programs reached with other plaintiff law firms we are

> > > confident that the settlement program outlined below has more

> favorable

> > > terms and for this reason we are recommending your participation.

> > > The defendants have argued that they refuse to pay anyone who cannot

> > > prove through medical records or via certification that they have

> used

> > > Seroquel. They also refuse to pay anyone whose case is not active in

> > > this litigation. We recently told you about the Order issued by the

> > > Court requiring you to confirm when you started taking Seroquel and

> when

> > > you stopped taking Seroquel. We cannot stress enough that you MUST

> read,

> > > complete and return this certification form to us immediately. The

> > > failure to return this form within the next 30 days will result in

> the

> > > permanent dismissal of your case. In order to protect your legal

> rights,

> > > to keep your case active and be permitted to participate in this

> > > Settlement Program you must take this Order very seriously and you

> must

> > > respond.

> > > Based on our experience in other litigations and having reviewed the

> > > media reports of the terms of other firms' Seroquel settlement

> programs,

> > > we know that the defendants are looking for a settlement program

> that

> > > includes all claimants (W & L Seroquel Plaintiffs) so that they will

> > > achieve complete closure of the entirYlitigation. Our goal in this

> > > negotiation was to obtain a settlement for the most amount of money

> > > using a fair method to pay our clients based upon the merits of

> their

> > > individual case. We also stressed our intentions that the case

> review

> > > and payment process be performed quickly yet fairly so that our

> clients

> > > can receive their settlements as soon as possible. A key part of

> this

> > > settlement program is that a claimant cannot be part of the

> settlement

> > > if their case is dismissed and unless they provide, at the very

> least, a

> > > certification that they in fact took Seroquel and suffered an

> injury.

> > > Therefore, please make sure that you return your certification form

> to

> > > us immediately

> > >

> > > We have hired Hon.Marina Corodemus to act as the Special Master for

> the

> > > W & L Seroquel settlement program. Judge Corodemus previously ran the

> New

> > > Jersey Mass Tort Court and has a lot of experience in this field.

> She

> > > was appointed as a Special Master by the Vioxx State and Federal

> Court

> > > Judges to determine the appropriateness of Vioxx settlements and to

> > > resolve Vioxx appeals. She has also served as the Special Master in

> many

> > > other litigations such as Bextra and Celebrex which used similar

> > > settlement terms. We have met several times with Judge Corodemus and

> > > discussed the goals outlined above to get the most amount of money

> to

> > > the most amount of claimants in the fastest amount of time possible.

> We

> > > believe that Judge Corodemus is the perfect choice to create and

> oversee

> > > a settlement program in accordance with these goals. The W & L

> Seroquel

> > > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> > > those clients with active cases (not dismissed as outlined above)

> can

> > > participate in this settlement program. Unlike other settlement

> programs

> > > that you may have read about in the media and internet, the W & L

> > > Settlement program does not award every case an equal settlement

> amount.

> > > The size of an individual's settlement will depend entirely on the

> merit

> > > of that individual's case. As a direct result of the large number of

> > > cases represented by W & L, and the merits of those cases, we are

> > > confident that we have obtained the best possible settlement for our

> > > clients. After complex negotiations, AstraZeneca

> > > has agreed to deposit $92.25 Million dollars into a trust account to

> be

> > > used for this Settlement Program. This amount is completely

> confidential

> > > and you should NOT discuss this with anyone. A settlement of this

> type

> > > is called an " Aggregate Settlement " where a fair and reasonable sum

> of

> > > money is obtained to resolve multiple cases. In order to maintain

> proper

> > > representation of each individual client, W & L is NOT involved in

> the

> > > allocation decision making, which will be handled exclusively by

> Judge

> > > Corodemus. W & L has reviewed the general framework of the settlement

> > > plan with Judge Corodemus and we strongly believe that it is fair

> and

> > > reasonable and offers each of our clients the best possible outcome

> > > under the circumstances of this litigation. Track I offers the

> Seroquel

> > > claimant a settlement of $12,000. This track involves a simple

> review of

> > > each case and will result in a quick approval by Judge Corodemus

> without

> > > an analysis of the specific details of the case such as injury,

> amount

> > > of Seroquel taken, how close the last Seroquel use was to the date

> of

> > > the injury or the individual claimant's risk factors. a) Cannot

> > > prove that they suffered diabetes or a diabetes related condition,

> > > and/or Cannot prove that they used Seroquel within 1 year of

> > > their claimed injury, and/or c) Had a large number of known

> > > risk factors for diabetes before they started taking Seroquel. For

> > > example - obesity, family history, smoking, etc.

> > >

> > > Therefore, all cases whose injuries are limited to weight gain or

> high

> > > blood sugar and whose medical records will confirm that they were

> never

> > > diagnosed with diabetes or pancreatitis, should choose Track 1.

> > > Similarly, any claimed injury that occurred long after the last use

> of

> > > Seroquel should also choose Track 1. These cases are likely to

> receive a

> > > small award in Track II (likely less than $12,000) because it is

> > > extremely difficult to prove that these injuries were caused by

> > > Seroquel. Therefore, we suggest that if your case falls into this

> > > category you should choose Track 1. Additionally, payment of Track I

> > > settlement awards will be processed first once AstaZeneca waives its

> > > " walk away right " . (See Section IV© below) Track II involves an

> > > in-depth review of the severity of the injury, the claimed use of

> > > Seroquel and its proximity to the injury as well the available proof

> > > found in the contemporaneous medical records. Additionally, Judge

> > > Corodemus will strongly consider many known risk factors for these

> > > injuries including but not limited to smoking, obesity and family

> > > history as well as the participation in the Zyprexa settlement for

> these

> > > same injuries. This model is very similar to the one used in the

> > > National Vioxx Settlement Program as well as dozens of other similar

> > > settlement programs which were successfully resolved in recent

> years.

> > > Judge Corodemus has established a points system and will consider

> all of

> > > the critical issues including but not limited to:

> > > - Nature of the injury - Severity of the injury - Age at the time of

> > > injury - Proximity of Seroquel use to the claimed injury - Changes

> in

> > > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> > > etc. After carefully reviewing all of the medical records and the

> > > individual fact sheet, Judge Corodemus will assign a point value to

> each

> > > case. The more points a case is awarded based on the specific facts

> of

> > > the case, the larger the settlement will be. At this time, there is

> no

> > > way to predict with accuracy how many points an individual case may

> be

> > > awarded and it is even more difficult to determine how much money

> each

> > > point will receive. The exact value of each point will depend on the

> > > number of participants in Track II and the total number of points

> > > assigned. All cases in Track II will be eligible for a settlement

> award

> > > but Judge Corodemus could award LESS than $12,000 (what people will

> > > receive automatically by choosing Track 1) if the case lacks merit.

> In

> > > the interest of fairness, Judge Corodemus has committed to review

> each

> > > case in Track II very carefully and this process will take time to

> > > complete. Judge Corodemus has stated that she hopes to have this

> process

> > > completed by the end of 2011 but please be warned that it could take

> a

> > > little longer due to the amount of work that is involved. However,

> in

> > > order to get this settlement process moving forward and ultimately

> paid

> > > you must send us your signed Release form as soon as possible. If

> you

> > > choose Track I your settlement award of $12,000 is set. If you

> choose

> > > Track II, Judge Corodemus will review your claim and will issue an

> > > award. We expect that we will contact you in approximately November

> 2011

> > > and notify you of your point award and the expected amount of your

> > > settlement. At that point, you will be given a choice to accept your

> > > award, appeal your award or withdraw from the settlement program. If

> you

> > > accept, we will forward your release to AstraZeneca for their review

> and

> > > approval. Please understand that this settlement is not official

> until

> > > we send AstraZeneca your signed Release Form, AstraZeneca approves

> it

> > > AND AstraZeneca waives its walk away right. In the interest of time,

> we

> > > are asking you to return your signed Release Form now so we can meet

> the

> > > tight deadlines associated with this settlement. If you are unhappy

> with

> > > your allocation amount and/or believe that your case involves

> > > " Extraordinary Injury or Circumstances " you have the right to appeal

> > > your award. Upon receipt of such an application, Judge Corodemus

> will

> > > re-review your records and make a final decision. Please be aware

> that

> > > there is no additional right of appeal (to Judge Corodemus or to any

> > > Court) once this final decision is made. If you decide to decline

> the

> > > settlement amount offered to you, you must notify us within ten days

> of

> > > your receipt of your allocation amount and your signed Release Form

> will

> > > no longer be valid. As in all settlements of this type, our

> agreement

> > > with the defendant depends on nearly full participation from all of

> our

> > > clients. Under the terms of our agreement, we must provide

> Qualifying

> > > Materials (Release Form and/or Dismissal) for 2,260 of our clients.

> Once

> > > we reach this number, AstraZeneca's " walk away right " is officially

> > > waived. We strongly believe that our clients will agree that this

> > > settlement program offers the best possible terms and we expect that

> we

> > > will meet this requirement in the next 90-120 days. In order to meet

> > > this deadline we MUST have your complete

> > > cooperation and immediate response. Of course, if we do not meet

> this

> > > required number of responses, Astrazeneca can decide to withdraw its

> > > settlement offer to everyone whether one signed the Release Form or

> not.

> > > Therefore, time is of the essence. A. Release Form: Enclosed you

> will

> > > find a Release Form which you must sign in front of a notary in

> Order to

> > > participate in the settlement. If you have a spouse he/she must sign

> the

> > > Release Form as well. Attached to the Release Form will be an

> > > instruction sheet to guide you to ensure that this important form is

> > > signed the right way. A Release Form that is signed the wrong way or

> > > that is not witnessed (by a notary) is useless and will not be

> accepted

> > > by the defendants. The Release Form is your agreement to participate

> in

> > > the settlement program and at the same time discontinue your lawsuit

> in

> > > exchange for your settlement award. Please turn to Page 2 of the

> Release

> > > Form and complete the details of your Seroquel use. You may refer to

> > > Page 1 of the Brief Questionnaire which lists the Seroquel

> information

> > > that was found in your medical records or that you have previously

> > > provided to us. If this information is inaccurate, please cross it

> out

> > > and write in when you started and when you stopped taking Seroquel

> on

> > > BOTH the Release Form and the Brief Questionnaire. Due to the fast

> > > approaching deadlines, and our goal to get you your settlement

> processed

> > > and paid as quickly as possible, we MUST receive this signed release

> > > form back from you before August 31, 2011. Please use the envelope

> > > provided herein and return the signed and notarized release form

> today

> > > before you forget about it. Please note that once we submit your

> release

> > > form to AstraZeneca it can not be revoked. B. Track Selection Form:

> > > Enclosed you will find a " Track Selection Form " which is the form

> used

> > > to officially notify the Special Master which Track you want your

> case

> > > to follow. Please Note that there are 4 options on this form. You

> MUST

> > > check one of the Options. If you want to participate in this

> settlement,

> > > and we strongly think that you should, you must check either Track I

> OR

> > > Track II and you must sign the bottom of the form. Your Track

> selection

> > > cannot be changed and is considered final once the Judge's

> Allocations

> > > are made. In other words, a person who chooses Track II and is

> awarded

> > > less than $12,000 CANNOT then choose to go to Track 1 for a higher

> > > award. C. Brief Questionnaire: Enclosed you will find a 3

> > > page Brief Questionnaire which has important information about your

> > > claim. For all claimants who choose to enter Track II, Judge

> Corodemus

> > > will be reviewing your medical records, your Fact Sheet and this

> Brief

> > > Questionnaire and will issue a point award. Judge Corodemus will

> > > consider the proof of your claim found in your medical records as

> well

> > > as the information that you provide in this Questionnaire.

> Therefore, it

> > > is important that you answer these questions honestly and completely

> and

> > > that they are consistent with what is found in your medical records.

> > > litigation and our conversations with our medical experts, it is

> clear

> > > that Seroquel lawsuits are very difficult to win, very expensive,

> and

> > > very time consuming to take through to trial, verdict and appeal.

> Over

> > > the past six years only I case (from W & L) of24,000 cases in the

> Country

> > > made it to and through trial. Countless other cases were prepared

> and

> > > then dismissed based on merit and/or inability to prove that

> Seroquel

> > > caused the injury. Just because an individual took Seroquel and

> suffered

> > > an injury like diabetes does not mean that such a case will win at

> > > trial. In order to succeed at trial, a plaintiff must prove both

> that

> > > Seroquel can cause such an injury in general AND that, within a

> > > reasonable degree of medical certainty, Seroquel caused this injury

> to

> > > this particular person (despite any individual risk factors such as

> > > smoking, weight, high blood sugar, family history etc.). We have

> told

> > > you in the past update letters that the Courts have consistently

> ruled

> > > in favor of the defendants on many of these issues and have

> prohibited

> > > medical experts from testifying because of a lack of scientific

> proof

> > > linking the plaintiff s injuries to his/her Seroquel use. It is also

> > > important to note that even if your case is able to advance past

> this

> > > judicial scrutiny, a trial of this magnitude will cost over $750,000

> per

> > > case and many of these costs are reimbursed off of the top of a

> > > favorable verdict reducing the amount received by the plaintiff.

> > > Furthermore, any case that is won at trial will surely face a

> lengthy

> > > and hard-fought appeal. Finally, nearly all of the Seroquel cases

> are

> > > being handled by three judges. Even at an accelerated pace, the

> chances

> > > are slim that your case would be tried in the next 10 years if not

> > > longer. In taking all of these factors into consideration, and

> > > considering the issues of risk and reward, we believe that a

> settlement

> > > of this type offers you the most advantageous resolution possible.

> You

> > > will be notified once the Special Master issues your point award at

> > > which point you can appeal to the Special Master if you believe that

> > > your case involves extraordinary circumstances. Thereafter, the

> decision

> > > of the Special Master is final, binding and non-appealable. We have

> > > retained the Garretson Law Firm to negotiate any and all Federal and

> > > State liens (Medicare/Medicaid/SSI) that may be applicable in your

> case.

> > > The Garretson Firm is a specialist in this field and they have

> obtained

> > > excellent results in their negotiation of similar liens in other

> > > litigations like Vioxx, Bextra, and Celebrex. Moreover, the

> Garretson

> > > Firm has already worked on thousands of other Seroquel cases and has

> > > been able to achieve excellent results in large part due to the

> volume

> > > of cases that they are able to include in a Global Resolution. At

> this

> > > time, the Garretson Firm has already negotiated with 44 individual

> > > states regarding Medicaid and they have reached an agreement to CAP

> > > Medicaid liens at a maximum of 20% of the settlement amount. Please

> see

> > > the enclosed blue booklet regarding governmental liens for more

> details.

> > > Additionally, please also be advised that if you or Weitz &

> Luxenberg

> > > are put on written notice of a private lien, for example from your

> > > medical provider, this lien must be resolved before any settlement

> > > proceeds can be distributed. If you have received any notice of a

> lien,

> > > please advise us immediately. The terms of your signed contingency

> fee

> > > agreement will be in effect. We have taken great effort to keep the

> case

> > > specific expenses as low as possible. Under the terms of your

> agreement,

> > > the

> > > contingency fee will be calculated after the expenses are deducted.

> > > Under the terms of our agreement with AstraZeneca, any interest

> earned

> > > on the settlement proceeds before allocation and payment to the

> > > individual clients will be used to offset the fixed costs of the

> Special

> > > Master and the Lien Administrator. Due to the low interest rates

> paid by

> > > all banks in this economy, we do not expect that there will be any

> > > leftover interest. However, in such a case, the leftover interest

> will

> > > be added to the settlement trust and will be distributed to all

> > > claimants as part of Judge Corodemus' allocation process. After

> careful

> > > analysis of the likelihood of success in the court system, as well

> as

> > > the cost and time elements involved, we strongly recommend that you

> > > AGREE to participate in this settlement. We are confident that this

> > > settlement is the best possible resolution of your claim especially

> in

> > > light of the history of this litigation. We expect that any case

> that

> > > does not agree to participate in this settlement will have a very

> > > difficult time navigating through the Court system and trial dates

> may

> > > not be set for many years. Moreover, as we have seen, these cases

> will

> > > be aggressively defended by AstraZeneca and we expect that we will

> > > receive motions to dismiss and unfavorable decisions from the Court

> on

> > > unsettled cases in the coming months. Moreover, if this settlement

> > > program is not successful (we fail to reach the 98% response rate)

> we

> > > highly doubt that we will ever obtain a settlement amount and terms

> as

> > > good as those contained in this program. While we hope that this

> letter

> > > and enclosures will help answer all of your questions, we understand

> > > that you may have additional questions for us. Please keep in mind

> that

> > > we are working very hard to evaluate each and every case

> individually

> > > and the many deadlines that are part of this settlement are fast

> > > approaching. Your case has been assigned to Judy Koenig. If you have

> an

> > > important question please call Judy Koenig at (800) 438-9786 and ask

> for

> > > extension 5860. If you reach a voice-mail, please leave a message

> and

> > > you will be called back as quickly as possible. Please do not leave

> > > multiple voicemail messages on the same day as that will slow down

> our

> > > ability to return your call. Additionally, if you have email access,

> > > please try to email your detailed questions to us at sqinfo@

> > > <mailto:sqinfo@ and we will get back to you quickly. If

> > > this letter has successfully answered your questions, and you have

> > > decided to participate, please carefully follow the directions on

> the

> > > front page of the enclosed release form and send your signed and

> > > witnessed release formes), your Track Selection AND your Brief

> > > Questionnaire to us as soon as possible. If you still have questions

> > > after reviewing this letter and after speaking to us over the

> telephone

> > > and you would like to meet us in person, we will be happy to

> schedule a

> > > meeting in our office at your convenience. Finally, please remember

> that

> > > the detailed information regarding this settlement program is

> COMPLETELY

> > > CONFIDENTIAL and should not be shared or discussed with anyone.

>

> > > Sedgh, Esq Glenn Zuckerman, Esq.

> > >

> >

>

[Guest guest]

That's interesting that you say the class-action lawyers are linked to CCHR --

years ago, the Scientologists were among the few who would speak out against

this mass drugging with SSRIs and other psychiatric drugs. I have been away for

several years from actice involvement in the issues, but I know a friend of

mine, many years ago, told a shrink that she found the side effects of Prozac

worrisome, and he told her not to listen to the Scientologists (she had never

heard of the Scientologists, that was just his way of throwing mud on the

windscreen, so to speak.)

> > >

> > > " Awry, " not " a rye " but I digress. This is exactly why I never urge

> anyone to sue. The deck is stacked against us in court and attorneys are

> looking for a quick and easy buck. No justice is to be had.

> > >

> > > Terry

> > > Sent via BlackBerry by AT & T

> > >

> > > SEROQUEL Law Firms have sold their clients

> down the river

> > >

> > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

> TO

> > > REJECT this Insult on Top of Injury

> > >

> [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

> \

> > >

> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

> \

> > >

> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

> \

> > >

> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

> \

> > >

> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

> \

> > >

> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

> \

> > >

> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

> \

> > >

> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

> \

> > >

> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

> \

> > >

> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

> \

> > >

> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

> \

> > >

> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

> \

> > >

> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

> \

> > >

> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

> \

> > >

> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

> \

> > >

> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

> \

> > >

> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

> \

> > >

> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

> \

> > >

> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

> \

> > >

> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

> \

> > >

> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

> \

> > >

> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

> \

> > >

> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

> \

> > >

> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

> \

> > >

> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

> \

> > >

> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

> \

> > >

> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

> \

> > >

> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

> \

> > >

> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

> \

> > >

> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

> \

> > >

> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

> \

> > >

> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

> \

> > >

> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

> \

> > >

> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

> \

> > >

> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

> \

> > >

> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

> \

> > >

> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

> \

> > >

> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

> \

> > >

> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

> \

> > >

> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

> \

> > >

> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

> \

> > >

> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

> \

> > >

> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

> \

> > >

> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

> \

> > >

> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

> \

> > >

> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

> \

> > >

> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

> \

> > >

> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

> \

> > >

> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

> \

> > >

> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

> \

> > >

> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

> \

> > >

> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

> \

> > >

> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

> \

> > >

> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

> \

> > >

> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

> \

> > >

> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

> \

> > >

> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

> \

> > >

> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

> \

> > >

> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

> \

> > >

> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

> \

> > >

> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

> \

> > >

> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

> \

> > >

> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

> \

> > >

> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

> \

> > >

> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

> \

> > >

> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

> \

> > >

> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

> \

> > >

> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

> \

> > >

> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

> \

> > >

> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

> \

> > >

> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

> \

> > >

> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

> \

> > >

> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

> \

> > >

> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

> \

> > >

> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

> \

> > >

> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

> \

> > >

> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

> \

> > >

> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

> \

> > >

> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

> \

> > >

> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

> \

> > >

> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

> \

> > >

> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

> \

> > >

> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

> \

> > >

> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

> \

> > >

> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

> \

> > >

> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

> \

> > >

> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

> \

> > >

> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

> \

> > >

> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

> \

> > >

> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

> \

> > >

> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

> \

> > >

> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

> \

> > >

> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

> \

> > >

> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

> \

> > >

> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

> \

> > >

> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

> \

> > >

> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

> \

> > >

> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

> \

> > >

> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

> \

> > >

> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

> \

> > >

> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

> \

> > >

> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

> \

> > >

> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

> \

> > >

> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

> \

> > >

> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

> \

> > >

> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

> \

> > >

> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

> \

> > >

> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

> \

> > >

> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

> \

> > >

> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

> \

> > >

> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

> \

> > >

> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

> \

> > >

> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

> \

> > >

> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

> \

> > >

> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

> \

> > >

> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

> \

> > >

> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

> \

> > >

> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

> \

> > >

> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

> \

> > >

> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

> \

> > >

> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

> \

> > >

> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

> \

> > >

> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

> \

> > >

> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

> \

> > >

> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

> \

> > >

> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

> \

> > >

> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

> \

> > >

> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

> \

> > >

> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

> \

> > >

> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

> \

> > >

> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

> \

> > >

> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

> \

> > >

> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

> \

> > >

> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

> \

> > >

> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

> \

> > >

> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

> \

> > >

> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

> \

> > >

> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

> \

> > >

> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

> \

> > >

> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

> \

> > >

> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

> \

> > >

> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

> \

> > >

> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

> \

> > >

> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

> \

> > >

> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

> \

> > >

> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

> \

> > >

> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

> \

> > >

> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

> \

> > >

> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

> \

> > >

> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

> \

> > >

> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

> \

> > >

> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

> \

> > >

> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

> \

> > >

> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

> \

> > >

> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

> \

> > >

> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

> \

> > >

> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

> \

> > >

> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

> \

> > >

> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

> \

> > >

> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

> \

> > >

> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

> \

> > >

> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

> \

> > >

> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

> \

> > >

> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

> \

> > >

> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

> \

> > >

> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

> \

> > >

> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

> \

> > >

> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

> \

> > >

> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

> \

> > >

> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

> \

> > >

> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

> \

> > >

> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

> \

> > >

> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

> \

> > >

> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

> \

> > >

> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

> \

> > >

> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

> \

> > >

> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

> \

> > >

> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

> \

> > >

> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

> \

> > >

> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

> \

> > >

> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

> \

> > >

> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

> \

> > >

> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

> \

> > >

> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

> \

> > >

> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

> \

> > >

> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

> \

> > >

> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

> \

> > >

> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

> \

> > >

> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

> \

> > >

> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

> \

> > >

> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

> \

> > >

> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

> \

> > >

> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

> \

> > >

> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

> \

> > >

> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

> \

> > >

> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

> \

> > >

> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

> \

> > >

> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

> \

> > >

> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

> \

> > >

> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

> \

> > >

> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

> \

> > >

> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

> \

> > >

> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

> \

> > >

> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

> \

> > >

> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

> \

> > >

> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

> \

> > >

> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

> \

> > >

> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

> \

> > >

> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

> \

> > >

> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

> \

> > >

> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

> \

> > >

> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

> \

> > >

> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

> \

> > >

> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

> \

> > >

> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

> \

> > >

> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

> \

> > >

> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

> \

> > >

> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

> \

> > >

> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

> \

> > >

> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

> \

> > >

> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

> \

> > >

> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

> \

> > >

> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

> \

> > >

> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

> \

> > >

> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

> \

> > >

> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

> \

> > >

> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

> \

> > >

> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

> \

> > >

> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

> \

> > >

> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

> \

> > >

> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

> \

> > >

> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

> \

> > >

> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

> \

> > >

> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

> \

> > >

> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

> \

> > >

> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

> \

> > >

> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

> \

> > >

> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

> \

> > >

> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

> \

> > >

> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

> \

> > >

> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

> \

> > >

> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

> \

> > >

> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

> \

> > >

> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

> \

> > >

> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

> \

> > >

> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

> \

> > >

> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

> \

> > >

> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

> \

> > >

> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

> \

> > >

> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

> \

> > >

> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

> \

> > >

> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

> \

> > >

> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

> \

> > >

> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

> \

> > >

> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

> \

> > >

> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

> \

> > >

> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

> \

> > >

> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

> \

> > >

> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

> \

> > >

> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

> \

> > >

> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

> \

> > >

> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

> \

> > >

> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

> \

> > >

> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

> \

> > >

> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

> \

> > >

> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

> \

> > >

> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

> \

> > >

> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

> \

> > >

> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

> \

> > >

> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

> \

> > >

> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

> \

> > >

> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

> \

> > >

> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

> \

> > >

> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

> \

> > >

> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

> \

> > >

> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

> \

> > >

> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

> \

> > >

> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

> \

> > >

> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

> \

> > >

> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

> \

> > >

> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

> \

> > > ElFTkSuQmCC]

> > >

> > >

> > >

> > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

> TO

> > > REJECT this Insult on Top of Injury

> > > I would like to thank a brave, courageous, and ethical anonymous

> source

> > > who has send in this letter correspondence they received from the

> law

> > > firm of Weitz & Luxenberg. This letter doesn't require a whole lot

> of

> > > commentary.

> > > It's obvious that Law Firms have sold their clients down the

> proverbial

> > > river while at the same time enriching themselves (who's best

> interest

> > > are you obligated too fulfill?). This settlement offer and the

> injured

> > > litigants legal representation has carried out a blatant miscarriage

> of

> > > justice, a forever horrible stain upon the American Justice system,

> and

> > > a orchestrated crime perpetrated upon victims of this well

> documented &

> > > evidenced unbridled & unregulated corporate criminal enterprise gone

> a

> > > rye.

> > > The time has now come for the victims to stand up to this criminal

> > > corporation " AstraZeneca " & their poison drug " Seroquel " , to reject

> this

> > > horrible injustice and settlement offer. We want, what America & our

> > > Constitution promises us all, our day in court before a jury of our

> > > peers....

> > > ____________________________________________________________

> > >

> > > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> > > We are happy to report excellent news! After a long and hard fought

> > > legal battle, AstraZeneca has agreed to participate in a Settlement

> > > Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> > > patience and aggressive litigating has resulted in very favorable

> > > settlement terms for our clients which will be further outlined

> below.

> > > We have carefully reviewed all of the factors of this agreement and

> we

> > > believe that this settlement offers you the best, and very likely

> the

> > > only opportunity to receive a fair resolution of your lawsuit.

> > > Therefore, we strongly recommend that you sign and complete the

> enclosed

> > > " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> > > AGREE to participate.

> > > As you know, we have engaged in a long legal battle with AstraZeneca

> > > over the past 6 years. Weitz & Luxenberg led the charge for the

> > > Plaintiffs around the Country. AstraZeneca put up a tremendous and

> > > expensive defense and they successfully were able to get a large

> number

> > > of cases to be permanently dismissed by the court. Weitz & Luxenberg

> is

> > > the only firm who took a case to trial anywhere in the Country.

> However,

> > > after a month-long trial, the jury unfortunately ruled in favor of

> the

> > > defendants. This loss did not affect the strength of our fight. Over

> the

> > > past year, even as almost every other plaintiffs firm settled their

> > > cases, Weitz & Luxenberg prepared two more cases for trial which was

> > > scheduled to begin this Summer. As a direct result of the endless

> and

> > > consistent pressure applied by the attorneys at Weitz & Luxenberg,

> we

> > > are happy to report that AstraZeneca has now agreed to participate

> in a

> > > favorable settlement program. Based on public reports regarding

> > > settlement programs reached with other plaintiff law firms we are

> > > confident that the settlement program outlined below has more

> favorable

> > > terms and for this reason we are recommending your participation.

> > > The defendants have argued that they refuse to pay anyone who cannot

> > > prove through medical records or via certification that they have

> used

> > > Seroquel. They also refuse to pay anyone whose case is not active in

> > > this litigation. We recently told you about the Order issued by the

> > > Court requiring you to confirm when you started taking Seroquel and

> when

> > > you stopped taking Seroquel. We cannot stress enough that you MUST

> read,

> > > complete and return this certification form to us immediately. The

> > > failure to return this form within the next 30 days will result in

> the

> > > permanent dismissal of your case. In order to protect your legal

> rights,

> > > to keep your case active and be permitted to participate in this

> > > Settlement Program you must take this Order very seriously and you

> must

> > > respond.

> > > Based on our experience in other litigations and having reviewed the

> > > media reports of the terms of other firms' Seroquel settlement

> programs,

> > > we know that the defendants are looking for a settlement program

> that

> > > includes all claimants (W & L Seroquel Plaintiffs) so that they will

> > > achieve complete closure of the entirYlitigation. Our goal in this

> > > negotiation was to obtain a settlement for the most amount of money

> > > using a fair method to pay our clients based upon the merits of

> their

> > > individual case. We also stressed our intentions that the case

> review

> > > and payment process be performed quickly yet fairly so that our

> clients

> > > can receive their settlements as soon as possible. A key part of

> this

> > > settlement program is that a claimant cannot be part of the

> settlement

> > > if their case is dismissed and unless they provide, at the very

> least, a

> > > certification that they in fact took Seroquel and suffered an

> injury.

> > > Therefore, please make sure that you return your certification form

> to

> > > us immediately

> > >

> > > We have hired Hon.Marina Corodemus to act as the Special Master for

> the

> > > W & L Seroquel settlement program. Judge Corodemus previously ran the

> New

> > > Jersey Mass Tort Court and has a lot of experience in this field.

> She

> > > was appointed as a Special Master by the Vioxx State and Federal

> Court

> > > Judges to determine the appropriateness of Vioxx settlements and to

> > > resolve Vioxx appeals. She has also served as the Special Master in

> many

> > > other litigations such as Bextra and Celebrex which used similar

> > > settlement terms. We have met several times with Judge Corodemus and

> > > discussed the goals outlined above to get the most amount of money

> to

> > > the most amount of claimants in the fastest amount of time possible.

> We

> > > believe that Judge Corodemus is the perfect choice to create and

> oversee

> > > a settlement program in accordance with these goals. The W & L

> Seroquel

> > > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> > > those clients with active cases (not dismissed as outlined above)

> can

> > > participate in this settlement program. Unlike other settlement

> programs

> > > that you may have read about in the media and internet, the W & L

> > > Settlement program does not award every case an equal settlement

> amount.

> > > The size of an individual's settlement will depend entirely on the

> merit

> > > of that individual's case. As a direct result of the large number of

> > > cases represented by W & L, and the merits of those cases, we are

> > > confident that we have obtained the best possible settlement for our

> > > clients. After complex negotiations, AstraZeneca

> > > has agreed to deposit $92.25 Million dollars into a trust account to

> be

> > > used for this Settlement Program. This amount is completely

> confidential

> > > and you should NOT discuss this with anyone. A settlement of this

> type

> > > is called an " Aggregate Settlement " where a fair and reasonable sum

> of

> > > money is obtained to resolve multiple cases. In order to maintain

> proper

> > > representation of each individual client, W & L is NOT involved in

> the

> > > allocation decision making, which will be handled exclusively by

> Judge

> > > Corodemus. W & L has reviewed the general framework of the settlement

> > > plan with Judge Corodemus and we strongly believe that it is fair

> and

> > > reasonable and offers each of our clients the best possible outcome

> > > under the circumstances of this litigation. Track I offers the

> Seroquel

> > > claimant a settlement of $12,000. This track involves a simple

> review of

> > > each case and will result in a quick approval by Judge Corodemus

> without

> > > an analysis of the specific details of the case such as injury,

> amount

> > > of Seroquel taken, how close the last Seroquel use was to the date

> of

> > > the injury or the individual claimant's risk factors. a) Cannot

> > > prove that they suffered diabetes or a diabetes related condition,

> > > and/or Cannot prove that they used Seroquel within 1 year of

> > > their claimed injury, and/or c) Had a large number of known

> > > risk factors for diabetes before they started taking Seroquel. For

> > > example - obesity, family history, smoking, etc.

> > >

> > > Therefore, all cases whose injuries are limited to weight gain or

> high

> > > blood sugar and whose medical records will confirm that they were

> never

> > > diagnosed with diabetes or pancreatitis, should choose Track 1.

> > > Similarly, any claimed injury that occurred long after the last use

> of

> > > Seroquel should also choose Track 1. These cases are likely to

> receive a

> > > small award in Track II (likely less than $12,000) because it is

> > > extremely difficult to prove that these injuries were caused by

> > > Seroquel. Therefore, we suggest that if your case falls into this

> > > category you should choose Track 1. Additionally, payment of Track I

> > > settlement awards will be processed first once AstaZeneca waives its

> > > " walk away right " . (See Section IV© below) Track II involves an

> > > in-depth review of the severity of the injury, the claimed use of

> > > Seroquel and its proximity to the injury as well the available proof

> > > found in the contemporaneous medical records. Additionally, Judge

> > > Corodemus will strongly consider many known risk factors for these

> > > injuries including but not limited to smoking, obesity and family

> > > history as well as the participation in the Zyprexa settlement for

> these

> > > same injuries. This model is very similar to the one used in the

> > > National Vioxx Settlement Program as well as dozens of other similar

> > > settlement programs which were successfully resolved in recent

> years.

> > > Judge Corodemus has established a points system and will consider

> all of

> > > the critical issues including but not limited to:

> > > - Nature of the injury - Severity of the injury - Age at the time of

> > > injury - Proximity of Seroquel use to the claimed injury - Changes

> in

> > > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> > > etc. After carefully reviewing all of the medical records and the

> > > individual fact sheet, Judge Corodemus will assign a point value to

> each

> > > case. The more points a case is awarded based on the specific facts

> of

> > > the case, the larger the settlement will be. At this time, there is

> no

> > > way to predict with accuracy how many points an individual case may

> be

> > > awarded and it is even more difficult to determine how much money

> each

> > > point will receive. The exact value of each point will depend on the

> > > number of participants in Track II and the total number of points

> > > assigned. All cases in Track II will be eligible for a settlement

> award

> > > but Judge Corodemus could award LESS than $12,000 (what people will

> > > receive automatically by choosing Track 1) if the case lacks merit.

> In

> > > the interest of fairness, Judge Corodemus has committed to review

> each

> > > case in Track II very carefully and this process will take time to

> > > complete. Judge Corodemus has stated that she hopes to have this

> process

> > > completed by the end of 2011 but please be warned that it could take

> a

> > > little longer due to the amount of work that is involved. However,

> in

> > > order to get this settlement process moving forward and ultimately

> paid

> > > you must send us your signed Release form as soon as possible. If

> you

> > > choose Track I your settlement award of $12,000 is set. If you

> choose

> > > Track II, Judge Corodemus will review your claim and will issue an

> > > award. We expect that we will contact you in approximately November

> 2011

> > > and notify you of your point award and the expected amount of your

> > > settlement. At that point, you will be given a choice to accept your

> > > award, appeal your award or withdraw from the settlement program. If

> you

> > > accept, we will forward your release to AstraZeneca for their review

> and

> > > approval. Please understand that this settlement is not official

> until

> > > we send AstraZeneca your signed Release Form, AstraZeneca approves

> it

> > > AND AstraZeneca waives its walk away right. In the interest of time,

> we

> > > are asking you to return your signed Release Form now so we can meet

> the

> > > tight deadlines associated with this settlement. If you are unhappy

> with

> > > your allocation amount and/or believe that your case involves

> > > " Extraordinary Injury or Circumstances " you have the right to appeal

> > > your award. Upon receipt of such an application, Judge Corodemus

> will

> > > re-review your records and make a final decision. Please be aware

> that

> > > there is no additional right of appeal (to Judge Corodemus or to any

> > > Court) once this final decision is made. If you decide to decline

> the

> > > settlement amount offered to you, you must notify us within ten days

> of

> > > your receipt of your allocation amount and your signed Release Form

> will

> > > no longer be valid. As in all settlements of this type, our

> agreement

> > > with the defendant depends on nearly full participation from all of

> our

> > > clients. Under the terms of our agreement, we must provide

> Qualifying

> > > Materials (Release Form and/or Dismissal) for 2,260 of our clients.

> Once

> > > we reach this number, AstraZeneca's " walk away right " is officially

> > > waived. We strongly believe that our clients will agree that this

> > > settlement program offers the best possible terms and we expect that

> we

> > > will meet this requirement in the next 90-120 days. In order to meet

> > > this deadline we MUST have your complete

> > > cooperation and immediate response. Of course, if we do not meet

> this

> > > required number of responses, Astrazeneca can decide to withdraw its

> > > settlement offer to everyone whether one signed the Release Form or

> not.

> > > Therefore, time is of the essence. A. Release Form: Enclosed you

> will

> > > find a Release Form which you must sign in front of a notary in

> Order to

> > > participate in the settlement. If you have a spouse he/she must sign

> the

> > > Release Form as well. Attached to the Release Form will be an

> > > instruction sheet to guide you to ensure that this important form is

> > > signed the right way. A Release Form that is signed the wrong way or

> > > that is not witnessed (by a notary) is useless and will not be

> accepted

> > > by the defendants. The Release Form is your agreement to participate

> in

> > > the settlement program and at the same time discontinue your lawsuit

> in

> > > exchange for your settlement award. Please turn to Page 2 of the

> Release

> > > Form and complete the details of your Seroquel use. You may refer to

> > > Page 1 of the Brief Questionnaire which lists the Seroquel

> information

> > > that was found in your medical records or that you have previously

> > > provided to us. If this information is inaccurate, please cross it

> out

> > > and write in when you started and when you stopped taking Seroquel

> on

> > > BOTH the Release Form and the Brief Questionnaire. Due to the fast

> > > approaching deadlines, and our goal to get you your settlement

> processed

> > > and paid as quickly as possible, we MUST receive this signed release

> > > form back from you before August 31, 2011. Please use the envelope

> > > provided herein and return the signed and notarized release form

> today

> > > before you forget about it. Please note that once we submit your

> release

> > > form to AstraZeneca it can not be revoked. B. Track Selection Form:

> > > Enclosed you will find a " Track Selection Form " which is the form

> used

> > > to officially notify the Special Master which Track you want your

> case

> > > to follow. Please Note that there are 4 options on this form. You

> MUST

> > > check one of the Options. If you want to participate in this

> settlement,

> > > and we strongly think that you should, you must check either Track I

> OR

> > > Track II and you must sign the bottom of the form. Your Track

> selection

> > > cannot be changed and is considered final once the Judge's

> Allocations

> > > are made. In other words, a person who chooses Track II and is

> awarded

> > > less than $12,000 CANNOT then choose to go to Track 1 for a higher

> > > award. C. Brief Questionnaire: Enclosed you will find a 3

> > > page Brief Questionnaire which has important information about your

> > > claim. For all claimants who choose to enter Track II, Judge

> Corodemus

> > > will be reviewing your medical records, your Fact Sheet and this

> Brief

> > > Questionnaire and will issue a point award. Judge Corodemus will

> > > consider the proof of your claim found in your medical records as

> well

> > > as the information that you provide in this Questionnaire.

> Therefore, it

> > > is important that you answer these questions honestly and completely

> and

> > > that they are consistent with what is found in your medical records.

> > > litigation and our conversations with our medical experts, it is

> clear

> > > that Seroquel lawsuits are very difficult to win, very expensive,

> and

> > > very time consuming to take through to trial, verdict and appeal.

> Over

> > > the past six years only I case (from W & L) of24,000 cases in the

> Country

> > > made it to and through trial. Countless other cases were prepared

> and

> > > then dismissed based on merit and/or inability to prove that

> Seroquel

> > > caused the injury. Just because an individual took Seroquel and

> suffered

> > > an injury like diabetes does not mean that such a case will win at

> > > trial. In order to succeed at trial, a plaintiff must prove both

> that

> > > Seroquel can cause such an injury in general AND that, within a

> > > reasonable degree of medical certainty, Seroquel caused this injury

> to

> > > this particular person (despite any individual risk factors such as

> > > smoking, weight, high blood sugar, family history etc.). We have

> told

> > > you in the past update letters that the Courts have consistently

> ruled

> > > in favor of the defendants on many of these issues and have

> prohibited

> > > medical experts from testifying because of a lack of scientific

> proof

> > > linking the plaintiff s injuries to his/her Seroquel use. It is also

> > > important to note that even if your case is able to advance past

> this

> > > judicial scrutiny, a trial of this magnitude will cost over $750,000

> per

> > > case and many of these costs are reimbursed off of the top of a

> > > favorable verdict reducing the amount received by the plaintiff.

> > > Furthermore, any case that is won at trial will surely face a

> lengthy

> > > and hard-fought appeal. Finally, nearly all of the Seroquel cases

> are

> > > being handled by three judges. Even at an accelerated pace, the

> chances

> > > are slim that your case would be tried in the next 10 years if not

> > > longer. In taking all of these factors into consideration, and

> > > considering the issues of risk and reward, we believe that a

> settlement

> > > of this type offers you the most advantageous resolution possible.

> You

> > > will be notified once the Special Master issues your point award at

> > > which point you can appeal to the Special Master if you believe that

> > > your case involves extraordinary circumstances. Thereafter, the

> decision

> > > of the Special Master is final, binding and non-appealable. We have

> > > retained the Garretson Law Firm to negotiate any and all Federal and

> > > State liens (Medicare/Medicaid/SSI) that may be applicable in your

> case.

> > > The Garretson Firm is a specialist in this field and they have

> obtained

> > > excellent results in their negotiation of similar liens in other

> > > litigations like Vioxx, Bextra, and Celebrex. Moreover, the

> Garretson

> > > Firm has already worked on thousands of other Seroquel cases and has

> > > been able to achieve excellent results in large part due to the

> volume

> > > of cases that they are able to include in a Global Resolution. At

> this

> > > time, the Garretson Firm has already negotiated with 44 individual

> > > states regarding Medicaid and they have reached an agreement to CAP

> > > Medicaid liens at a maximum of 20% of the settlement amount. Please

> see

> > > the enclosed blue booklet regarding governmental liens for more

> details.

> > > Additionally, please also be advised that if you or Weitz &

> Luxenberg

> > > are put on written notice of a private lien, for example from your

> > > medical provider, this lien must be resolved before any settlement

> > > proceeds can be distributed. If you have received any notice of a

> lien,

> > > please advise us immediately. The terms of your signed contingency

> fee

> > > agreement will be in effect. We have taken great effort to keep the

> case

> > > specific expenses as low as possible. Under the terms of your

> agreement,

> > > the

> > > contingency fee will be calculated after the expenses are deducted.

> > > Under the terms of our agreement with AstraZeneca, any interest

> earned

> > > on the settlement proceeds before allocation and payment to the

> > > individual clients will be used to offset the fixed costs of the

> Special

> > > Master and the Lien Administrator. Due to the low interest rates

> paid by

> > > all banks in this economy, we do not expect that there will be any

> > > leftover interest. However, in such a case, the leftover interest

> will

> > > be added to the settlement trust and will be distributed to all

> > > claimants as part of Judge Corodemus' allocation process. After

> careful

> > > analysis of the likelihood of success in the court system, as well

> as

> > > the cost and time elements involved, we strongly recommend that you

> > > AGREE to participate in this settlement. We are confident that this

> > > settlement is the best possible resolution of your claim especially

> in

> > > light of the history of this litigation. We expect that any case

> that

> > > does not agree to participate in this settlement will have a very

> > > difficult time navigating through the Court system and trial dates

> may

> > > not be set for many years. Moreover, as we have seen, these cases

> will

> > > be aggressively defended by AstraZeneca and we expect that we will

> > > receive motions to dismiss and unfavorable decisions from the Court

> on

> > > unsettled cases in the coming months. Moreover, if this settlement

> > > program is not successful (we fail to reach the 98% response rate)

> we

> > > highly doubt that we will ever obtain a settlement amount and terms

> as

> > > good as those contained in this program. While we hope that this

> letter

> > > and enclosures will help answer all of your questions, we understand

> > > that you may have additional questions for us. Please keep in mind

> that

> > > we are working very hard to evaluate each and every case

> individually

> > > and the many deadlines that are part of this settlement are fast

> > > approaching. Your case has been assigned to Judy Koenig. If you have

> an

> > > important question please call Judy Koenig at (800) 438-9786 and ask

> for

> > > extension 5860. If you reach a voice-mail, please leave a message

> and

> > > you will be called back as quickly as possible. Please do not leave

> > > multiple voicemail messages on the same day as that will slow down

> our

> > > ability to return your call. Additionally, if you have email access,

> > > please try to email your detailed questions to us at sqinfo@

> > > <mailto:sqinfo@ and we will get back to you quickly. If

> > > this letter has successfully answered your questions, and you have

> > > decided to participate, please carefully follow the directions on

> the

> > > front page of the enclosed release form and send your signed and

> > > witnessed release formes), your Track Selection AND your Brief

> > > Questionnaire to us as soon as possible. If you still have questions

> > > after reviewing this letter and after speaking to us over the

> telephone

> > > and you would like to meet us in person, we will be happy to

> schedule a

> > > meeting in our office at your convenience. Finally, please remember

> that

> > > the detailed information regarding this settlement program is

> COMPLETELY

> > > CONFIDENTIAL and should not be shared or discussed with anyone.

>

> > > Sedgh, Esq Glenn Zuckerman, Esq.

> > >

> >

>

[Guest guest]

That's interesting that you say the class-action lawyers are linked to CCHR --

years ago, the Scientologists were among the few who would speak out against

this mass drugging with SSRIs and other psychiatric drugs. I have been away for

several years from actice involvement in the issues, but I know a friend of

mine, many years ago, told a shrink that she found the side effects of Prozac

worrisome, and he told her not to listen to the Scientologists (she had never

heard of the Scientologists, that was just his way of throwing mud on the

windscreen, so to speak.)

> > >

> > > " Awry, " not " a rye " but I digress. This is exactly why I never urge

> anyone to sue. The deck is stacked against us in court and attorneys are

> looking for a quick and easy buck. No justice is to be had.

> > >

> > > Terry

> > > Sent via BlackBerry by AT & T

> > >

> > > SEROQUEL Law Firms have sold their clients

> down the river

> > >

> > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

> TO

> > > REJECT this Insult on Top of Injury

> > >

> [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

> \

> > >

> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

> \

> > >

> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

> \

> > >

> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

> \

> > >

> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

> \

> > >

> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

> \

> > >

> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

> \

> > >

> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

> \

> > >

> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

> \

> > >

> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

> \

> > >

> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

> \

> > >

> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

> \

> > >

> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

> \

> > >

> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

> \

> > >

> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

> \

> > >

> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

> \

> > >

> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

> \

> > >

> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

> \

> > >

> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

> \

> > >

> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

> \

> > >

> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

> \

> > >

> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

> \

> > >

> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

> \

> > >

> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

> \

> > >

> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

> \

> > >

> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

> \

> > >

> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

> \

> > >

> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

> \

> > >

> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

> \

> > >

> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

> \

> > >

> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

> \

> > >

> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

> \

> > >

> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

> \

> > >

> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

> \

> > >

> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

> \

> > >

> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

> \

> > >

> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

> \

> > >

> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

> \

> > >

> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

> \

> > >

> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

> \

> > >

> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

> \

> > >

> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

> \

> > >

> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

> \

> > >

> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

> \

> > >

> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

> \

> > >

> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

> \

> > >

> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

> \

> > >

> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

> \

> > >

> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

> \

> > >

> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

> \

> > >

> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

> \

> > >

> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

> \

> > >

> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

> \

> > >

> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

> \

> > >

> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

> \

> > >

> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

> \

> > >

> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

> \

> > >

> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

> \

> > >

> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

> \

> > >

> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

> \

> > >

> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

> \

> > >

> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

> \

> > >

> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

> \

> > >

> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

> \

> > >

> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

> \

> > >

> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

> \

> > >

> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

> \

> > >

> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

> \

> > >

> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

> \

> > >

> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

> \

> > >

> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

> \

> > >

> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

> \

> > >

> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

> \

> > >

> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

> \

> > >

> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

> \

> > >

> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

> \

> > >

> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

> \

> > >

> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

> \

> > >

> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

> \

> > >

> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

> \

> > >

> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

> \

> > >

> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

> \

> > >

> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

> \

> > >

> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

> \

> > >

> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

> \

> > >

> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

> \

> > >

> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

> \

> > >

> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

> \

> > >

> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

> \

> > >

> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

> \

> > >

> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

> \

> > >

> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

> \

> > >

> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

> \

> > >

> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

> \

> > >

> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

> \

> > >

> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

> \

> > >

> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

> \

> > >

> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

> \

> > >

> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

> \

> > >

> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

> \

> > >

> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

> \

> > >

> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

> \

> > >

> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

> \

> > >

> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

> \

> > >

> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

> \

> > >

> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

> \

> > >

> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

> \

> > >

> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

> \

> > >

> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

> \

> > >

> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

> \

> > >

> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

> \

> > >

> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

> \

> > >

> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

> \

> > >

> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

> \

> > >

> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

> \

> > >

> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

> \

> > >

> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

> \

> > >

> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

> \

> > >

> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

> \

> > >

> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

> \

> > >

> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

> \

> > >

> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

> \

> > >

> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

> \

> > >

> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

> \

> > >

> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

> \

> > >

> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

> \

> > >

> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

> \

> > >

> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

> \

> > >

> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

> \

> > >

> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

> \

> > >

> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

> \

> > >

> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

> \

> > >

> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

> \

> > >

> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

> \

> > >

> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

> \

> > >

> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

> \

> > >

> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

> \

> > >

> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

> \

> > >

> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

> \

> > >

> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

> \

> > >

> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

> \

> > >

> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

> \

> > >

> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

> \

> > >

> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

> \

> > >

> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

> \

> > >

> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

> \

> > >

> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

> \

> > >

> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

> \

> > >

> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

> \

> > >

> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

> \

> > >

> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

> \

> > >

> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

> \

> > >

> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

> \

> > >

> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

> \

> > >

> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

> \

> > >

> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

> \

> > >

> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

> \

> > >

> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

> \

> > >

> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

> \

> > >

> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

> \

> > >

> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

> \

> > >

> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

> \

> > >

> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

> \

> > >

> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

> \

> > >

> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

> \

> > >

> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

> \

> > >

> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

> \

> > >

> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

> \

> > >

> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

> \

> > >

> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

> \

> > >

> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

> \

> > >

> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

> \

> > >

> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

> \

> > >

> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

> \

> > >

> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

> \

> > >

> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

> \

> > >

> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

> \

> > >

> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

> \

> > >

> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

> \

> > >

> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

> \

> > >

> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

> \

> > >

> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

> \

> > >

> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

> \

> > >

> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

> \

> > >

> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

> \

> > >

> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

> \

> > >

> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

> \

> > >

> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

> \

> > >

> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

> \

> > >

> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

> \

> > >

> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

> \

> > >

> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

> \

> > >

> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

> \

> > >

> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

> \

> > >

> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

> \

> > >

> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

> \

> > >

> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

> \

> > >

> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

> \

> > >

> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

> \

> > >

> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

> \

> > >

> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

> \

> > >

> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

> \

> > >

> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

> \

> > >

> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

> \

> > >

> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

> \

> > >

> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

> \

> > >

> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

> \

> > >

> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

> \

> > >

> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

> \

> > >

> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

> \

> > >

> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

> \

> > >

> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

> \

> > >

> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

> \

> > >

> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

> \

> > >

> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

> \

> > >

> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

> \

> > >

> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

> \

> > >

> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

> \

> > >

> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

> \

> > >

> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

> \

> > >

> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

> \

> > >

> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

> \

> > >

> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

> \

> > >

> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

> \

> > >

> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

> \

> > >

> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

> \

> > >

> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

> \

> > >

> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

> \

> > >

> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

> \

> > >

> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

> \

> > >

> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

> \

> > >

> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

> \

> > >

> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

> \

> > >

> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

> \

> > >

> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

> \

> > >

> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

> \

> > >

> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

> \

> > >

> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

> \

> > >

> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

> \

> > >

> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

> \

> > >

> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

> \

> > >

> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

> \

> > >

> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

> \

> > >

> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

> \

> > >

> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

> \

> > >

> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

> \

> > >

> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

> \

> > >

> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

> \

> > >

> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

> \

> > >

> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

> \

> > >

> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

> \

> > >

> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

> \

> > >

> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

> \

> > >

> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

> \

> > >

> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

> \

> > >

> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

> \

> > >

> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

> \

> > >

> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

> \

> > >

> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

> \

> > >

> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

> \

> > >

> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

> \

> > >

> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

> \

> > >

> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

> \

> > >

> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

> \

> > >

> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

> \

> > >

> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

> \

> > >

> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

> \

> > >

> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

> \

> > >

> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

> \

> > >

> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

> \

> > >

> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

> \

> > >

> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

> \

> > >

> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

> \

> > >

> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

> \

> > >

> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

> \

> > >

> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

> \

> > >

> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

> \

> > >

> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

> \

> > >

> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

> \

> > >

> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

> \

> > >

> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

> \

> > > ElFTkSuQmCC]

> > >

> > >

> > >

> > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME

> TO

> > > REJECT this Insult on Top of Injury

> > > I would like to thank a brave, courageous, and ethical anonymous

> source

> > > who has send in this letter correspondence they received from the

> law

> > > firm of Weitz & Luxenberg. This letter doesn't require a whole lot

> of

> > > commentary.

> > > It's obvious that Law Firms have sold their clients down the

> proverbial

> > > river while at the same time enriching themselves (who's best

> interest

> > > are you obligated too fulfill?). This settlement offer and the

> injured

> > > litigants legal representation has carried out a blatant miscarriage

> of

> > > justice, a forever horrible stain upon the American Justice system,

> and

> > > a orchestrated crime perpetrated upon victims of this well

> documented &

> > > evidenced unbridled & unregulated corporate criminal enterprise gone

> a

> > > rye.

> > > The time has now come for the victims to stand up to this criminal

> > > corporation " AstraZeneca " & their poison drug " Seroquel " , to reject

> this

> > > horrible injustice and settlement offer. We want, what America & our

> > > Constitution promises us all, our day in court before a jury of our

> > > peers....

> > > ____________________________________________________________

> > >

> > > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> > > We are happy to report excellent news! After a long and hard fought

> > > legal battle, AstraZeneca has agreed to participate in a Settlement

> > > Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases. Our

> > > patience and aggressive litigating has resulted in very favorable

> > > settlement terms for our clients which will be further outlined

> below.

> > > We have carefully reviewed all of the factors of this agreement and

> we

> > > believe that this settlement offers you the best, and very likely

> the

> > > only opportunity to receive a fair resolution of your lawsuit.

> > > Therefore, we strongly recommend that you sign and complete the

> enclosed

> > > " Release Form " , " Track Selection Form " and " Brief Questionnaire " and

> > > AGREE to participate.

> > > As you know, we have engaged in a long legal battle with AstraZeneca

> > > over the past 6 years. Weitz & Luxenberg led the charge for the

> > > Plaintiffs around the Country. AstraZeneca put up a tremendous and

> > > expensive defense and they successfully were able to get a large

> number

> > > of cases to be permanently dismissed by the court. Weitz & Luxenberg

> is

> > > the only firm who took a case to trial anywhere in the Country.

> However,

> > > after a month-long trial, the jury unfortunately ruled in favor of

> the

> > > defendants. This loss did not affect the strength of our fight. Over

> the

> > > past year, even as almost every other plaintiffs firm settled their

> > > cases, Weitz & Luxenberg prepared two more cases for trial which was

> > > scheduled to begin this Summer. As a direct result of the endless

> and

> > > consistent pressure applied by the attorneys at Weitz & Luxenberg,

> we

> > > are happy to report that AstraZeneca has now agreed to participate

> in a

> > > favorable settlement program. Based on public reports regarding

> > > settlement programs reached with other plaintiff law firms we are

> > > confident that the settlement program outlined below has more

> favorable

> > > terms and for this reason we are recommending your participation.

> > > The defendants have argued that they refuse to pay anyone who cannot

> > > prove through medical records or via certification that they have

> used

> > > Seroquel. They also refuse to pay anyone whose case is not active in

> > > this litigation. We recently told you about the Order issued by the

> > > Court requiring you to confirm when you started taking Seroquel and

> when

> > > you stopped taking Seroquel. We cannot stress enough that you MUST

> read,

> > > complete and return this certification form to us immediately. The

> > > failure to return this form within the next 30 days will result in

> the

> > > permanent dismissal of your case. In order to protect your legal

> rights,

> > > to keep your case active and be permitted to participate in this

> > > Settlement Program you must take this Order very seriously and you

> must

> > > respond.

> > > Based on our experience in other litigations and having reviewed the

> > > media reports of the terms of other firms' Seroquel settlement

> programs,

> > > we know that the defendants are looking for a settlement program

> that

> > > includes all claimants (W & L Seroquel Plaintiffs) so that they will

> > > achieve complete closure of the entirYlitigation. Our goal in this

> > > negotiation was to obtain a settlement for the most amount of money

> > > using a fair method to pay our clients based upon the merits of

> their

> > > individual case. We also stressed our intentions that the case

> review

> > > and payment process be performed quickly yet fairly so that our

> clients

> > > can receive their settlements as soon as possible. A key part of

> this

> > > settlement program is that a claimant cannot be part of the

> settlement

> > > if their case is dismissed and unless they provide, at the very

> least, a

> > > certification that they in fact took Seroquel and suffered an

> injury.

> > > Therefore, please make sure that you return your certification form

> to

> > > us immediately

> > >

> > > We have hired Hon.Marina Corodemus to act as the Special Master for

> the

> > > W & L Seroquel settlement program. Judge Corodemus previously ran the

> New

> > > Jersey Mass Tort Court and has a lot of experience in this field.

> She

> > > was appointed as a Special Master by the Vioxx State and Federal

> Court

> > > Judges to determine the appropriateness of Vioxx settlements and to

> > > resolve Vioxx appeals. She has also served as the Special Master in

> many

> > > other litigations such as Bextra and Celebrex which used similar

> > > settlement terms. We have met several times with Judge Corodemus and

> > > discussed the goals outlined above to get the most amount of money

> to

> > > the most amount of claimants in the fastest amount of time possible.

> We

> > > believe that Judge Corodemus is the perfect choice to create and

> oversee

> > > a settlement program in accordance with these goals. The W & L

> Seroquel

> > > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only

> > > those clients with active cases (not dismissed as outlined above)

> can

> > > participate in this settlement program. Unlike other settlement

> programs

> > > that you may have read about in the media and internet, the W & L

> > > Settlement program does not award every case an equal settlement

> amount.

> > > The size of an individual's settlement will depend entirely on the

> merit

> > > of that individual's case. As a direct result of the large number of

> > > cases represented by W & L, and the merits of those cases, we are

> > > confident that we have obtained the best possible settlement for our

> > > clients. After complex negotiations, AstraZeneca

> > > has agreed to deposit $92.25 Million dollars into a trust account to

> be

> > > used for this Settlement Program. This amount is completely

> confidential

> > > and you should NOT discuss this with anyone. A settlement of this

> type

> > > is called an " Aggregate Settlement " where a fair and reasonable sum

> of

> > > money is obtained to resolve multiple cases. In order to maintain

> proper

> > > representation of each individual client, W & L is NOT involved in

> the

> > > allocation decision making, which will be handled exclusively by

> Judge

> > > Corodemus. W & L has reviewed the general framework of the settlement

> > > plan with Judge Corodemus and we strongly believe that it is fair

> and

> > > reasonable and offers each of our clients the best possible outcome

> > > under the circumstances of this litigation. Track I offers the

> Seroquel

> > > claimant a settlement of $12,000. This track involves a simple

> review of

> > > each case and will result in a quick approval by Judge Corodemus

> without

> > > an analysis of the specific details of the case such as injury,

> amount

> > > of Seroquel taken, how close the last Seroquel use was to the date

> of

> > > the injury or the individual claimant's risk factors. a) Cannot

> > > prove that they suffered diabetes or a diabetes related condition,

> > > and/or Cannot prove that they used Seroquel within 1 year of

> > > their claimed injury, and/or c) Had a large number of known

> > > risk factors for diabetes before they started taking Seroquel. For

> > > example - obesity, family history, smoking, etc.

> > >

> > > Therefore, all cases whose injuries are limited to weight gain or

> high

> > > blood sugar and whose medical records will confirm that they were

> never

> > > diagnosed with diabetes or pancreatitis, should choose Track 1.

> > > Similarly, any claimed injury that occurred long after the last use

> of

> > > Seroquel should also choose Track 1. These cases are likely to

> receive a

> > > small award in Track II (likely less than $12,000) because it is

> > > extremely difficult to prove that these injuries were caused by

> > > Seroquel. Therefore, we suggest that if your case falls into this

> > > category you should choose Track 1. Additionally, payment of Track I

> > > settlement awards will be processed first once AstaZeneca waives its

> > > " walk away right " . (See Section IV© below) Track II involves an

> > > in-depth review of the severity of the injury, the claimed use of

> > > Seroquel and its proximity to the injury as well the available proof

> > > found in the contemporaneous medical records. Additionally, Judge

> > > Corodemus will strongly consider many known risk factors for these

> > > injuries including but not limited to smoking, obesity and family

> > > history as well as the participation in the Zyprexa settlement for

> these

> > > same injuries. This model is very similar to the one used in the

> > > National Vioxx Settlement Program as well as dozens of other similar

> > > settlement programs which were successfully resolved in recent

> years.

> > > Judge Corodemus has established a points system and will consider

> all of

> > > the critical issues including but not limited to:

> > > - Nature of the injury - Severity of the injury - Age at the time of

> > > injury - Proximity of Seroquel use to the claimed injury - Changes

> in

> > > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,

> > > etc. After carefully reviewing all of the medical records and the

> > > individual fact sheet, Judge Corodemus will assign a point value to

> each

> > > case. The more points a case is awarded based on the specific facts

> of

> > > the case, the larger the settlement will be. At this time, there is

> no

> > > way to predict with accuracy how many points an individual case may

> be

> > > awarded and it is even more difficult to determine how much money

> each

> > > point will receive. The exact value of each point will depend on the

> > > number of participants in Track II and the total number of points

> > > assigned. All cases in Track II will be eligible for a settlement

> award

> > > but Judge Corodemus could award LESS than $12,000 (what people will

> > > receive automatically by choosing Track 1) if the case lacks merit.

> In

> > > the interest of fairness, Judge Corodemus has committed to review

> each

> > > case in Track II very carefully and this process will take time to

> > > complete. Judge Corodemus has stated that she hopes to have this

> process

> > > completed by the end of 2011 but please be warned that it could take

> a

> > > little longer due to the amount of work that is involved. However,

> in

> > > order to get this settlement process moving forward and ultimately

> paid

> > > you must send us your signed Release form as soon as possible. If

> you

> > > choose Track I your settlement award of $12,000 is set. If you

> choose

> > > Track II, Judge Corodemus will review your claim and will issue an

> > > award. We expect that we will contact you in approximately November

> 2011

> > > and notify you of your point award and the expected amount of your

> > > settlement. At that point, you will be given a choice to accept your

> > > award, appeal your award or withdraw from the settlement program. If

> you

> > > accept, we will forward your release to AstraZeneca for their review

> and

> > > approval. Please understand that this settlement is not official

> until

> > > we send AstraZeneca your signed Release Form, AstraZeneca approves

> it

> > > AND AstraZeneca waives its walk away right. In the interest of time,

> we

> > > are asking you to return your signed Release Form now so we can meet

> the

> > > tight deadlines associated with this settlement. If you are unhappy

> with

> > > your allocation amount and/or believe that your case involves

> > > " Extraordinary Injury or Circumstances " you have the right to appeal

> > > your award. Upon receipt of such an application, Judge Corodemus

> will

> > > re-review your records and make a final decision. Please be aware

> that

> > > there is no additional right of appeal (to Judge Corodemus or to any

> > > Court) once this final decision is made. If you decide to decline

> the

> > > settlement amount offered to you, you must notify us within ten days

> of

> > > your receipt of your allocation amount and your signed Release Form

> will

> > > no longer be valid. As in all settlements of this type, our

> agreement

> > > with the defendant depends on nearly full participation from all of

> our

> > > clients. Under the terms of our agreement, we must provide

> Qualifying

> > > Materials (Release Form and/or Dismissal) for 2,260 of our clients.

> Once

> > > we reach this number, AstraZeneca's " walk away right " is officially

> > > waived. We strongly believe that our clients will agree that this

> > > settlement program offers the best possible terms and we expect that

> we

> > > will meet this requirement in the next 90-120 days. In order to meet

> > > this deadline we MUST have your complete

> > > cooperation and immediate response. Of course, if we do not meet

> this

> > > required number of responses, Astrazeneca can decide to withdraw its

> > > settlement offer to everyone whether one signed the Release Form or

> not.

> > > Therefore, time is of the essence. A. Release Form: Enclosed you

> will

> > > find a Release Form which you must sign in front of a notary in

> Order to

> > > participate in the settlement. If you have a spouse he/she must sign

> the

> > > Release Form as well. Attached to the Release Form will be an

> > > instruction sheet to guide you to ensure that this important form is

> > > signed the right way. A Release Form that is signed the wrong way or

> > > that is not witnessed (by a notary) is useless and will not be

> accepted

> > > by the defendants. The Release Form is your agreement to participate

> in

> > > the settlement program and at the same time discontinue your lawsuit

> in

> > > exchange for your settlement award. Please turn to Page 2 of the

> Release

> > > Form and complete the details of your Seroquel use. You may refer to

> > > Page 1 of the Brief Questionnaire which lists the Seroquel

> information

> > > that was found in your medical records or that you have previously

> > > provided to us. If this information is inaccurate, please cross it

> out

> > > and write in when you started and when you stopped taking Seroquel

> on

> > > BOTH the Release Form and the Brief Questionnaire. Due to the fast

> > > approaching deadlines, and our goal to get you your settlement

> processed

> > > and paid as quickly as possible, we MUST receive this signed release

> > > form back from you before August 31, 2011. Please use the envelope

> > > provided herein and return the signed and notarized release form

> today

> > > before you forget about it. Please note that once we submit your

> release

> > > form to AstraZeneca it can not be revoked. B. Track Selection Form:

> > > Enclosed you will find a " Track Selection Form " which is the form

> used

> > > to officially notify the Special Master which Track you want your

> case

> > > to follow. Please Note that there are 4 options on this form. You

> MUST

> > > check one of the Options. If you want to participate in this

> settlement,

> > > and we strongly think that you should, you must check either Track I

> OR

> > > Track II and you must sign the bottom of the form. Your Track

> selection

> > > cannot be changed and is considered final once the Judge's

> Allocations

> > > are made. In other words, a person who chooses Track II and is

> awarded

> > > less than $12,000 CANNOT then choose to go to Track 1 for a higher

> > > award. C. Brief Questionnaire: Enclosed you will find a 3

> > > page Brief Questionnaire which has important information about your

> > > claim. For all claimants who choose to enter Track II, Judge

> Corodemus

> > > will be reviewing your medical records, your Fact Sheet and this

> Brief

> > > Questionnaire and will issue a point award. Judge Corodemus will

> > > consider the proof of your claim found in your medical records as

> well

> > > as the information that you provide in this Questionnaire.

> Therefore, it

> > > is important that you answer these questions honestly and completely

> and

> > > that they are consistent with what is found in your medical records.

> > > litigation and our conversations with our medical experts, it is

> clear

> > > that Seroquel lawsuits are very difficult to win, very expensive,

> and

> > > very time consuming to take through to trial, verdict and appeal.

> Over

> > > the past six years only I case (from W & L) of24,000 cases in the

> Country

> > > made it to and through trial. Countless other cases were prepared

> and

> > > then dismissed based on merit and/or inability to prove that

> Seroquel

> > > caused the injury. Just because an individual took Seroquel and

> suffered

> > > an injury like diabetes does not mean that such a case will win at

> > > trial. In order to succeed at trial, a plaintiff must prove both

> that

> > > Seroquel can cause such an injury in general AND that, within a

> > > reasonable degree of medical certainty, Seroquel caused this injury

> to

> > > this particular person (despite any individual risk factors such as

> > > smoking, weight, high blood sugar, family history etc.). We have

> told

> > > you in the past update letters that the Courts have consistently

> ruled

> > > in favor of the defendants on many of these issues and have

> prohibited

> > > medical experts from testifying because of a lack of scientific

> proof

> > > linking the plaintiff s injuries to his/her Seroquel use. It is also

> > > important to note that even if your case is able to advance past

> this

> > > judicial scrutiny, a trial of this magnitude will cost over $750,000

> per

> > > case and many of these costs are reimbursed off of the top of a

> > > favorable verdict reducing the amount received by the plaintiff.

> > > Furthermore, any case that is won at trial will surely face a

> lengthy

> > > and hard-fought appeal. Finally, nearly all of the Seroquel cases

> are

> > > being handled by three judges. Even at an accelerated pace, the

> chances

> > > are slim that your case would be tried in the next 10 years if not

> > > longer. In taking all of these factors into consideration, and

> > > considering the issues of risk and reward, we believe that a

> settlement

> > > of this type offers you the most advantageous resolution possible.

> You

> > > will be notified once the Special Master issues your point award at

> > > which point you can appeal to the Special Master if you believe that

> > > your case involves extraordinary circumstances. Thereafter, the

> decision

> > > of the Special Master is final, binding and non-appealable. We have

> > > retained the Garretson Law Firm to negotiate any and all Federal and

> > > State liens (Medicare/Medicaid/SSI) that may be applicable in your

> case.

> > > The Garretson Firm is a specialist in this field and they have

> obtained

> > > excellent results in their negotiation of similar liens in other

> > > litigations like Vioxx, Bextra, and Celebrex. Moreover, the

> Garretson

> > > Firm has already worked on thousands of other Seroquel cases and has

> > > been able to achieve excellent results in large part due to the

> volume

> > > of cases that they are able to include in a Global Resolution. At

> this

> > > time, the Garretson Firm has already negotiated with 44 individual

> > > states regarding Medicaid and they have reached an agreement to CAP

> > > Medicaid liens at a maximum of 20% of the settlement amount. Please

> see

> > > the enclosed blue booklet regarding governmental liens for more

> details.

> > > Additionally, please also be advised that if you or Weitz &

> Luxenberg

> > > are put on written notice of a private lien, for example from your

> > > medical provider, this lien must be resolved before any settlement

> > > proceeds can be distributed. If you have received any notice of a

> lien,

> > > please advise us immediately. The terms of your signed contingency

> fee

> > > agreement will be in effect. We have taken great effort to keep the

> case

> > > specific expenses as low as possible. Under the terms of your

> agreement,

> > > the

> > > contingency fee will be calculated after the expenses are deducted.

> > > Under the terms of our agreement with AstraZeneca, any interest

> earned

> > > on the settlement proceeds before allocation and payment to the

> > > individual clients will be used to offset the fixed costs of the

> Special

> > > Master and the Lien Administrator. Due to the low interest rates

> paid by

> > > all banks in this economy, we do not expect that there will be any

> > > leftover interest. However, in such a case, the leftover interest

> will

> > > be added to the settlement trust and will be distributed to all

> > > claimants as part of Judge Corodemus' allocation process. After

> careful

> > > analysis of the likelihood of success in the court system, as well

> as

> > > the cost and time elements involved, we strongly recommend that you

> > > AGREE to participate in this settlement. We are confident that this

> > > settlement is the best possible resolution of your claim especially

> in

> > > light of the history of this litigation. We expect that any case

> that

> > > does not agree to participate in this settlement will have a very

> > > difficult time navigating through the Court system and trial dates

> may

> > > not be set for many years. Moreover, as we have seen, these cases

> will

> > > be aggressively defended by AstraZeneca and we expect that we will

> > > receive motions to dismiss and unfavorable decisions from the Court

> on

> > > unsettled cases in the coming months. Moreover, if this settlement

> > > program is not successful (we fail to reach the 98% response rate)

> we

> > > highly doubt that we will ever obtain a settlement amount and terms

> as

> > > good as those contained in this program. While we hope that this

> letter

> > > and enclosures will help answer all of your questions, we understand

> > > that you may have additional questions for us. Please keep in mind

> that

> > > we are working very hard to evaluate each and every case

> individually

> > > and the many deadlines that are part of this settlement are fast

> > > approaching. Your case has been assigned to Judy Koenig. If you have

> an

> > > important question please call Judy Koenig at (800) 438-9786 and ask

> for

> > > extension 5860. If you reach a voice-mail, please leave a message

> and

> > > you will be called back as quickly as possible. Please do not leave

> > > multiple voicemail messages on the same day as that will slow down

> our

> > > ability to return your call. Additionally, if you have email access,

> > > please try to email your detailed questions to us at sqinfo@

> > > <mailto:sqinfo@ and we will get back to you quickly. If

> > > this letter has successfully answered your questions, and you have

> > > decided to participate, please carefully follow the directions on

> the

> > > front page of the enclosed release form and send your signed and

> > > witnessed release formes), your Track Selection AND your Brief

> > > Questionnaire to us as soon as possible. If you still have questions

> > > after reviewing this letter and after speaking to us over the

> telephone

> > > and you would like to meet us in person, we will be happy to

> schedule a

> > > meeting in our office at your convenience. Finally, please remember

> that

> > > the detailed information regarding this settlement program is

> COMPLETELY

> > > CONFIDENTIAL and should not be shared or discussed with anyone.

>

> > > Sedgh, Esq Glenn Zuckerman, Esq.

> > >

> >

>

[Guest guest]

Far from throwing mud on the windscreen, so to speak, if the CoS was not so much a "professionally paranoid" organisation it would realise that it's classic tactic of playing at being victimised by situations it itself creates, it would step out of the situation and examine the fruits of it's actions.

In terms of the UK & Ireland then it is fair to say once it's involvement becomes clear then credibility of anyones legitimate claims about problem psychiatric treatment goes out the window.

Nobody responsible person believes them & therefore anyone who goes along with them how ever passively looses any traction.

CoS has been in the field for decades yet SSRI are more out of control than ever !

The evidence is clear - http://tuesday1st.blogspot.com/2011/05/ssri-snri-total-annual-prescription_17.html

Data collection reference:Department of Health; NHS; Prescription Cost Analysis (PCA) - England

you can't argue against national statistical return of prescriptions encashed at the pharmacy shop

> > > >> > > > "Awry," not "a rye" but I digress. This is exactly why I never urge> > anyone to sue. The deck is stacked against us in court and attorneys are> > looking for a quick and easy buck. No justice is to be had.> > > >> > > > Terry> > > > Sent via BlackBerry by AT & T> > > >> > > > SEROQUEL Law Firms have sold their clients> > down the river> > > >> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME> > TO> > > > REJECT this Insult on Top of Injury> > > >> > [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\> > \> > > >> > ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\> > \> > > >> > A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\> > \> > > >> > oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\> > \> > > >> > 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\> > \> > > >> > DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\> > \> > > >> > HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\> > \> > > >> > oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\> > \> > > >> > 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\> > \> > > >> > EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\> > \> > > >> > VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\> > \> > > >> > 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\> > \> > > >> > IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\> > \> > > >> > kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\> > \> > > >> > /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\> > \> > > >> > 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\> > \> > > >> > CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\> > \> > > >> > ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\> > \> > > >> > zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\> > \> > > >> > T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\> > \> > > >> > N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\> > \> > > >> > HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\> > \> > > >> > gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\> > \> > > >> > w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\> > \> > > >> > 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\> > \> > > >> > wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\> > \> > > >> > TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\> > \> > > >> > Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\> > \> > > >> > NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\> > \> > > >> > LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\> > \> > > >> > yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\> > \> > > >> > rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\> > \> > > >> > pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\> > \> > > >> > 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\> > \> > > >> > bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\> > \> > > >> > rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\> > \> > > >> > XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\> > \> > > >> > AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\> > \> > > >> > sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\> > \> > > >> > uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\> > \> > > >> > 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\> > \> > > >> > aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\> > \> > > >> > 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\> > \> > > >> > mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\> > \> > > >> > 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\> > \> > > >> > A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\> > \> > > >> > QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\> > \> > > >> > UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\> > \> > > >> > ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\> > \> > > >> > /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\> > \> > > >> > i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\> > \> > > >> > Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\> > \> > > >> > DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\> > \> > > >> > 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\> > \> > > >> > zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\> > \> > > >> > hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\> > \> > > >> > i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\> > \> > > >> > gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\> > \> > > >> > m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\> > \> > > >> > VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\> > \> > > >> > Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\> > \> > > >> > bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\> > \> > > >> > MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\> > \> > > >> > RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\> > \> > > >> > RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\> > \> > > >> > 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\> > \> > > >> > AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\> > \> > > >> > jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\> > \> > > >> > okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\> > \> > > >> > kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\> > \> > > >> > HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\> > \> > > >> > cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\> > \> > > >> > tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\> > \> > > >> > YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\> > \> > > >> > +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\> > \> > > >> > sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\> > \> > > >> > 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\> > \> > > >> > QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\> > \> > > >> > kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\> > \> > > >> > Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\> > \> > > >> > Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\> > \> > > >> > QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\> > \> > > >> > t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\> > \> > > >> > MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\> > \> > > >> > VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\> > \> > > >> > nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\> > \> > > >> > SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\> > \> > > >> > tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\> > \> > > >> > 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\> > \> > > >> > ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\> > \> > > >> > J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\> > \> > > >> > m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\> > \> > > >> > 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\> > \> > > >> > 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\> > \> > > >> > 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\> > \> > > >> > zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\> > \> > > >> > 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\> > \> > > >> > 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\> > \> > > >> > oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\> > \> > > >> > hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\> > \> > > >> > 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\> > \> > > >> > vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\> > \> > > >> > fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\> > \> > > >> > aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\> > \> > > >> > +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\> > \> > > >> > HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\> > \> > > >> > aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\> > \> > > >> > jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\> > \> > > >> > 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\> > \> > > >> > /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\> > \> > > >> > G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\> > \> > > >> > GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\> > \> > > >> > +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\> > \> > > >> > kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\> > \> > > >> > h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\> > \> > > >> > NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\> > \> > > >> > rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\> > \> > > >> > T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\> > \> > > >> > C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\> > \> > > >> > at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\> > \> > > >> > 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\> > \> > > >> > X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\> > \> > > >> > kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\> > \> > > >> > PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\> > \> > > >> > tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\> > \> > > >> > 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\> > \> > > >> > ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\> > \> > > >> > DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\> > \> > > >> > cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\> > \> > > >> > Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\> > \> > > >> > qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\> > \> > > >> > wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\> > \> > > >> > aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\> > \> > > >> > zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\> > \> > > >> > KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\> > \> > > >> > BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\> > \> > > >> > XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\> > \> > > >> > fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\> > \> > > >> > R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\> > \> > > >> > xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\> > \> > > >> > SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\> > \> > > >> > BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\> > \> > > >> > BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\> > \> > > >> > iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\> > \> > > >> > Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\> > \> > > >> > Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\> > \> > > >> > dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\> > \> > > >> > BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\> > \> > > >> > whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\> > \> > > >> > Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\> > \> > > >> > NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\> > \> > > >> > 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\> > \> > > >> > 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\> > \> > > >> > D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\> > \> > > >> > amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\> > \> > > >> > UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\> > \> > > >> > n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\> > \> > > >> > nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\> > \> > > >> > 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\> > \> > > >> > e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\> > \> > > >> > nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\> > \> > > >> > CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\> > \> > > >> > 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\> > \> > > >> > MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\> > \> > > >> > X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\> > \> > > >> > 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\> > \> > > >> > qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\> > \> > > >> > e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\> > \> > > >> > oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\> > \> > > >> > CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\> > \> > > >> > 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\> > \> > > >> > GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\> > \> > > >> > ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\> > \> > > >> > Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\> > \> > > >> > AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\> > \> > > >> > ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\> > \> > > >> > vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\> > \> > > >> > +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\> > \> > > >> > kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\> > \> > > >> > e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\> > \> > > >> > hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\> > \> > > >> > 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\> > \> > > >> > DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\> > \> > > >> > ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\> > \> > > >> > suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\> > \> > > >> > 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\> > \> > > >> > yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\> > \> > > >> > c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\> > \> > > >> > rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\> > \> > > >> > FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\> > \> > > >> > 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\> > \> > > >> > GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\> > \> > > >> > UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\> > \> > > >> > I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\> > \> > > >> > xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\> > \> > > >> > IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\> > \> > > >> > EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\> > \> > > >> > Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\> > \> > > >> > S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\> > \> > > >> > WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\> > \> > > >> > mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\> > \> > > >> > Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\> > \> > > >> > QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\> > \> > > >> > IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\> > \> > > >> > 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\> > \> > > >> > FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\> > \> > > >> > FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\> > \> > > >> > lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\> > \> > > >> > Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\> > \> > > >> > Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\> > \> > > >> > +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\> > \> > > >> > aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\> > \> > > >> > Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\> > \> > > >> > wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\> > \> > > >> > yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\> > \> > > >> > QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\> > \> > > >> > CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\> > \> > > >> > kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\> > \> > > >> > Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\> > \> > > >> > 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\> > \> > > >> > AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\> > \> > > >> > eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\> > \> > > >> > sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\> > \> > > >> > gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\> > \> > > >> > 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\> > \> > > >> > hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\> > \> > > >> > KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\> > \> > > >> > 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\> > \> > > >> > /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\> > \> > > >> > 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\> > \> > > >> > qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\> > \> > > >> > LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\> > \> > > >> > iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\> > \> > > >> > wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\> > \> > > >> > A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\> > \> > > >> > A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\> > \> > > >> > 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\> > \> > > >> > h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\> > \> > > >> > X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\> > \> > > >> > TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\> > \> > > >> > kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\> > \> > > >> > SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\> > \> > > >> > mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\> > \> > > >> > 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\> > \> > > >> > XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\> > \> > > >> > U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\> > \> > > >> > +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\> > \> > > >> > SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\> > \> > > >> > WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\> > \> > > >> > gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\> > \> > > >> > YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\> > \> > > >> > tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\> > \> > > >> > HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\> > \> > > >> > bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\> > \> > > >> > ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\> > \> > > >> > IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\> > \> > > >> > HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\> > \> > > >> > wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\> > \> > > >> > NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\> > \> > > >> > 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\> > \> > > >> > n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\> > \> > > >> > kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\> > \> > > >> > X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\> > \> > > >> > rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\> > \> > > >> > x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\> > \> > > >> > Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\> > \> > > >> > tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\> > \> > > >> > Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\> > \> > > >> > fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\> > \> > > >> > UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\> > \> > > >> > xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\> > \> > > >> > IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\> > \> > > >> > 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\> > \> > > >> > fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\> > \> > > >> > Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\> > \> > > >> > 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\> > \> > > >> > iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\> > \> > > >> > oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\> > \> > > >> > KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\> > \> > > >> > 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\> > \> > > >> > RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\> > \> > > > ElFTkSuQmCC]> > > >> > > >> > > >> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME> > TO> > > > REJECT this Insult on Top of Injury> > > > I would like to thank a brave, courageous, and ethical anonymous> > source> > > > who has send in this letter correspondence they received from the> > law> > > > firm of Weitz & Luxenberg. This letter doesn't require a whole lot> > of> > > > commentary.> > > > It's obvious that Law Firms have sold their clients down the> > proverbial> > > > river while at the same time enriching themselves (who's best> > interest> > > > are you obligated too fulfill?). This settlement offer and the> > injured> > > > litigants legal representation has carried out a blatant miscarriage> > of> > > > justice, a forever horrible stain upon the American Justice system,> > and> > > > a orchestrated crime perpetrated upon victims of this well> > documented & > > > > evidenced unbridled & unregulated corporate criminal enterprise gone> > a> > > > rye.> > > > The time has now come for the victims to stand up to this criminal> > > > corporation "AstraZeneca" & their poison drug "Seroquel", to reject> > this> > > > horrible injustice and settlement offer. We want, what America & our> > > > Constitution promises us all, our day in court before a jury of our> > > > peers....> > > > ____________________________________________________________> > > >> > > > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>> > > > We are happy to report excellent news! After a long and hard fought> > > > legal battle, AstraZeneca has agreed to participate in a Settlement> > > > Program to resolve Weitz & Luxenberg ("W & L") Seroguel cases. Our> > > > patience and aggressive litigating has resulted in very favorable> > > > settlement terms for our clients which will be further outlined> > below.> > > > We have carefully reviewed all of the factors of this agreement and> > we> > > > believe that this settlement offers you the best, and very likely> > the> > > > only opportunity to receive a fair resolution of your lawsuit.> > > > Therefore, we strongly recommend that you sign and complete the> > enclosed> > > > "Release Form", "Track Selection Form" and "Brief Questionnaire" and> > > > AGREE to participate.> > > > As you know, we have engaged in a long legal battle with AstraZeneca> > > > over the past 6 years. Weitz & Luxenberg led the charge for the> > > > Plaintiffs around the Country. AstraZeneca put up a tremendous and> > > > expensive defense and they successfully were able to get a large> > number> > > > of cases to be permanently dismissed by the court. Weitz & Luxenberg> > is> > > > the only firm who took a case to trial anywhere in the Country.> > However,> > > > after a month-long trial, the jury unfortunately ruled in favor of> > the> > > > defendants. This loss did not affect the strength of our fight. Over> > the> > > > past year, even as almost every other plaintiffs firm settled their> > > > cases, Weitz & Luxenberg prepared two more cases for trial which was> > > > scheduled to begin this Summer. As a direct result of the endless> > and> > > > consistent pressure applied by the attorneys at Weitz & Luxenberg,> > we> > > > are happy to report that AstraZeneca has now agreed to participate> > in a> > > > favorable settlement program. Based on public reports regarding> > > > settlement programs reached with other plaintiff law firms we are> > > > confident that the settlement program outlined below has more> > favorable> > > > terms and for this reason we are recommending your participation.> > > > The defendants have argued that they refuse to pay anyone who cannot> > > > prove through medical records or via certification that they have> > used> > > > Seroquel. They also refuse to pay anyone whose case is not active in> > > > this litigation. We recently told you about the Order issued by the> > > > Court requiring you to confirm when you started taking Seroquel and> > when> > > > you stopped taking Seroquel. We cannot stress enough that you MUST> > read,> > > > complete and return this certification form to us immediately. The> > > > failure to return this form within the next 30 days will result in> > the> > > > permanent dismissal of your case. In order to protect your legal> > rights,> > > > to keep your case active and be permitted to participate in this> > > > Settlement Program you must take this Order very seriously and you> > must> > > > respond.> > > > Based on our experience in other litigations and having reviewed the> > > > media reports of the terms of other firms' Seroquel settlement> > programs,> > > > we know that the defendants are looking for a settlement program> > that> > > > includes all claimants (W & L Seroquel Plaintiffs) so that they will> > > > achieve complete closure of the entirYlitigation. Our goal in this> > > > negotiation was to obtain a settlement for the most amount of money> > > > using a fair method to pay our clients based upon the merits of> > their> > > > individual case. We also stressed our intentions that the case> > review> > > > and payment process be performed quickly yet fairly so that our> > clients> > > > can receive their settlements as soon as possible. A key part of> > this> > > > settlement program is that a claimant cannot be part of the> > settlement> > > > if their case is dismissed and unless they provide, at the very> > least, a> > > > certification that they in fact took Seroquel and suffered an> > injury.> > > > Therefore, please make sure that you return your certification form> > to> > > > us immediately> > > >> > > > We have hired Hon.Marina Corodemus to act as the Special Master for> > the> > > > W & L Seroquel settlement program. Judge Corodemus previously ran the> > New> > > > Jersey Mass Tort Court and has a lot of experience in this field.> > She> > > > was appointed as a Special Master by the Vioxx State and Federal> > Court> > > > Judges to determine the appropriateness of Vioxx settlements and to> > > > resolve Vioxx appeals. She has also served as the Special Master in> > many> > > > other litigations such as Bextra and Celebrex which used similar> > > > settlement terms. We have met several times with Judge Corodemus and> > > > discussed the goals outlined above to get the most amount of money> > to> > > > the most amount of claimants in the fastest amount of time possible.> > We> > > > believe that Judge Corodemus is the perfect choice to create and> > oversee> > > > a settlement program in accordance with these goals. The W & L> > Seroquel> > > > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only> > > > those clients with active cases (not dismissed as outlined above)> > can> > > > participate in this settlement program. Unlike other settlement> > programs> > > > that you may have read about in the media and internet, the W & L> > > > Settlement program does not award every case an equal settlement> > amount.> > > > The size of an individual's settlement will depend entirely on the> > merit> > > > of that individual's case. As a direct result of the large number of> > > > cases represented by W & L, and the merits of those cases, we are> > > > confident that we have obtained the best possible settlement for our> > > > clients. After complex negotiations, AstraZeneca> > > > has agreed to deposit $92.25 Million dollars into a trust account to> > be> > > > used for this Settlement Program. This amount is completely> > confidential> > > > and you should NOT discuss this with anyone. A settlement of this> > type> > > > is called an "Aggregate Settlement" where a fair and reasonable sum> > of> > > > money is obtained to resolve multiple cases. In order to maintain> > proper> > > > representation of each individual client, W & L is NOT involved in> > the> > > > allocation decision making, which will be handled exclusively by> > Judge> > > > Corodemus. W & L has reviewed the general framework of the settlement> > > > plan with Judge Corodemus and we strongly believe that it is fair> > and> > > > reasonable and offers each of our clients the best possible outcome> > > > under the circumstances of this litigation. Track I offers the> > Seroquel> > > > claimant a settlement of $12,000. This track involves a simple> > review of> > > > each case and will result in a quick approval by Judge Corodemus> > without> > > > an analysis of the specific details of the case such as injury,> > amount> > > > of Seroquel taken, how close the last Seroquel use was to the date> > of> > > > the injury or the individual claimant's risk factors. a) Cannot> > > > prove that they suffered diabetes or a diabetes related condition,> > > > and/or Cannot prove that they used Seroquel within 1 year of> > > > their claimed injury, and/or c) Had a large number of known> > > > risk factors for diabetes before they started taking Seroquel. For> > > > example - obesity, family history, smoking, etc.> > > >> > > > Therefore, all cases whose injuries are limited to weight gain or> > high> > > > blood sugar and whose medical records will confirm that they were> > never> > > > diagnosed with diabetes or pancreatitis, should choose Track 1.> > > > Similarly, any claimed injury that occurred long after the last use> > of> > > > Seroquel should also choose Track 1. These cases are likely to> > receive a> > > > small award in Track II (likely less than $12,000) because it is> > > > extremely difficult to prove that these injuries were caused by> > > > Seroquel. Therefore, we suggest that if your case falls into this> > > > category you should choose Track 1. Additionally, payment of Track I> > > > settlement awards will be processed first once AstaZeneca waives its> > > > "walk away right". (See Section IV© below) Track II involves an> > > > in-depth review of the severity of the injury, the claimed use of> > > > Seroquel and its proximity to the injury as well the available proof> > > > found in the contemporaneous medical records. Additionally, Judge> > > > Corodemus will strongly consider many known risk factors for these> > > > injuries including but not limited to smoking, obesity and family> > > > history as well as the participation in the Zyprexa settlement for> > these> > > > same injuries. This model is very similar to the one used in the> > > > National Vioxx Settlement Program as well as dozens of other similar> > > > settlement programs which were successfully resolved in recent> > years.> > > > Judge Corodemus has established a points system and will consider> > all of> > > > the critical issues including but not limited to:> > > > - Nature of the injury - Severity of the injury - Age at the time of> > > > injury - Proximity of Seroquel use to the claimed injury - Changes> > in> > > > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,> > > > etc. After carefully reviewing all of the medical records and the> > > > individual fact sheet, Judge Corodemus will assign a point value to> > each> > > > case. The more points a case is awarded based on the specific facts> > of> > > > the case, the larger the settlement will be. At this time, there is> > no> > > > way to predict with accuracy how many points an individual case may> > be> > > > awarded and it is even more difficult to determine how much money> > each> > > > point will receive. The exact value of each point will depend on the> > > > number of participants in Track II and the total number of points> > > > assigned. All cases in Track II will be eligible for a settlement> > award> > > > but Judge Corodemus could award LESS than $12,000 (what people will> > > > receive automatically by choosing Track 1) if the case lacks merit.> > In> > > > the interest of fairness, Judge Corodemus has committed to review> > each> > > > case in Track II very carefully and this process will take time to> > > > complete. Judge Corodemus has stated that she hopes to have this> > process> > > > completed by the end of 2011 but please be warned that it could take> > a> > > > little longer due to the amount of work that is involved. However,> > in> > > > order to get this settlement process moving forward and ultimately> > paid> > > > you must send us your signed Release form as soon as possible. If> > you> > > > choose Track I your settlement award of $12,000 is set. If you> > choose> > > > Track II, Judge Corodemus will review your claim and will issue an> > > > award. We expect that we will contact you in approximately November> > 2011> > > > and notify you of your point award and the expected amount of your> > > > settlement. At that point, you will be given a choice to accept your> > > > award, appeal your award or withdraw from the settlement program. If> > you> > > > accept, we will forward your release to AstraZeneca for their review> > and> > > > approval. Please understand that this settlement is not official> > until> > > > we send AstraZeneca your signed Release Form, AstraZeneca approves> > it> > > > AND AstraZeneca waives its walk away right. In the interest of time,> > we> > > > are asking you to return your signed Release Form now so we can meet> > the> > > > tight deadlines associated with this settlement. If you are unhappy> > with> > > > your allocation amount and/or believe that your case involves> > > > "Extraordinary Injury or Circumstances" you have the right to appeal> > > > your award. Upon receipt of such an application, Judge Corodemus> > will> > > > re-review your records and make a final decision. Please be aware> > that> > > > there is no additional right of appeal (to Judge Corodemus or to any> > > > Court) once this final decision is made. If you decide to decline> > the> > > > settlement amount offered to you, you must notify us within ten days> > of> > > > your receipt of your allocation amount and your signed Release Form> > will> > > > no longer be valid. As in all settlements of this type, our> > agreement> > > > with the defendant depends on nearly full participation from all of> > our> > > > clients. Under the terms of our agreement, we must provide> > Qualifying> > > > Materials (Release Form and/or Dismissal) for 2,260 of our clients.> > Once> > > > we reach this number, AstraZeneca's "walk away right" is officially> > > > waived. We strongly believe that our clients will agree that this> > > > settlement program offers the best possible terms and we expect that> > we> > > > will meet this requirement in the next 90-120 days. In order to meet> > > > this deadline we MUST have your complete> > > > cooperation and immediate response. Of course, if we do not meet> > this> > > > required number of responses, Astrazeneca can decide to withdraw its> > > > settlement offer to everyone whether one signed the Release Form or> > not.> > > > Therefore, time is of the essence. A. Release Form: Enclosed you> > will> > > > find a Release Form which you must sign in front of a notary in> > Order to> > > > participate in the settlement. If you have a spouse he/she must sign> > the> > > > Release Form as well. Attached to the Release Form will be an> > > > instruction sheet to guide you to ensure that this important form is> > > > signed the right way. A Release Form that is signed the wrong way or> > > > that is not witnessed (by a notary) is useless and will not be> > accepted> > > > by the defendants. The Release Form is your agreement to participate> > in> > > > the settlement program and at the same time discontinue your lawsuit> > in> > > > exchange for your settlement award. Please turn to Page 2 of the> > Release> > > > Form and complete the details of your Seroquel use. You may refer to> > > > Page 1 of the Brief Questionnaire which lists the Seroquel> > information> > > > that was found in your medical records or that you have previously> > > > provided to us. If this information is inaccurate, please cross it> > out> > > > and write in when you started and when you stopped taking Seroquel> > on> > > > BOTH the Release Form and the Brief Questionnaire. Due to the fast> > > > approaching deadlines, and our goal to get you your settlement> > processed> > > > and paid as quickly as possible, we MUST receive this signed release> > > > form back from you before August 31, 2011. Please use the envelope> > > > provided herein and return the signed and notarized release form> > today> > > > before you forget about it. Please note that once we submit your> > release> > > > form to AstraZeneca it can not be revoked. B. Track Selection Form:> > > > Enclosed you will find a "Track Selection Form" which is the form> > used> > > > to officially notify the Special Master which Track you want your> > case> > > > to follow. Please Note that there are 4 options on this form. You> > MUST> > > > check one of the Options. If you want to participate in this> > settlement,> > > > and we strongly think that you should, you must check either Track I> > OR> > > > Track II and you must sign the bottom of the form. Your Track> > selection> > > > cannot be changed and is considered final once the Judge's> > Allocations> > > > are made. In other words, a person who chooses Track II and is> > awarded> > > > less than $12,000 CANNOT then choose to go to Track 1 for a higher> > > > award. C. Brief Questionnaire: Enclosed you will find a 3> > > > page Brief Questionnaire which has important information about your> > > > claim. For all claimants who choose to enter Track II, Judge> > Corodemus> > > > will be reviewing your medical records, your Fact Sheet and this> > Brief> > > > Questionnaire and will issue a point award. Judge Corodemus will> > > > consider the proof of your claim found in your medical records as> > well> > > > as the information that you provide in this Questionnaire.> > Therefore, it> > > > is important that you answer these questions honestly and completely> > and> > > > that they are consistent with what is found in your medical records.> > > > litigation and our conversations with our medical experts, it is> > clear> > > > that Seroquel lawsuits are very difficult to win, very expensive,> > and> > > > very time consuming to take through to trial, verdict and appeal.> > Over> > > > the past six years only I case (from W & L) of24,000 cases in the> > Country> > > > made it to and through trial. Countless other cases were prepared> > and> > > > then dismissed based on merit and/or inability to prove that> > Seroquel> > > > caused the injury. Just because an individual took Seroquel and> > suffered> > > > an injury like diabetes does not mean that such a case will win at> > > > trial. In order to succeed at trial, a plaintiff must prove both> > that> > > > Seroquel can cause such an injury in general AND that, within a> > > > reasonable degree of medical certainty, Seroquel caused this injury> > to> > > > this particular person (despite any individual risk factors such as> > > > smoking, weight, high blood sugar, family history etc.). We have> > told> > > > you in the past update letters that the Courts have consistently> > ruled> > > > in favor of the defendants on many of these issues and have> > prohibited> > > > medical experts from testifying because of a lack of scientific> > proof> > > > linking the plaintiff s injuries to his/her Seroquel use. It is also> > > > important to note that even if your case is able to advance past> > this> > > > judicial scrutiny, a trial of this magnitude will cost over $750,000> > per> > > > case and many of these costs are reimbursed off of the top of a> > > > favorable verdict reducing the amount received by the plaintiff.> > > > Furthermore, any case that is won at trial will surely face a> > lengthy> > > > and hard-fought appeal. Finally, nearly all of the Seroquel cases> > are> > > > being handled by three judges. Even at an accelerated pace, the> > chances> > > > are slim that your case would be tried in the next 10 years if not> > > > longer. In taking all of these factors into consideration, and> > > > considering the issues of risk and reward, we believe that a> > settlement> > > > of this type offers you the most advantageous resolution possible.> > You> > > > will be notified once the Special Master issues your point award at> > > > which point you can appeal to the Special Master if you believe that> > > > your case involves extraordinary circumstances. Thereafter, the> > decision> > > > of the Special Master is final, binding and non-appealable. We have> > > > retained the Garretson Law Firm to negotiate any and all Federal and> > > > State liens (Medicare/Medicaid/SSI) that may be applicable in your> > case.> > > > The Garretson Firm is a specialist in this field and they have> > obtained> > > > excellent results in their negotiation of similar liens in other> > > > litigations like Vioxx, Bextra, and Celebrex. Moreover, the> > Garretson> > > > Firm has already worked on thousands of other Seroquel cases and has> > > > been able to achieve excellent results in large part due to the> > volume> > > > of cases that they are able to include in a Global Resolution. At> > this> > > > time, the Garretson Firm has already negotiated with 44 individual> > > > states regarding Medicaid and they have reached an agreement to CAP> > > > Medicaid liens at a maximum of 20% of the settlement amount. Please> > see> > > > the enclosed blue booklet regarding governmental liens for more> > details.> > > > Additionally, please also be advised that if you or Weitz & > > Luxenberg> > > > are put on written notice of a private lien, for example from your> > > > medical provider, this lien must be resolved before any settlement> > > > proceeds can be distributed. If you have received any notice of a> > lien,> > > > please advise us immediately. The terms of your signed contingency> > fee> > > > agreement will be in effect. We have taken great effort to keep the> > case> > > > specific expenses as low as possible. Under the terms of your> > agreement,> > > > the> > > > contingency fee will be calculated after the expenses are deducted.> > > > Under the terms of our agreement with AstraZeneca, any interest> > earned> > > > on the settlement proceeds before allocation and payment to the> > > > individual clients will be used to offset the fixed costs of the> > Special> > > > Master and the Lien Administrator. Due to the low interest rates> > paid by> > > > all banks in this economy, we do not expect that there will be any> > > > leftover interest. However, in such a case, the leftover interest> > will> > > > be added to the settlement trust and will be distributed to all> > > > claimants as part of Judge Corodemus' allocation process. After> > careful> > > > analysis of the likelihood of success in the court system, as well> > as> > > > the cost and time elements involved, we strongly recommend that you> > > > AGREE to participate in this settlement. We are confident that this> > > > settlement is the best possible resolution of your claim especially> > in> > > > light of the history of this litigation. We expect that any case> > that> > > > does not agree to participate in this settlement will have a very> > > > difficult time navigating through the Court system and trial dates> > may> > > > not be set for many years. Moreover, as we have seen, these cases> > will> > > > be aggressively defended by AstraZeneca and we expect that we will> > > > receive motions to dismiss and unfavorable decisions from the Court> > on> > > > unsettled cases in the coming months. Moreover, if this settlement> > > > program is not successful (we fail to reach the 98% response rate)> > we> > > > highly doubt that we will ever obtain a settlement amount and terms> > as> > > > good as those contained in this program. While we hope that this> > letter> > > > and enclosures will help answer all of your questions, we understand> > > > that you may have additional questions for us. Please keep in mind> > that> > > > we are working very hard to evaluate each and every case> > individually> > > > and the many deadlines that are part of this settlement are fast> > > > approaching. Your case has been assigned to Judy Koenig. If you have> > an> > > > important question please call Judy Koenig at (800) 438-9786 and ask> > for> > > > extension 5860. If you reach a voice-mail, please leave a message> > and> > > > you will be called back as quickly as possible. Please do not leave> > > > multiple voicemail messages on the same day as that will slow down> > our> > > > ability to return your call. Additionally, if you have email access,> > > > please try to email your detailed questions to us at sqinfo@> > > > <mailto:sqinfo@ and we will get back to you quickly. If> > > > this letter has successfully answered your questions, and you have> > > > decided to participate, please carefully follow the directions on> > the> > > > front page of the enclosed release form and send your signed and> > > > witnessed release formes), your Track Selection AND your Brief> > > > Questionnaire to us as soon as possible. If you still have questions> > > > after reviewing this letter and after speaking to us over the> > telephone> > > > and you would like to meet us in person, we will be happy to> > schedule a> > > > meeting in our office at your convenience. Finally, please remember> > that> > > > the detailed information regarding this settlement program is> > COMPLETELY> > > > CONFIDENTIAL and should not be shared or discussed with anyone.> > > > > > Sedgh, Esq Glenn Zuckerman, Esq.> > > >> > >> >>

[Guest guest]

Far from throwing mud on the windscreen, so to speak, if the CoS was not so much a "professionally paranoid" organisation it would realise that it's classic tactic of playing at being victimised by situations it itself creates, it would step out of the situation and examine the fruits of it's actions.

In terms of the UK & Ireland then it is fair to say once it's involvement becomes clear then credibility of anyones legitimate claims about problem psychiatric treatment goes out the window.

Nobody responsible person believes them & therefore anyone who goes along with them how ever passively looses any traction.

CoS has been in the field for decades yet SSRI are more out of control than ever !

The evidence is clear - http://tuesday1st.blogspot.com/2011/05/ssri-snri-total-annual-prescription_17.html

Data collection reference:Department of Health; NHS; Prescription Cost Analysis (PCA) - England

you can't argue against national statistical return of prescriptions encashed at the pharmacy shop

> > > >> > > > "Awry," not "a rye" but I digress. This is exactly why I never urge> > anyone to sue. The deck is stacked against us in court and attorneys are> > looking for a quick and easy buck. No justice is to be had.> > > >> > > > Terry> > > > Sent via BlackBerry by AT & T> > > >> > > > SEROQUEL Law Firms have sold their clients> > down the river> > > >> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME> > TO> > > > REJECT this Insult on Top of Injury> > > >> > [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\> > \> > > >> > ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\> > \> > > >> > A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\> > \> > > >> > oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\> > \> > > >> > 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\> > \> > > >> > DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\> > \> > > >> > HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\> > \> > > >> > oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\> > \> > > >> > 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\> > \> > > >> > EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\> > \> > > >> > VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\> > \> > > >> > 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\> > \> > > >> > IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\> > \> > > >> > kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\> > \> > > >> > /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\> > \> > > >> > 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\> > \> > > >> > CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\> > \> > > >> > ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\> > \> > > >> > zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\> > \> > > >> > T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\> > \> > > >> > N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\> > \> > > >> > HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\> > \> > > >> > gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\> > \> > > >> > w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\> > \> > > >> > 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\> > \> > > >> > wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\> > \> > > >> > TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\> > \> > > >> > Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\> > \> > > >> > NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\> > \> > > >> > LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\> > \> > > >> > yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\> > \> > > >> > rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\> > \> > > >> > pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\> > \> > > >> > 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\> > \> > > >> > bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\> > \> > > >> > rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\> > \> > > >> > XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\> > \> > > >> > AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\> > \> > > >> > sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\> > \> > > >> > uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\> > \> > > >> > 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\> > \> > > >> > aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\> > \> > > >> > 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\> > \> > > >> > mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\> > \> > > >> > 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\> > \> > > >> > A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\> > \> > > >> > QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\> > \> > > >> > UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\> > \> > > >> > ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\> > \> > > >> > /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\> > \> > > >> > i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\> > \> > > >> > Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\> > \> > > >> > DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\> > \> > > >> > 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\> > \> > > >> > zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\> > \> > > >> > hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\> > \> > > >> > i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\> > \> > > >> > gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\> > \> > > >> > m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\> > \> > > >> > VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\> > \> > > >> > Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\> > \> > > >> > bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\> > \> > > >> > MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\> > \> > > >> > RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\> > \> > > >> > RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\> > \> > > >> > 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\> > \> > > >> > AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\> > \> > > >> > jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\> > \> > > >> > okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\> > \> > > >> > kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\> > \> > > >> > HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\> > \> > > >> > cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\> > \> > > >> > tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\> > \> > > >> > YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\> > \> > > >> > +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\> > \> > > >> > sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\> > \> > > >> > 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\> > \> > > >> > QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\> > \> > > >> > kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\> > \> > > >> > Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\> > \> > > >> > Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\> > \> > > >> > QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\> > \> > > >> > t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\> > \> > > >> > MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\> > \> > > >> > VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\> > \> > > >> > nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\> > \> > > >> > SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\> > \> > > >> > tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\> > \> > > >> > 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\> > \> > > >> > ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\> > \> > > >> > J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\> > \> > > >> > m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\> > \> > > >> > 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\> > \> > > >> > 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\> > \> > > >> > 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\> > \> > > >> > zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\> > \> > > >> > 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\> > \> > > >> > 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\> > \> > > >> > oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\> > \> > > >> > hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\> > \> > > >> > 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\> > \> > > >> > vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\> > \> > > >> > fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\> > \> > > >> > aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\> > \> > > >> > +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\> > \> > > >> > HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\> > \> > > >> > aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\> > \> > > >> > jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\> > \> > > >> > 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\> > \> > > >> > /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\> > \> > > >> > G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\> > \> > > >> > GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\> > \> > > >> > +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\> > \> > > >> > kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\> > \> > > >> > h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\> > \> > > >> > NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\> > \> > > >> > rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\> > \> > > >> > T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\> > \> > > >> > C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\> > \> > > >> > at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\> > \> > > >> > 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\> > \> > > >> > X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\> > \> > > >> > kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\> > \> > > >> > PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\> > \> > > >> > tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\> > \> > > >> > 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\> > \> > > >> > ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\> > \> > > >> > DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\> > \> > > >> > cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\> > \> > > >> > Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\> > \> > > >> > qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\> > \> > > >> > wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\> > \> > > >> > aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\> > \> > > >> > zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\> > \> > > >> > KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\> > \> > > >> > BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\> > \> > > >> > XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\> > \> > > >> > fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\> > \> > > >> > R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\> > \> > > >> > xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\> > \> > > >> > SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\> > \> > > >> > BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\> > \> > > >> > BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\> > \> > > >> > iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\> > \> > > >> > Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\> > \> > > >> > Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\> > \> > > >> > dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\> > \> > > >> > BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\> > \> > > >> > whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\> > \> > > >> > Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\> > \> > > >> > NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\> > \> > > >> > 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\> > \> > > >> > 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\> > \> > > >> > D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\> > \> > > >> > amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\> > \> > > >> > UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\> > \> > > >> > n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\> > \> > > >> > nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\> > \> > > >> > 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\> > \> > > >> > e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\> > \> > > >> > nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\> > \> > > >> > CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\> > \> > > >> > 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\> > \> > > >> > MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\> > \> > > >> > X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\> > \> > > >> > 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\> > \> > > >> > qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\> > \> > > >> > e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\> > \> > > >> > oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\> > \> > > >> > CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\> > \> > > >> > 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\> > \> > > >> > GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\> > \> > > >> > ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\> > \> > > >> > Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\> > \> > > >> > AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\> > \> > > >> > ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\> > \> > > >> > vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\> > \> > > >> > +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\> > \> > > >> > kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\> > \> > > >> > e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\> > \> > > >> > hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\> > \> > > >> > 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\> > \> > > >> > DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\> > \> > > >> > ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\> > \> > > >> > suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\> > \> > > >> > 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\> > \> > > >> > yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\> > \> > > >> > c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\> > \> > > >> > rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\> > \> > > >> > FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\> > \> > > >> > 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\> > \> > > >> > GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\> > \> > > >> > UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\> > \> > > >> > I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\> > \> > > >> > xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\> > \> > > >> > IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\> > \> > > >> > EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\> > \> > > >> > Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\> > \> > > >> > S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\> > \> > > >> > WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\> > \> > > >> > mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\> > \> > > >> > Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\> > \> > > >> > QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\> > \> > > >> > IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\> > \> > > >> > 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\> > \> > > >> > FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\> > \> > > >> > FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\> > \> > > >> > lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\> > \> > > >> > Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\> > \> > > >> > Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\> > \> > > >> > +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\> > \> > > >> > aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\> > \> > > >> > Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\> > \> > > >> > wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\> > \> > > >> > yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\> > \> > > >> > QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\> > \> > > >> > CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\> > \> > > >> > kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\> > \> > > >> > Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\> > \> > > >> > 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\> > \> > > >> > AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\> > \> > > >> > eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\> > \> > > >> > sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\> > \> > > >> > gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\> > \> > > >> > 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\> > \> > > >> > hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\> > \> > > >> > KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\> > \> > > >> > 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\> > \> > > >> > /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\> > \> > > >> > 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\> > \> > > >> > qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\> > \> > > >> > LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\> > \> > > >> > iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\> > \> > > >> > wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\> > \> > > >> > A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\> > \> > > >> > A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\> > \> > > >> > 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\> > \> > > >> > h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\> > \> > > >> > X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\> > \> > > >> > TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\> > \> > > >> > kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\> > \> > > >> > SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\> > \> > > >> > mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\> > \> > > >> > 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\> > \> > > >> > XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\> > \> > > >> > U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\> > \> > > >> > +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\> > \> > > >> > SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\> > \> > > >> > WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\> > \> > > >> > gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\> > \> > > >> > YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\> > \> > > >> > tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\> > \> > > >> > HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\> > \> > > >> > bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\> > \> > > >> > ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\> > \> > > >> > IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\> > \> > > >> > HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\> > \> > > >> > wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\> > \> > > >> > NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\> > \> > > >> > 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\> > \> > > >> > n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\> > \> > > >> > kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\> > \> > > >> > X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\> > \> > > >> > rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\> > \> > > >> > x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\> > \> > > >> > Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\> > \> > > >> > tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\> > \> > > >> > Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\> > \> > > >> > fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\> > \> > > >> > UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\> > \> > > >> > xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\> > \> > > >> > IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\> > \> > > >> > 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\> > \> > > >> > fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\> > \> > > >> > Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\> > \> > > >> > 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\> > \> > > >> > iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\> > \> > > >> > oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\> > \> > > >> > KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\> > \> > > >> > 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\> > \> > > >> > RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\> > \> > > > ElFTkSuQmCC]> > > >> > > >> > > >> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME> > TO> > > > REJECT this Insult on Top of Injury> > > > I would like to thank a brave, courageous, and ethical anonymous> > source> > > > who has send in this letter correspondence they received from the> > law> > > > firm of Weitz & Luxenberg. This letter doesn't require a whole lot> > of> > > > commentary.> > > > It's obvious that Law Firms have sold their clients down the> > proverbial> > > > river while at the same time enriching themselves (who's best> > interest> > > > are you obligated too fulfill?). This settlement offer and the> > injured> > > > litigants legal representation has carried out a blatant miscarriage> > of> > > > justice, a forever horrible stain upon the American Justice system,> > and> > > > a orchestrated crime perpetrated upon victims of this well> > documented & > > > > evidenced unbridled & unregulated corporate criminal enterprise gone> > a> > > > rye.> > > > The time has now come for the victims to stand up to this criminal> > > > corporation "AstraZeneca" & their poison drug "Seroquel", to reject> > this> > > > horrible injustice and settlement offer. We want, what America & our> > > > Constitution promises us all, our day in court before a jury of our> > > > peers....> > > > ____________________________________________________________> > > >> > > > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>> > > > We are happy to report excellent news! After a long and hard fought> > > > legal battle, AstraZeneca has agreed to participate in a Settlement> > > > Program to resolve Weitz & Luxenberg ("W & L") Seroguel cases. Our> > > > patience and aggressive litigating has resulted in very favorable> > > > settlement terms for our clients which will be further outlined> > below.> > > > We have carefully reviewed all of the factors of this agreement and> > we> > > > believe that this settlement offers you the best, and very likely> > the> > > > only opportunity to receive a fair resolution of your lawsuit.> > > > Therefore, we strongly recommend that you sign and complete the> > enclosed> > > > "Release Form", "Track Selection Form" and "Brief Questionnaire" and> > > > AGREE to participate.> > > > As you know, we have engaged in a long legal battle with AstraZeneca> > > > over the past 6 years. Weitz & Luxenberg led the charge for the> > > > Plaintiffs around the Country. AstraZeneca put up a tremendous and> > > > expensive defense and they successfully were able to get a large> > number> > > > of cases to be permanently dismissed by the court. Weitz & Luxenberg> > is> > > > the only firm who took a case to trial anywhere in the Country.> > However,> > > > after a month-long trial, the jury unfortunately ruled in favor of> > the> > > > defendants. This loss did not affect the strength of our fight. Over> > the> > > > past year, even as almost every other plaintiffs firm settled their> > > > cases, Weitz & Luxenberg prepared two more cases for trial which was> > > > scheduled to begin this Summer. As a direct result of the endless> > and> > > > consistent pressure applied by the attorneys at Weitz & Luxenberg,> > we> > > > are happy to report that AstraZeneca has now agreed to participate> > in a> > > > favorable settlement program. Based on public reports regarding> > > > settlement programs reached with other plaintiff law firms we are> > > > confident that the settlement program outlined below has more> > favorable> > > > terms and for this reason we are recommending your participation.> > > > The defendants have argued that they refuse to pay anyone who cannot> > > > prove through medical records or via certification that they have> > used> > > > Seroquel. They also refuse to pay anyone whose case is not active in> > > > this litigation. We recently told you about the Order issued by the> > > > Court requiring you to confirm when you started taking Seroquel and> > when> > > > you stopped taking Seroquel. We cannot stress enough that you MUST> > read,> > > > complete and return this certification form to us immediately. The> > > > failure to return this form within the next 30 days will result in> > the> > > > permanent dismissal of your case. In order to protect your legal> > rights,> > > > to keep your case active and be permitted to participate in this> > > > Settlement Program you must take this Order very seriously and you> > must> > > > respond.> > > > Based on our experience in other litigations and having reviewed the> > > > media reports of the terms of other firms' Seroquel settlement> > programs,> > > > we know that the defendants are looking for a settlement program> > that> > > > includes all claimants (W & L Seroquel Plaintiffs) so that they will> > > > achieve complete closure of the entirYlitigation. Our goal in this> > > > negotiation was to obtain a settlement for the most amount of money> > > > using a fair method to pay our clients based upon the merits of> > their> > > > individual case. We also stressed our intentions that the case> > review> > > > and payment process be performed quickly yet fairly so that our> > clients> > > > can receive their settlements as soon as possible. A key part of> > this> > > > settlement program is that a claimant cannot be part of the> > settlement> > > > if their case is dismissed and unless they provide, at the very> > least, a> > > > certification that they in fact took Seroquel and suffered an> > injury.> > > > Therefore, please make sure that you return your certification form> > to> > > > us immediately> > > >> > > > We have hired Hon.Marina Corodemus to act as the Special Master for> > the> > > > W & L Seroquel settlement program. Judge Corodemus previously ran the> > New> > > > Jersey Mass Tort Court and has a lot of experience in this field.> > She> > > > was appointed as a Special Master by the Vioxx State and Federal> > Court> > > > Judges to determine the appropriateness of Vioxx settlements and to> > > > resolve Vioxx appeals. She has also served as the Special Master in> > many> > > > other litigations such as Bextra and Celebrex which used similar> > > > settlement terms. We have met several times with Judge Corodemus and> > > > discussed the goals outlined above to get the most amount of money> > to> > > > the most amount of claimants in the fastest amount of time possible.> > We> > > > believe that Judge Corodemus is the perfect choice to create and> > oversee> > > > a settlement program in accordance with these goals. The W & L> > Seroquel> > > > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only> > > > those clients with active cases (not dismissed as outlined above)> > can> > > > participate in this settlement program. Unlike other settlement> > programs> > > > that you may have read about in the media and internet, the W & L> > > > Settlement program does not award every case an equal settlement> > amount.> > > > The size of an individual's settlement will depend entirely on the> > merit> > > > of that individual's case. As a direct result of the large number of> > > > cases represented by W & L, and the merits of those cases, we are> > > > confident that we have obtained the best possible settlement for our> > > > clients. After complex negotiations, AstraZeneca> > > > has agreed to deposit $92.25 Million dollars into a trust account to> > be> > > > used for this Settlement Program. This amount is completely> > confidential> > > > and you should NOT discuss this with anyone. A settlement of this> > type> > > > is called an "Aggregate Settlement" where a fair and reasonable sum> > of> > > > money is obtained to resolve multiple cases. In order to maintain> > proper> > > > representation of each individual client, W & L is NOT involved in> > the> > > > allocation decision making, which will be handled exclusively by> > Judge> > > > Corodemus. W & L has reviewed the general framework of the settlement> > > > plan with Judge Corodemus and we strongly believe that it is fair> > and> > > > reasonable and offers each of our clients the best possible outcome> > > > under the circumstances of this litigation. Track I offers the> > Seroquel> > > > claimant a settlement of $12,000. This track involves a simple> > review of> > > > each case and will result in a quick approval by Judge Corodemus> > without> > > > an analysis of the specific details of the case such as injury,> > amount> > > > of Seroquel taken, how close the last Seroquel use was to the date> > of> > > > the injury or the individual claimant's risk factors. a) Cannot> > > > prove that they suffered diabetes or a diabetes related condition,> > > > and/or Cannot prove that they used Seroquel within 1 year of> > > > their claimed injury, and/or c) Had a large number of known> > > > risk factors for diabetes before they started taking Seroquel. For> > > > example - obesity, family history, smoking, etc.> > > >> > > > Therefore, all cases whose injuries are limited to weight gain or> > high> > > > blood sugar and whose medical records will confirm that they were> > never> > > > diagnosed with diabetes or pancreatitis, should choose Track 1.> > > > Similarly, any claimed injury that occurred long after the last use> > of> > > > Seroquel should also choose Track 1. These cases are likely to> > receive a> > > > small award in Track II (likely less than $12,000) because it is> > > > extremely difficult to prove that these injuries were caused by> > > > Seroquel. Therefore, we suggest that if your case falls into this> > > > category you should choose Track 1. Additionally, payment of Track I> > > > settlement awards will be processed first once AstaZeneca waives its> > > > "walk away right". (See Section IV© below) Track II involves an> > > > in-depth review of the severity of the injury, the claimed use of> > > > Seroquel and its proximity to the injury as well the available proof> > > > found in the contemporaneous medical records. Additionally, Judge> > > > Corodemus will strongly consider many known risk factors for these> > > > injuries including but not limited to smoking, obesity and family> > > > history as well as the participation in the Zyprexa settlement for> > these> > > > same injuries. This model is very similar to the one used in the> > > > National Vioxx Settlement Program as well as dozens of other similar> > > > settlement programs which were successfully resolved in recent> > years.> > > > Judge Corodemus has established a points system and will consider> > all of> > > > the critical issues including but not limited to:> > > > - Nature of the injury - Severity of the injury - Age at the time of> > > > injury - Proximity of Seroquel use to the claimed injury - Changes> > in> > > > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,> > > > etc. After carefully reviewing all of the medical records and the> > > > individual fact sheet, Judge Corodemus will assign a point value to> > each> > > > case. The more points a case is awarded based on the specific facts> > of> > > > the case, the larger the settlement will be. At this time, there is> > no> > > > way to predict with accuracy how many points an individual case may> > be> > > > awarded and it is even more difficult to determine how much money> > each> > > > point will receive. The exact value of each point will depend on the> > > > number of participants in Track II and the total number of points> > > > assigned. All cases in Track II will be eligible for a settlement> > award> > > > but Judge Corodemus could award LESS than $12,000 (what people will> > > > receive automatically by choosing Track 1) if the case lacks merit.> > In> > > > the interest of fairness, Judge Corodemus has committed to review> > each> > > > case in Track II very carefully and this process will take time to> > > > complete. Judge Corodemus has stated that she hopes to have this> > process> > > > completed by the end of 2011 but please be warned that it could take> > a> > > > little longer due to the amount of work that is involved. However,> > in> > > > order to get this settlement process moving forward and ultimately> > paid> > > > you must send us your signed Release form as soon as possible. If> > you> > > > choose Track I your settlement award of $12,000 is set. If you> > choose> > > > Track II, Judge Corodemus will review your claim and will issue an> > > > award. We expect that we will contact you in approximately November> > 2011> > > > and notify you of your point award and the expected amount of your> > > > settlement. At that point, you will be given a choice to accept your> > > > award, appeal your award or withdraw from the settlement program. If> > you> > > > accept, we will forward your release to AstraZeneca for their review> > and> > > > approval. Please understand that this settlement is not official> > until> > > > we send AstraZeneca your signed Release Form, AstraZeneca approves> > it> > > > AND AstraZeneca waives its walk away right. In the interest of time,> > we> > > > are asking you to return your signed Release Form now so we can meet> > the> > > > tight deadlines associated with this settlement. If you are unhappy> > with> > > > your allocation amount and/or believe that your case involves> > > > "Extraordinary Injury or Circumstances" you have the right to appeal> > > > your award. Upon receipt of such an application, Judge Corodemus> > will> > > > re-review your records and make a final decision. Please be aware> > that> > > > there is no additional right of appeal (to Judge Corodemus or to any> > > > Court) once this final decision is made. If you decide to decline> > the> > > > settlement amount offered to you, you must notify us within ten days> > of> > > > your receipt of your allocation amount and your signed Release Form> > will> > > > no longer be valid. As in all settlements of this type, our> > agreement> > > > with the defendant depends on nearly full participation from all of> > our> > > > clients. Under the terms of our agreement, we must provide> > Qualifying> > > > Materials (Release Form and/or Dismissal) for 2,260 of our clients.> > Once> > > > we reach this number, AstraZeneca's "walk away right" is officially> > > > waived. We strongly believe that our clients will agree that this> > > > settlement program offers the best possible terms and we expect that> > we> > > > will meet this requirement in the next 90-120 days. In order to meet> > > > this deadline we MUST have your complete> > > > cooperation and immediate response. Of course, if we do not meet> > this> > > > required number of responses, Astrazeneca can decide to withdraw its> > > > settlement offer to everyone whether one signed the Release Form or> > not.> > > > Therefore, time is of the essence. A. Release Form: Enclosed you> > will> > > > find a Release Form which you must sign in front of a notary in> > Order to> > > > participate in the settlement. If you have a spouse he/she must sign> > the> > > > Release Form as well. Attached to the Release Form will be an> > > > instruction sheet to guide you to ensure that this important form is> > > > signed the right way. A Release Form that is signed the wrong way or> > > > that is not witnessed (by a notary) is useless and will not be> > accepted> > > > by the defendants. The Release Form is your agreement to participate> > in> > > > the settlement program and at the same time discontinue your lawsuit> > in> > > > exchange for your settlement award. Please turn to Page 2 of the> > Release> > > > Form and complete the details of your Seroquel use. You may refer to> > > > Page 1 of the Brief Questionnaire which lists the Seroquel> > information> > > > that was found in your medical records or that you have previously> > > > provided to us. If this information is inaccurate, please cross it> > out> > > > and write in when you started and when you stopped taking Seroquel> > on> > > > BOTH the Release Form and the Brief Questionnaire. Due to the fast> > > > approaching deadlines, and our goal to get you your settlement> > processed> > > > and paid as quickly as possible, we MUST receive this signed release> > > > form back from you before August 31, 2011. Please use the envelope> > > > provided herein and return the signed and notarized release form> > today> > > > before you forget about it. Please note that once we submit your> > release> > > > form to AstraZeneca it can not be revoked. B. Track Selection Form:> > > > Enclosed you will find a "Track Selection Form" which is the form> > used> > > > to officially notify the Special Master which Track you want your> > case> > > > to follow. Please Note that there are 4 options on this form. You> > MUST> > > > check one of the Options. If you want to participate in this> > settlement,> > > > and we strongly think that you should, you must check either Track I> > OR> > > > Track II and you must sign the bottom of the form. Your Track> > selection> > > > cannot be changed and is considered final once the Judge's> > Allocations> > > > are made. In other words, a person who chooses Track II and is> > awarded> > > > less than $12,000 CANNOT then choose to go to Track 1 for a higher> > > > award. C. Brief Questionnaire: Enclosed you will find a 3> > > > page Brief Questionnaire which has important information about your> > > > claim. For all claimants who choose to enter Track II, Judge> > Corodemus> > > > will be reviewing your medical records, your Fact Sheet and this> > Brief> > > > Questionnaire and will issue a point award. Judge Corodemus will> > > > consider the proof of your claim found in your medical records as> > well> > > > as the information that you provide in this Questionnaire.> > Therefore, it> > > > is important that you answer these questions honestly and completely> > and> > > > that they are consistent with what is found in your medical records.> > > > litigation and our conversations with our medical experts, it is> > clear> > > > that Seroquel lawsuits are very difficult to win, very expensive,> > and> > > > very time consuming to take through to trial, verdict and appeal.> > Over> > > > the past six years only I case (from W & L) of24,000 cases in the> > Country> > > > made it to and through trial. Countless other cases were prepared> > and> > > > then dismissed based on merit and/or inability to prove that> > Seroquel> > > > caused the injury. Just because an individual took Seroquel and> > suffered> > > > an injury like diabetes does not mean that such a case will win at> > > > trial. In order to succeed at trial, a plaintiff must prove both> > that> > > > Seroquel can cause such an injury in general AND that, within a> > > > reasonable degree of medical certainty, Seroquel caused this injury> > to> > > > this particular person (despite any individual risk factors such as> > > > smoking, weight, high blood sugar, family history etc.). We have> > told> > > > you in the past update letters that the Courts have consistently> > ruled> > > > in favor of the defendants on many of these issues and have> > prohibited> > > > medical experts from testifying because of a lack of scientific> > proof> > > > linking the plaintiff s injuries to his/her Seroquel use. It is also> > > > important to note that even if your case is able to advance past> > this> > > > judicial scrutiny, a trial of this magnitude will cost over $750,000> > per> > > > case and many of these costs are reimbursed off of the top of a> > > > favorable verdict reducing the amount received by the plaintiff.> > > > Furthermore, any case that is won at trial will surely face a> > lengthy> > > > and hard-fought appeal. Finally, nearly all of the Seroquel cases> > are> > > > being handled by three judges. Even at an accelerated pace, the> > chances> > > > are slim that your case would be tried in the next 10 years if not> > > > longer. In taking all of these factors into consideration, and> > > > considering the issues of risk and reward, we believe that a> > settlement> > > > of this type offers you the most advantageous resolution possible.> > You> > > > will be notified once the Special Master issues your point award at> > > > which point you can appeal to the Special Master if you believe that> > > > your case involves extraordinary circumstances. Thereafter, the> > decision> > > > of the Special Master is final, binding and non-appealable. We have> > > > retained the Garretson Law Firm to negotiate any and all Federal and> > > > State liens (Medicare/Medicaid/SSI) that may be applicable in your> > case.> > > > The Garretson Firm is a specialist in this field and they have> > obtained> > > > excellent results in their negotiation of similar liens in other> > > > litigations like Vioxx, Bextra, and Celebrex. Moreover, the> > Garretson> > > > Firm has already worked on thousands of other Seroquel cases and has> > > > been able to achieve excellent results in large part due to the> > volume> > > > of cases that they are able to include in a Global Resolution. At> > this> > > > time, the Garretson Firm has already negotiated with 44 individual> > > > states regarding Medicaid and they have reached an agreement to CAP> > > > Medicaid liens at a maximum of 20% of the settlement amount. Please> > see> > > > the enclosed blue booklet regarding governmental liens for more> > details.> > > > Additionally, please also be advised that if you or Weitz & > > Luxenberg> > > > are put on written notice of a private lien, for example from your> > > > medical provider, this lien must be resolved before any settlement> > > > proceeds can be distributed. If you have received any notice of a> > lien,> > > > please advise us immediately. The terms of your signed contingency> > fee> > > > agreement will be in effect. We have taken great effort to keep the> > case> > > > specific expenses as low as possible. Under the terms of your> > agreement,> > > > the> > > > contingency fee will be calculated after the expenses are deducted.> > > > Under the terms of our agreement with AstraZeneca, any interest> > earned> > > > on the settlement proceeds before allocation and payment to the> > > > individual clients will be used to offset the fixed costs of the> > Special> > > > Master and the Lien Administrator. Due to the low interest rates> > paid by> > > > all banks in this economy, we do not expect that there will be any> > > > leftover interest. However, in such a case, the leftover interest> > will> > > > be added to the settlement trust and will be distributed to all> > > > claimants as part of Judge Corodemus' allocation process. After> > careful> > > > analysis of the likelihood of success in the court system, as well> > as> > > > the cost and time elements involved, we strongly recommend that you> > > > AGREE to participate in this settlement. We are confident that this> > > > settlement is the best possible resolution of your claim especially> > in> > > > light of the history of this litigation. We expect that any case> > that> > > > does not agree to participate in this settlement will have a very> > > > difficult time navigating through the Court system and trial dates> > may> > > > not be set for many years. Moreover, as we have seen, these cases> > will> > > > be aggressively defended by AstraZeneca and we expect that we will> > > > receive motions to dismiss and unfavorable decisions from the Court> > on> > > > unsettled cases in the coming months. Moreover, if this settlement> > > > program is not successful (we fail to reach the 98% response rate)> > we> > > > highly doubt that we will ever obtain a settlement amount and terms> > as> > > > good as those contained in this program. While we hope that this> > letter> > > > and enclosures will help answer all of your questions, we understand> > > > that you may have additional questions for us. Please keep in mind> > that> > > > we are working very hard to evaluate each and every case> > individually> > > > and the many deadlines that are part of this settlement are fast> > > > approaching. Your case has been assigned to Judy Koenig. If you have> > an> > > > important question please call Judy Koenig at (800) 438-9786 and ask> > for> > > > extension 5860. If you reach a voice-mail, please leave a message> > and> > > > you will be called back as quickly as possible. Please do not leave> > > > multiple voicemail messages on the same day as that will slow down> > our> > > > ability to return your call. Additionally, if you have email access,> > > > please try to email your detailed questions to us at sqinfo@> > > > <mailto:sqinfo@ and we will get back to you quickly. If> > > > this letter has successfully answered your questions, and you have> > > > decided to participate, please carefully follow the directions on> > the> > > > front page of the enclosed release form and send your signed and> > > > witnessed release formes), your Track Selection AND your Brief> > > > Questionnaire to us as soon as possible. If you still have questions> > > > after reviewing this letter and after speaking to us over the> > telephone> > > > and you would like to meet us in person, we will be happy to> > schedule a> > > > meeting in our office at your convenience. Finally, please remember> > that> > > > the detailed information regarding this settlement program is> > COMPLETELY> > > > CONFIDENTIAL and should not be shared or discussed with anyone.> > > > > > Sedgh, Esq Glenn Zuckerman, Esq.> > > >> > >> >>

[Guest guest]

Far from throwing mud on the windscreen, so to speak, if the CoS was not so much a "professionally paranoid" organisation it would realise that it's classic tactic of playing at being victimised by situations it itself creates, it would step out of the situation and examine the fruits of it's actions.

In terms of the UK & Ireland then it is fair to say once it's involvement becomes clear then credibility of anyones legitimate claims about problem psychiatric treatment goes out the window.

Nobody responsible person believes them & therefore anyone who goes along with them how ever passively looses any traction.

CoS has been in the field for decades yet SSRI are more out of control than ever !

The evidence is clear - http://tuesday1st.blogspot.com/2011/05/ssri-snri-total-annual-prescription_17.html

Data collection reference:Department of Health; NHS; Prescription Cost Analysis (PCA) - England

you can't argue against national statistical return of prescriptions encashed at the pharmacy shop

> > > >> > > > "Awry," not "a rye" but I digress. This is exactly why I never urge> > anyone to sue. The deck is stacked against us in court and attorneys are> > looking for a quick and easy buck. No justice is to be had.> > > >> > > > Terry> > > > Sent via BlackBerry by AT & T> > > >> > > > SEROQUEL Law Firms have sold their clients> > down the river> > > >> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME> > TO> > > > REJECT this Insult on Top of Injury> > > >> > [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\> > \> > > >> > ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\> > \> > > >> > A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\> > \> > > >> > oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\> > \> > > >> > 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\> > \> > > >> > DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\> > \> > > >> > HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\> > \> > > >> > oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\> > \> > > >> > 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\> > \> > > >> > EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\> > \> > > >> > VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\> > \> > > >> > 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\> > \> > > >> > IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\> > \> > > >> > kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\> > \> > > >> > /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\> > \> > > >> > 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\> > \> > > >> > CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\> > \> > > >> > ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\> > \> > > >> > zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\> > \> > > >> > T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\> > \> > > >> > N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\> > \> > > >> > HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\> > \> > > >> > gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\> > \> > > >> > w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\> > \> > > >> > 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\> > \> > > >> > wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\> > \> > > >> > TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\> > \> > > >> > Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\> > \> > > >> > NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\> > \> > > >> > LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\> > \> > > >> > yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\> > \> > > >> > rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\> > \> > > >> > pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\> > \> > > >> > 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\> > \> > > >> > bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\> > \> > > >> > rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\> > \> > > >> > XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\> > \> > > >> > AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\> > \> > > >> > sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\> > \> > > >> > uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\> > \> > > >> > 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\> > \> > > >> > aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\> > \> > > >> > 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\> > \> > > >> > mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\> > \> > > >> > 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\> > \> > > >> > A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\> > \> > > >> > QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\> > \> > > >> > UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\> > \> > > >> > ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\> > \> > > >> > /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\> > \> > > >> > i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\> > \> > > >> > Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\> > \> > > >> > DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\> > \> > > >> > 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\> > \> > > >> > zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\> > \> > > >> > hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\> > \> > > >> > i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\> > \> > > >> > gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\> > \> > > >> > m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\> > \> > > >> > VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\> > \> > > >> > Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\> > \> > > >> > bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\> > \> > > >> > MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\> > \> > > >> > RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\> > \> > > >> > RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\> > \> > > >> > 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\> > \> > > >> > AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\> > \> > > >> > jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\> > \> > > >> > okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\> > \> > > >> > kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\> > \> > > >> > HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\> > \> > > >> > cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\> > \> > > >> > tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\> > \> > > >> > YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\> > \> > > >> > +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\> > \> > > >> > sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\> > \> > > >> > 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\> > \> > > >> > QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\> > \> > > >> > kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\> > \> > > >> > Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\> > \> > > >> > Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\> > \> > > >> > QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\> > \> > > >> > t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\> > \> > > >> > MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\> > \> > > >> > VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\> > \> > > >> > nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\> > \> > > >> > SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\> > \> > > >> > tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\> > \> > > >> > 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\> > \> > > >> > ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\> > \> > > >> > J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\> > \> > > >> > m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\> > \> > > >> > 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\> > \> > > >> > 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\> > \> > > >> > 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\> > \> > > >> > zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\> > \> > > >> > 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\> > \> > > >> > 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\> > \> > > >> > oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\> > \> > > >> > hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\> > \> > > >> > 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\> > \> > > >> > vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\> > \> > > >> > fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\> > \> > > >> > aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\> > \> > > >> > +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\> > \> > > >> > HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\> > \> > > >> > aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\> > \> > > >> > jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\> > \> > > >> > 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\> > \> > > >> > /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\> > \> > > >> > G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\> > \> > > >> > GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\> > \> > > >> > +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\> > \> > > >> > kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\> > \> > > >> > h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\> > \> > > >> > NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\> > \> > > >> > rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\> > \> > > >> > T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\> > \> > > >> > C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\> > \> > > >> > at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\> > \> > > >> > 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\> > \> > > >> > X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\> > \> > > >> > kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\> > \> > > >> > PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\> > \> > > >> > tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\> > \> > > >> > 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\> > \> > > >> > ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\> > \> > > >> > DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\> > \> > > >> > cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\> > \> > > >> > Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\> > \> > > >> > qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\> > \> > > >> > wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\> > \> > > >> > aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\> > \> > > >> > zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\> > \> > > >> > KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\> > \> > > >> > BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\> > \> > > >> > XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\> > \> > > >> > fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\> > \> > > >> > R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\> > \> > > >> > xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\> > \> > > >> > SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\> > \> > > >> > BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\> > \> > > >> > BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\> > \> > > >> > iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\> > \> > > >> > Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\> > \> > > >> > Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\> > \> > > >> > dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\> > \> > > >> > BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\> > \> > > >> > whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\> > \> > > >> > Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\> > \> > > >> > NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\> > \> > > >> > 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\> > \> > > >> > 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\> > \> > > >> > D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\> > \> > > >> > amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\> > \> > > >> > UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\> > \> > > >> > n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\> > \> > > >> > nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\> > \> > > >> > 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\> > \> > > >> > e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\> > \> > > >> > nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\> > \> > > >> > CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\> > \> > > >> > 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\> > \> > > >> > MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\> > \> > > >> > X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\> > \> > > >> > 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\> > \> > > >> > qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\> > \> > > >> > e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\> > \> > > >> > oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\> > \> > > >> > CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\> > \> > > >> > 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\> > \> > > >> > GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\> > \> > > >> > ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\> > \> > > >> > Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\> > \> > > >> > AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\> > \> > > >> > ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\> > \> > > >> > vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\> > \> > > >> > +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\> > \> > > >> > kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\> > \> > > >> > e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\> > \> > > >> > hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\> > \> > > >> > 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\> > \> > > >> > DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\> > \> > > >> > ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\> > \> > > >> > suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\> > \> > > >> > 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\> > \> > > >> > yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\> > \> > > >> > c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\> > \> > > >> > rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\> > \> > > >> > FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\> > \> > > >> > 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\> > \> > > >> > GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\> > \> > > >> > UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\> > \> > > >> > I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\> > \> > > >> > xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\> > \> > > >> > IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\> > \> > > >> > EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\> > \> > > >> > Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\> > \> > > >> > S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\> > \> > > >> > WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\> > \> > > >> > mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\> > \> > > >> > Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\> > \> > > >> > QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\> > \> > > >> > IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\> > \> > > >> > 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\> > \> > > >> > FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\> > \> > > >> > FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\> > \> > > >> > lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\> > \> > > >> > Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\> > \> > > >> > Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\> > \> > > >> > +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\> > \> > > >> > aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\> > \> > > >> > Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\> > \> > > >> > wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\> > \> > > >> > yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\> > \> > > >> > QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\> > \> > > >> > CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\> > \> > > >> > kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\> > \> > > >> > Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\> > \> > > >> > 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\> > \> > > >> > AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\> > \> > > >> > eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\> > \> > > >> > sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\> > \> > > >> > gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\> > \> > > >> > 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\> > \> > > >> > hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\> > \> > > >> > KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\> > \> > > >> > 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\> > \> > > >> > /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\> > \> > > >> > 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\> > \> > > >> > qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\> > \> > > >> > LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\> > \> > > >> > iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\> > \> > > >> > wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\> > \> > > >> > A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\> > \> > > >> > A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\> > \> > > >> > 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\> > \> > > >> > h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\> > \> > > >> > X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\> > \> > > >> > TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\> > \> > > >> > kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\> > \> > > >> > SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\> > \> > > >> > mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\> > \> > > >> > 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\> > \> > > >> > XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\> > \> > > >> > U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\> > \> > > >> > +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\> > \> > > >> > SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\> > \> > > >> > WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\> > \> > > >> > gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\> > \> > > >> > YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\> > \> > > >> > tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\> > \> > > >> > HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\> > \> > > >> > bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\> > \> > > >> > ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\> > \> > > >> > IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\> > \> > > >> > HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\> > \> > > >> > wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\> > \> > > >> > NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\> > \> > > >> > 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\> > \> > > >> > n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\> > \> > > >> > kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\> > \> > > >> > X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\> > \> > > >> > rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\> > \> > > >> > x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\> > \> > > >> > Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\> > \> > > >> > tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\> > \> > > >> > Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\> > \> > > >> > fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\> > \> > > >> > UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\> > \> > > >> > xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\> > \> > > >> > IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\> > \> > > >> > 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\> > \> > > >> > fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\> > \> > > >> > Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\> > \> > > >> > 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\> > \> > > >> > iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\> > \> > > >> > oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\> > \> > > >> > KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\> > \> > > >> > 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\> > \> > > >> > RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\> > \> > > > ElFTkSuQmCC]> > > >> > > >> > > >> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME> > TO> > > > REJECT this Insult on Top of Injury> > > > I would like to thank a brave, courageous, and ethical anonymous> > source> > > > who has send in this letter correspondence they received from the> > law> > > > firm of Weitz & Luxenberg. This letter doesn't require a whole lot> > of> > > > commentary.> > > > It's obvious that Law Firms have sold their clients down the> > proverbial> > > > river while at the same time enriching themselves (who's best> > interest> > > > are you obligated too fulfill?). This settlement offer and the> > injured> > > > litigants legal representation has carried out a blatant miscarriage> > of> > > > justice, a forever horrible stain upon the American Justice system,> > and> > > > a orchestrated crime perpetrated upon victims of this well> > documented & > > > > evidenced unbridled & unregulated corporate criminal enterprise gone> > a> > > > rye.> > > > The time has now come for the victims to stand up to this criminal> > > > corporation "AstraZeneca" & their poison drug "Seroquel", to reject> > this> > > > horrible injustice and settlement offer. We want, what America & our> > > > Constitution promises us all, our day in court before a jury of our> > > > peers....> > > > ____________________________________________________________> > > >> > > > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>> > > > We are happy to report excellent news! After a long and hard fought> > > > legal battle, AstraZeneca has agreed to participate in a Settlement> > > > Program to resolve Weitz & Luxenberg ("W & L") Seroguel cases. Our> > > > patience and aggressive litigating has resulted in very favorable> > > > settlement terms for our clients which will be further outlined> > below.> > > > We have carefully reviewed all of the factors of this agreement and> > we> > > > believe that this settlement offers you the best, and very likely> > the> > > > only opportunity to receive a fair resolution of your lawsuit.> > > > Therefore, we strongly recommend that you sign and complete the> > enclosed> > > > "Release Form", "Track Selection Form" and "Brief Questionnaire" and> > > > AGREE to participate.> > > > As you know, we have engaged in a long legal battle with AstraZeneca> > > > over the past 6 years. Weitz & Luxenberg led the charge for the> > > > Plaintiffs around the Country. AstraZeneca put up a tremendous and> > > > expensive defense and they successfully were able to get a large> > number> > > > of cases to be permanently dismissed by the court. Weitz & Luxenberg> > is> > > > the only firm who took a case to trial anywhere in the Country.> > However,> > > > after a month-long trial, the jury unfortunately ruled in favor of> > the> > > > defendants. This loss did not affect the strength of our fight. Over> > the> > > > past year, even as almost every other plaintiffs firm settled their> > > > cases, Weitz & Luxenberg prepared two more cases for trial which was> > > > scheduled to begin this Summer. As a direct result of the endless> > and> > > > consistent pressure applied by the attorneys at Weitz & Luxenberg,> > we> > > > are happy to report that AstraZeneca has now agreed to participate> > in a> > > > favorable settlement program. Based on public reports regarding> > > > settlement programs reached with other plaintiff law firms we are> > > > confident that the settlement program outlined below has more> > favorable> > > > terms and for this reason we are recommending your participation.> > > > The defendants have argued that they refuse to pay anyone who cannot> > > > prove through medical records or via certification that they have> > used> > > > Seroquel. They also refuse to pay anyone whose case is not active in> > > > this litigation. We recently told you about the Order issued by the> > > > Court requiring you to confirm when you started taking Seroquel and> > when> > > > you stopped taking Seroquel. We cannot stress enough that you MUST> > read,> > > > complete and return this certification form to us immediately. The> > > > failure to return this form within the next 30 days will result in> > the> > > > permanent dismissal of your case. In order to protect your legal> > rights,> > > > to keep your case active and be permitted to participate in this> > > > Settlement Program you must take this Order very seriously and you> > must> > > > respond.> > > > Based on our experience in other litigations and having reviewed the> > > > media reports of the terms of other firms' Seroquel settlement> > programs,> > > > we know that the defendants are looking for a settlement program> > that> > > > includes all claimants (W & L Seroquel Plaintiffs) so that they will> > > > achieve complete closure of the entirYlitigation. Our goal in this> > > > negotiation was to obtain a settlement for the most amount of money> > > > using a fair method to pay our clients based upon the merits of> > their> > > > individual case. We also stressed our intentions that the case> > review> > > > and payment process be performed quickly yet fairly so that our> > clients> > > > can receive their settlements as soon as possible. A key part of> > this> > > > settlement program is that a claimant cannot be part of the> > settlement> > > > if their case is dismissed and unless they provide, at the very> > least, a> > > > certification that they in fact took Seroquel and suffered an> > injury.> > > > Therefore, please make sure that you return your certification form> > to> > > > us immediately> > > >> > > > We have hired Hon.Marina Corodemus to act as the Special Master for> > the> > > > W & L Seroquel settlement program. Judge Corodemus previously ran the> > New> > > > Jersey Mass Tort Court and has a lot of experience in this field.> > She> > > > was appointed as a Special Master by the Vioxx State and Federal> > Court> > > > Judges to determine the appropriateness of Vioxx settlements and to> > > > resolve Vioxx appeals. She has also served as the Special Master in> > many> > > > other litigations such as Bextra and Celebrex which used similar> > > > settlement terms. We have met several times with Judge Corodemus and> > > > discussed the goals outlined above to get the most amount of money> > to> > > > the most amount of claimants in the fastest amount of time possible.> > We> > > > believe that Judge Corodemus is the perfect choice to create and> > oversee> > > > a settlement program in accordance with these goals. The W & L> > Seroquel> > > > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only> > > > those clients with active cases (not dismissed as outlined above)> > can> > > > participate in this settlement program. Unlike other settlement> > programs> > > > that you may have read about in the media and internet, the W & L> > > > Settlement program does not award every case an equal settlement> > amount.> > > > The size of an individual's settlement will depend entirely on the> > merit> > > > of that individual's case. As a direct result of the large number of> > > > cases represented by W & L, and the merits of those cases, we are> > > > confident that we have obtained the best possible settlement for our> > > > clients. After complex negotiations, AstraZeneca> > > > has agreed to deposit $92.25 Million dollars into a trust account to> > be> > > > used for this Settlement Program. This amount is completely> > confidential> > > > and you should NOT discuss this with anyone. A settlement of this> > type> > > > is called an "Aggregate Settlement" where a fair and reasonable sum> > of> > > > money is obtained to resolve multiple cases. In order to maintain> > proper> > > > representation of each individual client, W & L is NOT involved in> > the> > > > allocation decision making, which will be handled exclusively by> > Judge> > > > Corodemus. W & L has reviewed the general framework of the settlement> > > > plan with Judge Corodemus and we strongly believe that it is fair> > and> > > > reasonable and offers each of our clients the best possible outcome> > > > under the circumstances of this litigation. Track I offers the> > Seroquel> > > > claimant a settlement of $12,000. This track involves a simple> > review of> > > > each case and will result in a quick approval by Judge Corodemus> > without> > > > an analysis of the specific details of the case such as injury,> > amount> > > > of Seroquel taken, how close the last Seroquel use was to the date> > of> > > > the injury or the individual claimant's risk factors. a) Cannot> > > > prove that they suffered diabetes or a diabetes related condition,> > > > and/or Cannot prove that they used Seroquel within 1 year of> > > > their claimed injury, and/or c) Had a large number of known> > > > risk factors for diabetes before they started taking Seroquel. For> > > > example - obesity, family history, smoking, etc.> > > >> > > > Therefore, all cases whose injuries are limited to weight gain or> > high> > > > blood sugar and whose medical records will confirm that they were> > never> > > > diagnosed with diabetes or pancreatitis, should choose Track 1.> > > > Similarly, any claimed injury that occurred long after the last use> > of> > > > Seroquel should also choose Track 1. These cases are likely to> > receive a> > > > small award in Track II (likely less than $12,000) because it is> > > > extremely difficult to prove that these injuries were caused by> > > > Seroquel. Therefore, we suggest that if your case falls into this> > > > category you should choose Track 1. Additionally, payment of Track I> > > > settlement awards will be processed first once AstaZeneca waives its> > > > "walk away right". (See Section IV© below) Track II involves an> > > > in-depth review of the severity of the injury, the claimed use of> > > > Seroquel and its proximity to the injury as well the available proof> > > > found in the contemporaneous medical records. Additionally, Judge> > > > Corodemus will strongly consider many known risk factors for these> > > > injuries including but not limited to smoking, obesity and family> > > > history as well as the participation in the Zyprexa settlement for> > these> > > > same injuries. This model is very similar to the one used in the> > > > National Vioxx Settlement Program as well as dozens of other similar> > > > settlement programs which were successfully resolved in recent> > years.> > > > Judge Corodemus has established a points system and will consider> > all of> > > > the critical issues including but not limited to:> > > > - Nature of the injury - Severity of the injury - Age at the time of> > > > injury - Proximity of Seroquel use to the claimed injury - Changes> > in> > > > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,> > > > etc. After carefully reviewing all of the medical records and the> > > > individual fact sheet, Judge Corodemus will assign a point value to> > each> > > > case. The more points a case is awarded based on the specific facts> > of> > > > the case, the larger the settlement will be. At this time, there is> > no> > > > way to predict with accuracy how many points an individual case may> > be> > > > awarded and it is even more difficult to determine how much money> > each> > > > point will receive. The exact value of each point will depend on the> > > > number of participants in Track II and the total number of points> > > > assigned. All cases in Track II will be eligible for a settlement> > award> > > > but Judge Corodemus could award LESS than $12,000 (what people will> > > > receive automatically by choosing Track 1) if the case lacks merit.> > In> > > > the interest of fairness, Judge Corodemus has committed to review> > each> > > > case in Track II very carefully and this process will take time to> > > > complete. Judge Corodemus has stated that she hopes to have this> > process> > > > completed by the end of 2011 but please be warned that it could take> > a> > > > little longer due to the amount of work that is involved. However,> > in> > > > order to get this settlement process moving forward and ultimately> > paid> > > > you must send us your signed Release form as soon as possible. If> > you> > > > choose Track I your settlement award of $12,000 is set. If you> > choose> > > > Track II, Judge Corodemus will review your claim and will issue an> > > > award. We expect that we will contact you in approximately November> > 2011> > > > and notify you of your point award and the expected amount of your> > > > settlement. At that point, you will be given a choice to accept your> > > > award, appeal your award or withdraw from the settlement program. If> > you> > > > accept, we will forward your release to AstraZeneca for their review> > and> > > > approval. Please understand that this settlement is not official> > until> > > > we send AstraZeneca your signed Release Form, AstraZeneca approves> > it> > > > AND AstraZeneca waives its walk away right. In the interest of time,> > we> > > > are asking you to return your signed Release Form now so we can meet> > the> > > > tight deadlines associated with this settlement. If you are unhappy> > with> > > > your allocation amount and/or believe that your case involves> > > > "Extraordinary Injury or Circumstances" you have the right to appeal> > > > your award. Upon receipt of such an application, Judge Corodemus> > will> > > > re-review your records and make a final decision. Please be aware> > that> > > > there is no additional right of appeal (to Judge Corodemus or to any> > > > Court) once this final decision is made. If you decide to decline> > the> > > > settlement amount offered to you, you must notify us within ten days> > of> > > > your receipt of your allocation amount and your signed Release Form> > will> > > > no longer be valid. As in all settlements of this type, our> > agreement> > > > with the defendant depends on nearly full participation from all of> > our> > > > clients. Under the terms of our agreement, we must provide> > Qualifying> > > > Materials (Release Form and/or Dismissal) for 2,260 of our clients.> > Once> > > > we reach this number, AstraZeneca's "walk away right" is officially> > > > waived. We strongly believe that our clients will agree that this> > > > settlement program offers the best possible terms and we expect that> > we> > > > will meet this requirement in the next 90-120 days. In order to meet> > > > this deadline we MUST have your complete> > > > cooperation and immediate response. Of course, if we do not meet> > this> > > > required number of responses, Astrazeneca can decide to withdraw its> > > > settlement offer to everyone whether one signed the Release Form or> > not.> > > > Therefore, time is of the essence. A. Release Form: Enclosed you> > will> > > > find a Release Form which you must sign in front of a notary in> > Order to> > > > participate in the settlement. If you have a spouse he/she must sign> > the> > > > Release Form as well. Attached to the Release Form will be an> > > > instruction sheet to guide you to ensure that this important form is> > > > signed the right way. A Release Form that is signed the wrong way or> > > > that is not witnessed (by a notary) is useless and will not be> > accepted> > > > by the defendants. The Release Form is your agreement to participate> > in> > > > the settlement program and at the same time discontinue your lawsuit> > in> > > > exchange for your settlement award. Please turn to Page 2 of the> > Release> > > > Form and complete the details of your Seroquel use. You may refer to> > > > Page 1 of the Brief Questionnaire which lists the Seroquel> > information> > > > that was found in your medical records or that you have previously> > > > provided to us. If this information is inaccurate, please cross it> > out> > > > and write in when you started and when you stopped taking Seroquel> > on> > > > BOTH the Release Form and the Brief Questionnaire. Due to the fast> > > > approaching deadlines, and our goal to get you your settlement> > processed> > > > and paid as quickly as possible, we MUST receive this signed release> > > > form back from you before August 31, 2011. Please use the envelope> > > > provided herein and return the signed and notarized release form> > today> > > > before you forget about it. Please note that once we submit your> > release> > > > form to AstraZeneca it can not be revoked. B. Track Selection Form:> > > > Enclosed you will find a "Track Selection Form" which is the form> > used> > > > to officially notify the Special Master which Track you want your> > case> > > > to follow. Please Note that there are 4 options on this form. You> > MUST> > > > check one of the Options. If you want to participate in this> > settlement,> > > > and we strongly think that you should, you must check either Track I> > OR> > > > Track II and you must sign the bottom of the form. Your Track> > selection> > > > cannot be changed and is considered final once the Judge's> > Allocations> > > > are made. In other words, a person who chooses Track II and is> > awarded> > > > less than $12,000 CANNOT then choose to go to Track 1 for a higher> > > > award. C. Brief Questionnaire: Enclosed you will find a 3> > > > page Brief Questionnaire which has important information about your> > > > claim. For all claimants who choose to enter Track II, Judge> > Corodemus> > > > will be reviewing your medical records, your Fact Sheet and this> > Brief> > > > Questionnaire and will issue a point award. Judge Corodemus will> > > > consider the proof of your claim found in your medical records as> > well> > > > as the information that you provide in this Questionnaire.> > Therefore, it> > > > is important that you answer these questions honestly and completely> > and> > > > that they are consistent with what is found in your medical records.> > > > litigation and our conversations with our medical experts, it is> > clear> > > > that Seroquel lawsuits are very difficult to win, very expensive,> > and> > > > very time consuming to take through to trial, verdict and appeal.> > Over> > > > the past six years only I case (from W & L) of24,000 cases in the> > Country> > > > made it to and through trial. Countless other cases were prepared> > and> > > > then dismissed based on merit and/or inability to prove that> > Seroquel> > > > caused the injury. Just because an individual took Seroquel and> > suffered> > > > an injury like diabetes does not mean that such a case will win at> > > > trial. In order to succeed at trial, a plaintiff must prove both> > that> > > > Seroquel can cause such an injury in general AND that, within a> > > > reasonable degree of medical certainty, Seroquel caused this injury> > to> > > > this particular person (despite any individual risk factors such as> > > > smoking, weight, high blood sugar, family history etc.). We have> > told> > > > you in the past update letters that the Courts have consistently> > ruled> > > > in favor of the defendants on many of these issues and have> > prohibited> > > > medical experts from testifying because of a lack of scientific> > proof> > > > linking the plaintiff s injuries to his/her Seroquel use. It is also> > > > important to note that even if your case is able to advance past> > this> > > > judicial scrutiny, a trial of this magnitude will cost over $750,000> > per> > > > case and many of these costs are reimbursed off of the top of a> > > > favorable verdict reducing the amount received by the plaintiff.> > > > Furthermore, any case that is won at trial will surely face a> > lengthy> > > > and hard-fought appeal. Finally, nearly all of the Seroquel cases> > are> > > > being handled by three judges. Even at an accelerated pace, the> > chances> > > > are slim that your case would be tried in the next 10 years if not> > > > longer. In taking all of these factors into consideration, and> > > > considering the issues of risk and reward, we believe that a> > settlement> > > > of this type offers you the most advantageous resolution possible.> > You> > > > will be notified once the Special Master issues your point award at> > > > which point you can appeal to the Special Master if you believe that> > > > your case involves extraordinary circumstances. Thereafter, the> > decision> > > > of the Special Master is final, binding and non-appealable. We have> > > > retained the Garretson Law Firm to negotiate any and all Federal and> > > > State liens (Medicare/Medicaid/SSI) that may be applicable in your> > case.> > > > The Garretson Firm is a specialist in this field and they have> > obtained> > > > excellent results in their negotiation of similar liens in other> > > > litigations like Vioxx, Bextra, and Celebrex. Moreover, the> > Garretson> > > > Firm has already worked on thousands of other Seroquel cases and has> > > > been able to achieve excellent results in large part due to the> > volume> > > > of cases that they are able to include in a Global Resolution. At> > this> > > > time, the Garretson Firm has already negotiated with 44 individual> > > > states regarding Medicaid and they have reached an agreement to CAP> > > > Medicaid liens at a maximum of 20% of the settlement amount. Please> > see> > > > the enclosed blue booklet regarding governmental liens for more> > details.> > > > Additionally, please also be advised that if you or Weitz & > > Luxenberg> > > > are put on written notice of a private lien, for example from your> > > > medical provider, this lien must be resolved before any settlement> > > > proceeds can be distributed. If you have received any notice of a> > lien,> > > > please advise us immediately. The terms of your signed contingency> > fee> > > > agreement will be in effect. We have taken great effort to keep the> > case> > > > specific expenses as low as possible. Under the terms of your> > agreement,> > > > the> > > > contingency fee will be calculated after the expenses are deducted.> > > > Under the terms of our agreement with AstraZeneca, any interest> > earned> > > > on the settlement proceeds before allocation and payment to the> > > > individual clients will be used to offset the fixed costs of the> > Special> > > > Master and the Lien Administrator. Due to the low interest rates> > paid by> > > > all banks in this economy, we do not expect that there will be any> > > > leftover interest. However, in such a case, the leftover interest> > will> > > > be added to the settlement trust and will be distributed to all> > > > claimants as part of Judge Corodemus' allocation process. After> > careful> > > > analysis of the likelihood of success in the court system, as well> > as> > > > the cost and time elements involved, we strongly recommend that you> > > > AGREE to participate in this settlement. We are confident that this> > > > settlement is the best possible resolution of your claim especially> > in> > > > light of the history of this litigation. We expect that any case> > that> > > > does not agree to participate in this settlement will have a very> > > > difficult time navigating through the Court system and trial dates> > may> > > > not be set for many years. Moreover, as we have seen, these cases> > will> > > > be aggressively defended by AstraZeneca and we expect that we will> > > > receive motions to dismiss and unfavorable decisions from the Court> > on> > > > unsettled cases in the coming months. Moreover, if this settlement> > > > program is not successful (we fail to reach the 98% response rate)> > we> > > > highly doubt that we will ever obtain a settlement amount and terms> > as> > > > good as those contained in this program. While we hope that this> > letter> > > > and enclosures will help answer all of your questions, we understand> > > > that you may have additional questions for us. Please keep in mind> > that> > > > we are working very hard to evaluate each and every case> > individually> > > > and the many deadlines that are part of this settlement are fast> > > > approaching. Your case has been assigned to Judy Koenig. If you have> > an> > > > important question please call Judy Koenig at (800) 438-9786 and ask> > for> > > > extension 5860. If you reach a voice-mail, please leave a message> > and> > > > you will be called back as quickly as possible. Please do not leave> > > > multiple voicemail messages on the same day as that will slow down> > our> > > > ability to return your call. Additionally, if you have email access,> > > > please try to email your detailed questions to us at sqinfo@> > > > <mailto:sqinfo@ and we will get back to you quickly. If> > > > this letter has successfully answered your questions, and you have> > > > decided to participate, please carefully follow the directions on> > the> > > > front page of the enclosed release form and send your signed and> > > > witnessed release formes), your Track Selection AND your Brief> > > > Questionnaire to us as soon as possible. If you still have questions> > > > after reviewing this letter and after speaking to us over the> > telephone> > > > and you would like to meet us in person, we will be happy to> > schedule a> > > > meeting in our office at your convenience. Finally, please remember> > that> > > > the detailed information regarding this settlement program is> > COMPLETELY> > > > CONFIDENTIAL and should not be shared or discussed with anyone.> > > > > > Sedgh, Esq Glenn Zuckerman, Esq.> > > >> > >> >>

[Guest guest]

Far from throwing mud on the windscreen, so to speak, if the CoS was not so much a "professionally paranoid" organisation it would realise that it's classic tactic of playing at being victimised by situations it itself creates, it would step out of the situation and examine the fruits of it's actions.

In terms of the UK & Ireland then it is fair to say once it's involvement becomes clear then credibility of anyones legitimate claims about problem psychiatric treatment goes out the window.

Nobody responsible person believes them & therefore anyone who goes along with them how ever passively looses any traction.

CoS has been in the field for decades yet SSRI are more out of control than ever !

The evidence is clear - http://tuesday1st.blogspot.com/2011/05/ssri-snri-total-annual-prescription_17.html

Data collection reference:Department of Health; NHS; Prescription Cost Analysis (PCA) - England

you can't argue against national statistical return of prescriptions encashed at the pharmacy shop

> > > >> > > > "Awry," not "a rye" but I digress. This is exactly why I never urge> > anyone to sue. The deck is stacked against us in court and attorneys are> > looking for a quick and easy buck. No justice is to be had.> > > >> > > > Terry> > > > Sent via BlackBerry by AT & T> > > >> > > > SEROQUEL Law Firms have sold their clients> > down the river> > > >> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME> > TO> > > > REJECT this Insult on Top of Injury> > > >> > [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\> > \> > > >> > ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\> > \> > > >> > A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\> > \> > > >> > oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\> > \> > > >> > 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\> > \> > > >> > DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\> > \> > > >> > HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\> > \> > > >> > oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\> > \> > > >> > 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\> > \> > > >> > EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\> > \> > > >> > VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\> > \> > > >> > 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\> > \> > > >> > IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\> > \> > > >> > kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\> > \> > > >> > /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\> > \> > > >> > 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\> > \> > > >> > CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\> > \> > > >> > ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\> > \> > > >> > zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\> > \> > > >> > T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\> > \> > > >> > N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\> > \> > > >> > HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\> > \> > > >> > gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\> > \> > > >> > w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\> > \> > > >> > 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\> > \> > > >> > wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\> > \> > > >> > TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\> > \> > > >> > Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\> > \> > > >> > NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\> > \> > > >> > LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\> > \> > > >> > yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\> > \> > > >> > rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\> > \> > > >> > pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\> > \> > > >> > 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\> > \> > > >> > bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\> > \> > > >> > rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\> > \> > > >> > XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\> > \> > > >> > AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\> > \> > > >> > sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\> > \> > > >> > uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\> > \> > > >> > 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\> > \> > > >> > aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\> > \> > > >> > 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\> > \> > > >> > mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\> > \> > > >> > 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\> > \> > > >> > A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\> > \> > > >> > QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\> > \> > > >> > UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\> > \> > > >> > ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\> > \> > > >> > /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\> > \> > > >> > i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\> > \> > > >> > Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\> > \> > > >> > DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\> > \> > > >> > 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\> > \> > > >> > zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\> > \> > > >> > hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\> > \> > > >> > i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\> > \> > > >> > gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\> > \> > > >> > m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\> > \> > > >> > VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\> > \> > > >> > Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\> > \> > > >> > bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\> > \> > > >> > MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\> > \> > > >> > RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\> > \> > > >> > RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\> > \> > > >> > 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\> > \> > > >> > AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\> > \> > > >> > jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\> > \> > > >> > okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\> > \> > > >> > kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\> > \> > > >> > HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\> > \> > > >> > cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\> > \> > > >> > tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\> > \> > > >> > YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\> > \> > > >> > +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\> > \> > > >> > sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\> > \> > > >> > 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\> > \> > > >> > QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\> > \> > > >> > kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\> > \> > > >> > Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\> > \> > > >> > Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\> > \> > > >> > QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\> > \> > > >> > t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\> > \> > > >> > MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\> > \> > > >> > VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\> > \> > > >> > nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\> > \> > > >> > SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\> > \> > > >> > tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\> > \> > > >> > 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\> > \> > > >> > ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\> > \> > > >> > J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\> > \> > > >> > m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\> > \> > > >> > 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\> > \> > > >> > 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\> > \> > > >> > 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\> > \> > > >> > zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\> > \> > > >> > 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\> > \> > > >> > 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\> > \> > > >> > oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\> > \> > > >> > hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\> > \> > > >> > 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\> > \> > > >> > vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\> > \> > > >> > fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\> > \> > > >> > aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\> > \> > > >> > +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\> > \> > > >> > HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\> > \> > > >> > aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\> > \> > > >> > jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\> > \> > > >> > 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\> > \> > > >> > /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\> > \> > > >> > G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\> > \> > > >> > GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\> > \> > > >> > +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\> > \> > > >> > kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\> > \> > > >> > h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\> > \> > > >> > NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\> > \> > > >> > rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\> > \> > > >> > T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\> > \> > > >> > C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\> > \> > > >> > at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\> > \> > > >> > 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\> > \> > > >> > X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\> > \> > > >> > kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\> > \> > > >> > PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\> > \> > > >> > tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\> > \> > > >> > 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\> > \> > > >> > ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\> > \> > > >> > DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\> > \> > > >> > cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\> > \> > > >> > Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\> > \> > > >> > qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\> > \> > > >> > wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\> > \> > > >> > aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\> > \> > > >> > zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\> > \> > > >> > KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\> > \> > > >> > BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\> > \> > > >> > XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\> > \> > > >> > fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\> > \> > > >> > R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\> > \> > > >> > xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\> > \> > > >> > SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\> > \> > > >> > BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\> > \> > > >> > BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\> > \> > > >> > iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\> > \> > > >> > Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\> > \> > > >> > Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\> > \> > > >> > dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\> > \> > > >> > BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\> > \> > > >> > whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\> > \> > > >> > Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\> > \> > > >> > NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\> > \> > > >> > 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\> > \> > > >> > 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\> > \> > > >> > D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\> > \> > > >> > amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\> > \> > > >> > UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\> > \> > > >> > n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\> > \> > > >> > nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\> > \> > > >> > 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\> > \> > > >> > e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\> > \> > > >> > nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\> > \> > > >> > CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\> > \> > > >> > 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\> > \> > > >> > MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\> > \> > > >> > X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\> > \> > > >> > 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\> > \> > > >> > qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\> > \> > > >> > e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\> > \> > > >> > oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\> > \> > > >> > CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\> > \> > > >> > 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\> > \> > > >> > GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\> > \> > > >> > ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\> > \> > > >> > Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\> > \> > > >> > AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\> > \> > > >> > ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\> > \> > > >> > vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\> > \> > > >> > +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\> > \> > > >> > kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\> > \> > > >> > e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\> > \> > > >> > hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\> > \> > > >> > 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\> > \> > > >> > DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\> > \> > > >> > ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\> > \> > > >> > suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\> > \> > > >> > 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\> > \> > > >> > yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\> > \> > > >> > c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\> > \> > > >> > rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\> > \> > > >> > FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\> > \> > > >> > 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\> > \> > > >> > GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\> > \> > > >> > UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\> > \> > > >> > I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\> > \> > > >> > xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\> > \> > > >> > IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\> > \> > > >> > EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\> > \> > > >> > Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\> > \> > > >> > S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\> > \> > > >> > WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\> > \> > > >> > mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\> > \> > > >> > Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\> > \> > > >> > QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\> > \> > > >> > IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\> > \> > > >> > 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\> > \> > > >> > FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\> > \> > > >> > FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\> > \> > > >> > lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\> > \> > > >> > Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\> > \> > > >> > Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\> > \> > > >> > +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\> > \> > > >> > aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\> > \> > > >> > Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\> > \> > > >> > wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\> > \> > > >> > yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\> > \> > > >> > QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\> > \> > > >> > CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\> > \> > > >> > kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\> > \> > > >> > Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\> > \> > > >> > 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\> > \> > > >> > AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\> > \> > > >> > eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\> > \> > > >> > sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\> > \> > > >> > gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\> > \> > > >> > 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\> > \> > > >> > hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\> > \> > > >> > KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\> > \> > > >> > 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\> > \> > > >> > /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\> > \> > > >> > 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\> > \> > > >> > qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\> > \> > > >> > LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\> > \> > > >> > iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\> > \> > > >> > wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\> > \> > > >> > A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\> > \> > > >> > A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\> > \> > > >> > 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\> > \> > > >> > h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\> > \> > > >> > X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\> > \> > > >> > TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\> > \> > > >> > kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\> > \> > > >> > SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\> > \> > > >> > mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\> > \> > > >> > 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\> > \> > > >> > XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\> > \> > > >> > U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\> > \> > > >> > +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\> > \> > > >> > SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\> > \> > > >> > WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\> > \> > > >> > gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\> > \> > > >> > YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\> > \> > > >> > tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\> > \> > > >> > HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\> > \> > > >> > bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\> > \> > > >> > ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\> > \> > > >> > IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\> > \> > > >> > HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\> > \> > > >> > wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\> > \> > > >> > NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\> > \> > > >> > 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\> > \> > > >> > n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\> > \> > > >> > kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\> > \> > > >> > X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\> > \> > > >> > rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\> > \> > > >> > x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\> > \> > > >> > Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\> > \> > > >> > tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\> > \> > > >> > Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\> > \> > > >> > fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\> > \> > > >> > UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\> > \> > > >> > xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\> > \> > > >> > IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\> > \> > > >> > 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\> > \> > > >> > fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\> > \> > > >> > Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\> > \> > > >> > 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\> > \> > > >> > iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\> > \> > > >> > oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\> > \> > > >> > KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\> > \> > > >> > 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\> > \> > > >> > RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\> > \> > > > ElFTkSuQmCC]> > > >> > > >> > > >> > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims - TIME> > TO> > > > REJECT this Insult on Top of Injury> > > > I would like to thank a brave, courageous, and ethical anonymous> > source> > > > who has send in this letter correspondence they received from the> > law> > > > firm of Weitz & Luxenberg. This letter doesn't require a whole lot> > of> > > > commentary.> > > > It's obvious that Law Firms have sold their clients down the> > proverbial> > > > river while at the same time enriching themselves (who's best> > interest> > > > are you obligated too fulfill?). This settlement offer and the> > injured> > > > litigants legal representation has carried out a blatant miscarriage> > of> > > > justice, a forever horrible stain upon the American Justice system,> > and> > > > a orchestrated crime perpetrated upon victims of this well> > documented & > > > > evidenced unbridled & unregulated corporate criminal enterprise gone> > a> > > > rye.> > > > The time has now come for the victims to stand up to this criminal> > > > corporation "AstraZeneca" & their poison drug "Seroquel", to reject> > this> > > > horrible injustice and settlement offer. We want, what America & our> > > > Constitution promises us all, our day in court before a jury of our> > > > peers....> > > > ____________________________________________________________> > > >> > > > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>> > > > We are happy to report excellent news! After a long and hard fought> > > > legal battle, AstraZeneca has agreed to participate in a Settlement> > > > Program to resolve Weitz & Luxenberg ("W & L") Seroguel cases. Our> > > > patience and aggressive litigating has resulted in very favorable> > > > settlement terms for our clients which will be further outlined> > below.> > > > We have carefully reviewed all of the factors of this agreement and> > we> > > > believe that this settlement offers you the best, and very likely> > the> > > > only opportunity to receive a fair resolution of your lawsuit.> > > > Therefore, we strongly recommend that you sign and complete the> > enclosed> > > > "Release Form", "Track Selection Form" and "Brief Questionnaire" and> > > > AGREE to participate.> > > > As you know, we have engaged in a long legal battle with AstraZeneca> > > > over the past 6 years. Weitz & Luxenberg led the charge for the> > > > Plaintiffs around the Country. AstraZeneca put up a tremendous and> > > > expensive defense and they successfully were able to get a large> > number> > > > of cases to be permanently dismissed by the court. Weitz & Luxenberg> > is> > > > the only firm who took a case to trial anywhere in the Country.> > However,> > > > after a month-long trial, the jury unfortunately ruled in favor of> > the> > > > defendants. This loss did not affect the strength of our fight. Over> > the> > > > past year, even as almost every other plaintiffs firm settled their> > > > cases, Weitz & Luxenberg prepared two more cases for trial which was> > > > scheduled to begin this Summer. As a direct result of the endless> > and> > > > consistent pressure applied by the attorneys at Weitz & Luxenberg,> > we> > > > are happy to report that AstraZeneca has now agreed to participate> > in a> > > > favorable settlement program. Based on public reports regarding> > > > settlement programs reached with other plaintiff law firms we are> > > > confident that the settlement program outlined below has more> > favorable> > > > terms and for this reason we are recommending your participation.> > > > The defendants have argued that they refuse to pay anyone who cannot> > > > prove through medical records or via certification that they have> > used> > > > Seroquel. They also refuse to pay anyone whose case is not active in> > > > this litigation. We recently told you about the Order issued by the> > > > Court requiring you to confirm when you started taking Seroquel and> > when> > > > you stopped taking Seroquel. We cannot stress enough that you MUST> > read,> > > > complete and return this certification form to us immediately. The> > > > failure to return this form within the next 30 days will result in> > the> > > > permanent dismissal of your case. In order to protect your legal> > rights,> > > > to keep your case active and be permitted to participate in this> > > > Settlement Program you must take this Order very seriously and you> > must> > > > respond.> > > > Based on our experience in other litigations and having reviewed the> > > > media reports of the terms of other firms' Seroquel settlement> > programs,> > > > we know that the defendants are looking for a settlement program> > that> > > > includes all claimants (W & L Seroquel Plaintiffs) so that they will> > > > achieve complete closure of the entirYlitigation. Our goal in this> > > > negotiation was to obtain a settlement for the most amount of money> > > > using a fair method to pay our clients based upon the merits of> > their> > > > individual case. We also stressed our intentions that the case> > review> > > > and payment process be performed quickly yet fairly so that our> > clients> > > > can receive their settlements as soon as possible. A key part of> > this> > > > settlement program is that a claimant cannot be part of the> > settlement> > > > if their case is dismissed and unless they provide, at the very> > least, a> > > > certification that they in fact took Seroquel and suffered an> > injury.> > > > Therefore, please make sure that you return your certification form> > to> > > > us immediately> > > >> > > > We have hired Hon.Marina Corodemus to act as the Special Master for> > the> > > > W & L Seroquel settlement program. Judge Corodemus previously ran the> > New> > > > Jersey Mass Tort Court and has a lot of experience in this field.> > She> > > > was appointed as a Special Master by the Vioxx State and Federal> > Court> > > > Judges to determine the appropriateness of Vioxx settlements and to> > > > resolve Vioxx appeals. She has also served as the Special Master in> > many> > > > other litigations such as Bextra and Celebrex which used similar> > > > settlement terms. We have met several times with Judge Corodemus and> > > > discussed the goals outlined above to get the most amount of money> > to> > > > the most amount of claimants in the fastest amount of time possible.> > We> > > > believe that Judge Corodemus is the perfect choice to create and> > oversee> > > > a settlement program in accordance with these goals. The W & L> > Seroquel> > > > Settlement Program involves Weitz & Luxenberg's 2,351 clients. Only> > > > those clients with active cases (not dismissed as outlined above)> > can> > > > participate in this settlement program. Unlike other settlement> > programs> > > > that you may have read about in the media and internet, the W & L> > > > Settlement program does not award every case an equal settlement> > amount.> > > > The size of an individual's settlement will depend entirely on the> > merit> > > > of that individual's case. As a direct result of the large number of> > > > cases represented by W & L, and the merits of those cases, we are> > > > confident that we have obtained the best possible settlement for our> > > > clients. After complex negotiations, AstraZeneca> > > > has agreed to deposit $92.25 Million dollars into a trust account to> > be> > > > used for this Settlement Program. This amount is completely> > confidential> > > > and you should NOT discuss this with anyone. A settlement of this> > type> > > > is called an "Aggregate Settlement" where a fair and reasonable sum> > of> > > > money is obtained to resolve multiple cases. In order to maintain> > proper> > > > representation of each individual client, W & L is NOT involved in> > the> > > > allocation decision making, which will be handled exclusively by> > Judge> > > > Corodemus. W & L has reviewed the general framework of the settlement> > > > plan with Judge Corodemus and we strongly believe that it is fair> > and> > > > reasonable and offers each of our clients the best possible outcome> > > > under the circumstances of this litigation. Track I offers the> > Seroquel> > > > claimant a settlement of $12,000. This track involves a simple> > review of> > > > each case and will result in a quick approval by Judge Corodemus> > without> > > > an analysis of the specific details of the case such as injury,> > amount> > > > of Seroquel taken, how close the last Seroquel use was to the date> > of> > > > the injury or the individual claimant's risk factors. a) Cannot> > > > prove that they suffered diabetes or a diabetes related condition,> > > > and/or Cannot prove that they used Seroquel within 1 year of> > > > their claimed injury, and/or c) Had a large number of known> > > > risk factors for diabetes before they started taking Seroquel. For> > > > example - obesity, family history, smoking, etc.> > > >> > > > Therefore, all cases whose injuries are limited to weight gain or> > high> > > > blood sugar and whose medical records will confirm that they were> > never> > > > diagnosed with diabetes or pancreatitis, should choose Track 1.> > > > Similarly, any claimed injury that occurred long after the last use> > of> > > > Seroquel should also choose Track 1. These cases are likely to> > receive a> > > > small award in Track II (likely less than $12,000) because it is> > > > extremely difficult to prove that these injuries were caused by> > > > Seroquel. Therefore, we suggest that if your case falls into this> > > > category you should choose Track 1. Additionally, payment of Track I> > > > settlement awards will be processed first once AstaZeneca waives its> > > > "walk away right". (See Section IV© below) Track II involves an> > > > in-depth review of the severity of the injury, the claimed use of> > > > Seroquel and its proximity to the injury as well the available proof> > > > found in the contemporaneous medical records. Additionally, Judge> > > > Corodemus will strongly consider many known risk factors for these> > > > injuries including but not limited to smoking, obesity and family> > > > history as well as the participation in the Zyprexa settlement for> > these> > > > same injuries. This model is very similar to the one used in the> > > > National Vioxx Settlement Program as well as dozens of other similar> > > > settlement programs which were successfully resolved in recent> > years.> > > > Judge Corodemus has established a points system and will consider> > all of> > > > the critical issues including but not limited to:> > > > - Nature of the injury - Severity of the injury - Age at the time of> > > > injury - Proximity of Seroquel use to the claimed injury - Changes> > in> > > > the Seroque11abel - Risk Factors including Smoking, Body Mass Index,> > > > etc. After carefully reviewing all of the medical records and the> > > > individual fact sheet, Judge Corodemus will assign a point value to> > each> > > > case. The more points a case is awarded based on the specific facts> > of> > > > the case, the larger the settlement will be. At this time, there is> > no> > > > way to predict with accuracy how many points an individual case may> > be> > > > awarded and it is even more difficult to determine how much money> > each> > > > point will receive. The exact value of each point will depend on the> > > > number of participants in Track II and the total number of points> > > > assigned. All cases in Track II will be eligible for a settlement> > award> > > > but Judge Corodemus could award LESS than $12,000 (what people will> > > > receive automatically by choosing Track 1) if the case lacks merit.> > In> > > > the interest of fairness, Judge Corodemus has committed to review> > each> > > > case in Track II very carefully and this process will take time to> > > > complete. Judge Corodemus has stated that she hopes to have this> > process> > > > completed by the end of 2011 but please be warned that it could take> > a> > > > little longer due to the amount of work that is involved. However,> > in> > > > order to get this settlement process moving forward and ultimately> > paid> > > > you must send us your signed Release form as soon as possible. If> > you> > > > choose Track I your settlement award of $12,000 is set. If you> > choose> > > > Track II, Judge Corodemus will review your claim and will issue an> > > > award. We expect that we will contact you in approximately November> > 2011> > > > and notify you of your point award and the expected amount of your> > > > settlement. At that point, you will be given a choice to accept your> > > > award, appeal your award or withdraw from the settlement program. If> > you> > > > accept, we will forward your release to AstraZeneca for their review> > and> > > > approval. Please understand that this settlement is not official> > until> > > > we send AstraZeneca your signed Release Form, AstraZeneca approves> > it> > > > AND AstraZeneca waives its walk away right. In the interest of time,> > we> > > > are asking you to return your signed Release Form now so we can meet> > the> > > > tight deadlines associated with this settlement. If you are unhappy> > with> > > > your allocation amount and/or believe that your case involves> > > > "Extraordinary Injury or Circumstances" you have the right to appeal> > > > your award. Upon receipt of such an application, Judge Corodemus> > will> > > > re-review your records and make a final decision. Please be aware> > that> > > > there is no additional right of appeal (to Judge Corodemus or to any> > > > Court) once this final decision is made. If you decide to decline> > the> > > > settlement amount offered to you, you must notify us within ten days> > of> > > > your receipt of your allocation amount and your signed Release Form> > will> > > > no longer be valid. As in all settlements of this type, our> > agreement> > > > with the defendant depends on nearly full participation from all of> > our> > > > clients. Under the terms of our agreement, we must provide> > Qualifying> > > > Materials (Release Form and/or Dismissal) for 2,260 of our clients.> > Once> > > > we reach this number, AstraZeneca's "walk away right" is officially> > > > waived. We strongly believe that our clients will agree that this> > > > settlement program offers the best possible terms and we expect that> > we> > > > will meet this requirement in the next 90-120 days. In order to meet> > > > this deadline we MUST have your complete> > > > cooperation and immediate response. Of course, if we do not meet> > this> > > > required number of responses, Astrazeneca can decide to withdraw its> > > > settlement offer to everyone whether one signed the Release Form or> > not.> > > > Therefore, time is of the essence. A. Release Form: Enclosed you> > will> > > > find a Release Form which you must sign in front of a notary in> > Order to> > > > participate in the settlement. If you have a spouse he/she must sign> > the> > > > Release Form as well. Attached to the Release Form will be an> > > > instruction sheet to guide you to ensure that this important form is> > > > signed the right way. A Release Form that is signed the wrong way or> > > > that is not witnessed (by a notary) is useless and will not be> > accepted> > > > by the defendants. The Release Form is your agreement to participate> > in> > > > the settlement program and at the same time discontinue your lawsuit> > in> > > > exchange for your settlement award. Please turn to Page 2 of the> > Release> > > > Form and complete the details of your Seroquel use. You may refer to> > > > Page 1 of the Brief Questionnaire which lists the Seroquel> > information> > > > that was found in your medical records or that you have previously> > > > provided to us. If this information is inaccurate, please cross it> > out> > > > and write in when you started and when you stopped taking Seroquel> > on> > > > BOTH the Release Form and the Brief Questionnaire. Due to the fast> > > > approaching deadlines, and our goal to get you your settlement> > processed> > > > and paid as quickly as possible, we MUST receive this signed release> > > > form back from you before August 31, 2011. Please use the envelope> > > > provided herein and return the signed and notarized release form> > today> > > > before you forget about it. Please note that once we submit your> > release> > > > form to AstraZeneca it can not be revoked. B. Track Selection Form:> > > > Enclosed you will find a "Track Selection Form" which is the form> > used> > > > to officially notify the Special Master which Track you want your> > case> > > > to follow. Please Note that there are 4 options on this form. You> > MUST> > > > check one of the Options. If you want to participate in this> > settlement,> > > > and we strongly think that you should, you must check either Track I> > OR> > > > Track II and you must sign the bottom of the form. Your Track> > selection> > > > cannot be changed and is considered final once the Judge's> > Allocations> > > > are made. In other words, a person who chooses Track II and is> > awarded> > > > less than $12,000 CANNOT then choose to go to Track 1 for a higher> > > > award. C. Brief Questionnaire: Enclosed you will find a 3> > > > page Brief Questionnaire which has important information about your> > > > claim. For all claimants who choose to enter Track II, Judge> > Corodemus> > > > will be reviewing your medical records, your Fact Sheet and this> > Brief> > > > Questionnaire and will issue a point award. Judge Corodemus will> > > > consider the proof of your claim found in your medical records as> > well> > > > as the information that you provide in this Questionnaire.> > Therefore, it> > > > is important that you answer these questions honestly and completely> > and> > > > that they are consistent with what is found in your medical records.> > > > litigation and our conversations with our medical experts, it is> > clear> > > > that Seroquel lawsuits are very difficult to win, very expensive,> > and> > > > very time consuming to take through to trial, verdict and appeal.> > Over> > > > the past six years only I case (from W & L) of24,000 cases in the> > Country> > > > made it to and through trial. Countless other cases were prepared> > and> > > > then dismissed based on merit and/or inability to prove that> > Seroquel> > > > caused the injury. Just because an individual took Seroquel and> > suffered> > > > an injury like diabetes does not mean that such a case will win at> > > > trial. In order to succeed at trial, a plaintiff must prove both> > that> > > > Seroquel can cause such an injury in general AND that, within a> > > > reasonable degree of medical certainty, Seroquel caused this injury> > to> > > > this particular person (despite any individual risk factors such as> > > > smoking, weight, high blood sugar, family history etc.). We have> > told> > > > you in the past update letters that the Courts have consistently> > ruled> > > > in favor of the defendants on many of these issues and have> > prohibited> > > > medical experts from testifying because of a lack of scientific> > proof> > > > linking the plaintiff s injuries to his/her Seroquel use. It is also> > > > important to note that even if your case is able to advance past> > this> > > > judicial scrutiny, a trial of this magnitude will cost over $750,000> > per> > > > case and many of these costs are reimbursed off of the top of a> > > > favorable verdict reducing the amount received by the plaintiff.> > > > Furthermore, any case that is won at trial will surely face a> > lengthy> > > > and hard-fought appeal. Finally, nearly all of the Seroquel cases> > are> > > > being handled by three judges. Even at an accelerated pace, the> > chances> > > > are slim that your case would be tried in the next 10 years if not> > > > longer. In taking all of these factors into consideration, and> > > > considering the issues of risk and reward, we believe that a> > settlement> > > > of this type offers you the most advantageous resolution possible.> > You> > > > will be notified once the Special Master issues your point award at> > > > which point you can appeal to the Special Master if you believe that> > > > your case involves extraordinary circumstances. Thereafter, the> > decision> > > > of the Special Master is final, binding and non-appealable. We have> > > > retained the Garretson Law Firm to negotiate any and all Federal and> > > > State liens (Medicare/Medicaid/SSI) that may be applicable in your> > case.> > > > The Garretson Firm is a specialist in this field and they have> > obtained> > > > excellent results in their negotiation of similar liens in other> > > > litigations like Vioxx, Bextra, and Celebrex. Moreover, the> > Garretson> > > > Firm has already worked on thousands of other Seroquel cases and has> > > > been able to achieve excellent results in large part due to the> > volume> > > > of cases that they are able to include in a Global Resolution. At> > this> > > > time, the Garretson Firm has already negotiated with 44 individual> > > > states regarding Medicaid and they have reached an agreement to CAP> > > > Medicaid liens at a maximum of 20% of the settlement amount. Please> > see> > > > the enclosed blue booklet regarding governmental liens for more> > details.> > > > Additionally, please also be advised that if you or Weitz & > > Luxenberg> > > > are put on written notice of a private lien, for example from your> > > > medical provider, this lien must be resolved before any settlement> > > > proceeds can be distributed. If you have received any notice of a> > lien,> > > > please advise us immediately. The terms of your signed contingency> > fee> > > > agreement will be in effect. We have taken great effort to keep the> > case> > > > specific expenses as low as possible. Under the terms of your> > agreement,> > > > the> > > > contingency fee will be calculated after the expenses are deducted.> > > > Under the terms of our agreement with AstraZeneca, any interest> > earned> > > > on the settlement proceeds before allocation and payment to the> > > > individual clients will be used to offset the fixed costs of the> > Special> > > > Master and the Lien Administrator. Due to the low interest rates> > paid by> > > > all banks in this economy, we do not expect that there will be any> > > > leftover interest. However, in such a case, the leftover interest> > will> > > > be added to the settlement trust and will be distributed to all> > > > claimants as part of Judge Corodemus' allocation process. After> > careful> > > > analysis of the likelihood of success in the court system, as well> > as> > > > the cost and time elements involved, we strongly recommend that you> > > > AGREE to participate in this settlement. We are confident that this> > > > settlement is the best possible resolution of your claim especially> > in> > > > light of the history of this litigation. We expect that any case> > that> > > > does not agree to participate in this settlement will have a very> > > > difficult time navigating through the Court system and trial dates> > may> > > > not be set for many years. Moreover, as we have seen, these cases> > will> > > > be aggressively defended by AstraZeneca and we expect that we will> > > > receive motions to dismiss and unfavorable decisions from the Court> > on> > > > unsettled cases in the coming months. Moreover, if this settlement> > > > program is not successful (we fail to reach the 98% response rate)> > we> > > > highly doubt that we will ever obtain a settlement amount and terms> > as> > > > good as those contained in this program. While we hope that this> > letter> > > > and enclosures will help answer all of your questions, we understand> > > > that you may have additional questions for us. Please keep in mind> > that> > > > we are working very hard to evaluate each and every case> > individually> > > > and the many deadlines that are part of this settlement are fast> > > > approaching. Your case has been assigned to Judy Koenig. If you have> > an> > > > important question please call Judy Koenig at (800) 438-9786 and ask> > for> > > > extension 5860. If you reach a voice-mail, please leave a message> > and> > > > you will be called back as quickly as possible. Please do not leave> > > > multiple voicemail messages on the same day as that will slow down> > our> > > > ability to return your call. Additionally, if you have email access,> > > > please try to email your detailed questions to us at sqinfo@> > > > <mailto:sqinfo@ and we will get back to you quickly. If> > > > this letter has successfully answered your questions, and you have> > > > decided to participate, please carefully follow the directions on> > the> > > > front page of the enclosed release form and send your signed and> > > > witnessed release formes), your Track Selection AND your Brief> > > > Questionnaire to us as soon as possible. If you still have questions> > > > after reviewing this letter and after speaking to us over the> > telephone> > > > and you would like to meet us in person, we will be happy to> > schedule a> > > > meeting in our office at your convenience. Finally, please remember> > that> > > > the detailed information regarding this settlement program is> > COMPLETELY> > > > CONFIDENTIAL and should not be shared or discussed with anyone.> > > > > > Sedgh, Esq Glenn Zuckerman, Esq.> > > >> > >> >>

[Guest guest]

I see what you are saying...yes, if their reputation makes them suspect, then

they become a liability to others who are working against the widespread use of

psychaitric drugs.

And yet, for a person to be told by an individual calling himself a doctor, that

the only reason she is concerned about the damage of SSRIs is that the

Scientologists told her to be, is an outrage. She herself was suffering bad

effects, and she is told she ought not be, her adverse effects are due to the

darn Scientologists, of whom she personally had never heard? Whew!

I know so many people who have been injured one way or another by these drugs,

even in my own household, and as Dr. Breggin stated way back in 1995, the

patient is often the last one to know he or she is being harmed. I guess I am

beating a dead horse here, every body on this list has probably moved on from

these things years ago, to more current issues, but I have been out of the loop

for several years, in part due to the mess SSRIs make of lives. I know there are

people on this list who have lost loved ones permanently because of them. I

guess we are lucky that our lives were simply ruined, with everybody surviving,

if you can call it that.

I know the use is not down all these years later. That is the crime of it all!

Until the pharmaceutical companies are reigned in with all the rest of the

special interests, the situation cannot improve. And now the Republican Party in

the US is gaga over Gov. , who did not hesitate to try to force every

schoolgirl in Texas to submit to Gardasil when it first came on the market.

Cate

> > > > >

> > > > > " Awry, " not " a rye " but I digress. This is exactly why I never

> urge

> > > anyone to sue. The deck is stacked against us in court and attorneys

> are

> > > looking for a quick and easy buck. No justice is to be had.

> > > > >

> > > > > Terry

> > > > > Sent via BlackBerry by AT & T

> > > > >

> > > > > SEROQUEL Law Firms have sold their

> clients

> > > down the river

> > > > >

> > > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims -

> TIME

> > > TO

> > > > > REJECT this Insult on Top of Injury

> > > > >

> > >

> [data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAeAAAAHgCAIAAADytinCAAAgA\

> \

> > > \

> > > > >

> > >

> ElEQVR4nO2dP08yzdfHt7qDzRV+WFuQWGBh5RuwotBX4NVYmPAK7HwBxNKSxI7qaehotWJtC\

> \

> > > \

> > > > >

> > >

> A2xMBZmY2JCZUJCrMw8xcFxL9hd9s+c+bffT6Z5nvxuL1hmPgxnzpwTCAAAAFYSmH4BAAAAk\

> \

> > > \

> > > > >

> > >

> oGgAQDAUiBoAACwFAgaAAAsBYIGAABLgaABAMBSIGhgKV/R+1f0vpq/fD6END7u7uPj9eo65\

> \

> > > \

> > > > >

> > >

> 3i7uY3/h4vhSP5N+ldMv1cAkoGggRm+l6vv5Yr8uxiOpHCfzy5nJ+ezk/PZ4ens8PSpdSzHJ\

> \

> > > \

> > > > >

> > >

> DiYNNpyPAb7OcfGfxj/m/SvzA5P6R+l10Ae/3wIV/MXep2mnxaoKRA04OV7uaKN8Gr+IkX8f\

> \

> > > \

> > > > >

> > >

> HY5OzwN9442xqTRngQHvyNm1fjY/g/zj+S/+e8/uvGfzA5Pn88uaSe+GI7ovXxF7xA34AaCB\

> \

> > > \

> > > > >

> > >

> oohHZOL325uaUcsN7wZHrR8bEicrE3BE7I2QiVAORA0qMr3ckUBYqnj2eHpRoTBuF6ZfC3f4\

> \

> > > \

> > > > >

> > >

> 1PreHZyThttCo9gfw2qA0GDMtAe+fXqmnT81DqOB4W9NPIOXzfa0tcU5qa49uvVNe2vTX9iw\

> \

> > > \

> > > > >

> > >

> EkgaJCLr+idtsmvV9dk5HAjZOxayIJd2T9Phv7P2eEpba4Rvwb5gaBBKhtS3jAORmFl/3yfS\

> \

> > > \

> > > > >

> > >

> VlTnp/pzxnYCwQNNlnNX9ZSjh/uYYOs2tT0VClyTbI2/ckD64CggRBCfC9XMqZMGcfwsk5Ty\

> \

> > > \

> > > > >

> > >

> 2NGilkjAAIICLq+UIYyefn3JggCykZlTRGkp9bx89nlYjhCtLrmQNC1Q2bFPZ9dhnSWpeICC\

> \

> > > \

> > > > >

> > >

> IaqEb8+E+4dyQAITF1DIOgaEfdyPZPhXBwUAwljpjY9j4A+IGj/+YreyctPrWNElt0dMlRNp\

> \

> > > \

> > > > >

> > >

> kb6Rx2AoL1luVwuhiPycviTlmvcMhgVhzwkiMepTc81wAUE7RsUYn67uV1nLiO47O+gOPVT6\

> \

> > > \

> > > > >

> > >

> /jt5hZBai+BoP2B8pefzy6RiVG3QScKFPrAtXKfgKB94PMhpMt+CDHXedCnT9cUcZboBxC0w\

> \

> > > \

> > > > >

> > >

> 9DtktnJeYgQM8bPkDNhdnKOOy+uA0E7yWr+so4yI4UZI2XQxJgdnr7d3CLu4SgQtGNQNCOks\

> \

> > > \

> > > > >

> > >

> CO8jJFjUBo14h4uAkE7A+XMUfUiqBmj0KBpE+4dUWae6bkM8gJB244MNEPNGNWHLKGH8LQTQ\

> \

> > > \

> > > > >

> > >

> ND2QjcAEWjGUD5kW0XcSLQcCNpGpJqxZcZgHZSWB01bCwRtF9/L1cfd/ezkHMWMMPQMKsY0O\

> \

> > > \

> > > > >

> > >

> zn/uLtH0MM2IGiLWAc0kNGMoX3IXlwfd/em1wH4BYI2T/wYEFe0MQyOtaZxhGgNELRhPh9CW\

> \

> > > \

> > > > >

> > >

> T3D+Pq0bci69TToKnPF8ds1Bj1wM558cPB8dom8aeNA0MagKydwRBjr9hQXMdVpo059z2eXN\

> \

> > > \

> > > > >

> > >

> N5ubt9ubl+vrqkrdp4h//c05J+i7ouyRvamvmv/O4aeA663mAWCNsBX9E5tAOuTpPHbxmlrh\

> \

> > > \

> > > > >

> > >

> HtHpODXq+u3m9uPu/vFcPT5EH4+hKv5y2r+Qn35aFR/+PJPfUXvNOjfWgxH0uak750vuw6DW\

> \

> > > \

> > > > >

> > >

> gS8Xl0jzcMIELRW1kka9TgJ3AgjPLWOZ4ens8NT2ghT9ya18lWFfEmr+Qv1CXu7uSVrzw5P4\

> \

> > > \

> > > > >

> > >

> w0Q6rDdjp8fWvUx1QEIWh+/4WZP1zNFKmTJ09nhKW2N325uaVPswS6MdtyL4SiubLrk6X2tV\

> \

> > > \

> > > > >

> > >

> 3l+aPpDqBEQtA5W8xePw80ycEzxYooOL4aj1fzF+w0X7bIpPPJ6dU1x7d9wtneyloFplMfTA\

> \

> > > \

> > > > >

> > >

> wTNDtUF9Wlv9RuKDQ6oMx61XFrNX5bLpennbRIZFaH99VPrWHYd8+bTD3/uH77d3Jp+3v4DQ\

> \

> > > \

> > > > >

> > >

> TPy+RDOTs792DjLeCtlPkgp2xY+tgd6MlLWs8PT+GM0/oEqmQ+zk3PkeLACQbPwFb2/3dzSP\

> \

> > > \

> > > > >

> > >

> Da+liquQ/q1Tod7r1fXuMJQDrqORGEQOiX2IAxC0/vt5taD0wU7gaDVQ9cCqfyuuyPe4A6tS\

> \

> > > \

> > > > >

> > >

> NVC7X2pjeTa1C5rmkp54PCQAwhaJZTg7PRvWPnTlSIY2BmxQjkh6+5lPxl7Lsqafg0gXVo5E\

> \

> > > \

> > > > >

> > >

> LQyFsORownOMrhMXq5D9oVtfEXv6z6TJ+fro0XXoh90aDw7PMVWWiEQtALWG2fXDuvpx3W4d\

> \

> > > \

> > > > >

> > >

> yT3y6YfJBDipwYAXWWkQJPxqVJoUk0abWylVQFBV+XzIaSNs/G1UWwVBQcUX8ahn538Hioen\

> \

> > > \

> > > > >

> > >

> rqo6dnhKb7yqwNBl+d7uXq7uaVfdsaXRP6VE/50DsUexwm+onfZL9ihmSaj0vj6rwIEXRKHc\

> \

> > > \

> > > > >

> > >

> pzlwqbLBQgxO8o6SB3LpzY+tfJMPORKVwGCLsPH3T2d5BhfAztWyM/pH22Z4WU/oA31uhqiC\

> \

> > > \

> > > > >

> > >

> 5PwqXWMRi3lgKCL8ZtIZ/dhoGw0h9M/X1mfJVIVARc0jZPDEkDQBaCwhuXHNTKRGa2a68C6A\

> \

> > > \

> > > > >

> > >

> bwL0Ta694TtQiEg6Lx83N3TJDM+0ZO9/JPkh2hGDaGiH+uDRItzPWn5INyRHwh6N5bfD4wHm\

> \

> > > \

> > > > >

> > >

> rE9qTmkaXnVxfjkTJiujTbCHfmBoHcgszWMz+zEITsSQc1AQuFpm3uqIbsjJxB0FovhyNpsD\

> \

> > > \

> > > > >

> > >

> XpVUDNIgzQd2lpSkX724V54NhB0Km83t3b+TqQ9EbpagDxQN5/w55TC+OzdcPQkOEDh/wwg6\

> \

> > > \

> > > > >

> > >

> AS+ovd180Cb7EyN76BmUAKpaQuDHpPg4PnsEiHpRCDoTVbzFwuDzrSucAwIqkBHiKF9yUgUk\

> \

> > > \

> > > > >

> > >

> sa2YxsI+h8+H0Lbgs4yrxnROqAEmc5v2zx/ah1j/7EBBP3Lx929VfVoKGhIBXaR1wwUQqXy1\

> \

> > > \

> > > > >

> > >

> uXLrYl40ItBlnQcCFqIeF06mybrU+v47eYWagZM0LS3KmlaHhti2hMQtPhertZHgnbYmebo8\

> \

> > > \

> > > > >

> > >

> 9klQnJAA6v5i21H4jT/4WgBQX9F71aV10D/TWAE2enYkm0KLQSkdtRa0FYVP6L9CyocAVNQ3\

> \

> > > \

> > > > >

> > >

> aXQmost5OiaHxvWV9D2tKqi6ApiGsAG1hEPO07L0TqrpoK2J52OajDi5BpYxcfd/brStOmIR\

> \

> > > \

> > > > >

> > >

> 83T7+oo6MVwZMMGgY5lcC0Q2AldPrTh8JBeQz0PZmon6LWdLdgXUIKz6ecBQBYyXdr4egn3j\

> \

> > > \

> > > > >

> > >

> mq4Xuol6Leb29D0GYjMosNhIHACS+qh076qbpWVaiRoG6rTUfnmGm4EgOtQo2TjKU91q35XF\

> \

> > > \

> > > > >

> > >

> 0GTnc3OrcdgH6kawF0owcP4yWGtHF0LQRu3M/3r9ZlVwGNsyJWuj6P9F/Q6smHuOx+5nMAz6\

> \

> > > \

> > > > >

> > >

> A6B2a10TRztuaDN2hnngcBXbGhqUQdH+yxos3ZGh3ngPRTuMHhy6L2jvRW02bgzwhqgJsiSC\

> \

> > > \

> > > > >

> > >

> QZ/p3rsaD8FbdzOCGuA+iDDHQZXnK+O9lDQi+HI4ERBuXFQT9YtL0xomu6weHm9wDdBG7zJj\

> \

> > > \

> > > > >

> > >

> UsooOYshiNTNch8vQvulaA/H0JTdkbQGQBhuorvpNH2bA36I2iDFUQRdAZAYjAk7V9tUk8Eb\

> \

> > > \

> > > > >

> > >

> ep7m4Jur1fXCDoDIPlerl6vro38nPXst6wPgqa+ggbs/HMkaPoBAGAjVLhD86pcO9qXfobOC\

> \

> > > \

> > > > >

> > >

> /p7uTLSV9Djg2MAqkPV7wxeE5udnHvwu9ZtQX8vV0a+pf0LdQGgkI+7e+NtMah4pOuOdlvQR\

> \

> > > \

> > > > >

> > >

> i6kUJALVUMBSGRd7s5006LQiwssDgvayLc0/XSCnQFIxIa98z+ObrSdrofjqqCNXEhBOh0AG\

> \

> > > \

> > > > >

> > >

> Xzc3RtvWrQtaKeTo50U9Gr+oj/lmezsekgLACZs2zvHV+5T69jRX73uCdpIUp0fBw4AMGFP3\

> \

> > > \

> > > > >

> > >

> DnN0Y4m3rknaP2XlB6DfVxFASANa/fOG452cY/lmKD1p23QRUHT7xsAS3HCznItO5fU4ZKgF\

> \

> > > \

> > > > >

> > >

> 8OR5iOIx2DfuU8UAG1YeCqYJehGexIcuHW5zBlB66+FhL0zABk4tHeOL2q3rpi5IWj9B4MUd\

> \

> > > \

> > > > >

> > >

> zb9vgGwFMtPBbMd7dCBoRuCfr26hp0BsAQX984bjnZlgTsgaIpz6fzwXDztBUAPrttZLnMnb\

> \

> > > \

> > > > >

> > >

> hjaLmjNTVJgZwAy8MPO4U9wxv5gtNWC1hx6xm0UADJYx50dydnY7WgXgtFWC/r16lpbKVEnP\

> \

> > > \

> > > > >

> > >

> i0ATOHN3jk+7D9tslfQOkPPqCAKQAZu5TsXXfs2B6MtFfQ661nL1/Wk0Xa3lgoA3Hi5d94Y1\

> \

> > > \

> > > > >

> > >

> gajbRQ0dbHS83VN/4q1Hw8AZjGY7zwJDjRt0YIDa/tj2ShobVnP6CsIQAam9s50XP92cxvq+\

> \

> > > \

> > > > >

> > >

> m6wNjPaOkHrzKtzsXgKAHowZWfaz1LIkYqjaXgN1tb1t0vQX9H77PBUT+aGtd+ZABjHrJ3jy\

> \

> > > \

> > > > >

> > >

> VTafk8/Bvuzw1Pb8rjsErS+4AYupACQgqm4c3zvLPlerrSVgLdw02aRoKnNoKZ5gKQ6AJIwd\

> \

> > > \

> > > > >

> > >

> Rslox3zav6i7Yd1uHdk1aGULYKm4IaOYJPLDcoAYMVUvnPi3jmOtjakk0bbqkCHLYKm4IaeH\

> \

> > > \

> > > > >

> > >

> bRV35AAWII9cedE6Be2nj2cPYEOKwS9bpWi5dEjbQOAbayKO6ehp+OdVRkd5gWtrSISDgYBS\

> \

> > > \

> > > > >

> > >

> MTCuHMaeg4M7anMY17Qbze3GsL/dubQAGAcG/Kd86MtE9eSfqSGBf35EOqZCm41IgNAD5bHn\

> \

> > > \

> > > > >

> > >

> RPR2Z7UuDQMC1pbcMPmglUAGIEiG/pH9QCCnlKX9DoVPvASmBS0tqf8fHZp8G0CYCEOxZ0T0\

> \

> > > \

> > > > >

> > >

> RaMNru3MybodeIz8yOmOykIPQMQx624cyI1EYgxQWvrlmI8igSAVVh7G6Uoek6wzHZdMSPoz\

> \

> > > \

> > > > >

> > >

> 4dQQ+KzJeewANiDi6eCGejJAZsEB6b2eQYEraceP5WU1f/uALAWU7dRVMWdE3k+u+R2tMErF\

> \

> > > \

> > > > >

> > >

> AYEreFsEAU3ANjAYPV9PjsLXWU6TJ0W6ha0nqJIk+AABTcAkHgTd06EakVwvxcjp4W6Ba2h4\

> \

> > > \

> > > > >

> > >

> jPy6gCI41ncORE9YtF/WqhV0BquABlPiwHAKpyoglQdDVl3Ri4kaxW0htS6x2AfwQ0ACF/jz\

> \

> > > \

> > > > >

> > >

> okshqPHYJ/1zepPudMnaA3dYOnxoV4dAMJ0ZMPIEb2GLaDmSqSaBE2NxVifHYIbAEjqEHfeR\

> \

> > > \

> > > > >

> > >

> kOgg/J3te0CNQlawzHrpNFGcAMAYboKktn0Vtl4he/7SWeSmCZBz07OWb/MkbkBAFGruHMi3\

> \

> > > \

> > > > >

> > >

> HWUJo22tip3OgQtZwzrpLFhZgBglhrGnbdZzV/Y32+jrefeCrug9USFUO4ZgHrGnRPhrtGh7\

> \

> > > \

> > > > >

> > >

> cSLXdDrK0xsk4YmBzI3QM2BneNoKPij5/I3r6DpMXF/leFsENQcL6sgVYQSE1zfGvIK+uPun\

> \

> > > \

> > > > >

> > >

> tvOOBsENQdx5zS4Tws1BFcZBf29XLHWRZo02ihZB2oOIhsZrAvdcSpodnjKuolmFLSG7TPq8\

> \

> > > \

> > > > >

> > >

> YM6Y7bOhuV2Jt5ubp3eRDMKmnv7zP3dBYDNIO6ch/XveE5Hs4qIS9B0n4fvoeBsENQZxJ3zo\

> \

> > > \

> > > > >

> > >

> +EaM5+LuATNmuOC1DpQZ2DnQnDnkrHqiEXQ8jo8y+NotFF2A9QWnAqWQEMpTSYjsQiatXAdu\

> \

> > > \

> > > > >

> > >

> sGC2oK9c2kclZJ6QWv4sjLVAh0Ag6AKUhU+H0LGL7BGm6lOtHpBs9bMnjTa+tuCAWAc7J2rw\

> \

> > > \

> > > > >

> > >

> 9q3kKnZimJBa6gj5cdcASA/iDsrwUU7KRY0a1q4ka66AJilJl1f9cC9iVZ+dU6loLnvdnN8Q\

> \

> > > \

> > > > >

> > >

> QFgM4g7q4U20XzPU/mlFZWCZr2cor+fLgBmQdyZA+5DMrX5dioFzdfXahIcPLWOkbwB6gPiz\

> \

> > > \

> > > > >

> > >

> kx8PoRPrWOmQIfybljKBM2bxYLoM6gTiDuzwreJVp5vp0zQfNF3KiuK7TOoCYg7c7PeRLP93\

> \

> > > \

> > > > >

> > >

> Fe4m1QjaNbGg5NGG1cHQU1A3FkPfLX81bYrVCNo1tLPTFd0ALANxJ21QReemZ6nwiLRCgT9v\

> \

> > > \

> > > > >

> > >

> Vzx3XPH9hnUBMSdNcO3iabSHEry7RQImrX4xiQ4wPYZeA8iG/r5fAjt/92vQNBvN7dc22fUf\

> \

> > > \

> > > > >

> > >

> QY1AHY2AtWJ5ttEK7lVWFXQX9E733mohqa5AJgFcWeDsB6eKblVWFXQfO1k1B6GAmAh6PpqF\

> \

> > > \

> > > > >

> > >

> t70MxVt+aoK+vns0ol0QgBsY21n5nZ5aXaubWRjA9ZLK9UTHCoJmi++gbvdwG8Qd7YEvksrd\

> \

> > > \

> > > > >

> > >

> MOu4s+USoLmm2ST4ADZdcBXEHe2Cr58u3DvqOIpWiVBs74xtIUFXgI728ZiOOJ75hU3muUFz\

> \

> > > \

> > > > >

> > >

> VoUSnlZVQBswFTcuT51NsrBVMi+eqi2vKD5MlQmwYHyxgQAGAdVkKyFrxVUxVzhkoJmvd4do\

> \

> > > \

> > > > >

> > >

> nMK8I6Pu/tJcICcDTvha1dY8dp3SUFT9WemHwXIrgOegbiz/bC2Kyz9BVlS0KzxDRwPAp9AF\

> \

> > > \

> > > > >

> > >

> SQnWAxHTE6rEuUoKWim/A3cHgSegXxnV+C7VVgll6OMoL+id6ZZhc6wwCdgZ7dg7Sdbbt9ZR\

> \

> > > \

> > > > >

> > >

> tB89TdCpD8DX0Dc2TlYE6LLma2MoJnqb6C4KPAG1NlwEb4CpJNGu1xsoLCgv5crvvobiG8AD\

> \

> > > \

> > > > >

> > >

> 8CpoLvw5XI8tY5L7D4LC3oxHD21jplmGKojAddB3Nlp6II002dUIspRWND0DcMx/2Yn50VfD\

> \

> > > \

> > > > >

> > >

> ABWgbizB8xOzu2JEBQWNFeMBte7geMg7uwHTNe+6WMq+mKKCZqvQNIkOMAMA+6COhvesJq/M\

> \

> > > \

> > > > >

> > >

> J0TPrWOi35SxQS9rifAEd9A+TrgLIg7+8T3csVX3K7olcJigmYqkKSqAy4A+jFbBQlxZw7eb\

> \

> > > \

> > > > >

> > >

> m6ZRFc0DF1A0F/RO18AGvkbwEXQ9dVLPh9CjlBBiU+tgKA/H0KO33GovwEcxZSdEXfmhrEuR\

> \

> > > \

> > > > >

> > >

> 6NdaDNaQNBMFexQfwO4COLOfsNUl6NoZbsCgmZ6xSUC5wCYBfnO3kNHCxyCLrQfzSvo9Z6fJ\

> \

> > > \

> > > > >

> > >

> 76B7QBwCNi5DqzmLxxRjkmjXSiim1fQXLmBpZK3ATAFur7WB76q9/nD0HkFzbThR4Ek4BCIO\

> \

> > > \

> > > > >

> > >

> 9cKpsJJhYK6eQX9enXNNC9RABo4Abq+1g0qDMfhvfy70ryCnh2eckw+XCAEToC4cw3hu1I4O\

> \

> > > \

> > > > >

> > >

> zzN+RpyCXo1f2H6JindqgsAbaAKUm1hak4S5u7znUvQTJ1gJo02bngDy0EVpDrzdnNrNrSbS\

> \

> > > \

> > > > >

> > >

> 9BMAWjc8AaWg1PBmkN3vtV/vrk7YOUSNFMJjnI9YADQA+LOgKnDX/704t2CXkfKlSdsBwfPZ\

> \

> > > \

> > > > >

> > >

> 5cQNLAT9BUEBEc2NF3Qy2O/3YJeF+lXPVNRYhRYCyIbQMJRepSK9+cJ8O4WNNNkfQz2EYAGF\

> \

> > > \

> > > > >

> > >

> oJ8ZxDn8yFkqUHUaOe5rrJb0Bw1ksp1fwFmiaIoiqLpdDpOYjqd0v/A9MusRK3izhkfqB+fp\

> \

> > > \

> > > > >

> > >

> hKYkoxzhhB2C5qjiwpNRwSgbWa5XI7H436///fiotvtdn5optOJ8ffiotfrDQaD6XS6XC5Nv\

> \

> > > \

> > > > >

> > >

> 5tc+G3n5XI5nU7zf6DtP632n1an0+l2u859lAr5Xq44siQeg/08t0B2CJqpi4rCGtDL5XKgj\

> \

> > > \

> > > > >

> > >

> vF4vDEFp9Opwr8/nU4z3st4PFb4b5XY/sg13O12m81moIhms9ntdvv9ftEVrvbDzebt5papI\

> \

> > > \

> > > > >

> > >

> fLO8X+Ndr/fT/z0K+5hlX+gzWbz78VFlRem8zNNY3uZZ8MSRcj3rbxD0OvtPYOgVdWAnk6n1\

> \

> > > \

> > > > >

> > >

> aedpP2ntTHz/l5cKPz7/X4/7Y0sl8tOp6Pw3xqPx/kfYxRFg8Gg2+0qfAGJdLvdQe7lHUUR9\

> \

> > > \

> > > > >

> > >

> +sh/v73PyNqJju3/7TSXlihDzGO9DLTE2s2m71er8TLU7tgS7/4Ql8wHL1KclZa3iHoxXDEN\

> \

> > > \

> > > > >

> > >

> HFV1UiaTqcK93qdTmfjk+v1eqr+eLBL0GqXU/7F0+/31X437KTT6fT7/Z27GD2C/vvf/4yoe\

> \

> > > \

> > > > >

> > >

> aedg1KCjqKo1+tl/1mFdLvdolsBhQu2HNvLPJvFcMSUKLFTgzsEbfCrIycQdBp5ls14PNas5\

> \

> > > \

> > > > >

> > >

> jidTif7RWoQtM12DooLut/va1OzhHbT+X8VOSdopuL9eQIJOwTNkgOo9IQQgk5j59oeDAYK/\

> \

> > > \

> > > > >

> > >

> 7nSZDwTbkFbbuegiKCjKNIQocpg59etfJ3OCZrvnHBnIkeWoL+XK6ZbNAqL2EHQaWSvln6/r\

> \

> > > \

> > > > >

> > >

> /Dfqkiv10t8kayCtt/OQW5Bj8dj49YjBoNB9kt1UdCCLZlt523qLEEz9R6fBAcK7xBC0Glkr\

> \

> > > \

> > > > >

> > >

> G2r7EwkPhk+QTth5yCfoC35JSTJdrSjgn67uWW58L0rkSNL0Kv5i/1dVCDoNNLW9ng8VvivK\

> \

> > > \

> > > > >

> > >

> GT7BTMJ2hU7Jz4TJz7NjJftqKCZSi6HuwpD7xA0xx3HnJfQcwJBp5G4SKIoMngqmE2n09nI6\

> \

> > > \

> > > > >

> > >

> +AQtEN2DnYJWu3kV0hGHpujguYrSZQtwyxBc+TYFe06vhMIOo3EtW1hcCPOxq9j5YJ2y87BL\

> \

> > > \

> > > > >

> > >

> kGbPRXMptvtJkZXHRX0Ot7LUHc0O5yQJWi+sEuhR5MNBJ1GYsTA+NrIptPpbLxghX/cOTsHr\

> \

> > > \

> > > > >

> > >

> h0kbJAYjLZhEpYQtKCy+AyCzs60yxI0R9fxSaOttg8hBJ3G9tq2f0kH/75shYJ20c5BuqBt0\

> \

> > > \

> > > > >

> > >

> NxOtmNWlrzycoLm6E84CQ6yi15kCZrlBanuQwhBp7G9ttVGn2V1JLXrLf6IVAnaUTsH6YJ24\

> \

> > > \

> > > > >

> > >

> rs2sPVnXDlBc/Qn3LlhTRU0X8txVVU4CAg6jY21oXBhNJvNwWAgN0dRFPX7fVV/vNvtxl9z9\

> \

> > > \

> > > > >

> > >

> T/orp0DXSe9VK+u1+upLZIV/PtpKp+HpSknaCp2qHySZLdWyRI006xVW6cfgk5jY20rzJZNj\

> \

> > > \

> > > > >

> > >

> C2q2tN1Oh05X6sL2mk7BymCVptat/FpKr/9v7Gg3BX050PIlHZcRtCr+QvTxFVbpx+CTmNjb\

> \

> > > \

> > > > >

> > >

> at6I4mBRULJwo4XFKwoaNftHKQIWmGFxb8XF9t/n/ULwF1Bf0Xv+pWYKujPh5Dp1ait0w9Bp\

> \

> > > \

> > > > >

> > >

> 7GxtlX98bRr2aqelSpBe2DnIEnQy+VS4YRPi3Er3ERvRDlsEHTRcqOEkaBCqqCpq7HykbOXb\

> \

> > > \

> > > > >

> > >

> X4g6DSYBJ3xFpREOTYEndHAZRv5R0zZeRIcKLRzkCRQhdvbDE8pnIrbqZNqBV1ohhDldtDrk\

> \

> > > \

> > > > >

> > >

> kkMUY6MVOgsQXPklOwsDlIUCDqNjbWtak+U8RaUhLnjgqa2WzmZTqf0Hg3aeXZ46lCuZLPZT\

> \

> > > \

> > > > >

> > >

> PsoFb6Lja8BtYJu/2kNBoO0PpkZU6WEhdbF4/TmTaQK+vXqWn/SXwkg6DTia1thu5aMt6Ckp\

> \

> > > \

> > > > >

> > >

> tp2U5v8dDodk3Y+OV/NX7gFrTAArU3QG7ntaheszjaJHFdDwr2jjMxj3YJWmwQtIOh0aijo/\

> \

> > > \

> > > > >

> > >

> 2u0OarH5LQzFTBwKJldj6CDf88JlQtaZ+txlsvVjXbGtjVV0EyVoNUmQQsIOp26CZrp1CSnn\

> \

> > > \

> > > > >

> > >

> ekgXsNtI4UBbgi6KB9395rr46cKmqmDgMJCowQEnUatBE1HJkxpqjntzP0hCtV2g6CLshiOm\

> \

> > > \

> > > > >

> > >

> DpMpf2LyYJeXyNkELTaJGgBQafDJOiMNDtTgjZr53hpRm5Bq53tEHRROCowZ7cATBY0Uy+Vn\

> \

> > > \

> > > > >

> > >

> cVPSwBBp8Ek6IwloSQDrGiOqj125v4QBXbQW2gW9OdDyFLgM70Csz5BT4KDp9YxdtBpb8QVQ\

> \

> > > \

> > > > >

> > >

> Qfp74JuCZfISy2do0pxZ/12fgz245ENPR+igKC30L+DVl62v4yg1+0D1Aq60Yag/RB0s9mcT\

> \

> > > \

> > > > >

> > >

> qeJbyFSQc6P3pK4s7YPUUDQW/gg6EZ7dniaJsZMQSv/otjVIbEEEHQaTDcJiU6nk+hobVhoZ\

> \

> > > \

> > > > >

> > >

> wFBp+CNoL+id47siYwugFoFrfwaoYCg02EVdLB1AUEnVsWd40DQiXgj6PVlQuOCXgxHEDThj\

> \

> > > \

> > > > >

> > >

> aDVvhFJv9/XeZVL2JHvnAYEnQgErVjQHDsUCDrwpR70Bt1uV9tW2tTeOe1UcAMIOhHPBM1xW\

> \

> > > \

> > > > >

> > >

> zXtBp8+QT8G+8oLcQgIOp3tta3wj2/z9+KCOyptZ9w5DgSdiDeCFkK83dyqT4VutMsIWu2Lg\

> \

> > > \

> > > > >

> > >

> KAD0z0JlYehN2g2m71ej2nBWBt3jgNBJ+KToF+vriHoAkDQaWwLmi/KEYdD06bynfPvnfV8i\

> \

> > > \

> > > > >

> > >

> BD0BpRNVCiJs+KRCYegw6IhDo6iTRB0YFrQaptxZNPpdAaDgRJNWx531vkhahO02raEfIIuw\

> \

> > > \

> > > > >

> > >

> XYf20JYEeLg+JZ4DPaV1xoVEHQ6iQd3Csu956HT6fT7/Sonw6bsHO4dFbWzhg9Rm6AHg0FPH\

> \

> > > \

> > > > >

> > >

> fHDCdcF/XF3z+HGtM2rVkErrzUqIOh0EgWt9kphTrrdbmIj8J0YtPP/NdolUlO8ETQfEDQEX\

> \

> > > \

> > > > >

> > >

> R7vBS1U92zOT7fbLZTmYSruHP50fYWgOYCgIejy1EHQQnugI07Oiy1m985UFB+C5gCChqDLU\

> \

> > > \

> > > > >

> > >

> xNBK39fhdi5lbbBzjsfoJEPEYKuDgQNQadij6CVv7VCNJvNtEdhiZ3zPED9HyIEXR0IGoJOx\

> \

> > > \

> > > > >

> > >

> SpBK393Rfl7cbER7jAed46/PAiaAwgagi5P3QQtjMajgyDodrvygduzdyYgaA4gaAi6PDUUt\

> \

> > > \

> > > > >

> > >

> BBiMBjoz72T0GWwxXBklZ0DCJoHCBqCLk89BS2EiKLo78WFwn+9EH//+5/yDj4V7RxA0DxA0\

> \

> > > \

> > > > >

> > >

> BB0eWoraGIwGKTZio+///1vEhxYtXcmIGgOIGgIujw1F7QQIoqiXq+nbQn9/e9/+r2cx87lH\

> \

> > > \

> > > > >

> > >

> iAEvRMIGoIuDwQtnyp3bdLAbjuXe4AQ9E4gaDWC5qhmB0G7ImhiPB7zadpyO5d7gBD0TlwXN\

> \

> > > \

> > > > >

> > >

> Ec1u8KCZqoHjWp2bgmaXhWHpu23c7kH6I2goyiaqiOe7e66oFkK9gcHaW5Ewf5/gKDTXpvCV\

> \

> > > \

> > > > >

> > >

> Dwn7FzuAXoj6G6321RH/F0oF3T7T6tThF6vV/RjjWNFwX4IWgJBS76Xq36/X1HTrti53AP0S\

> \

> > > \

> > > > >

> > >

> dCq/pUALa92jZItr5Q3jUWIw2lBE5TmUe4lOWTncg8Qgk4EgmYQtOpDwklw8Hx2WaW5RiIQd\

> \

> > > \

> > > > >

> > >

> BpMgibG43HRrbRbdi73ACHoRLwR9Pdy9Xx2qd6NRQX9+RA+tY7V7qAh6MAjQYuClw+ds3O5B\

> \

> > > \

> > > > >

> > >

> whBJwJB7xyL4SjxX4Sgd3ze3gh6PB73VbDxZ/M8HxftvP0A8wBBJwJBZ4+n1vHnQ5j4L2oV9\

> \

> > > \

> > > > >

> > >

> Ozk/Ct6V/vIIOg0Nta2qhyM7Syl7EfkqJ0DCFod3gj6K3qfHZ6aF/Rq/sIh6KfWcdE2yTuBo\

> \

> > > \

> > > > >

> > >

> NPYWNuq/vjfi4vtF58W63DXzgEErQ5vBM0ixka7sKA5vigg6MBfQUdRtL1Dd9rOAQStDgg6W\

> \

> > > \

> > > > >

> > >

> 4yzw9O00II+QdNLgaDT3ojTghZbhf9dt3MAQavDG0F/PoQc1wgLC/p7uZqdnHOU44Cg096I6\

> \

> > > \

> > > > >

> > >

> 4KOokhq0QM7BxC0OrwR9Gr+wiLok/O07IlkQQshmASdlk1SGgg6Dc2CFhPrUikAABr4SURBV\

> \

> > > \

> > > > >

> > >

> D+RaD/sHEDQ6vBG0IvhiEnQaf+iVkFPggPlBe0g6DT0C7rX65myMyVxqm3cBUGrwhtBc9Qap\

> \

> > > \

> > > > >

> > >

> amb9i+mCvr16lp5OY6Mok2lgaDT0C9opjoyO8djsE8ZnBB0ISDoorzd3HJcI8woUqRb0MrrJ\

> \

> > > \

> > > > >

> > >

> UHQaWgW9MfdvX41hz+/EOlsA4IuBARdFI5C+eHeURlBcxS0mzTayi8Tcgt6IzmhIr4KmqO6V\

> \

> > > \

> > > > >

> > >

> n47yxNw7wWtdrZD0IXgu+edEfhNFfRiOOJYURnnleWYTqeqPuzEz3swGCj8+14K2hI7ixoI+\

> \

> > > \

> > > > >

> > >

> nu5UngKCkEXYp3bxjDPywj68yFkWldqBT0ej1V92Imft6OCbv9pTafT+N9nErQpO1PceSNr0\

> \

> > > \

> > > > >

> > >

> 3tBq32P2gTNV7Bfs6CZJnPaNUKRIejV/IXp1agtx5G/oFq5z1vtF0DGCdtyuVS49rbfCIegz\

> \

> > > \

> > > > >

> > >

> e6dt3Pq6yBohX9fj6CbzWZ8KioXdLyfFit8Ssy4HZIqaCGE/q+LoqgNyQVJXouiSOHfz+iHp\

> \

> > > \

> > > > >

> > >

> nbibv9DygVtT2RDUgdBKzy11iPoTqfDN8+bzWa/3x+UoqjZPx9CptmeEVRIFfT3cjU7PNUcc\

> \

> > > \

> > > > >

> > >

> CnEdDpVuyCDlF9MCv+V9p9W2rRQG0zf3qqrWtj0ly20s9pPKrBV0Apjbht72zgK38XGXsF40\

> \

> > > \

> > > > >

> > >

> 1jJRgxwJxx5E+He0ezwtIyghRDPZ5cciRxFU6Gn0+l4PJ5Op1EUUbPh8Xjc6/U4PuZEQfMdm\

> \

> > > \

> > > > >

> > >

> MThzudTKOiPu/un1jHHcXb2SIw7x6mDoNV+kSe+x+VyqXBxbUxFdwX9dnPLIeiMWyoiW9AcS\

> \

> > > \

> > > > >

> > >

> X+UaVfouag1VzaJglabadfpdLZnhtqjyGazuf1PqHoXBu8KZttZ1EPQas8qEmNuamfjxlR0V\

> \

> > > \

> > > > >

> > >

> 9AsG9ZdV0OyBM3UmTDj4nkiOgXd7Xa3QxBq9yxBEDSbzV6vNxgMqMuJ2nPOYCvqRyg57bTZz\

> \

> > > \

> > > > >

> > >

> qIegla+IjZ2uOPxWO0h3sbvd3cFzVTgMzuikCXoxXDE8TM2o7ZeIjoFnZhl8b1cqV113PR6v\

> \

> > > \

> > > > >

> > >

> e13Uf13q1k755kzNRG02syiIAi6MdT+5e2AnqOCXldgVr2D3lk/LkvQHMVPw8z+LonoFHSi2\

> \

> > > \

> > > > >

> > >

> oTqH33cpJ38VPGX5Xvn6m9wG2sFrTbKwUdiwNBRQXN0AQxzVGDOEvRq/sJ0TF+o6KhOQaed4\

> \

> > > \

> > > > >

> > >

> CV2DLGTtO8YUSEMbcrOO08FN6iJoIUjO4bEa1mOCprpZnWYmQQtsgX9Fb0zFR0tlMihTdDtP\

> \

> > > \

> > > > >

> > >

> 62MW0lOLImMxClRNpjuxN6ZqI+g7d9EJx7nCGcFzVLHLkfsLkvQTMVBHoP9Qokc2gSdsfcUD\

> \

> > > \

> > > > >

> > >

> GuPg4yr5OUepv1x5zj1EbRgiESrJU1/jgr6+eySqRJ0dumLLEELId5ubjW3eNlGj6Cz956E8\

> \

> > > \

> > > > >

> > >

> ouLaul2uzufaqFNtEN7Z6JWghZ6o3+FSAsVCjcFzdcCcGcsYYegmToIzA5P8y8/PbNw596Ts\

> \

> > > \

> > > > >

> > >

> Hbbkr9qTM7n6UrcOU7dBG3nr7rsX6IuCno1f+HIsXsM9ndeq94haI4eXDTynxNqEHRGDaNtL\

> \

> > > \

> > > > >

> > >

> AxGN5vN/DbJs6qd2zsTdRO0sC8YnW1n4aagF8MRR2GDSXCwU4M7BG3wq0PCLei/FxdFK6Ba5\

> \

> > > \

> > > > >

> > >

> ejEq4nZRFGU4RG34s5xaihosevT1Emen6EuCpopkPDUOt65F9khaKZEjsdgP3/vK1ZB93q9c\

> \

> > > \

> > > > >

> > >

> vWpOUo1leDvxUW5cotpq9pdO4u6Cpr+XbPx6E6nk/OluihojmabOSf8DkELtuPL/OeETDOv2\

> \

> > > \

> > > > >

> > >

> +2WWIFxaFWYmm3tP62Mo5ic9Pv9+Ot3Me4cp7aCJsbjsf5NA9UtyF813zlB850Q5klm2y1ol\

> \

> > > \

> > > > >

> > >

> kSORjvP9p5QK+j2n9bfi4vqapNMp9Nut6tzznU6nX6/r6qRhHz9jsad49Rc0ES/39ej6Waz2\

> \

> > > \

> > > > >

> > >

> e12S4TX3BL0av7CdIcwTxRht6CZKv8+Bvs5L3xXrCXUbDY7nU6326X6REXnU06m06mGhdHtd\

> \

> > > \

> > > > >

> > >

> hWqOQ5Tu+KcdlbVZEdhv77AWUHTyxgMBsqLcEnaf1q9Xq/cUlJeeqw0OV8/U8WLSXCQ5xxut\

> \

> > > \

> > > > >

> > >

> 6D5LqHnvE9INaBLQ1Wk9fTFiaKICtQp3FPTPoW+WpjeBdV3NmVnJXtnoso82aZ0cN/4a4g/E\

> \

> > > \

> > > > >

> > >

> DK1kq1Dp9Pp9Xrj8bjKFmG5XCp8PlXI+Ww5Qghh7pJEuwW9bq3CcM1x5y0ap6GJOBgMer0er\

> \

> > > \

> > > > >

> > >

> ZBOp9PMpP2nRf+zvxcX1Mgn/zQqzcfdfbh3ZEnXV8DEcrmMomgwGFB52263u3NC0v9A/vTUt\

> \

> > > \

> > > > >

> > >

> suxCqbb1HQXJI/9dgtaCMERI6fvEI8FnUiUif4FYFvXV6CZjNlo+qVZwfdyxRE/yF8WP5egX\

> \

> > > \

> > > > >

> > >

> 6+uOdbwJDhQ2EAWFIUaMugPPcPOwBU+H0KOBbKzkYokl6CZSu2V6E8IVGFn11cArIKpD2GY+\

> \

> > > \

> > > > >

> > >

> yp1LkFTogmHoIv2JwRKQNwZgDxw9CGkkXMV5BK0oH5c2luOAw5M7Z1hZ+AW6/wIHu/lfA15B\

> \

> > > \

> > > > >

> > >

> c2XJ1uouwqoCOLOAOSEL7Sbv9BFXkFzdPgOiwTLQXUQdwYgP0y70pxXVIi8guY7zcyZbgIqg\

> \

> > > \

> > > > >

> > >

> rgzAIVgSi+eBAf5l0NeQa+7jvMkbGP1coO4MwCFYKq0PGm0Z4en+X9N5hW04NzwIwzNCm6jA\

> \

> > > \

> > > > >

> > >

> FCU9WkNwxWVQkHdAoLmqFodFqwNDYqCuDMAJeCoAR0W7FUiCgn68yFk6vtSaM8P8kNxZ/0De\

> \

> > > \

> > > > >

> > >

> 2fgNEwR3XDvaNJoF7o+XUDQjC8ad74ZQNwZgHJQTgRTCY5Cm9ECghac237c+VYL4s4AlIapx\

> \

> > > \

> > > > >

> > >

> GjOLipxigmaKxu60caVQoUg7gxAafguEBbKgCaKCXrd/cV0biDIAHtnAKrAdeej0c5ZpD9OM\

> \

> > > \

> > > > >

> > >

> UELzuRtRDmqg9soAFTk7eaW71Je0ThBYUHzFeXAlcKKYO8MQHVmJ+dMy6REPnFhQTMVEKGBX\

> \

> > > \

> > > > >

> > >

> I7SIO4MQHWoBSvTYilxI6+woJl6wISo318B2BkAJfBFCMp1+CssaL73UC5GAxB3BkAJ38sV1\

> \

> > > \

> > > > >

> > >

> xlb2eYkZQS9GI6Y3sOk0UZdjkIg7gyAKvjit6UrDpUR9Ff0zvQ2UJejELAzAAphuohHo1wks\

> \

> > > \

> > > > >

> > >

> IygBbXqYopyoC5HPhB3BkAhrKUsns8uywVvSwqaqbJduHf0GOwjyrETVEECQC2L4YjPaUUvE\

> \

> > > \

> > > > >

> > >

> EpKCno1f+FTAFp9Z4MqSAAohysq0GhPGu3Sq6akoL+Xq+ezS754DSyQBuLOAChnNX9hWlNUI\

> \

> > > \

> > > > >

> > >

> Kl0clpJQQvOKAeufaeBuDMAHDBd7w6rxTdEFUHTlRsmWaC43Tam8p2xdwbew1e+rkSBpDjlB\

> \

> > > \

> > > > >

> > >

> S3YojY0cFQYB3FnAJhgTX+ueKJWSdBkDTvfmE8g7gwAH6wbzSrxDVFR0F/RO19djoo/DbwBc\

> \

> > > \

> > > > >

> > >

> WcA+FjXuOdZX0+t44orqJKgBX35sJ1+4lYh4s4AsMJ3e7B0/Y04VQXNVJcjxK1CxJ0BYIbv9\

> \

> > > \

> > > > >

> > >

> mBYof5GnKqC5uvfFVbOUHEaxJ0B4IYvVzhUEd8Q1QUt2DrghjUuQIq4MwDc8BUXDfeOHoN9J\

> \

> > > \

> > > > >

> > >

> Zc5FAiaeizypXPU7ajQbNwZdgY1gak57Ho1NdpKxKVA0KzXvuuWb4fIBgB64Muuq3i9O44CQ\

> \

> > > \

> > > > >

> > >

> QvmUE5Ym16FsDMAevh8CPkWmsLDMzWC5j4MrcMmGnFnALTBt31Wm36mRtCCs9liHS6twM4Aa\

> \

> > > \

> > > > >

> > >

> IO1jtAkOFB4gUOZoD8fQj6P+H1pBbdRANAJ326ShsLdpDJBCyFmJ+d8X0q+bqIRdwZAJ+vtM\

> \

> > > \

> > > > >

> > >

> 9vP/dnJucJXq1LQfLcKQ0830bAzAJph7Qw7abTVluFUKWjWW4U0fHIK4s4AaIY6p/AtOuWF7\

> \

> > > \

> > > > >

> > >

> FUKWnDeKgxVR9/NYirujDoboM6wRp9V3R6Mo1jQ1EwWm+hsUAUJAP3wtbqW0lO+uBQLWvCHe\

> \

> > > \

> > > > >

> > >

> FzfRH/c3U+CA9ZD5ORHh7gzqDevV9esl1M41KRe0JRvRztE5Y+D/qC76RyIOwNgBNY8YBocX\

> \

> > > \

> > > > >

> > >

> lIvaCEEX2mO8OeeO8fL5gb5zgCYwlEpsQiarwlj+LM3d24TjYw6AExBRuJbfcqz6yQsgmYtt\

> \

> > > \

> > > > >

> > >

> Br+HHY5VCcadgbAFKQj1uwyPh2xCFrQpRVOHz0G+0xfWcpB3BkAgyyGI9Zam+HeEZ+LuATNf\

> \

> > > \

> > > > >

> > >

> Wll0mgrzwnnAHFnAAyi4fYcq4i4BC34i0RPggPlaeFqgZ0BMMvbzS1rSuskOGDtm8oo6PV3F\

> \

> > > \

> > > > >

> > >

> +fTeWodW6shxJ0BMMtq/sJXVjTU8jueUdBCyybazpQ7xJ0BMA5fVX4aCjunpMEraO50DpKgb\

> \

> > > \

> > > > >

> > >

> aeFsDMAxqHimozbZ87kDQmvoIW82ez4Y8rPOu6s/SY36mwAIOHeGob80WeCXdCs7QqlmzQ8q\

> \

> > > \

> > > > >

> > >

> Twg7gyADbCW1Qx/Gg9q2BeyC1rw50TTMK4ns1WQENkAgGCtWieHnk2hDkELzm5YUlJmTwsRd\

> \

> > > \

> > > > >

> > >

> wbAErjPBsO9I7V9rTLQJGjWblhymAp0oPo+AJZAWyXWdTcJDrQlJmgS9PdyxVpNKvyJCunfS\

> \

> > > \

> > > > >

> > >

> yLuDIAlaDjxoh/r2rISNAlaCPH5EHKLTH9jWUQ2ALAH6hbCejNFcylNfYIWzM1WpLm0/fqAn\

> \

> > > \

> > > > >

> > >

> QGwByqK5NkWUKug1zcvmX+A6Al0IN8ZAHv4it41uOWpday5Er1WQQvmrrryOXJ/yyHuDIBV+\

> \

> > > \

> > > > >

> > >

> CGWbXQLeh3Fd/mYFV1fAbAKPUliRnIQdAta/AiO+2kyFbpD3BkAq+AuWScXoJEsXgOCppQ7b\

> \

> > > \

> > > > >

> > >

> kdztHE0FXfG3hmANDTIxGDBHwOCFpRyx1lBSTpaYUV/U3tnnAoCkAZ3zY3QdJdqM4IWWlLua\

> \

> > > \

> > > > >

> > >

> Ch5sjgVBMA2Ph9CDWtQf2pdHGOC1nDnJ1SUdYe4MwC24ZBAqmBM0ELXaWHFYDT6CgJgIRpCz\

> \

> > > \

> > > > >

> > >

> 6G5s0GJSUELqnJn8VNGFSQALIS7DYj0hraqdWkYFrSeKFK5K0CIOwNgIZ8PIfelQTlMnQ1KD\

> \

> > > \

> > > > >

> > >

> AtaaDmHDWlPWiSWhLgzABZCoWc9xlCYA1Ya84L+it61BTpy1gmEnQGwE22hZ0tWonlBC5kWr\

> \

> > > \

> > > > >

> > >

> eW57/xWRNwZADt5u7nVYYlGW2dRzGysELTQUutEPv2MR4+4MwB2Qq1NNaxNI0WR0rBF0HqyG\

> \

> > > \

> > > > >

> > >

> sOfA8NEFaLrKwB2oqFS8XoxNtpmE583sEXQQlfz7zAl+RxxZwDsZDV/0bN7C3f9wtaPRYIWO\

> \

> > > \

> > > > >

> > >

> gMd/x4YIu4MgJ3oqa0mtWBPcIOwS9Dacmjkh/G9XKEKEgDWom3TVjQTVw92CVpo6S0bH89nl\

> \

> > > \

> > > > >

> > >

> 9qS3uMDp4IA7ERP2kZoumRdBtYJWmj8zgz3jri7TGbY2bbvagCsQuehvYXBDcJGQX8vV3qur\

> \

> > > \

> > > > >

> > >

> hgZiGwAsBMqAqHNzqbq8e/ERkELed1e+94WdgbAOHq6WMmhv1d3fiwVtNBVjFTnQNwZgJ3oT\

> \

> > > \

> > > > >

> > >

> KoLLSgomo29ghYau65oszPizgBkQJV5tK16s91S8mC1oLXVUdIwD7B3BiAbSnnWZmcn9kxWC\

> \

> > > \

> > > > >

> > >

> 1roPSuAnQEwhbSzzpMna0PPEtsFLRwPRiPuDMBOdF4XlAvT5tCzxAFBC72Z0crtbPlvKACMo\

> \

> > > \

> > > > >

> > >

> /m0ydqs523cELSLwWjsnQHIA9lZW2TDrW2TG4IWehuRVR+IOwOQB/pxrNPONmc9b+OMoAXVI\

> \

> > > \

> > > > >

> > >

> 9X4WVaZBLAzADvRHLq0qlVKTlwStNBYPKWinV35AQWAKfQfLOXpeGcbjgla6OoaCTsDwMT3c\

> \

> > > \

> > > > >

> > >

> qU5shH+lIA3/dYL456grT0wRNwZgJ0YyXd2d+fknqCFxgZlRWcA7AxABvrznWnnlNaG1H6cF\

> \

> > > \

> > > > >

> > >

> LTQXtff1+9nALTxFb3rvMkt16adlfhz4qqghbk2r7AzAEVZzV+oCpLmBTtptJ24MZiGw4IWF\

> \

> > > \

> > > > >

> > >

> iR1ILIBwE7IzkYayzmXtrGB24LWXP5qezyfXcLOAGRg6ooZpW3Y2SclP24LWvz0xzLiaA++n\

> \

> > > \

> > > > >

> > >

> wFg5ePuPtw70h+HpJQq1+0sPBC0MJ14B0cDkAhFII3snb05FvJB0EKIz4dQZ5uc36nQaFNlL\

> \

> > > \

> > > > >

> > >

> A++qwFQhZGrKL92Pjx1N21jA08ELYxWU6Jolx/f2ABUhNLpTK1Et2oh7cQfQQujydGefW8DU\

> \

> > > \

> > > > >

> > >

> A5Tv2VD91OeE/FK0EKIxXAUmjiUCH8uLLlVKwsAhSyGI4O/YieNtn+rzzdBix9HGxl0JIJjQ\

> \

> > > \

> > > > >

> > >

> 1BD3m5ujf1+bbRdv5CShoeCFvL42NAlQ4SkQa2QQWeDK87XXZGfghamLxkiJA1qgsGgs/d2F\

> \

> > > \

> > > > >

> > >

> h4LWpjeR9PdGS9/dgFA0D0Ug1d5/baz8FvQwlyqvJw9lCWNcAfwjN+whqnF1Wh7b2fhvaCF6\

> \

> > > \

> > > > >

> > >

> X10iHAH8A4Z1jC7rLy3s6iDoIXpeDRNphCXwoEXvN3cyikNO3NTC0ELCxwd7h09BvuofgfcZ\

> \

> > > \

> > > > >

> > >

> TV/0d+tqs52FvURtDAdj5aOfmod4+QQOMfH3b3xPnM1iTvHqZGghdFc+vj3P04OgUN8Re/ry\

> \

> > > \

> > > > >

> > >

> kemwxph/eKE9RK0kHfBTYc76OTQv5upwDMWw5HZNOe4nWu4XmonaCHEYjgyvo+mOfcY7L9eX\

> \

> > > \

> > > > >

> > >

> SMqDSxkNX95vbp+DPZtsLOXdTbyUEdBi1htUsPhjkb7MdifHZ4iKg2s4uPufnZ4avw8MPSxg\

> \

> > > \

> > > > >

> > >

> mghaipoYcEV1X82CMEBEjyADVCqBh3H2WDnmt8hqK+gBTnaUD/DxLkY7h293dzi8BAY4St6X\

> \

> > > \

> > > > >

> > >

> 7cQtGDXEv70FayznUXNBS1++hla4mg5KesZbgMGWQxHtBCM75pp+NRXsAp1F7QQ4nu5Mlssc\

> \

> > > \

> > > > >

> > >

> XtqIuIBtLGOaZjOottYAs9nl+jzKSBo4nu5siFFemOOPrWO325uMU0BEzTtbTgtj097uoqCa\

> \

> > > \

> > > > >

> > >

> U9A0L983N3T2YjxaRqfr5QujfkKFPK9XMkEZ3v2JajQuw0E/Q8GW4NnOJricQhMAyX8hpstm\

> \

> > > \

> > > > >

> > >

> +d1TqdLA4LeZDV/mZ2cWzV3w70jOr15PrvEDAal+XwIn88uQ6Ml9tPsPDs5x6HLNhB0AsaLk\

> \

> > > \

> > > > >

> > >

> SdP4kab1hUuH4Ki0LVA+U1vfDLHZzV6eGYAQadiQ/W75DkdHEDTICdSzfbEmuMzuW7V6YoCQ\

> \

> > > \

> > > > >

> > >

> WexGI5sC0lvaxpBD5DI50P4enVt27l3fAI/tY5xspINBL0Dum1o6RRvtKnANDQN4pCan1rHt\

> \

> > > \

> > > > >

> > >

> gU04nbGLcE8QNC7saQebsZcp80IjhABHQOu1WzldKUZi3roOYGg82JVmYI0TctMD+RN14rv5\

> \

> > > \

> > > > >

> > >

> YrUTIFmO3fNcvkg0zk/EHQBrCqulG3q2cn5x909NineQxWOLMxr3h4oflQCCLoYv+EOWzcpU\

> \

> > > \

> > > > >

> > >

> tNUaRrhaV+hQPO6arPdag4R1igLBF0GGxpo5lwVMjyN++LesBiO7A80xychGiWXBoIuiczus\

> \

> > > \

> > > > >

> > >

> HwrLTUd7h3NDk/fbm5X8xeY2kVW85e3m9vZ4Wn8M7V5UIYfwhpVgKDLs66B58JSics63Dt6v\

> \

> > > \

> > > > >

> > >

> bpeDEf4vekEX9H7YjhaXzZxYUNAgzL8UJeuIhB0VWxOlM7QNNXJI1NjCVkIFZyTUWZrM5rTJ\

> \

> > > \

> > > > >

> > >

> ljNW1WpAoJWwPrk0OL0pgxNh3tHs5NzXBy3h/Xp38l5SPtQt777G+1Jo43zQFVA0Mr4LbDr1\

> \

> > > \

> > > > >

> > >

> IoKY2eJs5NzClJjdWnmK3pfh5hPztcV9N2JZvyq+ad8uenH6Q8QtEosv3OYX9Z0nPj5EMLUr\

> \

> > > \

> > > > >

> > >

> HxF758PIR39eTBtsHFWDgStHtv6b5ZZb402xT0pTv1xd48AiEJW85ePu3uKL7u4Wd4YuIHCB\

> \

> > > \

> > > > >

> > >

> wTNwlf0/nZzG1p8NTyvqYMDaWoKVS+Go+VyafoBu4c89Hs+uyQvOxdfTpwe4d7R280tNs5MQ\

> \

> > > \

> > > > >

> > >

> NCM/OZKO74OQ1nrIzh4ah3TzReKgXwvV0gCSYNKZLzd3JKUf4PLvswHbJy5gaDZoQij0xGPf\

> \

> > > \

> > > > >

> > >

> 1bmTzkeOhSKyxpXYL6Xq9X8RUpZNsy2vIZR0UG/qFBoXwMQtA6oq4UfW6ftQe+LKlNTGOTj7\

> \

> > > \

> > > > >

> > >

> n4xHNXE16v5y2I4WseUT87pBrYH4YuMzxpJmdqAoPXh0O3wkqu30ZYx60mjTWFr2l8vhiM/c\

> \

> > > \

> > > > >

> > >

> kIo72IxHNEeeR1Q/jlT9eZ3UvLnGxyg5rhmIGitfC9XH3f3rudU5V/P8ZDrU+t4dng6OzwlZ\

> \

> > > \

> > > > >

> > >

> X/c3cuoiG2BbPmSSMcfd/frOPLJOYWS49Fk7z9KmXn5cXdv1cdUByBoA1C6tAxQGl+B7Cs8H\

> \

> > > \

> > > > >

> > >

> rbeGuHeEVn79eqaxE3bbdI33ZpRKPG4fOnvU9SYwhRvN7frRIuT8+wXb/ypavrsggPqqebBr\

> \

> > > \

> > > > >

> > >

> x8XgaCNse7p6fv+K68IGm25G5XhAtqrUpyExuvVtRxk8zyDtEv/ifxTFC+mr0n5L1LsuCZfn\

> \

> > > \

> > > > >

> > >

> Ds+kZ9wM2IaBoGgDbPuVARNJzriJ1dk292lx0ZoAo89+ckj3GwHELR56ArD7OScZGR8cWLUd\

> \

> > > \

> > > > >

> > >

> tBPh9nJOWocWgIEbRH1OT/EsG3ETwJNrwPwCwRtF+s0Dxd6gGL4MdbtK0/OkaRhIRC0jaxbN\

> \

> > > \

> > > > >

> > >

> Xt0/xDDziF3zUjSsBMI2l6kpuuW2oXBPWSsGWq2HAjaduJHiNhQY1Qc60ueOAZ0BAjaGRbD0\

> \

> > > \

> > > > >

> > >

> fPZpVxjxpc6hlvjMdgP946ezy7R8cQhIGjHoOstcr1hYOwcNFVw5cRFIGgnWfevQ3gaI2XIi\

> \

> > > \

> > > > >

> > >

> UF1QVF8zlEgaIeR4ekw1qIbo+Yj3qwdgWbXgaB9gOIelJaH0EdtR7yNJKIZfgBB+wO1IkVlj\

> \

> > > \

> > > > >

> > >

> xoOutb0fHaJ9r6eAUH7huyD51MHPIyNEe86RlFm6g9pevYBxUDQ3vIVvVNm3lPrWNaEM24Wj\

> \

> > > \

> > > > >

> > >

> IpDVkOlbpCIMvsNBO0/dCORTO19WyaPh6yRTaEM3ACsAxB0jaDuTc9nl+tLidhQuzComFG4d\

> \

> > > \

> > > > >

> > >

> 0RexulfrYCgawcFqcnUYewns3ETYcSHLA4uvYxQRg2BoOsL9eWTcWocKho28r8Ndl+vrhfDE\

> \

> > > \

> > > > >

> > >

> fVjND1TgDEgaCDEz52X16tr6tRHP6uxs9bjZZm/PDs5Jy9DyoCAoMEmMgAiS+jhXFGxlBvt9\

> \

> > > \

> > > > >

> > >

> Vdgo033SpC/DBKBoEEqX9E7yZquKf42WoWsy3n55wFKKX8+hEjGABlA0CAXX9E73VQkWW9LB\

> \

> > > \

> > > > >

> > >

> 9b+x8WxZuT0/9mQMoIYIA8QNCjDav4iY9azw1O6C0PBkHom8EkdU+DiqXUcjykjfAHKAUGDq\

> \

> > > \

> > > > >

> > >

> iyXSxkJoci1vBGzPmn00ddSx/EjvuezS7lNxh4ZVAeCBoqhYMhiOPq4u3+7uX0+u6S61VLWL\

> \

> > > \

> > > > >

> > >

> oZE4iEL2dDv+ezy7eb24+6e9siIJgPlQNCAF8q2Xs1fyNpvN7frjXYskL2xLd1QodqmBPE/u\

> \

> > > \

> > > > >

> > >

> KndlH9udngqt8bkYtIx9siAGwgamOF7ufperlbzFwqPUIREBkkotE3RbTk2xCrDCzvHhnnlH\

> \

> > > \

> > > > >

> > >

> 6R/Yj1OzilkLEX8+RCu5i/0Ok0/LVBTIGhgKV/RO+X50aCYiRy0E8854v8hBYhp0EYYoQlgL\

> \

> > > \

> > > > >

> > >

> RA0AABYCgQNAACWAkEDAIClQNAAAGApEDQAAFgKBA0AAJYCQQMAgKX8P0HSsuTfzO1nAAAAA\

> \

> > > \

> > > > > ElFTkSuQmCC]

> > > > >

> > > > >

> > > > >

> > > > > Weitz & Luxenberg p.c. Settlement Letter to Seroquel Victims -

> TIME

> > > TO

> > > > > REJECT this Insult on Top of Injury

> > > > > I would like to thank a brave, courageous, and ethical anonymous

> > > source

> > > > > who has send in this letter correspondence they received from

> the

> > > law

> > > > > firm of Weitz & Luxenberg. This letter doesn't require a whole

> lot

> > > of

> > > > > commentary.

> > > > > It's obvious that Law Firms have sold their clients down the

> > > proverbial

> > > > > river while at the same time enriching themselves (who's best

> > > interest

> > > > > are you obligated too fulfill?). This settlement offer and the

> > > injured

> > > > > litigants legal representation has carried out a blatant

> miscarriage

> > > of

> > > > > justice, a forever horrible stain upon the American Justice

> system,

> > > and

> > > > > a orchestrated crime perpetrated upon victims of this well

> > > documented &

> > > > > evidenced unbridled & unregulated corporate criminal enterprise

> gone

> > > a

> > > > > rye.

> > > > > The time has now come for the victims to stand up to this

> criminal

> > > > > corporation " AstraZeneca " & their poison drug " Seroquel " , to

> reject

> > > this

> > > > > horrible injustice and settlement offer. We want, what America &

> our

> > > > > Constitution promises us all, our day in court before a jury of

> our

> > > > > peers....

> > > > > ____________________________________________________________

> > > > >

> > > > > Weitz & Luxenberg P.C. <http://www.weitzlux.com/>

> > > > > We are happy to report excellent news! After a long and hard

> fought

> > > > > legal battle, AstraZeneca has agreed to participate in a

> Settlement

> > > > > Program to resolve Weitz & Luxenberg ( " W & L " ) Seroguel cases.

> Our

> > > > > patience and aggressive litigating has resulted in very

> favorable

> > > > > settlement terms for our clients which will be further outlined

> > > below.

> > > > > We have carefully reviewed all of the factors of this agreement

> and

> > > we

> > > > > believe that this settlement offers you the best, and very

> likely

> > > the

> > > > > only opportunity to receive a fair resolution of your lawsuit.

> > > > > Therefore, we strongly recommend that you sign and complete the

> > > enclosed

> > > > > " Release Form " , " Track Selection Form " and " Brief Questionnaire "

> and

> > > > > AGREE to participate.

> > > > > As you know, we have engaged in a long legal battle with

> AstraZeneca

> > > > > over the past 6 years. Weitz & Luxenberg led the charge for the

> > > > > Plaintiffs around the Country. AstraZeneca put up a tremendous

> and

> > > > > expensive defense and they successfully were able to get a large

> > > number

> > > > > of cases to be permanently dismissed by the court. Weitz &

> Luxenberg

> > > is

> > > > > the only firm who took a case to trial anywhere in the Country.

> > > However,

> > > > > after a month-long trial, the jury unfortunately ruled in favor

> of

> > > the

> > > > > defendants. This loss did not affect the strength of our fight.

> Over

> > > the

> > > > > past year, even as almost every other plaintiffs firm settled

> their

> > > > > cases, Weitz & Luxenberg prepared two more cases for trial which

> was

> > > > > scheduled to begin this Summer. As a direct result of the

> endless

> > > and

> > > > > consistent pressure applied by the attorneys at Weitz &

> Luxenberg,

> > > we

> > > > > are happy to report that AstraZeneca has now agreed to

> participate

> > > in a

> > > > > favorable settlement program. Based on public reports regarding

> > > > > settlement programs reached with other plaintiff law firms we

> are

> > > > > confident that the settlement program outlined below has more

> > > favorable

> > > > > terms and for this reason we are recommending your

> participation.

> > > > > The defendants have argued that they refuse to pay anyone who

> cannot

> > > > > prove through medical records or via certification that they

> have

> > > used

> > > > > Seroquel. They also refuse to pay anyone whose case is not

> active in

> > > > > this litigation. We recently told you about the Order issued by

> the

> > > > > Court requiring you to confirm when you started taking Seroquel

> and

> > > when

> > > > > you stopped taking Seroquel. We cannot stress enough that you

> MUST

> > > read,

> > > > > complete and return this certification form to us immediately.

> The

> > > > > failure to return this form within the next 30 days will result

> in

> > > the

> > > > > permanent dismissal of your case. In order to protect your legal

> > > rights,

> > > > > to keep your case active and be permitted to participate in this

> > > > > Settlement Program you must take this Order very seriously and

> you

> > > must

> > > > > respond.

> > > > > Based on our experience in other litigations and having reviewed

> the

> > > > > media reports of the terms of other firms' Seroquel settlement

> > > programs,

> > > > > we know that the defendants are looking for a settlement program

> > > that

> > > > > includes all claimants (W & L Seroquel Plaintiffs) so that they

> will

> > > > > achieve complete closure of the entirYlitigation. Our goal in

> this

> > > > > negotiation was to obtain a settlement for the most amount of

> money

> > > > > using a fair method to pay our clients based upon the merits of

> > > their

> > > > > individual case. We also stressed our intentions that the case

> > > review

> > > > > and payment process be performed quickly yet fairly so that our

> > > clients

> > > > > can receive their settlements as soon as possible. A key part of

> > > this

> > > > > settlement program is that a claimant cannot be part of the

> > > settlement

> > > > > if their case is dismissed and unless they provide, at the very

> > > least, a

> > > > > certification that they in fact took Seroquel and suffered an

> > > injury.

> > > > > Therefore, please make sure that you return your certification

> form

> > > to

> > > > > us immediately

> > > > >

> > > > > We have hired Hon.Marina Corodemus to act as the Special Master

> for

> > > the

> > > > > W & L Seroquel settlement program. Judge Corodemus previously ran

> the

> > > New

> > > > > Jersey Mass Tort Court and has a lot of experience in this

> field.

> > > She

> > > > > was appointed as a Special Master by the Vioxx State and Federal

> > > Court

> > > > > Judges to determine the appropriateness of Vioxx settlements and

> to

> > > > > resolve Vioxx appeals. She has also served as the Special Master

> in

> > > many

> > > > > other litigations such as Bextra and Celebrex which used similar

> > > > > settlement terms. We have met several times with Judge Corodemus

> and

> > > > > discussed the goals outlined above to get the most amount of

> money

> > > to

> > > > > the most amount of claimants in the fastest amount of time

> possible.

> > > We

> > > > > believe that Judge Corodemus is the perfect choice to create and

> > > oversee

> > > > > a settlement program in accordance with these goals. The W & L

> > > Seroquel

> > > > > Settlement Program involves Weitz & Luxenberg's 2,351 clients.

> Only

> > > > > those clients with active cases (not dismissed as outlined

> above)

> > > can

> > > > > participate in this settlement program. Unlike other settlement

> > > programs

> > > > > that you may have read about in the media and internet, the W & L

> > > > > Settlement program does not award every case an equal settlement

> > > amount.

> > > > > The size of an individual's settlement will depend entirely on

> the

> > > merit

> > > > > of that individual's case. As a direct result of the large

> number of

> > > > > cases represented by W & L, and the merits of those cases, we are

> > > > > confident that we have obtained the best possible settlement for

> our

> > > > > clients. After complex negotiations, AstraZeneca

> > > > > has agreed to deposit $92.25 Million dollars into a trust

> account to

> > > be

> > > > > used for this Settlement Program. This amount is completely

> > > confidential

> > > > > and you should NOT discuss this with anyone. A settlement of

> this

> > > type

> > > > > is called an " Aggregate Settlement " where a fair and reasonable

> sum

> > > of

> > > > > money is obtained to resolve multiple cases. In order to

> maintain

> > > proper

> > > > > representation of each individual client, W & L is NOT involved

> in

> > > the

> > > > > allocation decision making, which will be handled exclusively by

> > > Judge

> > > > > Corodemus. W & L has reviewed the general framework of the

> settlement

> > > > > plan with Judge Corodemus and we strongly believe that it is

> fair

> > > and

> > > > > reasonable and offers each of our clients the best possible

> outcome

> > > > > under the circumstances of this litigation. Track I offers the

> > > Seroquel

> > > > > claimant a settlement of $12,000. This track involves a simple

> > > review of

> > > > > each case and will result in a quick approval by Judge Corodemus

> > > without

> > > > > an analysis of the specific details of the case such as injury,

> > > amount

> > > > > of Seroquel taken, how close the last Seroquel use was to the

> date

> > > of

> > > > > the injury or the individual claimant's risk factors. a) Cannot

> > > > > prove that they suffered diabetes or a diabetes related

> condition,

> > > > > and/or Cannot prove that they used Seroquel within 1 year of

> > > > > their claimed injury, and/or c) Had a large number of known

> > > > > risk factors for diabetes before they started taking Seroquel.

> For

> > > > > example - obesity, family history, smoking, etc.

> > > > >

> > > > > Therefore, all cases whose injuries are limited to weight gain

> or

> > > high

> > > > > blood sugar and whose medical records will confirm that they

> were

> > > never

> > > > > diagnosed with diabetes or pancreatitis, should choose Track 1.

> > > > > Similarly, any claimed injury that occurred long after the last

> use

> > > of

> > > > > Seroquel should also choose Track 1. These cases are likely to

> > > receive a

> > > > > small award in Track II (likely less than $12,000) because it is

> > > > > extremely difficult to prove that these injuries were caused by

> > > > > Seroquel. Therefore, we suggest that if your case falls into

> this

> > > > > category you should choose Track 1. Additionally, payment of

> Track I

> > > > > settlement awards will be processed first once AstaZeneca waives

> its

> > > > > " walk away right " . (See Section IV© below) Track II involves

> an

> > > > > in-depth review of the severity of the injury, the claimed use

> of

> > > > > Seroquel and its proximity to the injury as well the available

> proof

> > > > > found in the contemporaneous medical records. Additionally,

> Judge

> > > > > Corodemus will strongly consider many known risk factors for

> these

> > > > > injuries including but not limited to smoking, obesity and

> family

> > > > > history as well as the participation in the Zyprexa settlement

> for

> > > these

> > > > > same injuries. This model is very similar to the one used in the

> > > > > National Vioxx Settlement Program as well as dozens of other

> similar

> > > > > settlement programs which were successfully resolved in recent

> > > years.

> > > > > Judge Corodemus has established a points system and will

> consider

> > > all of

> > > > > the critical issues including but not limited to:

> > > > > - Nature of the injury - Severity of the injury - Age at the

> time of

> > > > > injury - Proximity of Seroquel use to the claimed injury -

> Changes

> > > in

> > > > > the Seroque11abel - Risk Factors including Smoking, Body Mass

> Index,

> > > > > etc. After carefully reviewing all of the medical records and

> the

> > > > > individual fact sheet, Judge Corodemus will assign a point value

> to

> > > each

> > > > > case. The more points a case is awarded based on the specific

> facts

> > > of

> > > > > the case, the larger the settlement will be. At this time, there

> is

> > > no

> > > > > way to predict with accuracy how many points an individual case

> may

> > > be

> > > > > awarded and it is even more difficult to determine how much

> money

> > > each

> > > > > point will receive. The exact value of each point will depend on

> the

> > > > > number of participants in Track II and the total number of

> points

> > > > > assigned. All cases in Track II will be eligible for a

> settlement

> > > award

> > > > > but Judge Corodemus could award LESS than $12,000 (what people

> will

> > > > > receive automatically by choosing Track 1) if the case lacks

> merit.

> > > In

> > > > > the interest of fairness, Judge Corodemus has committed to

> review

> > > each

> > > > > case in Track II very carefully and this process will take time

> to

> > > > > complete. Judge Corodemus has stated that she hopes to have this

> > > process

> > > > > completed by the end of 2011 but please be warned that it could

> take

> > > a

> > > > > little longer due to the amount of work that is involved.

> However,

> > > in

> > > > > order to get this settlement process moving forward and

> ultimately

> > > paid

> > > > > you must send us your signed Release form as soon as possible.

> If

> > > you

> > > > > choose Track I your settlement award of $12,000 is set. If you

> > > choose

> > > > > Track II, Judge Corodemus will review your claim and will issue

> an

> > > > > award. We expect that we will contact you in approximately

> November

> > > 2011

> > > > > and notify you of your point award and the expected amount of

> your

> > > > > settlement. At that point, you will be given a choice to accept

> your

> > > > > award, appeal your award or withdraw from the settlement

> program. If

> > > you

> > > > > accept, we will forward your release to AstraZeneca for their

> review

> > > and

> > > > > approval. Please understand that this settlement is not official

> > > until

> > > > > we send AstraZeneca your signed Release Form, AstraZeneca

> approves

> > > it

> > > > > AND AstraZeneca waives its walk away right. In the interest of

> time,

> > > we

> > > > > are asking you to return your signed Release Form now so we can

> meet

> > > the

> > > > > tight deadlines associated with this settlement. If you are

> unhappy

> > > with

> > > > > your allocation amount and/or believe that your case involves

> > > > > " Extraordinary Injury or Circumstances " you have the right to

> appeal

> > > > > your award. Upon receipt of such an application, Judge Corodemus

> > > will

> > > > > re-review your records and make a final decision. Please be

> aware

> > > that

> > > > > there is no additional right of appeal (to Judge Corodemus or to

> any

> > > > > Court) once this final decision is made. If you decide to

> decline

> > > the

> > > > > settlement amount offered to you, you must notify us within ten

> days

> > > of

> > > > > your receipt of your allocation amount and your signed Release

> Form

> > > will

> > > > > no longer be valid. As in all settlements of this type, our

> > > agreement

> > > > > with the defendant depends on nearly full participation from all

> of

> > > our

> > > > > clients. Under the terms of our agreement, we must provide

> > > Qualifying

> > > > > Materials (Release Form and/or Dismissal) for 2,260 of our

> clients.

> > > Once

> > > > > we reach this number, AstraZeneca's " walk away right " is

> officially

> > > > > waived. We strongly believe that our clients will agree that

> this

> > > > > settlement program offers the best possible terms and we expect

> that

> > > we

> > > > > will meet this requirement in the next 90-120 days. In order to

> meet

> > > > > this deadline we MUST have your complete

> > > > > cooperation and immediate response. Of course, if we do not meet

> > > this

> > > > > required number of responses, Astrazeneca can decide to withdraw

> its

> > > > > settlement offer to everyone whether one signed the Release Form

> or

> > > not.

> > > > > Therefore, time is of the essence. A. Release Form: Enclosed you

> > > will

> > > > > find a Release Form which you must sign in front of a notary in

> > > Order to

> > > > > participate in the settlement. If you have a spouse he/she must

> sign

> > > the

> > > > > Release Form as well. Attached to the Release Form will be an

> > > > > instruction sheet to guide you to ensure that this important

> form is

> > > > > signed the right way. A Release Form that is signed the wrong

> way or

> > > > > that is not witnessed (by a notary) is useless and will not be

> > > accepted

> > > > > by the defendants. The Release Form is your agreement to

> participate

> > > in

> > > > > the settlement program and at the same time discontinue your

> lawsuit

> > > in

> > > > > exchange for your settlement award. Please turn to Page 2 of the

> > > Release

> > > > > Form and complete the details of your Seroquel use. You may

> refer to

> > > > > Page 1 of the Brief Questionnaire which lists the Seroquel

> > > information

> > > > > that was found in your medical records or that you have

> previously

> > > > > provided to us. If this information is inaccurate, please cross

> it

> > > out

> > > > > and write in when you started and when you stopped taking

> Seroquel

> > > on

> > > > > BOTH the Release Form and the Brief Questionnaire. Due to the

> fast

> > > > > approaching deadlines, and our goal to get you your settlement

> > > processed

> > > > > and paid as quickly as possible, we MUST receive this signed

> release

> > > > > form back from you before August 31, 2011. Please use the

> envelope

> > > > > provided herein and return the signed and notarized release form

> > > today

> > > > > before you forget about it. Please note that once we submit your

> > > release

> > > > > form to AstraZeneca it can not be revoked. B. Track Selection

> Form:

> > > > > Enclosed you will find a " Track Selection Form " which is the

> form

> > > used

> > > > > to officially notify the Special Master which Track you want

> your

> > > case

> > > > > to follow. Please Note that there are 4 options on this form.

> You

> > > MUST

> > > > > check one of the Options. If you want to participate in this

> > > settlement,

> > > > > and we strongly think that you should, you must check either

> Track I

> > > OR

> > > > > Track II and you must sign the bottom of the form. Your Track

> > > selection

> > > > > cannot be changed and is considered final once the Judge's

> > > Allocations

> > > > > are made. In other words, a person who chooses Track II and is

> > > awarded

> > > > > less than $12,000 CANNOT then choose to go to Track 1 for a

> higher

> > > > > award. C. Brief Questionnaire: Enclosed you will find a 3

> > > > > page Brief Questionnaire which has important information about

> your

> > > > > claim. For all claimants who choose to enter Track II, Judge

> > > Corodemus

> > > > > will be reviewing your medical records, your Fact Sheet and this

> > > Brief

> > > > > Questionnaire and will issue a point award. Judge Corodemus will

> > > > > consider the proof of your claim found in your medical records

> as

> > > well

> > > > > as the information that you provide in this Questionnaire.

> > > Therefore, it

> > > > > is important that you answer these questions honestly and

> completely

> > > and

> > > > > that they are consistent with what is found in your medical

> records.

> > > > > litigation and our conversations with our medical experts, it is

> > > clear

> > > > > that Seroquel lawsuits are very difficult to win, very

> expensive,

> > > and

> > > > > very time consuming to take through to trial, verdict and

> appeal.

> > > Over

> > > > > the past six years only I case (from W & L) of24,000 cases in the

> > > Country

> > > > > made it to and through trial. Countless other cases were

> prepared

> > > and

> > > > > then dismissed based on merit and/or inability to prove that

> > > Seroquel

> > > > > caused the injury. Just because an individual took Seroquel and

> > > suffered

> > > > > an injury like diabetes does not mean that such a case will win

> at

> > > > > trial. In order to succeed at trial, a plaintiff must prove both

> > > that

> > > > > Seroquel can cause such an injury in general AND that, within a

> > > > > reasonable degree of medical certainty, Seroquel caused this

> injury

> > > to

> > > > > this particular person (despite any individual risk factors such

> as

> > > > > smoking, weight, high blood sugar, family history etc.). We have

> > > told

> > > > > you in the past update letters that the Courts have consistently

> > > ruled

> > > > > in favor of the defendants on many of these issues and have

> > > prohibited

> > > > > medical experts from testifying because of a lack of scientific

> > > proof

> > > > > linking the plaintiff s injuries to his/her Seroquel use. It is

> also

> > > > > important to note that even if your case is able to advance past

> > > this

> > > > > judicial scrutiny, a trial of this magnitude will cost over

> $750,000

> > > per

> > > > > case and many of these costs are reimbursed off of the top of a

> > > > > favorable verdict reducing the amount received by the plaintiff.

> > > > > Furthermore, any case that is won at trial will surely face a

> > > lengthy

> > > > > and hard-fought appeal. Finally, nearly all of the Seroquel

> cases

> > > are

> > > > > being handled by three judges. Even at an accelerated pace, the

> > > chances

> > > > > are slim that your case would be tried in the next 10 years if

> not

> > > > > longer. In taking all of these factors into consideration, and

> > > > > considering the issues of risk and reward, we believe that a

> > > settlement

> > > > > of this type offers you the most advantageous resolution

> possible.

> > > You

> > > > > will be notified once the Special Master issues your point award

> at

> > > > > which point you can appeal to the Special Master if you believe

> that

> > > > > your case involves extraordinary circumstances. Thereafter, the

> > > decision

> > > > > of the Special Master is final, binding and non-appealable. We

> have

> > > > > retained the Garretson Law Firm to negotiate any and all Federal

> and

> > > > > State liens (Medicare/Medicaid/SSI) that may be applicable in

> your

> > > case.

> > > > > The Garretson Firm is a specialist in this field and they have

> > > obtained

> > > > > excellent results in their negotiation of similar liens in other

> > > > > litigations like Vioxx, Bextra, and Celebrex. Moreover, the

> > > Garretson

> > > > > Firm has already worked on thousands of other Seroquel cases and

> has

> > > > > been able to achieve excellent results in large part due to the

> > > volume

> > > > > of cases that they are able to include in a Global Resolution.

> At

> > > this

> > > > > time, the Garretson Firm has already negotiated with 44

> individual

> > > > > states regarding Medicaid and they have reached an agreement to

> CAP

> > > > > Medicaid liens at a maximum of 20% of the settlement amount.

> Please

> > > see

> > > > > the enclosed blue booklet regarding governmental liens for more

> > > details.

> > > > > Additionally, please also be advised that if you or Weitz &

> > > Luxenberg

> > > > > are put on written notice of a private lien, for example from

> your

> > > > > medical provider, this lien must be resolved before any

> settlement

> > > > > proceeds can be distributed. If you have received any notice of

> a

> > > lien,

> > > > > please advise us immediately. The terms of your signed

> contingency

> > > fee

> > > > > agreement will be in effect. We have taken great effort to keep

> the

> > > case

> > > > > specific expenses as low as possible. Under the terms of your

> > > agreement,

> > > > > the

> > > > > contingency fee will be calculated after the expenses are

> deducted.

> > > > > Under the terms of our agreement with AstraZeneca, any interest

> > > earned

> > > > > on the settlement proceeds before allocation and payment to the

> > > > > individual clients will be used to offset the fixed costs of the

> > > Special

> > > > > Master and the Lien Administrator. Due to the low interest rates

> > > paid by

> > > > > all banks in this economy, we do not expect that there will be

> any

> > > > > leftover interest. However, in such a case, the leftover

> interest

> > > will

> > > > > be added to the settlement trust and will be distributed to all

> > > > > claimants as part of Judge Corodemus' allocation process. After

> > > careful

> > > > > analysis of the likelihood of success in the court system, as

> well

> > > as

> > > > > the cost and time elements involved, we strongly recommend that

> you

> > > > > AGREE to participate in this settlement. We are confident that

> this

> > > > > settlement is the best possible resolution of your claim

> especially

> > > in

> > > > > light of the history of this litigation. We expect that any case

> > > that

> > > > > does not agree to participate in this settlement will have a

> very

> > > > > difficult time navigating through the Court system and trial

> dates

> > > may

> > > > > not be set for many years. Moreover, as we have seen, these

> cases

> > > will

> > > > > be aggressively defended by AstraZeneca and we expect that we

> will

> > > > > receive motions to dismiss and unfavorable decisions from the

> Court

> > > on

> > > > > unsettled cases in the coming months. Moreover, if this

> settlement

> > > > > program is not successful (we fail to reach the 98% response

> rate)

> > > we

> > > > > highly doubt that we will ever obtain a settlement amount and

> terms

> > > as

> > > > > good as those contained in this program. While we hope that this

> > > letter

> > > > > and enclosures will help answer all of your questions, we

> understand

> > > > > that you may have additional questions for us. Please keep in

> mind

> > > that

> > > > > we are working very hard to evaluate each and every case

> > > individually

> > > > > and the many deadlines that are part of this settlement are fast

> > > > > approaching. Your case has been assigned to Judy Koenig. If you

> have

> > > an

> > > > > important question please call Judy Koenig at (800) 438-9786 and

> ask

> > > for

> > > > > extension 5860. If you reach a voice-mail, please leave a

> message

> > > and

> > > > > you will be called back as quickly as possible. Please do not

> leave

> > > > > multiple voicemail messages on the same day as that will slow

> down

> > > our

> > > > > ability to return your call. Additionally, if you have email

> access,

> > > > > please try to email your detailed questions to us at sqinfo@

> > > > > <mailto:sqinfo@ and we will get back to you quickly. If

> > > > > this letter has successfully answered your questions, and you

> have

> > > > > decided to participate, please carefully follow the directions

> on

> > > the

> > > > > front page of the enclosed release form and send your signed and

> > > > > witnessed release formes), your Track Selection AND your Brief

> > > > > Questionnaire to us as soon as possible. If you still have

> questions

> > > > > after reviewing this letter and after speaking to us over the

> > > telephone

> > > > > and you would like to meet us in person, we will be happy to

> > > schedule a

> > > > > meeting in our office at your convenience. Finally, please

> remember

> > > that

> > > > > the detailed information regarding this settlement program is

> > > COMPLETELY

> > > > > CONFIDENTIAL and should not be shared or discussed with anyone.

> > >

> > > > > Sedgh, Esq Glenn Zuckerman, Esq.

> > > > >

> > > >

> > >

> >

>